Maryland Court Reporting 6 The Reporters Group Court Reporting Video Video Services LLC Stephenson. VA 23655 6 Libigation Technology 6 Libigation Technology 8 Ereckentidgs C0 8042: www.marylandreporting.com www.advlegaltech.com www.advlegaltech.com
--

FIFRA SCIENTIFIC ADVISORY PANEL (SAP)

OPEN MEETING

SCIENTIFIC ISSUES ASSOCIATED WITH THE AGENCY'S PROPOSED ACTION UNDER FIFRA 6(b) NOTICE OF INTENT TO CANCEL CARBOFURAN

U.S. ENVIRONMENTAL PROTECTION AGENCY CONFERENCE CENTER- LOBBY LEVEL ONE POTOMAC YARD (SOUTH BUILDING) 2777 SOUTH CRYSTAL DRIVE ARLINGTON, VIRGINIA 22202 FEBRUARY 6, 2008 8:32 A.M.

-	EPA MEETING 02/06/08 CCR# 15796-2 Page 2
1	U.S. ENVIRONMENTAL PROTECTION AGENCY
2	FIFRA SCIENTIFIC ADVISORY PANEL (SAP)
3	OPEN MEETING
4	February 6, 2008
5	DR. MATTEN: Good morning. We're going
6	to start the second day or our meeting on carbofuran
7	issues. My name is Sharlene Matten. I work in the
8	office of Science Coordination and Policy. I'm the
9	designated federal official for this meeting. We're
10	going to continue our discussions that follow Dr.
11	Reaves' presentation yesterday. And I'm going to turn
12	the floor over to Dr. Heeringa, who will then continue
13	leading the panel through the various discussions.
14	Thank you.
15	DR. HEERINGA: Good morning, everyone,
16	and welcome back to the second day of our multi-day
17	session of the FIFRA Science Advisory Panel; addressing
18	the topic of scientific issues associated with the
19	Agency's proposed action under FIFRA 6 (b) Notice of
20	Intent to Cancel Carbofuran.
21	I am Steve Heeringa of the University of
22	Michigan. I am the President Chair of the FIFRA
23	Science Advisory Panel. Today, we're joined, as
24	yesterday, by an expert panel, to address the specific
25	charge questions and scientific issues associated with



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 3
1	this meeting topic.
2	I'd like to have them introduce themselves
3	again this morning, beginning with Dr. Chambers.
4	DR. CHAMBERS: I'm Jan Chambers with
5	the College of Veterinary Medicine at Mississippi State
6	University. And I'm a member of the permanent panel.
7	My area of expertise is pesticide toxicology.
8	DR. HANDWERGER: I'm Stuart Handwerger.
9	I'm Professor of Pediatrics and Cell and Cancer Biology
10	at the University of Cincinnati College for Medicine.
11	I'm and endocrinologist whose primary research is in
12	molecular and developmental biology.
13	DR. PORTIER: Good morning. I'm Ken
14	Portier, Director of Statistics, the American Cancer
15	Society National Home Office in Atlanta. And I'm a
16	member of the permanent panel.
17	DR. SCHLENK: My name is Dan Schlenk.
18	I'm a professor in the Department of Environmental
19	Sciences at the University of California, Riverside.
20	My area of expertise is aquatic toxicology and I'm a
21	member of the permanent panel.
22	DR. CLARK: My name is Larry Clark. I'm
23	the Assistant Director of the USDA's National Wildlife
24	Research Center. And my areas of expertise are
25	wildlife oncology, sensory biology and wildlife



	EPA MEETING 02/06/08 CCR# 15796-2 Page 4
1	diseases.
2	DR. DELORME: Good morning. My name is
3	Peter Delorme. I'm currently Acting Director of the
4	Environmental Assessment Director of the Pest
5	Management Regulatory Agency at Health Canada.
6	DR. GRUE: Good morning. My name is
7	Chris Grue. I'm leader of the Washington Cooperative
8	Fish and Wildlife Research Unit, University of
9	Washington. My area of expertise is fish and wildlife
10	toxicology.
11	DR. HILL: I'm Elwood Hill. I am a
12	wildlife toxicologist. My area is primarily organic
13	phosphorus, carbamate and mercury toxicology.
14	DR. MCCARTY: My name is John McCarty.
15	I'm a Professor of Biology at University of Nebraska at
16	Omaha. I'm an ecologist, and specialize in the ecology
17	of birds.
18	DR. MONTGOMERY: I'm Cheryl Montgomery.
19	I'm a consultant with Montgomery and Associates. I am
20	a chemist, and I practice risk assessment.
21	DR. SAMPLE: I'm Brad Sample CMSM
22	HILL, ecological risk assessor.
23	DR. SPARLING: Don Sparling with
24	Cooperative Wildlife Lab in Department of Zoology at
25	the Southern Illinois University. My area of expertise



	EPA MEETING 02/06/08 CCR# 15796-2 Page 5
1	is wildlife toxicology.
2	DR. STINCHCOMB: Audra Stinchcomb,
3	University of Kentucky, College of Pharmacy. I'm an
4	associate professor there. And my area of expertise is
5	dermal absorption.
6	DR. REED: Nu-may Ruby Reed. I'm with
7	the California Environmental Protection Agency. I do
8	pesticide health risk assessment.
9	DR. MACDONALD: Peter Macdonald,
10	Professor of Mathematics and Statistics at McMaster
11	University in Canada. I have general expertise in
12	applied statistics.
13	DR. LU: Alex Lu from Rollins School of
14	Public Health at Emory University. I do human exposure
15	to pesticides and the hazard factor and biomarkers.
16	DR. KEHRER: Jim Kehrer, Dean of the
17	College of Pharmacy at Washington State University.
18	I'm in molecular toxicology.
19	DR. HATTIS: Dale Hattis, Clark
20	University. I specialize in issues of uncertainty and
21	variability in mechanistic modeling.
22	DR. EDLER: Lutz Edler, German Cancer
23	Research Center head of the Bio-statistics
24	Department there, and responsible for experimental and
25	clinical studies, and also interested in risk



EPA MEETING 02/06/08 CCR# 15796-2 Page 6 1 assessment. 2 DR. BUNGE: Annette Bunge. I'm a 3 Professor at Chemical Engineering at the Colorado School of Mines, and I specialize in dermal absorption 4 5 issues and risk assessment. 6 DR. BAILEY: Ted Bailey, Department of Statistics at Iowa State University. 7 8 DR. HEERINGA: Thank you very much, 9 again, members of the panel. Before we begin, just a 10 little synopsis of where we are in the agenda. Ιf 11 you're joining us for the first time today. We do have 12 a floating agenda that is currently scheduled over four 13 days -- or three-and-a-half days. We are about two or 14 three hours behind the posted times on the agenda. Ι 15 guess I anticipated that. We are in the process of 16 hearing and asking questions of clarification of the EPA scientific staff of their presentations. 17 After 18 that, we'll turn to the period of public comment, and 19 it will be an extensive period of public comment today. 20 Throughout this process, it's my intent that 21 we fully develop each of these issue and have 22 appropriate time to ask these questions of 23 clarification. So, I would anticipate us to sort of 24 remain behind the agenda schedule today; probably about 25 the same lag that we experienced yesterday.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 7
1	It's also my current thinking in terms of
2	planning for the week that I anticipate that we will,
3	in fact, return Friday morning for a continuation and a
4	wrap-up of this session on Friday just based on my
5	experience with these and the fact that I don't intend
6	to have us rush through things. This is a very serious
7	matter here. We want to make sure we have full
8	development and exploration.
9	So, with that, this morning, I'd like to turn
10	to Dr. Debbie Edwards or to Steve Bradbury possibly for
11	some opening comments.
12	DR. BRADBURY: Thank you, Dr. Heeringa.
13	Again, welcome to the panel and I'm looking forward to
14	the second day of discussions. I know there's a couple
15	of follow -up at least one set of follow-up
16	questions that we want to handle shortly with regard to
17	drinking water half-life question and we'll cover that.
18	And then, I believe we'll continue with clarifying
19	questions.
20	There's one topic that came up yesterday a
21	couple of times, and if I could just touch on that very
22	briefly. It has to do with the conditional label
23	changes that the registrant has submitted. And I know
24	a couple of times there were panel members that had
25	some questions about that.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 8
1	The proposed label changes that were
2	submitted to the Agency in mid-December include
3	continuing, I believe, four uses, but also, adding a
4	new use for their further use of the product on cotton.
5	And that requires that would be a new use, a new
6	registration, and would require both an ecological and
7	dietary risk assessment. And that goes through a
8	process. It typically takes for a new use about twelve
9	to fifteen months to go through the process of that
10	evaluation.
11	So, it's important to realize that some of
12	these changes on the current label are contingent upon
13	the addition of a new use. So it isn't a use by use
14	proposal that was submitted to the Agency. It's sort
15	of package deal. It includes adding further use on
16	cotton in addition to reducing a number of uses that
17	are currently on the label.
18	Now, having said that, I believe the charge
19	questions or the issues that the Agency's focusing on
20	in terms of ecological risk and human health risk, and
21	the feedback we'll get from the panel will be helpful
22	regardless of whatever you chair use patterns may
23	or may not occur for carbofuran.

On the context of human health risk
assessments, as we were starting to discuss yesterday,



- T	EPA MEETING 02/06/08 CCR# 15796-2 Page 9
1	the Agency's primary interest in getting feedback from
2	the panel concerns aspects of the cholinesterase. How
3	to take a look at red blood cells versus brain. How to
4	be taking a look at the dose response curves for those
5	response. How to think about oral route to dermal
6	route extrapolation those kinds of issues, which
7	will be important regardless of what food-use pattern
8	may exist or not exist for carbofuran in the future.
9	Certainly the overall dietary exposure that could exist
10	with a different pattern of uses will change, but the
11	underlying interpretation of the cholinesterase
12	inhibition and and the various extrapolation issues
13	are sort of even dependant of what the uses would be at
14	the end of the day. So we don't think that has a major
15	impact in the deliberations we'll be having in the next
16	few days.
17	In terms of the ecological risk assessment,
18	as we discussed yesterday, the risk assessment is
19	focused at a spacial scale of the field. And, so,
20	you're looking at the scenarios that have been done
21	thus far for the ecological risk assessment while
22	there's alfalfa and corn being used as a surrogate, the
23	idea is or the issue is that those are spanning a
24	range of use patterns that transcend the use patterns
25	that are on the label in terms of application rates,



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 10
1	and kinds of application methodologies, and the alfalfa
2	analysis, for example, isn't a water fowl risk
3	assessment, it's a risk assessment on passing birds in
4	row crops.
5	So alfalfa and corn are being used as
6	surrogates for row crops across a span of application
7	rates, application methods, and trying to get handle on
8	how to estimate risk on a field where carbofuran or
9	foliar carbofuran has been applied.
10	So, again, from the Agency's perspective
11	understanding how to interpret studies to try to get at
12	matrix effects on carbofuran potency. Trying to
13	understand how to take into account recovery of
14	cholinesterase in brain tissue of birds in terms of the
15	probabilistic risk assessment how to interpret
16	incidents data or field studies with foliar carbofuran
17	how to interpret the risk quotient methodology in
18	assessing the potency of carbofuran to birds in many
19	ways transcends what use patterns may exist in the
20	future.
21	So all the use patterns may change. The
22	underlying fundamental scientific issues in assessing
23	the risk transcend the use patterns to in the
24	Agency's opinion. And so we think that as we move
25	forward in the charge questions we'll get useful



EPA MEETING 02/06/08 CCR# 15796-2 Page 11 1 information, regardless of what the use patterns may or 2 may not be in the future. 3 If there are any follow-up questions, I'll be 4 happy to handle that. But then maybe we could move 5 into the clarifying questions from the Human Health 6 Topic. 7 DR. HEERINGA: Thank you very much, Dr. 8 Bradbury. 9 Dr. Brimijoin? 10 DR. BRIMIJOIN: Could I ask a follow-up 11 question? Supposing that the Notice of Intent to 12 Cancel is, in fact, carried through to cancellation, 13 and yet the company has a new-use application pending 14 -- I mean, is there -- what would -- is there an open 15 procedure for them to go forward with the request for a 16 new registration, let's say for cotton -- providing, of 17 course, new data to convince EPA then, in fact, the 18 product is safe? 19 DR. BRADBURY: Yeah, there is a -- there 20 is a process to do that. When -- and Debbie you could 21 help me, or GC could help me, but I believe if we go 22 through a process then it's cancelled there is a 23 process whereby a cancelled pesticide can have a use 24 come forward, but there's a process that you have to go 25 through to do that.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 12
1	MR. HEERINGA: Okay, let's return then
2	to the presentations yesterday afternoon from Jack
3	Housenger and Anna Lowit and Elissa Reaves on the human
4	health risks. And I know that there have certainly
5	are some residual questions from this afternoon and
6	some new questions that may have occurred to people as
7	they thought more about this last evening.
8	Dr. Bunge, you had a question before we
9	are we ready to go?
10	DR. LOWIT: We had a couple follow-ups
11	from yesterday.
12	DR. HEERINGA: Okay. Well, let's
13	DR. LOWIT: Do you want us to start with
14	those?
15	DR. HEERINGA: do those to start
16	with, please.
17	DR. LOWIT: And, I believe David Jones
18	also had a follow-up from yesterday on the
19	DR. HEERINGA: Please, go ahead then.
20	DR. LOWIT: I'll start and then Dick can
21	go, and then return it back to the panel.
22	(WHEREUPON, conversations took place off the record.)
23	DR. LOWIT: There was a question from a
24	Dr. Hattis conceptually around biological time the
25	differences between rats and humans. And as we stated



	EPA MEETING 02/06/08 CCR# 15796-2 Page 13
1	previously as part of review of the review board, you
2	won't hear us talking about the carbofuran human study,
3	however, there are three human studies for carbamates
4	that did go through the review of the HSRB and were
5	okayed for use in the risk assessment. And they do
6	provide some context for that question. And I've got
7	some tables in front of me with the parallel rat data.
8	So just in sort of basics of those studies they're each
9	ascending ascending acute single doses with the
10	number of subjects ranging from somewhere in the order
11	of twenty to thirty or fifty.
12	They each have pretty good time course
13	ranging from a few minutes after post-dose up to the
14	following day. Clinical signs, as we said yesterday,
15	it's very difficult to match clinical signs with
16	cholinesterase inhibition. In some ways that's a very
17	chemical specific situation. You can have some
18	carbamates where you get signs of very low levels of
19	inhibition and others where you see clinical signs they
20	don't sort of kick in, for a lack of better term, until
21	much greater inhibition.
22	But the question from Dr. Hattis was around
23	the half-life in a relationship between the humans and
24	the rats. So you see the last two levels here in this
25	slide that Dr. Reaves put together (Indicating.), the



EPA MEETING 02/06/08 CCR# 15796-2 Page 14 1 half-life for each of those is roughly about two hours with decent confidence limits of a little bit less --2 3 about an hour -- somewhere in the order of three to 4 four hours. And with regard to the rat for those three 5 compounds, just as point of comparison, in the adult 6 rat, I didn't have at my fingertips quickly this first 7 thing this morning, the RBC numbers, but brain and RBC 8 are usually not that different.

9 For aldicarb in the adult rat, the recovery 10 half-life is an hour-and-a half. For methomyl, it's between three-quarters of an hour and an hour depending 11 12 on the study. For oxamyl it's approximately an hour. 13 For both methomyl and oxamyl, they tend to have -- both 14 of those compounds have very strong data bases, and the 15 confidence limits on the rat numbers are very tight --16 arranging from about half-an-hour to one-and-a quarterhours for both. 17

For aldicarb, the confidence limits on the half-life range from about an hour to about two hours. So, still pretty tight. So, regarding -- at least in adults, I would say that the rats and the humans are pretty comparable of about two hours.

For the pups, for methomyl and oxamyl in rats, for methomyl, the half-life in a PND 11 brain is about -- roughly half-an-hour -- point four hours, so



	EPA MEETING 02/06/08 CCR# 15796-2 Page 15
1	about half-an-hour. I don't have the confidence
2	limits. And oxamyl, the half-life is about an hour-
3	and-a half. But if we look across the carbamates, and
4	this is a table right out of the accumulative it's
5	more like other situations that keep in mind it's a
6	dose dependent situation. So, it ranges in the table.
7	The low being methomyl about point four hours, the high
8	being fermintinite of about nine hours. So what we
9	call sulpha-carbofuran is somewhere in between those.
10	I think I had
11	MR. HATTIS: So why? Carbofuran is a
12	little unusual in having an appreciatively different
13	half-life for the pups versus the adults?
14	DR. REAVES: I wouldn't say it's
15	appreciable. I'm not sure if we have enough data to
16	really set a trend. But what we do know from the pups
17	is that the range across the class is much greater than
18	what's seen in the adults. The range in the pups
19	across the class, we got I've got data for five
20	chemicals, carbaryl, carbofuran, fermintinite, methomyl
21	and oxamyl. The shortest being methomyl of point
22	four, the longest being fermintinite of nine,
23	carbofuran is in the middle there (Indicating).
24	DR. HATTIS: So, there is a tendency for
25	the pups to be longer half-lives shorter lessor



EPA MEETING 02/06/08 CCR# 15796-2 Page 16 1 inhibition rates then the adults in the examples we 2 have in front of you. 3 DR. REAVES: Yes, yes, with caveat that there's a dose dependance to it. 4 5 DR. HATTIS: Yes. 6 DR. REAVES: And we would have to go 7 back to see 8 DR. HATTIS: Yes. 9 DR. REAVES: inhibition 10 DR. HATTIS: Right. 11 DR. REAVES: -- was in the studies to 12 make sure you're comparing apples and apples. 13 MR. HATTIS: Right. 14 DR. REAVES: I think we had one more 15 slide. Just of point of transparency, I'd shown a plot 16 yesterday out of the 2005 --17 (WHEREUPON, conversations were held off the record.) 18 **DR. LOWIT:** I had shown a plot yesterday 19 out of the 2005 preliminary accumulative assessment for 20 the carbamates. Making two points -- one of them was a 21 derivation of the original five factor for the 2006 22 risk assessment, the other one where I was trying to 23 make the point that aldicarb and carbofuran really 24 aren't that different of potency. Just for point of 25 transparency so the panel has a more recent



1 information, we pulled these plots this plot and the 2 next one (Indicating.), excuse me, out of the 2007 3 revised assessment, which includes updated data for 4 most compound including carbofuran. So there are two 5 of them. The first one is for RBC go back you 6 can see the blue dots where the aldicarb and 7 carbofuran were essentially the same; so they are 8 similar in potency when you compare apples and apples 9 with regard to the brain. You can see carbofuran is 10 I think that's a three-fold difference. That's a log 11 scale right there (Indicating). I'm pretty sure 12 aldicarb and carbofuran in the brain is about three- 13 fold difference. 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. LOWIT: It is publically available 23 </th <th></th> <th>EPA MEETING 02/06/08 CCR# 15796-2 Page 17</th>		EPA MEETING 02/06/08 CCR# 15796-2 Page 17
revised assessment, which includes updated data for most compound including carbofuran. So there are two of them. The first one is for RBC go back you can see the blue dots where the aldicarb and carbofuran were essentially the same; so they are similar in potency when you compare apples and apples with regard to the brain. You can see carbofuran is I think that's a three-fold difference. That's a log scale right there (Indicating). I'm pretty sure aldicarb and carbofuran in the brain is about three- fold difference. So I just wanted to make sure the panel had the most recent information. GR. HEERINGA: Dr. Lowit, that particular plot is is that in a document that we have received? DR. LOWIT: It's not on a document you've received. We certainly can make copies. DR. HEERINGA: That would be great. DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the	1	information, we pulled these plots this plot and the
4 most compound including carbofuran. So there are two 5 of them. The first one is for RBC go back you 6 can see the blue dots where the aldicarb and 7 carbofuran were essentially the same; so they are 8 similar in potency when you compare apples and apples 9 with regard to the brain. You can see carbofuran is 10 I think that's a three-fold difference. That's a log 12 scale right there (Indicating). I'm pretty sure 13 scale right there (Indicating). I'm pretty sure 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 W. HEERINGA: That would be great. 21 DR. HEERINGA: Esth the	2	next one (Indicating.), excuse me, out of the 2007
5 of them. The first one is for REC go back you 6 can see the blue dots where the aldicarb and 7 carbofuran were essentially the same; so they are 8 similar in potency when you compare apples and apples 9 with regard to the brain. You can see carbofuran is 10 I think that's a three-fold difference. That's a log 11 scale right there (Indicating). I'm pretty sure 12 aldicarb and carbofuran in the brain is about three- 13 fold difference. 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 uve received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	3	revised assessment, which includes updated data for
 can see the blue dots where the aldicarb and carbofuran were essentially the same; so they are similar in potency when you compare apples and apples with regard to the brain. You can see carbofuran is I think that's a three-fold difference. That's a log scale right there (Indicating). I'm pretty sure aldicarb and carbofuran in the brain is about three- fold difference. So I just wanted to make sure the panel had the most recent information. DR. HEERINGA: Dr. Lowit, that particular plot is is that in a document that we have received? DR. LOWIT: It's not on a document you've received. We certainly can make copies. DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the 	4	most compound including carbofuran. So there are two
7 carbofuran were essentially the same; so they are 8 similar in potency when you compare apples and apples 9 with regard to the brain. You can see carbofuran is 10 I think that's a three-fold difference. That's a log 11 scale right there (Indicating). I'm pretty sure 12 aldicarb and carbofuran in the brain is about three- 13 fold difference. 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	5	of them. The first one is for RBC go back you
similar in potency when you compare apples and apples with regard to the brain. You can see carbofuran is I think that's a three-fold difference. That's a log scale right there (Indicating). I'm pretty sure aldicarb and carbofuran in the brain is about three- fold difference. So I just wanted to make sure the panel had the most recent information. DR. HEERINGA: Dr. Lowit, that particular plot is is that in a document that we have received? DR. LOWIT: It's not on a document you've received. We certainly can make copies. DR. HEERINGA: That would be great. DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the	6	can see the blue dots where the aldicarb and
9 with regard to the brain. You can see carbofuran is I think that's a three-fold difference. That's a log scale right there (Indicating). I'm pretty sure aldicarb and carbofuran in the brain is about three- fold difference. 14 So I just wanted to make sure the panel had the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we have received? 19 DR. LOWIT: It's not on a document you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	7	carbofuran were essentially the same; so they are
 I think that's a three-fold difference. That's a log scale right there (Indicating). I'm pretty sure aldicarb and carbofuran in the brain is about three- fold difference. So I just wanted to make sure the panel had the most recent information. DR. HEERINGA: Dr. Lowit, that particular plot is is that in a document that we have received? DR. LOWIT: It's not on a document you've received. We certainly can make copies. DR. HEERINGA: That would be great. DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the 	8	similar in potency when you compare apples and apples
11 scale right there (Indicating). I'm pretty sure 12 aldicarb and carbofuran in the brain is about three- 13 fold difference. 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	9	with regard to the brain. You can see carbofuran is
12 aldicarb and carbofuran in the brain is about three- 13 fold difference. 14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	10	I think that's a three-fold difference. That's a log
fold difference. So I just wanted to make sure the panel had the most recent information. DR. HEERINGA: Dr. Lowit, that particular plot is is that in a document that we have received? DR. LOWIT: It's not on a document you've received. We certainly can make copies. DR. HEERINGA: That would be great. DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the	11	scale right there (Indicating). I'm pretty sure
14 So I just wanted to make sure the panel had 15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	12	aldicarb and carbofuran in the brain is about three-
15 the most recent information. 16 DR. HEERINGA: Dr. Lowit, that 17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	13	fold difference.
16DR. HEERINGA: Dr. Lowit, that17particular plot is is that in a document that we18have received?19DR. LOWIT: It's not on a document20you've received. We certainly can make copies.21DR. HEERINGA: That would be great.22DR. LOWIT: It is publically available23in the in the risk assessment.24DR. HEERINGA: Both the	14	So I just wanted to make sure the panel had
<pre>17 particular plot is is that in a document that we 18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the</pre>	15	the most recent information.
18 have received? 19 DR. LOWIT: It's not on a document 20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	16	DR. HEERINGA: Dr. Lowit, that
19DR. LOWIT: It's not on a document20you've received. We certainly can make copies.21DR. HEERINGA: That would be great.22DR. LOWIT: It is publically available23in the in the risk assessment.24DR. HEERINGA: Both the	17	particular plot is is that in a document that we
20 you've received. We certainly can make copies. 21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	18	have received?
21 DR. HEERINGA: That would be great. 22 DR. LOWIT: It is publically available 23 in the in the risk assessment. 24 DR. HEERINGA: Both the	19	DR. LOWIT: It's not on a document
DR. LOWIT: It is publically available in the in the risk assessment. DR. HEERINGA: Both the	20	you've received. We certainly can make copies.
<pre>23 in the in the risk assessment. 24 DR. HEERINGA: Both the</pre>	21	DR. HEERINGA: That would be great.
24 DR. HEERINGA: Both the	22	DR. LOWIT: It is publically available
	23	in the in the risk assessment.
25 DR. LOWIT: The accumulative assessment.	24	DR. HEERINGA: Both the
	25	DR. LOWIT: The accumulative assessment.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 18
1	DR. HEERINGA: Both that and the half-
2	life chart I think we could use.
3	DR. LOWIT: Definitely.
4	DR. JONES: I'm responding to first,
5	I'm Dave Jones of EFED. I'm responding to the question
6	about drinking water treatment and environmental
7	degradation rates. Yesterday, I indicated that it is
8	driven by hydrolysis and pH dependent. At pH 5, we
9	have no evidence of degradation. It's a thirty day
10	study, so take that into account. At pH 7, it's
11	twenty-one days. And at pH 9, it's fifteen hours.
12	That's the twenty-five degrees. It's faster at higher
13	temperatures and slower at lower temperatures, and we
14	do have some data on that.
15	We have an aerobic slow metabolism study. We
16	had two of them done in the same soil, and the second
17	one was limed to raise the pH. It was three hundred
18	and twenty-one days at the lower pH, and a hundred and
19	twenty-nine days when it was raised above seven. That
20	study is a little hard to interpret because there was a
21	great deal of un-extractable residue in the study and
22	it's hard to say whether that was truly un-extractable
23	or just poorly extracted. There was degrade, three
24	hydroxy carbofuran. We do occasionally see that in
0 F	

25 water resources.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 19
1	In if carbofuran is on a surface or in
2	clear shallow waters it does degrade by photolysis with
3	about a six day half-life. But that would only be
4	operative in certain environments where a lot of light
5	can get to it.
6	Carbofuran is not bound tightly. The median
7	K/F is point 7. So it's below one most of the time.
8	The range is the measurements we had goes from point
9	one to thirty point three. So this is a pretty mobile
10	compound.
11	One comment to add on the drinking water
12	treatment. The water sources we are most concern
13	about, which are private rural wells, tend not to have
14	a whole lot of treatment done to them. So, the
15	question about treating it mostly relates to community
16	water supplies that are both surface and ground water.
17	DR. HEERINGA: Thank you very much.
18	In summary I don't Mr. Jones, with
19	regard to community water systems and the original I
20	read, I didn't see much concern there in terms of
21	community water systems levels, sub-part per billion.
22	Is that correct or is that
23	DR. JONES: For ground water, our
24	concern is mainly with the private rural wells and that
25	certain environment shallow, a lot of sandy soil,



EPA MEETING 02/06/08 CCR# 15796-2 Page 20 1 organic carbon acid water. 2 DR. HEERINGA: Right. Okay. 3 Are there additional clarifications from 4 yesterday from the EPA Scientific staff? 5 Well, let me open the floor to questions --6 clarification from the panel. Dr. Bunge? 7 DR. BUNGE: Thank you. Annette Bunge. 8 Just a couple points of clarification, and I 9 apologize. As you can imagine, we've been overwhelmed 10 both by information and piles of papers. So there will 11 probably be really simple things that we've just lost, 12 or I've just lost. So just a point of clarification --13 on the red blood cell, cholinesterase measurements by 14 FMC, they use the modified Elmans Assay in the two 15 dermal studies, and I thought from yesterday's 16 presentation in the second oral study, but I didn't 17 catch what assay was used in the first oral study? 18 DR. LOWIT: Yes, in the first FMC 19 comparative study, they used the modified Elmans, but 20 it was performed at a different laboratory. 21 DR. BUNGE: Okay. I see. 2.2 DR. LOWIT: So the dermal study for 23 carbofuran and the second FMC CCA study were performed 24 at the same laboratory. 25 DR. BUNGE: Okay. Thank you.



Now, I'd like to ask just a few questions then about the dermal-tox studies, and especially directed towards the decision to not use the results in the risk assessment. As I understood it okay, first of all point of clarification. The I see cholinesterase measurements were done it says one hour post exposure, and just to be sure I understand when that occurs relative, does that mean one hour after the six hour exposure on the last day? DR. LOWIT: Yes, that's correct. One	
<pre>3 directed towards the decision to not use the results in 4 the risk assessment. 5 As I understood it okay, first of all 6 point of clarification. The I see cholinesterase 7 measurements were done it says one hour post 8 exposure, and just to be sure I understand when that 9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
<pre>4 the risk assessment. 5 As I understood it okay, first of all 6 point of clarification. The I see cholinesterase 7 measurements were done it says one hour post 8 exposure, and just to be sure I understand when that 9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
As I understood it okay, first of all point of clarification. The I see cholinesterase measurements were done it says one hour post exposure, and just to be sure I understand when that occurs relative, does that mean one hour after the six hour exposure on the last day?	
<pre>6 point of clarification. The I see cholinesterase 7 measurements were done it says one hour post 8 exposure, and just to be sure I understand when that 9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
<pre>7 measurements were done it says one hour post 8 exposure, and just to be sure I understand when that 9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
<pre>8 exposure, and just to be sure I understand when that 9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
<pre>9 occurs relative, does that mean one hour after the six 10 hour exposure on the last day?</pre>	
10 hour exposure on the last day?	
11 DR. LOWIT: Yes, that's correct. One	
12 hour post exposure, so actually, seven hours from the	
13 beginning of exposure. One after the six hours.	
14 DR. BUNGE: But it's the exposure on the	
15 last day?	
16 DR. LOWIT: Correct.	
17 DR. BUNGE: Okay. Now	
18 DR. LOWIT: Just to be clear. As this	
19 is a carbamate and recovery is rapid, the fact that it	
20 was a twenty-one day study, and it was the last day, is	
21 less important then the hours and the minutes.	
22 DR. BUNGE: I appreciate that. I	
23 understand that.	
And of course there's two studies. There's	
25 the seven day study also. And so it would be on the	



EPA MEETING 02/06/08 CCR# 15796-2 Page 22 1 last day of the seventh day study. 2 Now, in my understanding of the decision 3 making for not using the dermal studies in the risk 4 assessment, the first was that the red blood cell data 5 were considered unreliable; correct? 6 DR. LOWIT: Because there was concerns 7 from the CCA study with the same protocol, the red 8 blood cell data, there was no dose response. So, 9 correct. 10 DR. BUNGE: Right. 11 But the brain data were considered adequate? 12 DR. LOWIT: In the CCA study; correct. 13 DR. BUNGE: Okay. 14 DR. LOWIT: But not the dermal. 15 DR. BUNGE: No, I'm talking about the 16 dermal -- just the data themselves, not back to the 17 time course, which I'm going to address in my next 18 question. 19 DR. LOWIT: Okay. 20 DR. BUNGE: But in the list of reasons 21 why the dermal-tox study was not included -- or not 22 used in the risk assessment, the list said that the red 23 blood cell data were considered unreliable. I assume 24 then -- though -- that the brain data -- the time 25 course issues aside for the moment, were considered



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 23
1	adequate or apparently reliable?
2	DR. LOWIT: For that compartment.
3	DR. LICCIONE: Yes, we had hi, my
4	name is John Liccione from ATB. We had like the CCA
5	study more confidence in the brain cholinsterase
6	measurements.
7	DR. BUNGE: Okay. So there's not a
8	question of reliability on the data from the brain,
9	it's now the time course issue that's the critical one?
10	Is that correct in the decision making?
11	DR. LICCIONE: Yes.
12	DR. BUNGE: Okay.
13	DR. LOWIT: There are two points here I
14	just want to make sure that you don't mix them up. One
15	is the reliability of the conduct of the study itself.
16	And then the second issue is the usability of that for
17	point of departure. So make sure in your mind that
18	you're separating that.
19	DR. BUNGE: I understand that.
20	Okay. So, it seems to me that the really
21	crux-point then in the decision making on whether or
22	not to use the dermal study in the risk assessment
23	relies really on the time course; is that right?
24	DR. LICCIONE: Well, there's two issues.
25	One is the time course, but also, the RBC that we



	EPA MEETING 02/06/08 CCR# 15796-2 Page 24
1	it's a method problem. All those factors that were
2	considered. So the of the oral studies are showing
3	the RBC to be more sensitive. So there's two levels.
4	One is that the RBC is just simply unreliable, and
5	that's the more sensitive compartment. And then you
6	have the issue about the time to course. That would be
7	relevant to the brain, but also would be relevant to
8	the RBC, if they did RBC properly. We would still have
9	to make sure you're in the dermal study that you
10	have the right kind of peak measurements and things
11	like that.
12	DR. BUNGE: Let me clarify it then. So,
13	the fact that so, you've decided that the red blood
14	cell assay is the key one. And so if that is deemed
15	unreliable then the other issues aside is still the
16	fact that the brain data seemed to be consistent and
17	has a dose response and so forth, you wouldn't use it
18	even if the time course wasn't a separate issue?
19	DR. LICCIONE: Right. We would we
20	would want
21	DR. BUNGE: I mean, you made the
22	decision that the red blood cell is the assay that
23	matters here?
24	DR. LICCIONE: Right.
25	DR. BUNGE: Okay.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 25
1	DR. LICCIONE: That's the most
2	important.
3	DR. BUNGE: Now, if I can, then, because
4	I want to be sure that I understand better the rational
5	for the time course data. And I think that could be
6	best explained is if you could explain what data you
7	would have needed to make it possible to use the
8	dermal-tox study you believe? What was missing
9	just saying time course is not helpful. We need to
10	know a little more specifics about what sort of time
11	course information you required?
12	DR. LOWIT: Typically specifically,
13	from the carbamates, we like to have you say time
14	course but measurements within that peak inhibition
15	and recovery phrase like I showed yesterday. So,
16	for other dermal studies for carbamates, we have
17	measurements taken, say for example, at fifteen
18	minutes, thirty minutes, you know, every fifteen
19	minutes for the first, at least, hour to two hours.
20	DR. BUNGE: Can you identify whether you
21	mean post exposure?
22	DR. LOWIT: Yes, post exposure.
23	DR. BUNGE: Or how about the length of
24	the exposure?
25	DR. LOWIT: Six hours. Six hours of



- I	EPA MEETING 02/06/08 CCR# 15796-2 Page 26
1	exposure. So, like it was done here. But then we
2	would need the fifteen minute post exposure
3	measurements so that we can define the peak inhibition
4	and the recovery phrase.
5	So, like I said yesterday, for this dermal
6	study, we have a snap-shot in time. And we don't know
7	where that fits. So we don't know if these inhibition
8	data that we have now for brain is the peak or if we're
9	coming back off the peak, in order to be protective.
10	DR. BUNGE: Can I ask you a question
11	then about the six hours? Why not eight, why not ten,
12	why not four or two, is there a reason for the six?
13	DR. LICCIONE: Well, the typical
14	well, the guideline studies requires asks for six
15	hour exposure just by convention. That's been
16	considered usually relevant for an eight hour exposure
17	roughly. They could do it longer if they wanted to.
18	But the guideline specifies six.
19	DR. BUNGE: Right. I didn't know that.
20	I'm more familiar with the dermal absorption guidelines
21	then the dermal-tox guidelines. Thank you. Those are
22	my questions.
23	DR. HEERINGA: Dr. Brimijoin?
24	DR. BRIMIJOIN: This is a real quick
25	follow-up.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 27
1	Do the guidelines also specify that you want
2	the fifteen minutes, the thirty minuets, the one hour,
3	etcetera?
4	DR. LICCIONE: The guidelines don't
5	specify that specifically. However, in the dermal-tox
6	guidelines do say that you should consider formal
7	pharmacal-kinetics and what you know about the
8	information about the chemical. So knowing that this
9	is a rapid reversible inhibitor and that reactivates,
10	and that we see this to be an issue with the oral
11	studies, why shouldn't it be pertinent to the dermal,
12	as well. Because the dermal pharmacal-kinetics might
13	be actually a little more complicated, because some
14	evidence that we have on the dermal absorption although
15	be it limited on carbofuran is that it follows more the
16	it doesn't follow fixed law diffusion. So it could
17	be a little more complicated then the oral absorption,
18	which is just rapid.
19	So that that should be included in the
20	assessment of the Cholinesterase inhibition in dermal
21	if you really want to get down to the bottom-line where
22	you're looking at the time course and being able to
23	reliably measure the cholinesterase inhibition.
24	DR. HEERINGA: Just a reminder to all of
25	the panelists and the speakers. State your name for



EPA MEETING 02/06/08 CCR# 15796-2 Page 28 1 the record so we could that on the transcript. No 2 problem though. 3 Dr. Brimijoin? 4 **DR. BRIMIJOIN:** That was essentially my 5 question, and I think you answered it. And, in fact, 6 it wasn't in the guideline that they must do this. It 7 was a rather vague understanding and 8 DR. LICCIONE: Correct. But it's open 9 to -- so that anyone that really wants to do it can do 10 good science. 11 DR. LOWIT: The -- I have one comment 12 about the guideline issue. The guidelines are meant to 13 be flexible. They're not meant to be recipes to 14 follow. Carbamate studies tend to come in with time 15 course. FMC did time course with the oral studies. Ιt 16 would make sense to do some sort of time course. 17 DR. HEERINGA: Dr. Bailey and Dr. Macdonald. 18 19 DR. BAILEY: Good morning. I wondered 20 if I could see slide number -- it's on page 16, or 21 slide 16? 22 (WHEREUPON, there was no response.) 23 DR. BAILEY: Last night when we left we 24 were looking at some graphs. 25 **DR. HEERINGA:** Of what?



EPA MEETING 02/06/08 CCR# 15796-2 Page 29 1 DR. BAILEY: Oh, yes, right here 2 (Indicating). 3 DR. LOWIT: For which study? 4 DR. BAILEY: That was -- the PMD 17, the 5 carbofuran, and it was just before the carbofuran acute 6 database. Okay. Thank you. 7 These are two statistical questions. I believe this is a plat of means here; is that correct? 8 9 And the dots represent means? 10 DR. REAVES: Yes, that's correct. 11 DR. BAILEY: Okay. And can you tell me 12 how many number were used to compute those means? 13 DR. MOSER: Yes. Good morning, Ginger 14 Moser. 15 We had, in that study, ten animals in each dose group. And the motor activity and both 16 17 cholinesterase were measured in the same animals. So it was ten animals per dose. 18 19 DR. BAILEY: Thank you. 20 DR. MOSER: And those are standard 21 errors shown. 22 DR. BAILEY: And I'm curious why the 23 lengths of the bars are so different as you go around the different means? 24 25 DR. MOSER: I'm assuming you're talking



	EPA MEETING 02/06/08 CCR# 15796-2 Page 30
1	about the motor activity data. Because that's really
2	the one where the variability changes so much of the
3	doses?
4	DR. BAILEY: Yes, I am. But this is
5	characteristic of a lot almost all of the graphs
6	that I've seen.
7	DR. MOSER: What tends to happen is when
8	you get to the higher doses, for instance with the
9	motor activity, pretty much all the animals are down
10	around zero and so you do end-up having less
11	variability when you get at the lower doses or in the
12	controls. You can look at the controlled values, even
13	though that's a hundred percent, that's the average of
14	the, you know, the main control, and you can see there
15	that the motor activity in the PMD 17 animals are much
16	more variable and that rank that variability is the
17	same in the lowest dose animal of animals. But then
18	as you go up in dose, and you start having the effect
19	of the chemical, they become more consistent as they
20	get down to zero, which of course you can't get below
21	zero.
22	DR. BAILEY: Yes, and that's a I
23	understand that. That's a very good answer. But then
24	on slide number 12 then I see that that doesn't
25	seem to hold that was the slide I'm referring to



EPA MEETING 02/06/08 CCR# 15796-2 Page 31 1 is carbofuran acute database oral -- the slide just 2 before that section? 3 It's the time course data? 4 DR. REAVES: For which? The FMC study? 5 Or the EPA study? Or? 6 DR. BAILEY: I'm sorry. I've lost track 7 from where we were yesterday afternoon. Let -- the one 8 in the middle would be fine. So some of these -- now, 9 here again -- they're quite different lengths. It's 10 indicating the variability is -- of the estimation of 11 those means is quite different. No matter -- sort of 12 throughout the range and during the time course. I've 13 seen this in many of your graphs, and I'm just curious 14 as to why those -- there's so much variability? 15 **DR. MOSER:** I think one of the answers 16 could be provided by FMC, but I know that as you saw in 17 the tables with what they call the DNRs and the cases 18 where they had to throw out the data completely. 19 Sometimes the sample size would go from ten to maybe 20 only four, and I believe those are still standard 21 errors. And so it's heavily dependent on the sample 22 size. So, it -- I don't -- those are my data of course, but I know that there were many cases where 23 24 some of those groups only had two to three animals, and 25 other groups for some reason didn't have as many data



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 32
1	points thrown out and they may have eight, nine or ten
2	animal, and so of course the standard error is going to
3	be much lower. I believe that to be the case to at
4	least contribute to that those differences in the
5	variability.
6	DR. REAVES: And maybe later on today,
7	FMC could answer more questions around their specific
8	data.
9	DR. HEERINGA: I think that's fair to
10	assume. And I think an explanation of not only the
11	natural variability in the original measurements, but
12	the changes in sample sizes resulted the DNRs and the
13	development.
14	DR. BAILEY: Right. Though our concern
15	is does this just does this represent my question
16	about reliability in the data or is this, in fact,
17	reflect an underlying biological process that's going
18	on?
19	The second question I had back to the
20	first draft we were looking at and the mark on the
21	scale lines was in percent change, and I'm concerned
22	about using percent as the scale as the scale,
23	because you could go a ten percent change could be
24	one hundred on the basis of a thousand if the units are
25	in the thousands. You'd take ten percent of that



	EPA MEETING 02/06/08 CCR# 15796-2 Page 33
1	would be a hundred, but if the basic levels are at ten,
2	the change would be only one unit. And isn't the
3	actual units that it's measured in of interest to
4	biologists? Or is the percent change around a thousand
5	or is it around units of, you know, ten units or
6	something? That was my second question about aren't
7	we interested in terms of the actual units, as well as
8	the percent change?
9	Thank you.
10	DR. MOSER: We are interested in both.
11	And because of that, the statistical analysis are
12	always conducted on the actual data the raw values.
13	The reason we put everything as a percent control for a
14	lot for these comparative graphs, was because there
15	is such difference in the control values. For
16	instance, the brain Cholinsterase is, you know, the
17	numbers that we get for the brain Cholinsterase is
18	about ten-fold that what we get for the red blood
19	cells. So to put the actual raw values on the same
20	graph it would look, you know, you would have to change
21	the scale and it would be very difficult to compare.
22	But the statistical analysis are always
23	conducted on the raw values.
24	DR. BAILEY: One last comment. Then
25	maybe you could use both axis on the right vertical



	EPA MEETING 02/06/08 CCR# 15796-2 Page 34
1	axis, you could put down there what their scale is and
2	then people could see both what the actual units are.
3	DR. MOSER: Well, that would be possible
4	
5	DR. BAILEY: Thank you.
6	DR. MOSER: But would be difficult with
7	the motor activity as well, but if you care to see
8	those data, you know, the raw data at some point, we
9	could provide it. But there are differences obviously
10	in the control values. Especially and also across
11	ages. The younger animals have much less brain
12	Cholinsterase activity then the adults do.
13	DR. HEERINGA: Dr. Setzer?
14	DR. SETZER: Yeah, this is what from
15	the U.S. EPA If I could expand on that just a little
16	bit First of all, when we're trying to put different
17	say data from different age groups or whatever on the
18	same graphs, what Ginger just said is exactly right.
19	You really want to represent that as percentage control
20	just so you can see things because the background
21	levels change a lot.
22	Secondly, in terms of the biological effect
23	or the significance of the biological effect, since
24	this is since this is an enzyme and it sort of it
25	tends to act sort of multiplicatively. So what matters



	EPA MEETING 02/06/08 CCR# 15796-2 Page 35
1	is relative changes from backgrounds. So it really
2	doesn't matter what I mean, if you were going to
3	actually try to build a mathematical model of recovery
4	of nerve function, you certainly would want to know
5	absolute units. But if you want but if you're
6	trying to get an idea of the relative effect, what you
7	really care about is the fractional change. So one
8	percent one percent is different from ten percent,
9	but the actual units you use aren't so important.
10	When we do the analysis for these data
11	regardless of how we're doing them, we always work on
12	the original scales and because obviously sort of
13	re-scaling like that can be risky. But and if
14	you're not careful can introduce correlations you've
15	got to then deal with in the analysis. But for
16	representational purposes, we use percent change, and
17	that's actually the right way to think about it
18	mechanistically as well.
19	DR. HEERINGA: Thank you, Dr. Setzer.
20	Dr. Macdonald?
21	DR. MACDONALD: Yesterday, we saw a very
22	useful table entitled EPA and FMC Net Analysis
23	Estimates for Juvenile and Adult Rats. Page 25. Next
24	time, it would help if you would numbered the
25	numbered the individual slides. It was just before



	EPA MEETING 02/06/08 CCR# 15796-2 Page 36
1	the end of section three.
2	Yeah, I think this is very useful. And I
3	think this is very important for our discussion of
4	charge question one in human health and I would find it
5	really useful if I could have a list showing the source
6	of each of those numbers. Because I know they've come
7	from various various sources. But it would really
8	help if I could find out where each one came in the
9	background material so we can have a discussion of that
10	when we get to charge question one.
11	DR. LOWIT: Can I ask a clarification on
12	what you mean by source?
13	MR. MACDONALD: Sure.
14	DR. LOWIT: Do you mean which of the
15	mountain of papers we have?
16	MR. MACDONALD: Yeah.
17	DR. LOWIT: Those numbers came from
18	or the source being which data which studies
19	MR. MACDONALD: No, I
20	DR. LOWIT: including the numbers?
21	MR. MACDONALD: Where can I find them in
22	the pile of paper?
23	DR. LOWIT: Okay.
24	MR. MACDONALD: You see at the moment,
25	being a distrustful statistician, I won't even I'm



	EPA MEETING 02/06/08 CCR# 15796-2 Page 37
1	not even willing to assume there aren't typos on that
2	table. So, as well as just making sure that the
3	numbers got transcribed correctly, I'd like to know
4	where each one came from, and then, if I could find it
5	in the background material, I can get some idea of the
6	reliability of each of those numbers, which makes the
7	comparison easer to do.
8	DR. LOWIT: I think we know roughly
9	where they come from, but I can't quote you the titles
10	right this second. At the break, we'll talk about some
11	titles.
12	MR. MACDONALD: If we can have this
13	if I could see this before we have to prepare for
14	charge question one and Human Health that would be
15	really useful.
16	DR. HEERINGA: Dr. Lowit, is that
17	something that you can do I guess in a reasonable
18	period of time?
19	DR. LOWIT: It should only take a few
20	I hope it should only take a few minutes, but
21	there's a mountain of stuff there. I'm pretty sure it
22	will only take a few minutes.
23	DR. HEERINGA: It certainly is a
24	reasonable request.
25	DR. LOWIT: Very much so.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 38
1	DR. HEERINGA: And I think that's
2	given the amount of material I think certainly the
3	comparative tables are very useful, but to have this
4	side by side and then others the opportunity to
5	actually go to those original sources and make sure
6	that he understands.
7	DR. LOWIT: As a point just to make
8	sure that we give you what you want, Dr. Macdonald and
9	this may be for the whole panel because you each
10	come to the table with a different skill set. Are you
11	just interested in the let's see the code and the
12	stats behind the numbers? Or you're interested more of
13	the summary information and that sort of thing?
14	Because they may be two different places.
15	DR. GRUE: This is Dr. Grue. I'm kind
16	of interjecting because he can't help it.
17	DR. LOWIT: I'm thinking that you want
18	something different than he does.
19	DR. GRUE: I think these tables that
20	you're showing here are very nice for a talk for sort
21	of presentation of data for leading an audience
22	through your thinking process. I think we're going to
23	be asked to get at the nitty-gritty, and I think you
24	should treat these tables the way you would do if you
25	were submitting this for a peer review publication.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 39
1	And, in such a case, a table would come with a detailed
2	legend that would indicate where the numbers come from,
3	which study, etcetera. I think that would help Dr.
4	Macdonald and the rest of us.
5	DR. LOWIT: Okay. If you want
6	something like that it will take longer than the break.
7	But certainly by the time certainly we can
8	probably do it this evening or maybe first thing in the
9	morning.
10	DR. HEERINGA: Dr. Macdonald?
11	DR. MACDONALD: Yeah, the other picture,
12	I'd like a little bit more explanation of, which I
13	can't locate it in mine. It was Dr. Setzer's work on
14	giving you had a grey band around the fitted line
15	indicating the uncertainty in the extrapolation. And
16	it would be good if you could give us a little more
17	technical detail on how you did that calculation. It
18	would save us having to do it.
19	Yes, that one. Yeah, that's very pretty.
20	Thank you.
21	DR. SETZER: I'll see if I can submit it
22	somewhere okay, let me remember this. The issue
23	okay, what we have here are predictions of inhibition
24	based on the dose response model in the PND 11 data set
25	in red blood cell and in brain. So we have two



	EPA MEETING 02/06/08 CCR# 15796-2 Page 40
1	different dose response models predicting brain
2	activity from those you derive inhibition. The
3	so the solid line through the middle is just is just
4	the prediction based on the maximum likelihood of
5	approximate maximum likelihood estimates for those
6	for the parameters for those models.
7	The little cloud on either side the intent
8	here was to sort of get an indication of the relative
9	the relative uncertainty and estimates of BND 10 and
10	BND 50 on these curves. So the way the clouds were
11	generated were by drawing a sample of parameter
12	estimates with multi-variant normal distribution with
13	mean and covariance matrix derived from the maximum
14	likelihood affixed to the data. Since I didn't
15	actually calculate Cholinesterase of that distribution,
16	that simply two draws from that distribution. Again,
17	it wasn't intended to be quantitative, but suggested.
18	So it's two hundred draws from those distributions, but
19	for the red blood cells is the gray and the brain is
20	the light blue. I should say Carolina blue, I guess.
21	DR. HEERINGA: Yes, Dr. Lu?
22	DR. LU: Just quick question. Could you
23	comment on the use of six percent dermal absorption
24	versus 8.8 percent as actually concluding the paper you
25	cite in the document?



EPA MEETING 02/06/08 CCR# 15796-2 Page 41 1 The six percent dermal absorption reverses 2 8.8 --3 DR. LOWIT: We're bringing someone else 4 to the table. 5 Make sure you identify DR. HEERINGA: 6 yourself. 7 DR. LICCIONE: John Liccione, oh, pardon 8 me, John Liccione from HEV. 9 Of the six percent from dermal absorption --10 what's your question? 11 DR. LU: Because you refer to a paper 12 that published earlier 13 DR. LICCIONE: Right. 14 DR. LU: -- which did an animal study on 15 dermal absorption. And the conclusion in the paper, as 16 I remember, I read through is that it was about twelve 17 percent for the juvenile rat and about eight point 18 eight percent for the adult rat -- the absorptions, so 19 in the article I couldn't find six percent anywhere. 20 DR. LICCIONE: Okay. I could show you 21 -- in fact, I've got the paper her and I can actually 22 show you the actual chart. It's one of the tables 23 where they show the six percent actually goes with the 24 24 hour measurement. Because there was no eight hour 25 or ten hour measurement that we would use for work or



EPA MEETING 02/06/08 CCR# 15796-2 Page 42 1 So it's in the table and it was the one -- where risk. 2 they looked at one dose for a certain amount of time. 3 And the absorption is greater in younger rats as you 4 mention. However, for work or risk, we usually use the 5 adult number. But I could go get the 6 DR. HEERINGA: May I suggest that you 7 just have a copy made to provide to him. 8 DR. LU: Yeah, the copy is actually on 9 the cd. 10 DR. LICCIONE: Right. I could actually, 11 if you'd like just show you the exact 12 DR. LU: Okay. Sure. That would be 13 great. 14 DR. LICCIONE: I'd be more than 15 grateful. 16 DR. HEERINGA: Dr. Bunge? 17 DR. BUNGE: So just to clarify, the six 18 percent number was from the adult rat? 19 DR. LICCIONE: Exactly. 20 DR. BUNGE: After a twenty-four hour 21 exposure? 22 DR. LICCIONE: Right. We did not have 23 an eight to ten -- ten hour exposure, which we usually 24 use for adult work or risk. Because we typically 25 DR. BUNGE: Right. I understand that.



- -	EPA MEETING 02/06/08 CCR# 15796-2 Page 43
1	But on the other hand a dermal-tox study is a six hour
2	study; is that right?
3	DR. LICCIONE: That's correct.
4	DR. BUNGE: Okay. You do have a six hour
5	dermal absorption number in that paper. Was there a
6	reason to not use the six hour number since you would
7	have normally used a six hour dermal-tox results if
8	you'd had the time course data network to make it feel
9	comfortable in your risk assessment?
10	DR. LICCIONE: I'm going to turn it over
11	to the author of the actual study PV could explain
12	more.
13	DR. HEERINGA: Please introduce
14	yourself.
15	DR. PRAKASHCHANDRA: P. V. Shab, USEPA.
16	I think the reason the six hours that I did not use is
17	that in this study, the skin bound residue couldn't
18	actually remaining on the skin was considered as an
19	actual dose. Typically, the EPA guideline requires six
20	hours exposure, washing and then we follow it through
21	forty-eight hours, seventy-two hours depending on that.
22	And look at the activity in the urinary excretions.
23	That will help us in deciding whether the skin bound
24	residue is acerbic, acerbic or not. In this study, the
25	data did not the skin was not washed. The skin



	EPA MEETING 02/06/08 CCR# 15796-2 Page 44
1	bound residue was considered as an incidental. So to
2	be on the conservative side twenty four hours later
3	were used which is six percent in the adult.
4	DR. BUNGE: If I can follow up, I have
5	further at least one further question. If I recall
6	the paper correctly, it says that in six hours,
7	seventy-five percent of the absorbed dose had been
8	eliminated in urine. And, so, you've it seems as
9	though the dose we're assuming the six percent dose
10	that was observed over those twenty-four hours was all
11	absorbed as one bolus when we do the risk assessment.
12	Whereas we know from your data in the paper that in
13	that same six in a six hour period already, you
14	didn't you may have quoted the other number for the
15	twenty-four hour, but I don't remember it, but already
16	only 25 percent of that bolus is even still in the
17	body.
18	I don't know what how that would exactly
19	affect the risk assessment yet, because I haven't
20	thought it through that whole process, but would you
21	like to comment on the fact that in the risk assessment
22	calculation, we're using this twenty-four absorption
23	number twenty-four hour absorption number basically
24	assuming it's all introducing into the body or the
25	bolus even though we know that most of it, at least



	EPA MEETING 02/06/08 CCR# 15796-2 Page 45
1	three quarters of it, probably isn't there any longer?
2	DR. PRAKASHCHANDRA: The only thing the
3	data indicates that at six hours in an adult there was
4	two percent absorption. And in twenty-four hours we
5	had five point seven. So it looks like it's not a
6	bolus because we have a continued absorption appearing
7	in that.
8	DR. BUNGE: But in the risk assessment,
9	basically it's being assumed to be introduced as a
10	bolus. We understand that it's not, and your data
11	shows that it's not, but in the risk assessment the
12	assumption is six percent absorption, and then it's
13	that number is used based upon the oral, which is
14	assumed to be a hundred percent absorbed; correct?
15	DR. PRAKASHCHANDRA: Correct.
16	DR. HEERINGA: Thank you, Dr. Shab.
17	Other questions of clarification? Again, we
18	can return to some of this later.
19	Dr, Bunge, are you Dr. Brimijoin, I think
20	no, no. I'm turning to you because I think you're
21	probably are have questions of most of everybody
22	here. Are you satisfied at this point? And again, if
23	anything else comes up, let us know, we'll ask it.
24	Yes, Dr. Schlenk? Oh, that's Dr. Bunge.
25	DR. BUNGE: Having said I didn't have



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 46
1	anymore questions. Annette Bunge. I do have one last
2	one. I think it was the very last slide where you talk
3	about the dermal exposure for workers, and this is in
4	the risk assessment. And going from the 2006 risk
5	assessment to the 2007/08 risk assessment, and the
6	number that you're using now increases by two-fold, you
7	may have said why that was, but I missed it?
8	DR. REAVES: Right. In the 2006 this
9	is Melissa Reaves. In the 2006 risk assessment, we
10	only had the first FMC study to base our oral end point
11	for the dermal scenario. The same for the oral end
12	point from the CCA study. However, in 2007, we
13	received all the other oral data; the EPA data, the
14	second FMC/CCA study, and so new BMD analysis was rerun
15	with all the data, and the difference in the BMDs then
16	is two-fold.
17	DR. BUNGE: Okay. So, it's just the
18	difference in the oral
19	DR. REAVES: Right.
20	DR. BUNGE: calculation of the BMD?
21	DR. REAVES: Right. So there's more
22	data in the point oh two BMDL.
23	DR. HEERINGA: Dr. Schlenk?
24	DR. SCHLENK: Dan Schlenk. I just
25	wanted to follow-up on a question that was asked



	EPA MEETING 02/06/08 CCR# 15796-2 Page 47
1	yesterday before everyone left. I forget who maybe
2	it was Jim or somebody. But there was a question that
3	was asked the correlation between the RBC inhibition
4	of Cholinesterase with some of the motor activity, or
5	was there actually some Cholinesterase measurements
6	done in diaphragm or in the neuromuscular tissues, and
7	I think there was somebody who said that there was a
8	correlation somewhere. I went to the McDaniel and
9	Padia papers and I didn't see the only
10	correlation I saw was with motor activity. I didn't
11	see any correlation with sort of muscular enzyme
12	activity.
13	I was wondering has that been done? And just
14	so that I understand this, it seems to me because
15	it's very confusing because of all the different age
16	groups I think. But in that paper, at least the last
17	line says that brain Cholinesterase activities let's
18	see if I get this right says, these current data
19	support the use of brain Cholinesterase activity of all
20	RBC when evaluating neuro-toxicity for these chemicals.
21	Now, I assume that that's in the adult rats.
22	And then when I was looking at the
23	presentation yesterday, you have a presentation that
24	shows where the PMD 11 rats that motor activity was not
25	evaluated. So but brain and RBC data was or



	EPA MEETING 02/06/08 CCR# 15796-2 Page 48
1	Cholinesterase was. So, my question is, are you
2	extrapolating well, first of all, is there any
3	measurement of toxicity in the PMD 11 animals? And has
4	that measured toxicity been compared to the indicator
5	of exposure, which is RBC Cholinesterase? I guess
6	that's my question in PMD 11 animals?
7	DR. MOSER: This is Ginger Moser.
8	That's a great topic, and I could spend all morning
9	talking about it. But in the McDaniel paper, as you
10	say, we did the regression analysis with the brain
11	Cholinesterase and the motor activity, which is what's
12	up there right now. We actually did look at the same
13	regression with the red blood cell data, and the
14	correlation coefficient was a little bit lower. Now,
15	whether that was because of the higher variability in
16	the red blood cell data or is it just that it's less
17	correlated with motor activity it could be either
18	one you can't tease that out.
19	Some of the statements of the I had made
20	about corresponding to other types of motor effects or
21	other types of toxicity effects comes from some older
22	data that we published at least ten years ago. Mostly
23	with organic phosphates, and in particular,
24	chlorpyrophos. And in one paper we did actually look
25	at a lot of different kinds of in points, including



	EPA MEETING 02/06/08 CCR# 15796-2 Page 49
1	salivation and lacrimation some of the ergonomic end
2	points some of the other motor end points, as well as
3	tremors and fasciculations, and we did aggression
4	analysis with many different Cholinesterase measures,
5	including diaphragm, and including muscle, and
6	different areas of the brain, as well as plasma and
7	blood, and whole blood and red blood cell. And
8	basically, the bottom line from that was that the
9	there was no one one tissue Cholinesterase
10	inhibition that correlated much much better than
11	anything else. And because the Cholinesterase
12	inhibition is all kind of correlated within the same
13	animal anyway, I think that's part of the reason why.
14	And that was all on adults.
15	Now, when you switch to the younger animals,
16	PMD 17, we have used a lot because of the fact that at
17	PMD 17 the animals are mature enough to start showing
18	motor responses and that sort of thing. At eleven days
19	of age, they don't move. They're very little. The
20	nervous systems are very immature. And, in fact, it's
21	somewhat difficult to even see signs of toxicity in the
22	PMD 11 pups because, for instance, tremors is one that
23	I'm always a little skeptical about. If you've ever
24	watched a PMD 11 pup, when it tries to take a step it
25	will kind of shiver, and some people call that tremors.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 50
1	It's not tremors. It's, you know, just something that
2	they're doing. It's the way they're moving. They're
3	not very they don't have fine movement yet. The
4	nervous system is not myelinating at all. And, so, you
5	can't look at that. You can't look at motor activity.
6	Their cholinergic system is not well developed either.
7	So some of the cholinergic responses are sometimes not
8	there. So it's much more difficult to see clear signs
9	of toxicity until you get to the really high does where
10	you're getting out right convulsions and death and we
11	don't go that high. We don't want to.
12	So that's why in the PMD 11s, we have just
13	limited our analysis to the Cholinesterase inhibition,
14	and I think that that's why when other laboratories do
15	try to do some kinds of observations on those animals
16	it's variable a lot of it's going to depend on the
17	technician who's doing the observations. But maybe
18	they don't even understand the very limited repertoire
19	of the PMD 11 animal. So, therefore, we don't have
20	much of the toxicity data. We've never tried to do any
21	analysis of regression or correlations with
22	Cholinesterase inhibition in those animals.
23	I think that answers all your questions.
24	DR. SCHLENK: I think so. I just
25	just to make sure that so you're basically



	EPA MEETING 02/06/08 CCR# 15796-2 Page 51
1	extrapolating from the PMD 17 to the PMD 11 as far as
2	the toxicity's concerned? Because you only have motor
3	activity in the 17 animals, and you're assuming then
4	that the toxicity would be the same in the 11 animals.
5	Is that would that be accurate?
6	DR. MOSER: We're assuming that because
7	we see changes in the adults in a lot of different
8	affects we see changes in the PMD 17 animals at low
9	dose you know, variable low levels Cholinesterase
10	inhibition that there is some toxicity going on in
11	the PMD 11 that we can't observe. But there is so many
12	other things going on in that PMD 11 animal that you
13	need to predict. You still got the whole nervous
14	system is being developed, and we know that
15	Cholinesterase has a major role on the development of
16	the nervous system that we're not going to get into
17	developmental neuro-tox at this point. But, I mean,
18	the assumption is that you need to protect against the
19	very low levels of Cholinesterase inhibition in the
20	young just like you do in the older animals.
21	DR. SCHLENK: Okay.
22	DR. LOWIT: Can I answer add one more
23	clarification.
24	DR. HEERINGA: Yeah. I want to move
25	things along here at this point.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 52
1	DR. LOWIT: Sure.
2	DR. HEERINGA: Because I want to make
3	sure we're pressing on the point where we may not
4	even get public comment in. Dr. Lowit?
5	DR. LOWIT: I'm glad you're the chair.
6	We need to keep moving.
7	There's a context saying to the McDaniel
8	paper I just don't want to lose. That the McDaniel and
9	the Padia papers were developed in part of
10	accumulative to look at the class as a whole. But
11	certainly our experience has shown us that where
12	classes have patterns that each individual chemical
13	has it's own unique properties and unique
14	characteristics. So, take the conclusions on those
15	papers with the caveat that each chemical has it's own
16	properties.
17	DR. SCHLENK: Yeah. Actually, I looked
18	at the table that actually shows the piercing
19	coefficients for each chemical and actually that's what
20	I was basing my comments on is that table.
21	DR. HEERINGA: Dr. McCarty?
22	DR. MCCARTY: John McCarty. Just a
23	quick follow-up about the correlation here, and you've
24	shown some of the correlations, and you've also shown
25	Cholinesterase recovery in the rats. Is the same



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 53
	I'm assuming these are based on point estimates of
2	maximum inhibition. Is the same trend going to be
3	evident if we look at recovery? Will recovery of
4	behavior follow a similar time course as the recovery
5	in Cholinesterase activity based on this figure?
6	DR. MOSER: This is Ginger Moser, and
7	that's a very tricky question. Because it has been
8	shown that recovery of the behavioral of functional
9	deficits happens actually a bit more quickly then the
10	Cholinesterase recovery. Mostly the POPs because the
11	Cholinesterase inhibition lasts for so much longer.
12	But somewhat with the carbamates as well, and there are
13	other transient things that go on at the nervous system
14	synapse that are producing that recovery at a quicker
15	level.
16	DR. HEERINGA: Dr. Lowit, any last
17	DR. LOWIT: Yes, we're going to make
18	Bill Jordan, who's now sitting here next to me, wants
19	to provide a little bit of context around to help
20	the panel, before you cut us off.
21	DR. HEERINGA: Okay. And there will be
22	opportunities to return to this, because I think you
23	have summaries before the charge questions. Dr.
24	Jordan?
25	DR. JORDAN: Thank you, Dr. Heeringa.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 54
1	I understand that earlier in the discussion,
2	a question arose regarding the 21-day dermal toxicity
3	study in rodents, and some questions arose about the
4	basis for rejecting EPA's decision to reject that
5	study as a starting point for our analysis.
6	Our decision is grounded on concerns about
7	the methodology used in that study, which have been
8	explained. And I want to attempt to recover cover
9	that ground again. But another question arose about
10	whether it is appropriate to look at the human toxicity
11	human dermal toxicity study with carbofuran in order
12	to make some sense out of the 21-day dermal toxicity
13	study in rodents.
14	EPA has in place, as some of you will know, a
15	regulation regarding the consideration of human
16	intentional dosing studies. And we have evaluated the
17	human dermal toxicity study with carbofuran and
18	determined that we are not going to rely on it in our
19	decision making. That judgment, therefore, means that
20	we EPA have not cited that as part of our part
21	of the factors that we consider in evaluating the 21-
22	day dermal study in rodents.
23	However, if the SAP wishes to look at the
24	human study, we don't regard under our regulation that
25	EPA is relying on it. And if you think it is relevant



	EPA MEETING 02/06/08 CCR# 15796-2 Page 55
1	to evaluate the compare, for example, the levels in
2	human dermal toxicity study that elicited clinical
3	signs with levels in the 21-day dermal study that were
4	tested that would be permissible under our regulation.
5	DR. HEERINGA: Thank you, very much.
6	I guess, Dr. Bunge is taking notes.
7	DR. BUNGE: Just one clarification.
8	Under the Federal Advisory Committee Act, the two
9	separate functions of the two advisory committees are
10	distinct, and one doesn't revisit in a second federal
11	advisory committee of another advisory committee's
12	recommendations, so we're not going to discuss that
13	study at all during this meeting.
14	The human studies review board has already
15	made their decision. The agency's made their
16	recommendations, and those issues are not on the table.
17	DR. HEERINGA: Okay. At this point,
18	what I would like to do is we are about to enter the
19	period of public comment. And the period of public
20	comment if you just do the simple addition as
21	I've done on the agenda, which stretched for six
22	hours without any questions that obviously the
23	likelihood that there will be no questions is very
24	small. Not impossible, but probably small. So we'll
25	move right now to I want to call just a twelve



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 56
1	minute break to give people a chance to stretch and
2	everything's going to be shortened up. We're on march
3	time today. So, a twelve minute break. Let's meet
4	back here at 10:00 a.m., and we'll continue with a
5	period of public comments.
6	(WHEREUPON Session A was concluded and a break was
7	taken.)
8	DR. HEERINGA: Okay, welcome back,
9	everybody, to the continuation of the morning session
10	from the second day of our meeting of the FIFRA Science
11	Advisory Panel on Scientific Issues Associated with the
12	Agency's Proposed Action under FIFRA 6(b) of a Notice
13	of Intent to Cancel carbofuran.
14	At this point in time, we are at the period
15	of public comment. The period of public comment will
16	include a number of contributions from people who have
17	registered to speak with the Designated Federal
18	Official, Sharlene Matten. Presentations will be given
19	in the order established by Dr. Matten which, I
20	believe, is the order of initial requests to speak.
21	We begin with a series of presentations by
22	FMC that we expect to last about three and a half
23	hours. I think that's in presentation time, and I
24	suspect it will go longer than that with questions,
25	followed in order by other registered public



	EPA MEETING 02/06/08 CCR# 15796-2 Page 57
1	commenters.
2	If anyone is in the audience and has not had
3	the opportunity to register as a public commenter, if
4	you would like five minutesand that's sort of the
5	late arrival time limitplease see Dr. Matten during
6	the break or at noon hour. Otherwise, I think we're
7	set to being.
8	At this point in the process, I'd like to
9	open it up by turning to Dr. John Cummings of FMC
10	Corporation who will do introduction and overview on
11	new carbofuran use patterns and use production. Dr.
12	Cummings?
13	DR. CUMMINGS: Okay, thank you, Dr.
13 14	DR. CUMMINGS: Okay, thank you, Dr. Heeringa, and thank you to the panel for allowing us
14	Heeringa, and thank you to the panel for allowing us
14 15	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very
14 15 16	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning.
14 15 16 17	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this
14 15 16 17 18	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this morning is to present a brief presentation prior to the
14 15 16 17 18 19	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this morning is to present a brief presentation prior to the scientific presentations to set the stage for ourfor
14 15 16 17 18 19 20	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this morning is to present a brief presentation prior to the scientific presentations to set the stage for ourfor our comments and ourfor our scientific position.
14 15 16 17 18 19 20 21	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this morning is to present a brief presentation prior to the scientific presentations to set the stage for ourfor our comments and ourfor our scientific position. I would like to echo a couple of the EPA's
14 15 16 17 18 19 20 21 22	Heeringa, and thank you to the panel for allowing us the time on the agenda, because this is a very important action. And good morning. What I'd like to start with isis this morning is to present a brief presentation prior to the scientific presentations to set the stage for ourfor our comments and ourfor our scientific position. I would like to echo a couple of the EPA's opening comments from yesterday and would agree with



	EPA MEETING 02/06/08 CCR# 15796-2 Page 58
1	yesterday.
2	And the other comment I would like to echo
3	from the EPA's opening remarks yesterday is that
4	certainly, the SAP should consider all relevant and
5	currently available data in determining the nature and
6	magnitude of risk that carbofuran presents to public
7	health and the environment.
8	Also, as you heard yesterday, FMC, the
9	registrant, has submitted significant amount of
10	newnew data, new information that refines the risk
11	assessments, and following the scientific
12	presentations, hopefully, you will conclude, as we
13	believe, strongly supports the continued registration
14	of carbofuran in the United States. Said another way,
15	that it meetscarbofuran meets the FIFRA and FQPA
16	scientific standards for registration and re-
17	registration.
18	So, the format of the presentations today, as
19	Dr. Heeringa has mentioned, is that I'll be providing
20	aan introduction which primarily focuses on two
21	pieces. One is on the use of carbofuran, how much is
22	used and where it is used and the relevance for risk
23	assessment. And then, also, to focus in on registrant-
24	initiated mitigation measures that have occurred over
25	the past several years to mitigate potential concerns



	EPA MEETING 02/06/08 CCR# 15796-2 Page 59
1	as well as to detail, provide a little bit of detail,
2	on the proposed label as we'veas we've briefly
3	discussed over the last day to provide some context for
4	that as well.
5	Following the introduction, I think it
6	probably appropriate to pause after that, any
7	clarifying questions if theif the chair chooses to
8	do so, and then move into the scientific presentations
9	on avian risk, worker risk, human health and dietary
10	risk, as well as water risk, and you'll hear that from
11	a panel of experts which I'll detail in a few moments.
12	On this slide, really, the key message here
13	is that if you look at the table to the right-hand side
14	of the screen, carbofuran used to be widely used in the
15	late '70s, early '80s very widely on numerous crops.
16	If you look at it, for a typical year in the peak year
17	of sales was aroundtyptypical use was 10 million
18	pounds of active ingredient per year. And, again, this
19	was in the late '70s and early '80s.
20	Primarily due to market forces, the
21	introduction of alternatives andandand other
22	elements, this use has declined in 2006 to roughly 6
23	percent of its peak year sales. So, only 600,000
24	pounds of active ingredient per year.
25	This is important, I think, in consideration,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 60
1	as you heard yesterday from the incident reports and
2	other elements that the Agency presented. We certainly
3	do need to consider thisthis limit, very limited use
4	in the relevance of the incident reports, incident
5	reporting, that were pre-1995. Is that information
6	relevant? Andandand it is our position that that
7	probably should be weighted much less than the most
8	recent data post 1995.

 $\pi\pi\pi\pi$

9 As you see on this slide also, there is a 10 projected sales, and this is projected at about 300,000 11 pounds, only half of what is currently being used. And 12 this...I'll...I'll spend a little bit more time on 13 this, and this is really what FMC and many of our 14 experts project will be used in the future based on our 15 proposed label changes.

16 The...and, also as you heard from the Agency 17 yesterday, really, the 99 percent of this...of the use 18 of that 600,000 pounds currently being used is in the 19 flowable or liquid formulation. There is a very small 20 use of granulars, accounting for 2500 pounds, 2,500 21 pounds of active ingredient per year, and this was 22 arrived at with a...through negotiated settlement with 23 the Agency back in 1991. So, very limited use, and the 24 focus will be on the liquid formulation. 25 A question may arise from the panel on why is



	EPA MEETING 02/06/08 CCR# 15796-2 Page 61
1	FMC, the registrant, interested ininin retaining
2	carbofuran for 300,000 pounds of active ingredient per
3	year when we used to sell 10 million pounds, and that's
4	a very good question to ask. Really, there's two
5	primary reasons.
6	One is that we have gotten strong indications
7	from the growers, from the users of our product, that
8	there are essentially five uses that are critical.
9	There are no viable alternatives available out on the
10	marketplace today or in the near horizon. And,
11	certainly, from an economic perspective as the company
12	who sells this product, we see that there is an
13	ececonomic reason to continue that registration.
14	The other reason is we are firm believers, as
15	members ofresponsible members of the agricultural
16	chemical industry, that regulatory decisions should be
17	based on sound scientific principles, and I think
18	that's why we're all here today. And, certainly, as
19	you'll hear throughout the day, our position is that if
20	sound science is used, then carbofuran should be
21	registered, and, certainly, we are willingwe
22	arewe are interested in keeping this product on the
23	market because risks are acceptable. Okay? So, you
24	factor those two pieces in together.
25	Now, I mentioned the critical uses, and I'm



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 62
1	not going to spend a lot of time on this. However, I
2	think it's important as context.
3	Benefits assessments, both from a biological
4	and economic perspective, have been provided to the
5	Agency. They have not been provided to the science
6	advisory panel. However, there is extreme economic
7	value for retaining the following uses, that is, use on
8	corn, use on cotton. I'll spend a little bit more time
9	on that. Potato growers have indicated it's critical
10	for use in the Pacific Northwest. Melon growers and
11	sunflower growers have all said there is not a viable
12	alternatives, and there's significant information
13	that's been provided to the Agency to show the economic
14	and biological value of these productsof this
15	product on these uses.
16	Moving to the scientific partportion of
17	this discussion, when the interim re-registration
18	eligibility decision came out in 2006, August of 2006,
19	FMC assembled a world class panel of experts in these
20	four areas, avian, worker, acute dietary, and ground
21	and surface water, to advise us to say this is the
22	current risk assessment by the Agency. Assess the
23	scientific validity of their assumptions, recommend are
24	there other studies, data that could be developed to
25	refine this, and are there refinements in the



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 63
1	riskother refinements in the risk assessment that
2	would be useful in reducing the uncertainty and
3	improving the risk assessments.
4	As I mentioned previously, also in that time
5	period, experts were assembled to address the benefits
6	of these products as well, working closely with the
7	commodity organizations and the individual growers of
8	theseofof these commodities.
9	There have been significant mitigation
10	measures that have been put in place, and I think
11	thethe EPA did highlight some of these yesterday and
12	mentioned that FMC has implemented significant
13	mitigation measures over the years, over the last 20
14	years, primarily the firstI'm not going to walk
15	through these individually, but the first five bullet
16	points, really, I think the Agency had similar
17	presentation yesterday indicating that FMC has
18	initiated an effort to mitigate any concerns in
19	potential vulnerable areas on risks for carbofuran to
20	reach groundwater and surface water.
21	And many of these are geographic
22	restrictions, reducing number of application rates,
23	reducingor, I'm sorryapplication rates and
24	numbers of application rates, and the geographic
25	restrictions being focused on vulnerable soils.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 64
1	Again, these arethese have been
2	implemented. They are on the current label, that is,
3	in the marketplace today.
4	Shifting to worker exposure, the next to last
5	bullet point on the slide before you, all furidan,
6	carbofuran-containing products, areliquid products
7	are in state-of-the-art mixing and loading closed
8	systems. You'll hear a lot more about that when
9	ourour panel of experts from workfrom the worker
10	risk assessment come up to show that, really, there is
11	minimal exposure tominimal occupational exposure to
12	the workers.
13	Also, last but not least, there is an
14	extensive product stewardship program that FMC heads
15	up, including brochures, extensive education programs
16	out for the users of our products. Unfortunately, with
17	the time today, we don't necessarily have a lot of time
18	to cover that, but it is extensive.
19	Unfortunately, as you look at this list of
20	already implemented programs andand label changes, a
21	lot of these mitigation measures have not been
22	accounted for in the current EPA assessment that's
23	beenthat's before you at this point and really led
24	to overly conservative assumpconclusions from our
25	perspective.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 65
1	Let me shift now. What I just talked about
2	was the mitigation measures that have been implemented.
3	Let me shift to sayingtoto the major items of the
4	proposed label that has been briefly discussed over the
5	past day.
6	Essentially, what FMC has proposed is to only
7	retain five uses, those critical uses that I mentioned
8	before, in the current label. That results in the
9	removal of 12 federally registered uses, removal of 13
10	state registered, what's known as special local need
11	uses, as well as additional prohibitions and
12	restrictions in areas essentially vulnerable
13	tovulnerin vulnerable water bodies, and I'll
14	detail that in a little bit more ininin a future
15	slide.
16	So, if we look at the usesand this is just
17	more of aa graphic representation of what uses are
18	being proposed to be retained. If you look on the
19	right-hand side of the slide, there are those five uses
20	which I touched on before, melons, sunflowers, field
21	corn for post-application only, potatoes in the Pacific
22	Northwest, and the pending cotton use.
23	And I do want to pause there briefly to just
24	mention someprovide some clarification, because
25	there wereDr. Bradbury this morning did mention the



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 66
1	cotton use not being registered. I just want to
2	provide some clarification on the situation there.
3	If you look on the left-hand side of the
4	screen, there is a registered use on cotton at plant.
5	We are proposing to cancel that use. The pending use
6	which EPA petitioned EPA for adding the use of cotton
7	foliar treatments for control of aphids in 1995. That
8	petition has been pending at the Agency since 1995.
9	Okay?

10 We have included that in our proposed label, 11 and after we submitted the label in early December or 12 mid December of this past year to the Agency, we 13 received notification from the EPA that there was a 14 deficiency in that pending petition. Okay? So, we 15 are...we feel it is our right to include cotton, 16 because it is a pending use. It is not a new 17 submission. We're not proposing to add a new use. It 18 has been pending at the Agency for the past 13 years. 19 Included on the retained...in the proposed 20 label are also the phase-out crops which the Agency has

21 proposed to phase out over four years as well as, as I 22 mentioned before, the existing granular uses that are 23 very limited, limited to 2500 pounds per year. 24 Also included on the...included on the

25 proposed label are further limitations, mitigations, to



	EPA MEETING 02/06/08 CCR# 15796-2 Page 67
1	address potential for surface and groundwaterwell,
2	for carbofuran reaching surface and groundwater. These
3	are based on our panel of experts which you'll hear
4	from shortly, looking at the data, identifying
5	vulnerable areas, and we took those recommendations and
6	included those conservative mitigation measures on our
7	proposed label.
8	They include geographic restrictions, best
9	management practices, and they are consistent in as you
10	look at currently registered labels of other
11	carbamates. These mitigation measures are consistent
12	with other carbamate labels.
13	The end result, from our perspective and in
14	our conservative risk assessments, that these result in
15	drinking water concentrations estimated below the level
16	of concern by the Agency.
17	And I'm not going to go through this slide in
18	detail. You have this packet before you. But,
19	essentially, this highlights the restrictions that we
20	are proposing on the label for bothvulnerable both
21	ground and surface water areas. They include
22	prohibited applications within a certain distance,
23	buffers, in specific counties and, in some cases,
24	statewide, to address surface water areas. And from a
25	groundwater perspective, there are statewide



	EPA MEETING 02/06/08 CCR# 15796-2 Page 68
1	prohibitions, as you canas you can read from the
2	slide in front of you, as well as applications being
3	prohibited within a certain distance, well setbacks,
4	from all wells in several states and several counties
5	that have been identified by our experts as being
6	potentially vulnerable.
7	The final mitigation measures in the proposed
8	label address avian concerns, and, again, our avian
9	effects advisory panel, again, which you'll hear much
10	more in detail in a few moments, have done conservative
11	risk assessments onon the five critical uses as well
12	as alfalfa. And the inclusion for alfalfa is it is a
13	very economically important critical use. However,
14	based on ourour avian effects advisory panel's
15	recommendation, we are proposing to remove alfalfa
16	because of the risk assessment did identify relatively
17	higher risks on gorge feeding waterfowl.
18	Generally, the remaining uses, the five
19	critical crops, have low or de minimis avian risk, and
20	you'll hear much more in detail from the avian panel
21	shortly.
22	Let me just introduceand this is the order
23	ofof presentation. Let me just introduce thethe
24	principal presenters and the members of these various
25	advisory panels.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 69
1	The first presentation will be on avian
2	effects. Dr. Dwayne Moore and Dr. Keith Solomon will
3	be presenting on behalf of this avian effects advisory
4	panel, made up also of Lou BeDr. Lou Best and Larry
5	Brewer and Dr. John Geisy.
6	Dr. Solomon will bewill be reviewing the
7	additional studies that have been submitted by the
8	Agencyor bysubmitted by FMC, and then, Dr. Dwayne
9	Moore will be presenting the Liquid PARAM which was
10	briefly discussed yesterday.
11	That will be followed by a worker risk
12	presentation. Dr. Jim Lam will be presenting the
13	toxicology studies that will be the dermal tox studies
14	and theand our position on the appropriate
15	endpoints, and then, Dr. Jeffrey Driver will be
16	presenting the exposure and risk assessment for
17	workers.
18	The third presentation will be on human
19	health and dietary risk. Again, DrDr. Lam will be
20	presenting on the toxicology point of departure and use
21	of uncertainty factors. Then, Dr. Bob Silken will be
22	presenting a statistical analysis on this data, and
23	finishing off will be Dr. Robert Morris to again do the
24	exposure and risk assessments for dietary.
25	The final presentation will be fromwill be



	EPA MEETING 02/06/08 CCR# 15796-2 Page 70
1	from our water panel of experts, Dr. Engel, Dr.
2	Fawcett, and Martin Williams, addressing exposure and
3	risk assessments relating to ground and surface water.
4	So, prior to concluding, I just want to make
5	a couple of conclusionconcluding comments. As you
6	heard from the Agency yesterday, carbofuran has been
7	registered since 1969. FMC has been the sole
8	registrant in the U.S. for 40 years. We take very
9	seriously our responsibility to comply with the law as
10	well as steward our products.
11	We feel confident, based on real-world
12	experience using carbofuran for the past 40 years, that
13	it can be used safely in the United States and does not
14	pose unreasonable adverseunreasonable risks or
15	adverse effects to human health and the environment.
16	As you will see over the next several hours
17	as we present the additional data and the refined risk
18	assessments, we further believe this more strongly
19	supports, in addition to thethe 40 years of use,
20	that carbofuran does meet the FIFRA and FQPA regulatory
21	standard, and its products should not be canceled.
22	At this point, I'll turn it back to theDr.
23	Heeringa.
24	DR. HEERINGA: Thank you very much, Dr.
25	Cummings. Any quick questions of clarification for Dr.



EPA MEETING 02/06/08 CCR# 15796-2 Page 71 1 Cummings? Yes, Dr. Brimijoin? 2 DR. BRIMIJOIN: So what happens to the 3 projected volume of use if the foliar treatment of cotton is added? 4 5 DR. CUMMINGS: That is actually included in those projections, yes. 6 7 DR. HEERINGA: Dr. McCarty and then Dr. 8 Montgomery. 9 DR. MCCARTY: One of the, quote, 10 special...special local needs uses is for Conservation 11 Reserve Program land. 12 DR. CUMMINGS: Yes. 13 DR. MCCARTY: I... in the documents, 14 there may be something there, but I haven't seen 15 anything about the extent or frequency that that's 16 permitted. Do you have any comment on when this...when 17 and how often this is used on CRP? 18 DR. CUMMINGS: I actually don't have 19 that information. I'd ask Dr. Carlson if he has...if 20 he'd like to come forward and address that. 21 DR. CARLSON: My name is Don Carlson... 22 DR. HEERINGA: Step up to the 23 microphone, Dr. Carlson. 24 DR. CARLSON: My name is Don Carlson. 25 I'm with FMC Corporation. My responsibilities are



EPA MEETING 02/06/08 CCR# 15796-2 Page 72 1 product development and registrations for carbofuran. 2 The answer to your question is that there is 3 relatively little use in the Conservation Reserve 4 Program at the current time. The primary use was for 5 control of grasshoppers, and there are other 6 alternatives for that particular use. 7 DR. HEERINGA: Dr. Montgomery had a 8 question, too. 9 DR. MONTGOMERY: Hello, this is Cheryl 10 Montgomery. I just have a quick question for you on 11 your slide that deals with amended label reflecting the 12 limited uses of carbofuran. 13 On the alfalfa, you specified on a slide 14 subsequent to this was being removed because of the 15 potential for gorge feeding of wildlife. I was 16 wondering, without going into detail, just kind of 17 categories, what the reasons for removal of...there was 18 quite a few removals that are here, and I was wondering 19 if you could give us some broad categories of reasons 20 why you are voluntarily removing these. 21 DR. CUMMINGS: Well, generally, there is 22 still limited use in some of these areas, but 23 generally, there are adequate alternatives, and in some 24 cases, there...they may be a identified as a critical, 25 very niche use of the product, very small volumes, but



	EPA MEETING 02/06/08 CCR# 15796-2 Page 73
1	in some cases, they may be aligning with some of
2	ourthe vulnerable areas that our experts havehave
3	identified, for instance, in Florida. There are some
4	uses that just fit the Florida use pattern that we're
5	proposing to remove. Okay?
6	So, I think broad categories, it's limited
7	use, adequate alternatives, and really, the predominant
8	geography where that would be used is we're proposing
9	to remove from the label. Those are kind of the
10	twotwo buckets.
11	DR. HEERINGA: Thank you very much, Dr.
12	Cummings. And I think at this point, let's move on to
13	the first of the scientific presentations, and I think
14	Dr. Keith Solomon of the University of Guelph is here,
15	along with Dwayne Moore, and Dr. Solomon will be up
16	first.
17	Panel members, II think Dr. Solomon can
18	confirm, but I'd let both individuals do their
19	presentations before we open it up for questions.
20	DR. SOLOMON: Mr. Chairman, panel
21	members, EPA staff, others, I am Keith Solomon from the
22	University of Guelph, and I'm here at the request of
23	FMC Corporation and a panel member of the avian panel
24	that advised FMC on risk assessment, additional
25	studies, and also modeling issues.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 74
1	So, next to me, is Dwayne Moore who will
2	present the modeling part of the presentation, but also
3	at the table, Lou Best and Larry Brewer. Larry Brewer
4	conducted many of the studies that were talked about
5	yesterday and that we will touch on briefly today. Lou
6	Best has extensive experience in field work and perhaps
7	best answer questions from the panel members in that
8	regard.

9 Dr. John Geisy has a longstanding teaching 10 assignment in China, and he sends his apologies for not 11 being able to attend.

12 The RED and the Notice of Intent to Cancel in 13 2006 and 2008 concluded that carbofuran poses an unreasonable risk to the environment based on effects 14 15 on avian species. In coming to this conclusion, EPA used a TIM 1 model which predicted high mortality in 16 17 some species of birds and was based on a number of 18 conservative assumptions.

19 The TIM 1 model which was talked about 20 yesterday is... is inappropriate, I think, for the 21 use...for risk...doing risk assessments on carbamate 22 pesticides, because, for one...just for one thing 23 alone, the time step involved is not...not appropriate. 24 But we did try to use the TIM 2 model, but, 25 unfortunately, could not get it to function on our



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 75
1	computers. The TIM 2.1 model which we heard about on
2	January 8th this year we have not been able to use.
3	So, based on that, we set up our own model
4	which Dr. Moore will talk to you about a little bit
5	later.
6	The avian effects advisory panel conducted a
7	refined risk assessment, and we started off by
8	identifying data gaps. We then commissioned studies to
9	fill these gaps. We developed a higher tier risk
10	assessment model, Liquid PARAM, and we also looked at
11	other lines of evidence from real-world studies and
12	incident data.
13	We have concluded that carbofuran can
14	continue to be safely used on all of the crops
15	considered in thisin the assessment. The exception
16	to thisand you heard about this earlierwas for
17	the unique situation where waterfowl gorge feed in
18	alfalfa, and this is now being removed from the label.
19	All of the documents that support our
20	discussions here today have been provided to the panel.
21	The slides are in hard copy. There are some overview
22	reports in hard copy, and there's also a CD which has
23	all the information onin PDF and other files.
24	There's also a copy of the model, if anybody's
25	interested in that.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 76
1	So, our objectives were to defineto refine
2	the risk assessment and to generate new data and also
3	to incorporate this in a more definitive model to
4	consider several lines of evidence, and this was based
5	on, as you heard yesterday, advice that came from
6	earlier saps in 2001 and 2004.
7	And for the studies that we developed, there
8	are no guideline studies here. These arethese are
9	really studies to understand the science and not yet
10	used widely, so no guideline studies, and at least in
11	my experience, if you take those protocols in to EPA,
12	they will decline to comment on them.
13	So, we did studies on avoidance repellence,
14	on the effect of dietary matrix, and rate of recovery
15	of cholinesterase, as you heard about from Robert
16	yesterday. We also incorporated in the model the
17	significance of time distributed feeding and increased
18	the number of use scenarios and also increased the
19	number of species in the model, as Dr. Moore will tell
20	you about later.
21	And these results were then verifiedthis
22	is perhaps a touchy word, verifiedagainst field
23	data, but if you go back to 1992 guidance on ecological
24	risk assessment, this is one of the points that they
25	make about models, that they can be verified against



	EPA MEETING 02/06/08 CCR# 15796-2 Page 77
1	field data.
2	Just to explain some of the issues that we
3	were looking here in terms of avian effects, when one
4	thinks of a bird and hot it becomes exposed and how the
5	carbofuran might get to the target site, there are a
6	number of steps involved in thisin this process. Of
7	course, the first of these is the uptake of the
8	material by the animal and repellence, whether it's
9	gustatory or symptomatic, can reduce uptake of the
10	material.
11	And then, the other fact, it's quite
12	different from a laboratory study where you dose an
13	animal with a single gavage dose. Feeding would be
14	spread over a period of time, short or long, depending
15	on the nature of the birds involved, but all of these
16	would change the way the material enters the organism.
17	Once in the gut, one can see that the
18	absorption rate might be affected by the matrix that is
19	present in the gut at the same time as theas the
20	substance, so if it's on food particles or in the water
21	that's consumed while the animal is feeding, the matrix
22	in the gut could reduce uptake into the body.
23	After that, metabolismand this is well
24	understoodcan remove the material from the blood and
25	the other organs, and then finallyand you can see



	EPA MEETING 02/06/08 CCR# 15796-2 Page 78
1	the diminishing size of the arrowssome material will
2	get to the target site, cholinesterase in the central
3	nervous system which, we know, recovers quickly via
4	hydrolysis of the carbomanated enzyme via K3.
5	So, this results, really, in ain a
6	diminishing of the potential for adverse effects
7	through all of these intermediate steps in the process.
8	These processes are additive and, possibly,
9	multiplicative. We don't know. But all of them appear
10	inin the real world, and there's a sequence that you
11	have to go through.
12	And the TIM 1 model really only addresses
13	metabolism. It doesn't address these other factors
14	that we've listed on this slide.
15	So, our first approach was to do a study on
16	repellence and avoidance, and this is not captured in
17	acute toxicity studies where a material would be
18	administered in a water bolus or an air bolus. And,
19	incidently, there's no formal guideline for this, but
20	there is an OECD draft guideline from 2003, and there
21	has been work done in the literature on this as well,
22	and we used this as guidance to develop the protocol
23	with a choice of uncontaminated and contaminated feed,
24	as you heard yesterday.
25	Mallard was used as a test species,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 79
1	consistent with the literature, and food consumption
2	and spillage was very carefully measured. And if you
3	need more detail on that, Larry Brewer will be able to
4	help you out there.
5	To basically go to the results fairly
6	quickly, what this shows here isfirst of all, you
7	heard yesterday that there was aa change in the
8	feeding pattern of the animals in both the controls and
9	the treated animals, the animals in thein the test.
10	Soand this is probably because of the increased
11	observation that occurred over the changeover time and
12	the animals reacting to the presence of humans in the
13	system, but it occurred in both the controls and the
14	test organisms.
15	So, what we did here was to take the initial
16	weight adjusted, because animals of different weight
17	consume different amounts of food, and we took the zero
18	day weights, and we did a mean reduction in food
19	consumption relative to the controls. So, this is
20	standard biological experimental technique, is to
21	compare results to control.
22	And what you see here is a very significant
23	reduction in food intake shown in these numbers
24	belowzero would be the controlwith increasing
25	exposure in the diet. We then took this data and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 80
1	modeled it on theon the presumption that turned out
2	to be correct, that there was a threshold of avoidance.
3	And this, on the y axis, you see the
4	reduction in food intake rate which is abbreviated as
5	FIR, and concentration in the diet in a log scale on
6	the x axis, and there's a threshold of repellence or
7	avoidance here at 3 mg/kg in the diet which translates
8	to 0.119 mg/kg body weight.
9	And thenso, this would not be considered
10	in the model below this threshold. However, exposures
11	above the threshold we would use thethe slope of
12	that regression there to factor this avoidance into
13	aa model which you'll hear about later.
14	We believe this was an appropriately
15	conducted study. One of the suggestions was to scatter
16	the food around on the surface to more directly mimic
17	the environment, but it's extremely difficult to get
18	accurate measurements if you do this or even if you put
19	it in numerous feeders.
20	If you do it on an hourly time scale which
21	would, we agree, would be very useful, the hourly
22	disturbance of the birds inin the cages would, I
23	think, have a greater influence on the results than the
24	actual chemical itself.
25	Starved birds, we don't believe it's



	EPA MEETING 02/06/08 CCR# 15796-2 Page 81
1	appropriate to use them. It distorts the initial
2	feeding rate, and it's not realistic. Birds in the
3	field would not starve themselves in anticipation of
4	the carbofuran application.
5	There's no learning of the location of the
6	food or contaminated food items, because the feeders
7	were switched each day to prevent that from happening,
8	and we heard yesterday some discussion about feeder
9	location bias, and there was no consistent propensity
10	to use left or right, and so, we had, I guess, right-
11	wing and left-wing birds in our system, and weI'll
12	show you the data for that in a moment, but this was
13	basically controlled for by switching feeders each day.
14	This is just a distribution of all of the
15	birds used in the study color coded. I apologize for
16	the Christmas tree-like effect here, but it'sso, the
17	birds that are on the right-hand side of that line in
18	the center, they were biased towards the right feeder
19	consistently over the study. On the other side, they
20	were biased towards the left feeder, and there's no
21	obvious relationship here to the treatments that they
22	were receiving or the control or the different doses in
23	thein the feed.
24	So, repellence andand avoidance, this
25	reduces the food intake rate at dietary concentrations



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 82
1	that are relevant to field exposures. It's not
2	applicable to gorge feeding waterfowl, andand we
3	have never claimed that orand we would not use it in
4	that situation anyway.
5	The reduced food intake rate did not lead to

6 mortality. The animals continued to eat, and they ate 7 both the treated and the untreated feed but at...at a 8 slower rate. The increased food...the increase that we 9 might expect in food intake rate at...after cessation 10 of exposure was only observed at the highest 11 concentration, and, again, this is consistent with what 12 you see in the literature.

I think also interesting is the fact there there was no weight loss in the birds. They didn't gain weight, but they didn't lose weight, either, so they were able to maintain at least their baseline metabolic needs over the period.

18 The next issue I'd like to address, a lot of 19 evidence here, is the absorption of carbofuran from out 20 of the food matrix. The food...the food matrix is 21 basically toxicologically inert, and any binding to 22 this or just the mere physical presence of a matrix 23 there will slow diffusion of any chemical 24 into...through the gut to the body wall and then, of 25 course, up...the subsequent uptake.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 83
1	So, both of these factors may reduce the rate
2	at which the chemical enters the body, and this,
3	obviously, can have a significant effect when you have
4	metabolism and recovery of cholinesterase operating at
5	the same time.
6	The animals were given a bolus dose in a
7	mixture, a slurry of water and food, by gavage. These
8	were compared to animals that were given a water bolus
9	which is common in toxicity testing. And this was the
10	hypothesis we were testing, is there a difference
11	between a feed bolus and a water bolus?
12	The controlyou heard some discussion about
13	controls yesterday. The appropriate control for this,
14	in fact, is the food matrix bolus, because this is an
15	unusual dosing technique. The water boluses are used
16	routinely, andand we know what they mean in terms of
17	acute toxicity testing, but the food matrix bolus here
18	was used as a control to make sure that the matrix
19	itself and the handling the birds were receiving was
20	not causing any adverse effects, and there were no
21	adverse effects in the control.
22	Then we look at the data showing initially
23	bobwhite quail and the increase in response to
24	increasing doses of carbofuran via the water bolus
25	route. When you give those same animalsor



	EPA MEETING 02/06/08 CCR# 15796-2 Page 84
1	notsorry, not the same animals, but when you give
2	bobwhite quail the slurry of the food matrix, you see
3	it shifts the toxicity values toto much higher
4	concentrations or doses, in this particular case.
5	You'll see no response in the matrix dosed animals
6	there and only the initiation of response at this
7	concentration here.
8	You see essentially the same effects in
9	mallards, although there were fewer doses tested here
10	because of availability of animals, but, basically, one
11	sees the same general pattern.
12	But when you take a percent mortalityand
13	this is in the bobwhite dataand you look at the dose
14	of carbofuran in mg/kg body weight which would be then
15	equivalent to the LD50 via a water bolus route, you'll
16	notice the data there with an LD50 of 2.64. When it's
17	mixed with a matrix, what you see is a different LD50.
18	Now, this doesn't mean that theand I'm now
19	teaching you to suck eggs here, I guess, but this does
20	not mean that thethat there's toxicity. It means
21	there's less exposure, and in conjunction with
22	metabolism, there is less material reaching the target
23	sites. So, 3.8 times less toxic.
24	This study, we believe, again was a good
25	quality study. There was no initial regurgitation of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 85
1	food. There were very careful procedures put in place
2	to observe this, a white paper put under the animal
3	cages so that anything that was regurgitated could be
4	seen. There was some regurgitation of opaque fluids,
5	not food matrix, and this was seen later and was
6	probably a symptom relatedin relation to the effects
7	of cholinesterase inhibition on saliva production, et
8	cetera.
9	There was a slight delay in symptoms in the
10	matrix fed birds, but, of course, you needed a much
11	higher dose in them anyway, but this was expressed
12	within the 1-hour time step that was appropriate to use
13	in Liquid PARAM, so this was used in the modeling.
14	So, the rate of absorption of carbofuran is
15	significantly reduced from a food matrix, and,
16	therefore, the use of acute toxicity test results such
17	as the traditional water bolus or oil bolus, LD50,
18	overstates the potential risks posed, and for this
19	reason, we used a dietary adjustment factor that Dr.
20	Moore will talk to you about in a minute in the Liquid
21	PARAM model.
22	The last issue I wanted to just introduce
23	quickly was the recovery of cholinesterase, and we
24	heard a lot about that yesterday afternoon and more
25	this morning. What this does is really gets around all



	EPA MEETING 02/06/08 CCR# 15796-2 Page 86
1	of these issues and focuses just on the target site
2	which there's a well-known process that occurs here
3	that you're already familiar with, but the key reaction
4	here is the hydrolysis of the carbomanated
5	cholinesterase which releases the serine hydroxyl to
6	allow the enzyme to return to its normal function, and
7	this is governed by K3.
8	This is dependent on the tertiary structure
9	of the enzyme itself, and the group, the carbamyl group
10	here, which is the same for most carbamates and is
11	consistent across many of the carbamates.
12	So, what you're really doing here is looking
13	at a combination, in a sense, of metabolism, because
14	the chemical is now in the animal, and the target site,
15	and this is important, because this is the target site.
16	This is the mechanism by which the chemical is directly
17	toxic. So, this integrates a very important effect
18	measure that is relevant to the assessment in point of
19	mortality.
20	So, in this study, we used animals that were
21	dosed with water, so there's no matrix effect, and the
22	brain cholinesterase, acetylcholinesterase, is measured
23	at time intervals after dosing, and then recovery
24	assessed against control values. So, plotting the
25	cholinesterase activity on the y axis in terms of brain



- Г	EPA MEETING 02/06/08 CCR# 15796-2 Page 87
1	weights and time since initiation of exposure, when you
2	look at the controls, what you see is a mean of around
3	12, with a 95 percent confidence interval going below
4	and above that, so that would be the range we would
5	normally expect to see the controls in.
6	At the lowest dose tested, we saw rapid
7	recovery into the control range. Atand this, with
8	increasing dose, became longer.
9	Now, the reason for the increased length
10	here is not because the cholinesterase is somehow
11	changing. It's because there's a combination here of
12	metabolism trying to catch up, and if there's a larger
13	amount in the body, if the enzyme is reactivated, then
14	there still may be enough carbofuran to re-inhibit
15	again which would lengthen the recovery time.
16	These recovery times were used to calculate
17	the half-lives, but it's perhaps interesting that the
18	half-life of recovery of cholinesterase is used as sort
19	of a forensic threshold, and in thein the trade, if
20	an animal is above half of the control value in terms
21	of brain cholinesterase, it will be likely to survive.
22	So, this would be an indication of no permanent adverse
23	effect.
24	So, using this relationship between the half-
25	life on the y axis and the dose on the x axis in mg/kg



	EPA MEETING 02/06/08 CCR# 15796-2 Page 88
1	body weight, we chose from this relationship a
2	conservative value of 4.4 hours as the half-life for
3	integration for recovery into the Liquid PARAM model.
4	So, it's a rapid half-life. It'sit's a
5	little bit conservative, and it's definitely quite
6	different from EPA's elimination half-life which is
7	based on metabolism in chickens that was used in TIM 1,
8	and that isit's probably inappropriate to use that
9	type of data for carbamates because of the very rapid
10	recovery of cholinesterase in those organisms.
11	So, with this, I would pass over directly to
12	Dr. Moore, and with the permission of the panel, we'll
13	hold our questions until the end of his presentation.
14	DR. HEERINGA: Thank you, Dr. Solomon.
15	Dr. Moore?
16	DR. MOORE: I thank you to the panel, to
17	the chairman, and interested observers for the
18	opportunity to speak this morning. My name is Dwayne
19	Moore. I'm with Intrinsik Environmental Sciences in
20	Canada. Asas with Keith and the rest of the panel,
21	I was asked by FMC to assist with the avian risk
22	assessment for carbofuran.
23	What I want to talk about over the next 45
24	minutes to an hour, very briefly, a little bit about
25	model development history, talk about the exposure



EPA MEETING 02/06/08 CCR# 15796-2 Page 89

1 assessment, and that would be the majority of my talk. 2 Will talk about model structure, the inputs, and also 3 spend some time talking about how we evaluated model performance. Then finish with discussion about the 4 5 risk characterization and results that we obtained, the 6 results that we obtained when we looked at better lines 7 of evidence, and then have some conclusions and 8 thoughts for the panel to consider.

9 Just for your information, the...the model 10 itself that I'm going to spend most of the time talking 11 about is described in, I would consider, in exquisite 12 detail in the...the refined risk assessment report that 13 was included in your package. It's Moore, et.al., 2007 14 is how I refer to that. If you're like me, you have a 15 social life...or don't have social life, you would 16 consider it exquisite, and otherwise, you would consider it excruciating. 17

The exposure assessment is described in chapter 3, the effects portion of the model is described in chapter 4, and the risk portion of the model is described in chapter 5.

A little bit of background, and you've heard some of this yesterday and this morning. TIM Version 1 was originally developed by EPA and submitted to the science advisory panel for review in 2001, and as you



	EPA MEETING 02/06/08 CCR# 15796-2 Page 90
1	heard yesterday, EPA believes that that review plus the
2	subsequent review in 2004 of a different version of the
3	model allows them to then us that model and not have to
4	worry about questions concerning model structure for
5	this carbofuran assessment that you're charged with
6	reviewing here today.
7	But I would like to suggest, at least, that
8	the mere act of reviewing models does not constitute
9	endorsement of the models. Lou Best and I were both
10	participants in those science advisory panel meetings,
11	and there was no endorsement of those models.
12	What there was was encouragement to continue
13	the model development. I think that's a very important
14	point. Avian risk assessment models for flowable
15	pesticides are just really getting going. That model
16	that was developed in 2001 was the first probabilistic
17	avian risk assessment model for pesticides, and so, as
18	you would expect with any young science, there is as
19	need for continued development, maybe a need for
20	continued development going forward from today
21	andand I hope five or six years from now, we're
22	talking about new versions andand better models than
23	what we have before us.
24	At that sciencescience advisory panel
25	meeting in 2001, as I said, the panel was encouraging,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 91
1	but they made many suggestions for improvement of that
2	model. And as you heard from Keith, new studies have
3	also been commissioned and completed by the registrant,
4	and there's new information available in the literature
5	that are relevant to model development.
6	So, itit'sit seemed an opportunity,
7	then, for FMC to take advantage of the model
8	development that had already occurred, the
9	recommendations that had been provided by the science
10	advisory panel, and with the new information that had
11	been commissioned by the registrant as well as what's
12	in the literature, it seemed time to develop a much
13	more refined risk assessment model.
14	That's what FMC commissioned this panel to
15	do. That model and the accompanying avian risk
16	assessment was presented to the Agency on July 12th,
17	2007. Subsequently, we submitted the full risk
18	assessment report to the Agency on September 7th, 2007,
19	and the model and the accompanying user guide were
20	submitted to the Agency on October 19th, 2007, and I
21	believe you have all those documents as part of your
22	package.
23	EPA recently used TIM Version 2.1 to
24	investigate the relevance of some of the studies that
25	FMC had submitted to the risk assessment conclusions,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 92
1	but I would caution that TIM Version 2.1 was not used
2	in the ecological risk assessment that you're charged
3	with reviewing here, the 2005 report, and I think even
4	more importantly, that model has not been released, nor
5	has information on model structure and inputs been
6	provided to the public, the SAP, or the registrant.
7	And so, we are in no position to evaluate the model
8	structure or the inputs oror its outputs.
9	And a final caution, inin the comments we
10	heard yesterday, there was the argument put forth that
11	the fact that the outputs from TIM Version 2.1 and
12	Version 1 tend to agree with each other somehow
13	constitutes validation of the model. I'd have been
14	surprised if they didn't agree, for the most part,
15	because they're obviously heavily related models. The
16	fact that they had similar outputs means that they
17	either did things really well and they both do it
18	really well, or they do things badly and they both do
19	it really badly. It has no relationship to validation
20	against field data.
21	Since completing Liquid PARAM, we have
22	indicated our willingness to assist EPA with the use of
23	the model or answer any questions that they may have.

24 As you can see from up above, that was several months

25 ago.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 93
1	I was a little disappointed to hear yesterday
2	that, you know, when they first evaluated the model,
3	they had some difficulties running the model. We were
4	never contacted to help them through that.
5	This model was developed in Excel with
6	Crystal Ball added. Anybody who uses Excel extensively
7	would know that you sometimes need to have exact
8	matching versions of the model. Microsoft does not
9	make them backwards compatible in all cases. So,
10	sometimes you have to make sure that lilibrary
11	references are checked off and things like that. All
12	very easy to do, and with a phone call, we would have
13	been haphappy to assist EPA with that.
14	As EPA noted yesterday, there are no errors
15	in the model code onceonce they had a chance to work
16	with the model.
17	Liquid PARAM or what it stands for is Liquid
18	Pesticide Avian Risk Assessment Model. That's what was
19	developed for this assessment. And we did incorporate
20	many parts of TIM Version 1 in this model.
21	Thereas I said, the panel was very
22	encouraging in 2001, and so, for those things that
23	theythey were particularly supportive of, we kept
24	those pieces. But then we moved on and actually
25	systematically went through all the recommendations



	EPA MEETING 02/06/08 CCR# 15796-2 Page 94
1	provided by the science advisory panels and tried to
2	incorporate those that we could.
3	The model was expanded to include a number of
4	additional components related to things like avoidance,
5	the toxicity adjustment factor for the dietary matrix,
6	and so on. We added a number of crops so that we'd be
7	able to evaluate all the critical uses that John talked
8	about for the amended label as well as alfalfa, and we
9	added a number of focal species. We wanted to make
10	sure that we had bird species in the model that
11	frequent those six different crops that we are most
12	interested in.
13	The model has goneundergone extensive
14	sensitivity analysis, and I'll talk about an evaluation
15	of model performance that was conducted.
16	Some of the similarities to TIM Version 1, we
17	kept three original crops, corn, cotton, and alfalfa.
18	Similar with the original focal species that were in
19	TIM Version 1, and we have three application methods,
20	in furrow, banded, and foliar broadcast.
21	Much of the information about the bird
22	species themselves, at least the focal species that are
23	common to both models, we kept, such as dietary
24	composition and body weight, and gross energy of
25	different prey items and the efficiency with which they



	EPA MEETING 02/06/08 CCR# 15796-2 Page 95
1	are assimilated by birds. That information was
2	retained.
3	The drinking water scenarios in the two
4	models are the exact same. So, we have puddle
5	scenarios day of and day after. We also have a dew
6	scenario for both. The drinking water ingestion rates,
7	concentrations in dew and puddles and so on, the same.
8	The food intake rate equations and dietary
9	nomograms aren't quite the same, but they're pretty
10	similar, certainly a similar approach, but we updated
11	the food intake rate equations to account for more
12	recent data, and we also include the error term
13	associated with those allometric equations in our
14	modeling which TIM Version 1 does not.
15	Degradation rates in water and food are the
16	same. The effects component, that notion of using
17	species sensitivity distribution to generate
18	hypothetical risk curves for a sensitive, a median, and
19	a tolerant bird species, that component is very similar
20	to whatto what is in TIM Version 1.
21	And, finally, the output from our model is
22	the same as TIM Version 1. Essentially, what Liquid
23	PARAM does is it determines the fate for each of 20
24	birds on each of 1000 fields for whatever use pattern
25	you're investigating.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 96
1	It is a field level model. Dr. Sample
2	commented or asked yesterday whether the model, TIM
3	Version 1, can say something about landscape risk,
4	whether it's a mixture of fields that might be treated.
5	This model does not do that, nor do any of the TIM
6	version models.
7	The next few slides, I'm going to go through
8	some of the major comments that the science advisory
9	panel provided on TIM Version 1 and indicate how we
10	responded, very briefly, in developing Liquid PARAM.
11	Subsequent to this series of slides, I will then go
12	into detail about the major components in Liquid PARAM.
13	So, one of the first comments that science
14	advisorthe science advisory panel had in 2001 was
15	that the use of two time steps per day, that is, 12-
16	hour time steps, in TIM Version 1 is overly simplistic,
17	and that's because of the rapid processes associated
18	with compounds such as carbofuran. So, Liquid PARAM
19	has a 1-hour time step, as does TIM Version 2.0 and
20	2.1.
21	The panel commented that the use of an on/off
22	approach for each 12-hour time step misrepresents how
23	birds forage in the field. What happens in TIM Version
24	1 is that aa draw is taken from a distribution by
25	random chance. That is entered into a binomial



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 97
1	distribution and, by random chance, the bird is
2	assigned tofor each time step as to whether it
3	forages entirely on the field for that time step or
4	entirely off the field for that time step.
5	In reality, birds foragemake many foraging
6	trips in a time step, even a 1-hour time step, and
7	theythey can quite commonly move to areas on the
8	field or off the field, depending on where they're
9	nesting andandand their preferences.
10	So, they'rethey're not necessarily going
11	to spend one 12-hour time step completely off the field
12	and then, during a subsequent time step, completely on
13	the field. I think that's an unrealistic assumption.
14	So, this is just shown graphically here.
15	This is a horned lark nesting on the perimeter of a
16	field, and in any given time step, whether it's 1 hour
17	or a longer time step, it can make multiple foraging
18	trips, and it can go sometimes into the field or
19	sometimes off the field. This is a fairly simple
20	concept.
21	The panel noted that the distribution of
22	individual foraging behavior on fields is different
23	from the distribution average population behavior
24	between fields. I think that's fairly obvious.
25	The data, the census data that you heard



	EPA MEETING 02/06/08 CCR# 15796-2 Page 98
1	about yesterday where you do in and do counts of birds
2	on and off the field, essentially is a representation
3	of average population behavior for that field. To then
4	somehow assume that that represents the distribution of
5	individual foraging behaviors within a field is not
6	supported.
7	We partitioned these two sources of variation
8	in Liquid PARAM, and I'll describe how that was done in
9	ain a few slides.
10	A similar concern was raised by the SAP with
11	regard to dietary residue levels. As you would expect,
12	there's variation between dietary resiin dietary
13	residues between fields and within fields. In TIM
14	Version 1, those two sources of variation are merged
15	together. In Liquid PARAM, we partition those sources
16	of variation, and, again, I'll talk about that.
17	The SAP noted that it would be more logical
18	to look at recovery at the active site of toxicity
19	which Keith talked about, recovery of
20	acetylcholinesterase inhibition, rather than whole body
21	elimination, and FMC commissioned a study to quantify
22	that, and those results were incorporated in Liquid
23	PARAM.
24	The SAP noted that in birds, the
25	regurgitation could be important in reducing risk. A



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 99
1	study was conducted to determine that and quantify that
2	behavior, and those results were incorporated in Liquid
3	PARAM.
4	The SAP noted that acute oral sites do not
5	account for the effect of a dietary matrix for an
6	absorption rate of theof a compound into birds. As
7	Keith described, a study was conducted to better
8	understand the importance of dietary matrix on toxicity
9	to birds and the results incorporated in Liquid PARAM.
10	And, finally, the panel noted that field
11	validation of a model, particular a model that's early
12	in the development for thefor this science of avian
13	risk assessment, is critical. As Dr. Bradbury alluded
14	yesterday, validation is kind of a hoary concept. I
15	like to think of it as evaluation of model performance.
16	I don't think you can ever fully validate a model, but
17	we do want to have some idea about performance relative
18	to what is observed in the field.
19	So, a little bit about Liquid PARAM. This is
20	the 30,000 foot view of Liquid PARAM. We certainly
21	don't have enough detail or time to get into the
22	details of the equations and so on, although there are
23	over 10,000 equations in the model, so itit is a

24 beast. Takes about two and a half hours to run.

25

The first component of...of the model...and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 100
1	I'm going to talk about the exposure side of the model
2	hereis to define the pesticide use scenario. Here
3	you would specify the crop, the application method, the
4	application rate and so on, and that information
5	determines what the initial concentrations of
6	carbofuran will be in food and water on the field.
7	Now, this model has a time step, and it
8	continues for 28 days. So, it's an hourly time step.
9	It goes for 28 days. The reason why it is twice as
10	long as TIM Version 1 is this model can handle two
11	applications, so we had to extend thethe time frame
12	out.
13	So, we want to then know something about how
14	those initial concentrations in food and water change
15	over time. To do that, we need some information on
16	degradation rates, and when you combine those
17	degradation rates in food and water that have been
18	measured with the initial concentrations in field, what
19	you get is a picture of concentrations in food and
20	water over time.
21	On thethe biological side of the model,
22	there are a number of focal species associated with
23	each crop use that you can choose from. Once you
24	select a species, you can then select a foraging
25	behavior, whether you want to look at gorge feeding or



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 101
1	more even feeding throughout the day. And so, that
2	information then determines the ingestion rates over
3	time for each hour of each day in the model.
4	Knowing what's in the dietary items and in
5	water over time and knowing ingestion rates over time
6	allows us to then estimate hourly pesticide dose. So,
7	we have an hourly pesticide dose for each of the 24-
8	hour time steps per day and 28 days in the model which
9	is 680 time steps.
10	As Ed and Christopher described yesterday,
11	the birds, however, carry over some of the preceding
12	doses in their body, and that's a function of rate of
13	metabolism. So, knowing something about the rate of
14	metabolism and how much dose they've already received,
15	we can specify a body burden. Then, in the current
16	time step, a new hourly pesticide dose comes in, and
17	so, we have something called hourly retained dose.

18 That's the current dose plus what was retained from 19 before. Hourly retained dose is the same as a body 20 burden.

So, that's the exposure side of the model. What's carried over from the exposure side of the model, that hourly retained dose or body burden for each time step in the model, and what the model then does is it searches through all of the hourly time



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 102 steps and finds the maximum retained dose, the maximum
2	body burden that occurred at whatever time period it
3	occurred at following application, and that is the
4	exposure metric that will be used in determining
5	whether the bird lives or dies.
6	And now, the effects side. As was described
7	yesterday, for almost all of the focal species, we do
8	not have toxicity data. We did have it for northern
9	bobwhites, and, as mentioned, there's also data for
10	red-winged blackbirds, and so, if that information was
11	available, we could use that dose response curve, and
12	thatthat would be used in the estimation of risk.
13	For the remaining focal species, though, we
14	did not have species-specific toxicity data, so we used
15	that sensitivity distribution process described
16	yesterday, and I'll show a picture of that later on.
17	And knowing the LD50 for the 5th percentile species, a
18	very sensitive species, for the 50th percentile
19	species, and for the 95th percentile species and a
20	slope where we took the average slope measured across
21	all focal species or across all tested species, just as
22	EPA did, we can come up with three hypothetical dose
23	response curves that represent sensitive, median, and
24	tolerant bird species.
25	And for each simulation that we did, because

25 And for each simulation that we did, because



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 103
1	we didn't know the sensitivity ofof those focal
2	species, we did all three, and that at least allows you
3	to get an idea of what the range of risk could be for
4	untested species. This is all very similar to what EPA
5	did.
6	So, we have a maximum retained dose, we have
7	a value randomly drawn from each dose response curve,
8	and it's very simple. If exposure is greater than
9	effects, the bird dies. If exposure is less than
10	effects, the bird lives.
11	And then, this simulation is repeated for 20
12	birds on each field, and then the whole thing is
13	repeated for 1000 fields. And on the risk results we
14	show are just results for those 20,000 birds combined.
15	Talk a bita little bit about time step.
16	In the arguments yesterday and in the comments
17	previously submitted to the panel, EPA stated that
18	decreasing the time step from 12 hours to 1 hour did
19	not impact the exposure estimates, and that's a rather
20	surprising result, given how fast some of the processes
21	are associated with exposure to carbofuran, when you
22	consider the recovery rate from acetylcholinesterase
23	inhibition, decay in the field, avoidance behavior, and
24	so on.
25	So, let's consider a really simple example.



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 104
1	This is hypothetical. A food intake rate of 1 kg, wet
2	weight per kg body weight per day. We'll just assume
3	for simplicity that the bird feeds on only one item,
4	and that item had an initial concentration in the field
5	of 5 mg/kg wet weight. We'll further assume a half-
6	life on that dietary item of 3.1 days. That is the
7	measured half-life for carbofuran on seeds and insects
8	in the field. And we'll assume a metabolism half-life
9	based on the brain acetylcholinesterase recovery of 4.4
10	hours, and that was based on theon the study that
11	Keith described. So, these are all values used in our
12	assessment.
13	Here are the results if we have a 12-hour
14	time step and a 1-hour time step. On the x axis is
15	time since application, going from zero hours up to 250
16	hours. On the y axis is body burden or maximumor
17	dose retained in mg/kg body weight. The blue curve is
18	the results for the 12-hour time step; the red curve is
19	the results for the 1-hour time step. Note no other
20	differences between these two applications.
21	What you find is that the peak is much higher
22	with the 12-hour time step, peak body burden, and then,

of course, it started to decline. In fact, the maximum body burden with the 12-hour time step is 5.23 mg/kg which is more than double the maximum body burden with



	EPA MEETING 02/06/08 CCR# 15796-2 Page 105
1	a 1-hour time step of 2.4 mg/kg. And it is that
2	maximum body burden that is the exposure metric used to
3	determine whether a bird lives or dies.
4	And we have not considered avoidance in this
5	analysis and some of the other rapid processes that go
6	on when you estimate exposure and risk of carbofuran to
7	birds. So, this very simple example illustrates the
8	importance of time step.
9	Daily foraging behavior. As I mentioned,
10	birds vary somewhat in their foraging behavior over
11	time during the course of a day. To try to get a
12	better understanding of that, we reviewed the
13	literature to determine how daily foraging patterns
14	vary from species to species.
15	You can see there's a long list of passerine
16	bird species for which that information has been
17	determined, been determined over a number of years and
18	generally involve nesting birds. And what we found was
19	that most passerine bird species, during nesting, have
20	relatively even feeding throughout the day with slight
21	peaks early and late in the day.
22	This isn't really surprising. When they're
23	nesting, thethe nestlings have high demands, and
24	theand the adults are quite active in trying
25	toto, quote, provide for the nestlings as well as



	EPA MEETING 02/06/08 CCR# 15796-2 Page 106
1	for themselves, and so, they'rethey're required to
2	feed throughout the day toto be successful.
3	Both peaks in the early and late in the day
4	are just small peaks. It's relatively even feeding
5	throughout the day but a slight bubble in the pattern.
6	Waterfowl may exhibit gorge feedingthis is
7	a little bit different feeding behaviorparticularly
8	during migration. Because they are flying for long
9	hours, when theywhen they do alight on fields, they
10	may exhibit gorge feeding, and this has been
11	demonstrated in a number of studies.
12	So, in our model, we have two options to
13	explore these different range of foraging behaviors.
14	On the x axis is time. There's an overnight time step
15	right at the far left, and then we begin at 6:00 a.m.
16	in the morning and continue to sunset at the end of the
17	day.
18	For those passerine bird species that are
19	nesting, we would expect something like that bimodal
20	feeding pattern shown with the purple diagonal, shown
21	there. A slight peak in the morning, a slight peak in
22	the evening, and a little bit lower intake the rest of
23	the day.
24	For waterfowl, what we assumed in the model
25	iswas essentially a gorge feeding pattern, a large



	EPA MEETING 02/06/08 CCR# 15796-2 Page 107
1	intake in the early morning and a large intake later in
2	the day. The y axis is proportion of total daily
3	intake.
4	So, in Liquid PARAM, for our waterfowl
5	analyses, we assume that gorge feeding pattern shown in
6	black. For the remaining bird species, we assumed that
7	slight bimodal distribution shown in purple.
8	It's interesting to contrast that with what
9	is in TIM Version 2.0. Because TIM Version 1 has as
10	12-hour time step, there is no consideration of
11	variation in daily foraging pattern, but in TIM Version
12	2.0 and 2.1, there's a 1-hour time step, so it is
13	possible to consider variation in daily foraging
14	behavior.
15	And thisthis figure here is based on a
16	report prepared by EPA and submitted to the science
17	advisory panel in 2004 for their consideration, and
18	what this shows is the kinds of patterns that their
19	model generated for individual birds throughout the
20	day.
21	And you'll note that those patternsand
22	these are generated through a fairly sophisticated
23	randomization modelis that there's actually no
24	feeding in the middle of the day for the example shown
25	here and fairly large peaks in the early morning and



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 108
1	later in the day. And this is much more or at least
2	approaches gorge feeding pattern, andand they used
3	these patterns for non-waterfowl species.
4	So, it's interesting to note that even though
5	we're considering similar bird species, very different
6	assumptions about daily foraging behavior.
7	Although thethe statistical model used to
8	generate these distributions is pretty sophisticated,
9	it's not in any way based or corroborated by field
10	data. There are no citations in their report referring
11	back to field observations to support these
12	distributions.
13	So thatand that gorge feeding pattern, as
14	you'll find out later, oror approaching a gorge
15	feeding pattern almost certainly results in higher risk
16	estimates, as I'll show later.
17	So, that's daily foraging pattern. I want to
18	talk about proportion of time that birds spend foraging
19	in fields and foraging out of fields. This is a major
20	consideration in estimating risk to birds.
21	If you go back to the original data set, the
22	proportion time data for bird species is based on the
23	proportions of birds observed in and out of fields.
24	Lou Best was involved in reviewing much of that
25	literature. He's sitting here. And so, if theythis



	EPA MEETING 02/06/08 CCR# 15796-2 Page 109
1	is obviously a very simplistic example, but if the
2	field observer noted 3 birds within a field and 3 birds
3	outside of a field, then the proportion time foraging
4	in the field for that population, the average PT value,
5	would be 0.5. That's a very simple example.
6	So, each datum is, thus, an average PT for
7	the population of birds on the field.
8	PT varies, though, quite a bit between fields
9	even with the same bird species, and it also varies
10	between row crops versus a field crop such as alfalfa,
11	because alfalfa is quite a different crop. Birds
12	actually will consume alfalfa.
13	So, here's another example where we have 6
14	birds inside the field, 2 birds outside the field, so
15	the average PT for that population would be 0.75.
16	These differences arise because the relative
17	attractiveness of the fields themselves and the
18	surrounding habitat varies from field to field. So, in
19	some areas, the edge habitat would be far more
20	attractive to the species of interest, and so they
21	won't spend very much time in the field. In other
22	areas, the field itself might be more attractive to the
23	birds.
24	TIM Version 1 does not distinguish between
25	population or between field variation in proportion



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 110
1	time foraging in fields versus the variation that you
2	would expect to find between individuals within a
3	field.
4	For each individual in each field, what we
5	did is a distribution was developed that captures that
6	between field variation and average PT. We sample from
7	that. That determinesI'm sorryfor TIM Version 1,
8	that determines the probability for an individual
9	within a field of being on or off the field for that
10	time step. So, essentially, variation between fields,
11	the average PT is being used to determine for each time
12	step whether an individual is on or off the field.
13	Those sources of variability were partitioned
14	in Liquid PARAM. I'll show how that was done
15	momentarily, andand reason we did that is it
16	rerepresents a more appropriate use of the data. It
17	respects the source of data andand captures the
18	variability as its represented in the data.
19	I would still caution, as you heard
20	yesterday, this variable still is uncertain. The mere
21	fact that a bird is in the field for a proportion, a
22	certain proportion of the day, does not necessarily
23	equate to that same proportion of their diet being from
24	that field. That's an assumption. It's an assumption
25	for all the TIM version models as well as our own.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 111
1	So, how did we do it in Liquid PARAM? On the
2	upper left, we have a typical result forfrom the
3	census data thatthat Lou Best and co-authors
4	collected information on. So, this is for dickcissel,
5	and this is for row crops.
6	And the little red dots shown here on the x
7	axis are the actual observations for individual fields
8	or groups of fields in the samesimilar location.
9	What you see for dickcissel is that you have some
10	fields where the birds rarely spend time in the
11	fieldthat would be down at the zero endand you
12	have other fields where all of the individuals were
13	almost always on the field. Quite a range of behaviors
14	even though this is the same species foraging in row
15	crop fields.
16	What we did in Liquid PARAM is we fit or
17	estimated a distribution that would represent that
18	variability in average population behaviors between
19	fields. You'll note that this distribution is weighted
20	more towards the conservative end, that is, assuming
21	that birds spend more time foraging in fields. So, in
22	all cases where we had rather limited data such as in
23	this example, we were conservative.
24	Let's take ana hypothetical example here
25	and say field number 4. What we do is we randomly



	EPA MEETING 02/06/08 CCR# 15796-2 Page 112
1	chose a value from that distribution. We combined that
2	randomly chosen value and assumed that a minimum of
3	zero and a maximum of 1 would represent the variability
4	of individuals within field number 4. We don't have
5	that information, so we maximized uncertainty by
6	assuming the two extreme values.
7	So, that was used to characterize a
8	distribution for field number 4, and that's shown here
9	in brightin the thick orange line. So, if you
10	choose that value for fieldfield number 4, assume a
11	min of zero and a max of 1, what you get is this
12	distribution here shown as the thick orange line. What
13	that indicates is that for individuals in field number
14	4, the majority will spend more than 50 percent of
15	their time foraging in the field. A few will forage a
16	lot in the field, and a few won't spend much time in
17	the field at all.
18	And you repeat this exercise for all of the
19	fields. You'll get different curves that represent
20	proportion of time foraging in the fields within a
21	field. And in some fields, by random chance, almost
22	the entire population will always be in the field. By
23	random chance, other fields will spendwill have all
24	the individuals barely spending any time in the field.
25	Continuing on with this example, so for our



	EPA MEETING 02/06/08 CCR# 15796-2 Page 113
1	field number 4, we would next draw 20 values from that
2	thick orange distribution and come up with individual
3	PT values for each bird in field number 4. That's
4	shown here. So, we have a bird that spends about 27
5	percent of its time foraging in the field. We have the
6	majority of birds somewhere around 60 to 75 percent of
7	their time in the field, and a couple of birds that
8	spend almost all their time foraging in the field.
9	So, what we've done is we have effectively
10	partitioned between field and within field partitioning
11	dator foraging behavior in the fields.
12	This process was repeated for all the other
13	fields. It's quite a laborious process. You can see
14	in chapter 3 the exposure assessment part of our
15	refined assessment, all the distributions that we came
16	up with, all these green distributions that we came up
17	for each of our focal species for row crops and for
18	field crops such as alfalfa.
19	Dietary residues. As indicated yesterday,
20	TIM Version 1 samples from those between field residue
21	distributions at every time step within every field.
22	So, much like the case with proportion time foraging in
23	the field, the original data represent variability
24	between fields in dietary residues.
25	So, that information is then being used in



	EPA MEETING 02/06/08 CCR# 15796-2 Page 114
1	TIM Version 1 to look as an example of the variability
2	that you would get within a field and between time
3	steps. And because of this, you often get several fold
4	increases in dietary concentrations from one 12-hour
5	time step to the next which seems a little bit
6	counterintuitive, given the rapid decay of the compound
7	in the field.
8	And it's just by random chance. You would
9	have a distribution. By random chance, you could
10	select a rather low value in the first time step and
11	then, in a subsequent time step, by random chance,
12	select a higher value.
13	It's important to remember that those
14	original nomogram distributions by Fletcher, et.al. and
15	Garner, et.al. were based on between field variability,
16	and you would expect between field variability to be
17	important, because there are differences in slope, soil
18	type, operator skill, quality of the machinery, and so
19	on. And you would expect those differences to be much
20	more important between fields than you would within.
21	Just as a side comment, it was noted
22	yesterday that our insect residue values for the
23	nomogram differed from what EPA used in TIM Version 1.
24	We used the result from Fisher and Bowers, just as EPA
25	did, but we removed the granular value result, because



	EPA MEETING 02/06/08 CCR# 15796-2 Page 115
1	it obviously is not applyapplicable to a flowable
2	pesticide likelike we're looking at. And there were
3	a number of studies where they didn't specify the
4	application method, and beingwanting to be able to
5	be specific to in furrow, banded, or foliar, we removed
6	those studies from our distribution that we developed.
7	Those calculations are all spelled out in
8	gory detail in chapter 3 of our document.
9	So, Liquid PARAM samples from each nomogram
10	to determine initial residue concentrations from each
11	field and then declines them thereafter due to
12	degradation. We basically assume that intrafield
13	variability is unimportant.
14	As you found out in thatin the documents
15	that you received prior to this meeting, the EPA
16	believes that intrafield variability is important, and
17	they show that there are a number of studies that have
18	been conducted to determine coefficients of variations
19	within fields. They range from 0.08 to 0.93 for
20	vegetation, so the ratio of standard deviation to the
21	mean varied from .08 to 0.93 for vegetation, 0.23 to
22	0.71 for insects. These valthese coefficients of
23	variation are much lower than what you would find for
24	between fields, as you would expect.
25	But I think it's important to remember that



	EPA MEETING 02/06/08 CCR# 15796-2 Page 116
1	birds don't just go into a field once during a 12-hour
2	or 1-hour time step. They go in multiple times. They
3	make multiple foraging trips, and as a result, they
4	spatially and temporally average their exposures even
5	within a relatively short 1-hour time step.
6	Based on a review of the literatureand all
7	of the citations are provided in our documentwe
8	found that birds typically make three to about 4 leaf
9	foraging trips per hour. So, let's just consider a
10	worst case example.
11	The highest coefficient in variation that was
12	found by EPA, that 0.93 value, and we'll assume a
13	minimum number of trips per hour, 3 trips per hour.
14	That wouldif you add more trips per hour for a lower
15	coefficient of variation, you would expect even more
16	spatial and temporal averaging.
17	If you just characterize the distribution for
18	residue concentration as shown on the X axis, that blue
19	dash line would represent thethe dispersion that you
20	would expect within a field with a coefficient of
21	variation of 0.93. Now, if you assume that the bird
22	makes 3 foraging trips per hour and thus comes up with
23	a spatial average, and you do this for a simulation,
24	say, 10,000 times, what you find is the distribution
25	tightens up quite dramatically.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 117 I'm sure the statisticians find this to be a
2	
	really simplistic example. But what you find is aa
3	much stronger indication of centrality in the
4	distribution, much smaller dispersion in the
5	distribution, and as a result, intrafield variability
6	is a relative minor issue once you actually account for
7	how birds forage within a field. And remember, this is
8	a worst case example.
9	So, I'll just give you a pictorial
10	representation ofof how Liquid PARAM works then. We
11	take those between field nomograms, randomly sample
12	from them for each field. We do this for each of the
13	dietary items, such as grass, foliage, insects, seeds,
14	and so on.
15	Here are some randomly chosen values for
16	grams in mg/kg for the first 8 fields. You can see
17	they vary by quite a bit. There is a lot of between
18	field variability. Similar for forage onin this
19	column.
20	And then what happens in Liquid PARAM, this
21	is for field 1, and we have an initial concentration,
22	as specified in theon the upper left there, and then
23	it is just decayed through time according to the
24	degradation rate that has been observed for grass in
25	laboratory studies. So, there's no within field



	EPA MEETING 02/06/08 CCR# 15796-2 Page 118
1	variability once the application occurs.
2	The reason you see zeros up here is in Liquid
3	PARAM, we can specify what time of day the application
4	occurs. In this particular example, the application
5	occurred at noon.
6	Avoidance behavior. You heard a lot of
7	discussion about this yesterday. Keith described the
8	study itself. In Liquid PARAM, we incorporate a 1-hour
9	time lag, so it's the preceding body burden that
10	determines how much avoidance behavior they'll have in
11	the current time step. That's a 1-hour time lag.
12	In these studies that were conducted on
13	behalf of the registrant, we found thatthat recovery
14	begins, actually, in about 30 minutes, so this is a
15	fairly conservative assumption. Dr. Sample raised the
16	issue yesterday or asked a question about whether the
17	error term in this regression model is incorporated in
18	Liquid PARAM, and it is not. It would be a
19	computationally challenging exercise to do that, but I
20	think it might be something worth exploring in the
21	future.
22	So, what is that regression relationship?
23	What we have on the x axis is average dose. This is
24	from the experiment. And on the y axis, reduction in
25	food intake rate. There's no effect at all on food



	EPA MEETING 02/06/08 CCR# 15796-2 Page 119
1	intake rate at zero, and what you find is at very low
2	doses, there was actuallyindicates no change in food
3	intake rate.
4	Then at a certain dose, 0.119, there's a
5	threshold. Thereafter, as dose increases, there's an
6	increasing amount of reduction in food intake rate.
7	And so, in the model happensis at the
8	preceding time dose, we have a body burden. To convert
9	itso, what would normally happen is you would then
10	find that dose, read up to the curve, go across to the
11	left, and figure out what the reduction in food intake
12	rate will be for the current time step.
13	Now, asas indicated yesterday, thethe
14	laboratory study was not able to determine food
15	consumption on an hourly basis. That would have been
16	too invasive. It was done on a daily basis, but the
17	time step in the model is an hourly time step. So, we
18	had to make an extrapolation.
19	The way we did that is if you go back to the
20	original protocol for the laboratory study, the
21	exposure period is 8 hours per day. It was 8 hours
22	light, 16 hours dark, and mallards wouldn't feed in the
23	dark.
24	So, what we did is then with the preceding
25	dose for the preceding time step, the 1 hour, we would



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 120
	multiply it by 8, then go to this model, read off the
2	axx axis, so say 0.6 mg/kg body weight per day. Go
3	up to the curve. That would be roughly a 35 percent
4	reduction in food intake. Apply that to the dose for
5	the current time step, and continue on. Okay?
6	So, that's how we converted frombetween
7	the two types, between the laboratory study and the
8	model. That's exactly how Ed explained it yesterday
9	later in the day, so the EPA did have a correct
10	understanding of it.
11	That is an extrapolation uncertainty.
12	Obviously, we are assuming basically even feeding
13	throughout the day, for example. We don't really know
14	that.
15	Species sensitivity distribution. You had
16	some questions yesterday about slopes and how much
17	difference therethere is between sensitivities when
18	you assume the 5th, 50th, and 95th percentile of
19	sensitivity, so I thought I'd throw this figure up.
20	Basically, what we have on the x axis is dose shown
21	here in mg/kg body weight. Percent mortality here.
22	And if you fit a distribution to the LD50s that have
23	been determined for other test species, you can get a
24	5th percentile LD50, 50th percentile LD50, and a 95th
25	percentile LD50.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 121
1	And then, if you go ahead and obtain all the
2	slopes from those toxicity studiesand we averaged
3	them just as EPA didyou get an average slope as
4	shown here, and that information, the LD50 and the
5	slope, can be used to generate this dose response curve
6	for a very sensitive species, for a medium tolerant
7	species, and for a highly tolerant species. So, that's
8	how the SSD approach works.
9	And the major difference between what we did
10	in our effects component and what is done in TIM
11	Version 1 and TIM Version 2.0 and 2.1 is these three
12	curves are shifted to the right along this x axis by a
13	factor of 3.8, and that's to account for the
14	differences in toxicity between and oral or a water
15	bolus dose test that's done with the standard acute
16	oral test and what you find with the dietary matrix as
17	the vehicle for exposure.
18	Sensitivity analysis. As described in
19	section 3.4 of our refined risk assessment, we
20	conducted extensive sensitivity analyses for Liquid
21	PARAM. We created two exposure scenarios. One was a
22	high exposure scenario involving the maximum
23	application rate for potatoes in the Northwest and a
24	lower exposure scenario which involved application at a
25	much lower rate in cotton.



- I	EPA MEETING 02/06/08 CCR# 15796-2 Page 122
1	And then, we looked at two different bird
2	species, one that would be expected to spend a lot of
3	time in the fieldhorned larks spend a lot of their
4	time foraging within fieldsand we applied that to
5	the high exposure scenario. For the low exposure
6	scenario, wewe focused on a bird species that
7	wouldn't be expected to spend much time in fields, and
8	that was the American bobwhite. So, wewe kind of
9	have two extreme scenarios that we used in our
10	sensitivity analysis.
11	When you do those analyses, we varied quite a
12	number of different parameters to find out which ones
13	were the most important. What you find is that there
14	are four key variables that have a dramatic impact of
15	predicted mortality of bird species. They are foraging
16	patternthat's the difference between gorge feeding
17	and that much more even feeding pattern throughout the
18	day. That is critically important. As gorgeif you
19	strictly keep everything else constant and compare the
20	results between even feeding throughout the day and
21	gorge feeding, gorge feeding will have much higher
22	mortality.
23	Rate of metabolism, as you would expect, is
24	important. Whether you use a half-life of 4.4 hours or

25 9.4 hours, as used by EPA, makes a difference.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 123
1	Incorporation of avoidance behavior makes a
2	big difference, and incorporation of a dietary matrix
3	adjustment factor makes a big difference, and I'm
4	showing that particular example here to the right.
5	And we have the results for the high exposure
6	scenario for horned lark on potatoes. What we have on
7	the x axis are the results for assuming high
8	sensitivity of the species, median sensitivity, and low
9	sensitivity.
10	For assuming high sensitivity, what you find
11	is that if you don't incorporate the adjustment for the
12	dietary matrix, mortality is quite high. You
13	incorporate that dietary matrix adjustment factor of
14	3.8, the mortality ispredicted mortality is reduced
15	by over a full third. So, this is a very important
16	variable.
17	For the more tolerant bird species, it's not
18	as important. We don't predict much mortality for
19	horned larks in potatoes if they are of median
20	sensitivity or if they're a highly tolerant species
21	whether or not you use that matrix adjustment factor.
22	We weren't able to do sensitivity analyses in
23	Liquid PARAM to investigate the importance of time
24	step. That would be a great structural reconfiguring
25	of the model, but based on that simplistic analysis I



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 124
1	showed you earlier, I would expect that time
2	steptime step is critical in explaining differences
3	in predicted mortality between TIM Version 1 and Liquid
4	PARAM. And I would also expect that the different
5	assumptions that TIM Version 2 and Liquid PARAM make
6	regarding daily foraging behavior is critically
7	important, because I know we have a much more even
8	foraging pattern for non-waterfowl species than does
9	TIM Version 2 or, presumably, 2.1.

10 And there are also differences between EPA 11 models and our model with regard to how proportion time 12 foraging in the field is dealt with, dietary residues 13 is dealt with. Food intake rates have been updated somewhat in our model, and we also consider the error 14 15 So, there are a number of other differences term. 16 between the models that can also explain the dramatic 17 differences that you're seeing predicted mortality 18 between the two models.

Okay, evaluation of model performance. You heard...you heard about some of the field studies yesterday. We reviewed the literature for field studies involving application of carbofuran and then monitoring the impacts on avian species. In reviewing the literature, it became apparent that the most useful studies for actually quantifying mortality in the field



	EPA MEETING 02/06/08 CCR# 15796-2 Page 125
1	was Jorgensen, et.al., 1989 and Booth, et.al., 1989.
2	These were studies you heard about yesterday.
3	Those studies were conducted in Nebraska and
4	Texas-New Mexico for corn, in Kansas-Oklahoma for
5	alfalfa. These studies determined pre and post-
6	application bird mortality in treated and in control
7	fields. The experimental design was 8 times 2 paired
8	plots.
9	There was no randomization as to which of
10	those paired plots was control or treatment.
11	Essentially, what happened was a number of farmers were
12	identified that would apply carbofuran to their fields,
13	and then what the study authors did is they looked
14	around for a very similar field in terms of surrounding
15	habitat, surroundingand the type of bird species
16	that used those fields. So, it was a paired
17	control/treatment.
18	And this was 8 times 2 paired plots per
19	state. Those paired plots were separated by at least a
20	quarter of a mile, so, hopefully, that minimized birds
21	foraging in both the control and treatment fields.
22	The protocol used for these studies followed
23	EPA guidance and took account of EPA comments that had
24	been provided onon preceding field studies to the
25	extent that they could.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 126
1	So, for example, dogs were used to assist in
2	carcass searches, and thatand dogs, they
3	don'tthey don't care if it's a small little bird or
4	a large bird. Theythey move by smell, so there's no
5	size dependence in in their ability to find birds.
6	And it's really important to note here that
7	the results for every single plot were corrected for
8	carcass search efficiency and the disappearance rate of
9	birds from those fields. It was determined in every
10	single plot in these studies.
11	And so, when we determine percent mortality
12	for each plot, we corrected for these search
13	efficiencies and disappearance rates. So, all those
14	arguments you heard about well, might not be able to
15	find every single dead bird, we corrected for that.
16	It was a really well conducted study. There
17	was a lot of information collected, and that's what
18	allowed us to do a lot of these appropriate
19	manipulations of the data.
20	You heard yesterday that the control plots
21	maymay not be true control plots in the sense that
22	they had no pesticide applied. That is true.
23	Synthetic pyrethroids were used in the corn control
24	plots, and chlorpyriphos was used in the alfalfa
25	control plots.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 127
	I wouldn't expect any issues with the
2	synthetic pyrethroids, because they have low toxicity
3	to birds. The chlorpyriphos is toxic to birds, and so,
4	that's an issue.
5	Note that those pesticides that were applied
6	in the control plots were applied two to three weeks
7	before carbofuran treatment.
8	Also important to note that edge fields were
9	treated with a variety of pesticides. Some neighboring
10	fields were treated with a vara variety of
11	pesticides but not carbofuran. Again, something to
12	consider.
13	But in the end, as I'll show inin the next
14	two slides from now, there was little avian mortality
15	on control plots. And we will show you the results
16	corrected for mortality on the control plots and not
17	correct for mortality on the control plots, and you can
18	judge for yourself which is the appropriate method, but
19	we'llwe provided both in our report and in this
20	presentation.
21	So, how was mortality in the field estimated?
22	Christopher Salice yesterday noted that when
23	theythey applied the DREAP formula to try to
24	estimate how much mortality occurred in those treated
25	fields. That formula was deemed inappropriate by the



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 128
1	study authors, and there's a rationale provided in the
2	field study reports.
3	And it's primarily due to the fact that the
4	birds were in pre-migratory phase. They don't have
5	high site fidelity at the time that these studies were
6	conducted, and so, the DREAP formula really doesn't
7	work in that situation.
8	So, we took a different approach, aswe
9	took the approach suggested by the study authors where
10	we determined the number of live birds observed per
11	dead bird found. And we convert that to percent
12	mortality. We do that for each plot, and we did that
13	for all birds across each plot, each field.
14	These calculations, again, are shown in gory
15	detail in our assessment report. There's tables
16	provided of all the raw data, and then all the formulas
17	that were used to process the data are included in our
18	report.
19	Unfortunately, the calculation that EPA used
20	to calculate percent mortality using the DREAP formula
21	have not been provided to us, and I don't believe
22	they've been provided to the SAP. The first time we
23	saw that was actually yesterday during the
24	presentation.
25	So, that allowed us to estimate percent



	EPA MEETING 02/06/08 CCR# 15796-2 Page 129
1	mortality for treated plots and for control plots for
2	both the corn and the alfalfa field studies.
3	So, what did we do with Liquid PARAM? We ran
4	scenarios that replicated those field studies for each
5	of our focal species. So, that's 1 pound of active
6	ingredient per acre, foliar spray. And we determined
7	percent mortality across all of our bird species. So,
8	we combined the results for all of our focal bird
9	species across 1000 fields, and those calculations are
10	all shown in our report.
11	What were the results? On the x axis with
12	the two crops, corn and alfalfa. The y axis is
13	mortality per application expressed as percent going
14	from zero to 50.
15	Here are the results, depending on how you
16	calculate them for the field. Overall, there's very
17	low mortality for both corn and alfalfa in the field,
18	less than 1 percent no matter how you calculate it.
19	For corn, if you make no correction for pre-
20	application or control mortality, then observed
21	mortality was 0.88 percent of the birds. If you
22	correct for only pre-application mortality, that drops
23	somewhat, because some birds did die pre-application.
24	So, that's 0.69 percent, and in this case, control
25	mortality was so low for corn that it doesn't change



	EPA MEETING 02/06/08 CCR# 15796-2 Page 130
1	when you correct for that.
2	For alfalfa, even lower mortality, 0.3
3	percent if you don't correct for control or pre-
4	application mortality, 0.26 percent if you just correct
5	for pre-application mortality, and it actually drops to
6	a negative value if you correct for control mortality,
7	the reason being is that, in this case, control
8	mortality exceeded what was observed in the treated
9	plots.
10	And I would take that with a heavy grain of
11	salt, because chlorpyriphos was used in these control
12	plots. So, it's a reasonable argument to not consider
13	that correction for control mortality for alfalfa in
14	particular.
15	What were the results for Liquid PARAM? For
16	corn, we predicted 0.78 percent mortality across all
17	the focal bird species. A very low value. Certainly
18	comparable to what was observed in the field, depending
19	on which correction you want to compare to.
20	And for alfalfa, 0.33 percent. Again, pretty
21	comparable to the field.
22	Apparently, having a perfect model like this
23	is a bad thing. Had we not replicated observed
24	mortality very well, I'm sure we would have been
25	criticized for that, but it's interesting to see that



	EPA MEETING 02/06/08 CCR# 15796-2 Page 131
1	we're criticized for good performance. But, anyhow, I
2	take that with a grain of salt.
3	Therethere wasthis is only two field
4	studies. The model performed pretty well. We weren't
5	expecting, actually, this close a match. What we were
6	hoping for was that it was in the ball park, and I
7	think that's all you should take away from this. Let's
8	get realistic. There are issues associated with the
9	field studies.
10	So, all we can really say is that Liquid
11	PARAM is certainly within the ball park of what you
12	would observe in field studies. How about TIM Version
13	1?
14	Dramatically different predictions. With the
15	same scenarios that we ran in Liquid PARAM, using the
16	corn scenario, TIM Version 1 predicts 40 percent
17	mortality across all the bird species that would use
18	treated fields and 39 percent for alfalfa. That is a
19	mass mortality event, and there is no conceivable way
20	that a study as well conducted as these two studies
21	were that that kind of mortality would have been missed
22	in this kind of controlled field study.
23	I should note that waterfowl were not present
24	in the area during the conduct of the alfalfa field
25	study, so we do not include alfalfa in our model



	EPA MEETING 02/06/08 CCR# 15796-2 Page 132
1	simulations, nor did we include them in the TIM Version
2	1 simulations, and that's exactly analogous to what EPA
3	did when they did their alfalfa analyses.
4	Okay, so that's the model itself, and now I
5	want to talk about the risk results that we got.
6	To help communicate risk, because risk curves
7	are kind of a gnarly beast to communicate, we developed
8	a risk categorization scheme. So, we took each of our
9	outputs, and we categorized them as to whether they
10	were de minimis, mild, intermediate, or high risk.
11	This was strictly a communication tool, not meant to
12	imply anything with regard to decision making.
13	So, how did we come up with those risk
14	categories? If you read through the ecological
15	literature, there's a general understanding that
16	effects of less than 10 percent are unlikely to be
17	ecologically significant to a low poplocal
18	population. Thatthat statement would not include
19	threatened and endangered species.
20	And it's because of things like density
21	dependence. There's a certain amount of mortality that
22	local populations can observecan absorb without
23	affecting overall abundance of the population.
24	Glenn Sutor, in a review of the literature,
25	concluded that effects of 20 percent or less are



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 133
1	generally acceptable in EPA regularegulatory
2	practice. So, we kind of started with those two
3	concepts andand started to think about how we would
4	categorize risk.
5	And what we figured is if there was a low
6	probability ofof 10 percent or greater effect, so an
7	effect that's, you know, unlikely toto affect the
8	local population, if there's only a low probability of
9	exceeding that, then that's low risk. So, in our
10	analysis, we say if there was a less than 20 percent
11	probability of a 10 percent or greater effect, that was
12	low risk.
13	On the other hand, if there was a high
14	probability, a greater than 50 percent probability of a
15	20 percent or greater effect, the threshold that Glenn
16	Sutor refers to, wewe considered that high risk.
17	At any values between those two, we consider
18	it intermediate risk, and then we further came up with
19	something called de minimis risk, and that's a
20	situation where you have a very low probability, less
21	than 5 percent probability, of even a small effect, a 5
22	percent or greater effect.
23	And so, that'sthat's kind of thethere's
24	more thinking to it than that, but that's just boiled
25	down to the simple situation that we came up with.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 134
1	Now, we kind of extended this a little bit
2	further. If you take those probabilities and in
3	magnitude effect and multiply them together, you get
4	something called a risk product. So, if you take 20
5	percent probability times 10 percent effect or greater,
6	that's awhat we call a risk product of 2. If you
7	take the 50 percent probability of 20 percent effect,
8	that's a risk product of 10. And we can do that for
9	the other categories as well.
10	And so, what we did is we defined these
11	regions, and I'll show them, these regions that
12	describe high risk, intermediate risk, low risk and de
13	minimis risk using these risk products, and I'll show
14	you what that means.
15	So, on the x axis, we have percent mortality.
16	On the y axis is exceedence probability, and that whole
17	area to the right and above that blue line, if we get a
18	risk curve that goes into that area, that's high risk.
19	That's a high probability of a major mortality event.
20	That risk product of 10 that I alluded to as
21	the criterion for high risk is what is used to
22	calculate this line. So, 100 percent probability of 10
23	percent effect, that's a risk product of 10, just as
24	100 percent probability of 10 percent effect is a risk
25	product of 10, and if you do that at multiple points



. 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 135
1	along the line, you have this line here equal to a risk
2	product of 10.
3	Do that for the line dividing intermediate
4	and low risk, that would be a risk product of 2, and so
5	on for low and de minimis risk.
6	So, any risk curve that crossed into here is
7	high risk. Any risk curve that crossed into here is
8	intermediate risk, and any risk curve that was in here
9	is low risk, and any curve that had a very low
10	probability of even minor effects so it hugged the
11	axes, was categorized as de minimis risk. Again, this
12	is just a communication tool.
13	So now, I'm going to get into our actual
14	results. We looked at a number of use patterns
15	associated with the six crops that we were interested
16	in, the five that the registrant would like to have on
17	the amended label as well as alfalfa which has been
18	removed from that label. We looked at the application
19	methods that were onon the label, the maximum single
20	application rate, and we applied it at the maximum
21	number of applications allowed according to the label.
22	For each of those crops, we identified a
23	number of focal species. These are species from field
24	studies that have been observed in these crops and
25	using these fields quite frequently. So, these are the



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 136
1	birds that you would expect to be most at risk in
2	treated fields.
3	Some of these overlap with what EPA considers
4	in TIM Version 1. The ones that are in bold italic are
5	species that we've added to Liquid PARAM.
6	Verytaken a lot of results, and
7	there'sthere's every single risk curve that we
8	developed and all the statistics and assocassociated
9	with those risk curves are all presented in our
10	appendices, but boiling it down to a couple of really
11	simple slides, here are the results. We looked at, all
12	together, 208 scenarios. That's combinations of use
13	patterns times focal species, and in the case
14	ofcases where we did not have species-specific
15	toxicity data, three different sensitivities.
16	We found de minimis risk, very low risk, in
17	other words, in 166 of our 208 scenarios, and if you go
18	back and look at the numbers, de minimis risk turned
19	out to range from 99.4 percent to 100 percent survival.
20	We found low risk for 27 of our 208 scenarios
21	that we looked at. And, again, if you go back to
22	thethe data that was generated to put those risk
23	curves together, that indicates 95.2 to 99.5 percent
24	survival, just to give you an intuitive feel of what
25	low risk means.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 137 Intermediate risk was found in 10 of 208
2	scenarios. That's associated with 77.4 to 95 percent
3	survival. And we found high risk for 5 of 208
4	scenarios which range from almost complete mortality to
5	65.8 percent survival. All of the high risk scenarios
6	were associated with gorge feeding waterfowl in
7	alfalfa.
8	So, Christopher Salice's statement that
9	Liquid PARAM predicts no risk for modeled uses except
10	waterfowl on alfalfa, that was obviously false. That
11	was a statement that was provide yesterday.
12	Clearly, in the vast majority of modeled
13	scenarios, we did find risk, even if it was minor. No
14	risk would imply 100 percent survival for the entire
15	use pattern.
16	A little bit more discussion of risk results.
17	For non-waterfowl species which are mostly passerines,
18	de minimis risk in all scenarios if the species have
19	loware assumed to have low or median sensitivity to
20	liquid carbofuran, generally de minimis or low risk if
21	species have high sensitivity to liquid carbofuran, but
22	we did find intermediate risk for highly sensitive
23	species if they forage extensively in potato fields
24	which has the highest application rate for the product.
25	Waterfowl species in alfalfa is quite a



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 138
1	different scenario. Alfalfa isis actually
2	attractive to waterfowl. Waterfowl will actually feed
3	directly on alfalfa which is different from other
4	crops. And during migration, they have the potential
5	to gorge feed, because theythey've been undergoing a
6	high energy activity, flying, for a number of hours,
7	and so, they gorge feed quite often when they alight on
8	fields.
9	So, to account for this behavior, we assume
10	gorge feeding for waterfowl species in alfalfa, and we
11	further assumed 100 percent foraging time on treated
12	fields. And when you make those assumptions, American
13	widgeon are at high risk regardless of sensitivity, and
14	Canada goose are at high risk if they have high or
15	median sensitivity, intermediate risk otherwise.
16	Now, I think there's a little context needed
17	here. For a waterfowl species to actually gorge feed
18	in a treated fieldthis is actually a fairly
19	infrequent event, because the fields would actually
20	have to be in the flyways. They would have to be
21	treated at the time that the birds are migrating
22	through the area, and in fact, most of the time, by the
23	time treatment occurs in alfalfa, the waterfowl species
24	are much further to the north, but, occasionally, it

25 does happen, and so we wanted to look at this scenario.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 139
	So, it's a relatively infrequent event is the
2	message I want to say, but when all the things align,
3	flyways are in the area where there are treated fields
4	and the birds happen to land on treated fields shortly
5	after application, there can be very high mortality,
6	according to the model.
7	Let's look at a typical result. Here are the
8	risk categories shown here for thethat separate
9	high, intermediate, low, and de minimis risk. The
10	example being presented here is killdeer in corn.
11	Post-emergent foliar spray. Application rate of 1
12	pound of active ingredient per acre. So, what do the
13	risk curves look like?
14	Here's the result if we assume that killdeer
15	are a sensitive species, a 5th percenta 5th
16	percentile species. That's that red line that just
17	came across here. And how you read this is there's
18	about just less than 20 percent probability that
19	mortality will be 5 percent or greater.
20	Whereas if you go over to, say, 30 percent
21	mortality and you read back across here, that would be
22	roughly about an 8 percent probability of 30 percent or
23	greater mortality for killdeer in treated fields. And
24	that's how you read one of these curves.
25	Because this risk curve, at least part of it,



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 140
1	is between this line here and this line here, that's
2	the low risk area. So, this outcome would be
3	categorized as low risk.
4	If we assumeif we assume that killdeer are
5	a median sensitivitywe really don't know what their
6	sensitivity ishere is the result, and, basically,
7	that's a de minimis risk result. There's a very low
8	probability of any mortality to killdeer in corn.
9	And, as you would expect, same sort of result
10	if they're a tolerant species. That's a green line
11	here. It's actually right underneath that blue line.
12	You can't see it here. Okay?
13	So, that's an example of what results look
14	like for a lot of our passerine bird species in crops
15	like corn, cotton. Potatoes, sometimes the curves are
16	higher than that, and if you look at the risk curves
17	for waterfowl gorge feeding in alfalfa, they would be
18	up here. They would be up in this high risk area, very
19	high probability of severe mortality.
20	All those risk curves are presented in our
21	report.
22	In the abas has become clear, I think, in
23	the absence of species-specific toxicity data, the
24	uncertainty regarding predicted mortality can be quite
25	high. This point was made yesterday, and we certainly



	EPA MEETING 02/06/08 CCR# 15/96-2 Page 141
1	concur.
2	To get at that issue, what EFED did in their
3	2005 report is they used their mean mortality estimates
4	for the entire species complexso that's all the
5	focal species they looked attimes the three
6	sensitivities to estimate what risk might be for the
7	communityat the community level for birds that
8	forage in treated fields. This is aa very
9	interesting approach, and we repeated these analyses
10	for each of the exposure scenarios that we did.
11	Here's an example output. This is banded
12	application on corn, 1 pound of active ingredient per
13	acre. On the x axis is bird mortality going from zero
14	to 100 percent. And on the y axis, we have percent
15	species affected.
16	We did the analysis for TIM Version 1. This
17	is the exact same result that EPA got and presented in
18	their report, and we did the analogous simulations in
19	Liquid PARAM. That's the blue curve.
20	So, let's get an idea of what this really
21	means. If you look at the predictions from TIM Version
22	1, it's predicted that for this use pattern, 67 percent
23	of the species would have greater than zero percent
24	mortality.
25	28 percent of the species would have at least

EPA MEETING 02/06/08 CCR# 15796-2 Page 141



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 142
	27 percent mortality. So, if you go to the x axis
2	here, at 27 percent, go up and read across to the y
3	axis. That's a 28 percent of species would have at
4	least 27 percent mortality.
5	And for the species at greatest risk, they
6	would experience 86 percent mortality.
7	In Liquid PARAM, the vast majority of species
8	would not be predicted to have any mortality from this
9	scenario, and the species at greatest risk would
10	experience 3.3 percent mortality. Obviously, dramatic
11	differences between the two models, and I would state
12	that this kind of curve that you're seeing for a very
13	common application scenario in recent decades is a mass
14	mortality event.
15	This is even more dramatic for foliar spray
16	on corn, again, a common use pattern of carbofuran in
17	recent decades. Here, you're seeing greater than 50
18	percent of the species experiencing more than 50
19	percent mortality. That is a massive bird kill with
20	some bird species experiencing as high as 95 or even
21	100 percent mortality. Quitequite a bit lower
22	predictions in Liquid PARAM.
23	Based on the evaluation of model performance
24	that we did for TIM Version 1 and Liquid PARAM, we
25	would argue that TIM Version 1 dramatically



	EPA MEETING 02/06/08 CCR# 15796-2 Page 143
1	overestimates risk. And why is that the case?
2	I think time step is a major reason, because
3	time step reduceswith a longer time step like 12
4	hours, that reduces the influence of rapid processes
5	such as metabolism and degradation in the field.
6	The rate of metabolism that was used by EPA
7	in their assessment was based on whole body
8	elimination. We used a value based on recovery of
9	brainfrom brain acetylcholinesterase inhibition, a
10	much faster number
11	Avoidance was not included in TIM Version 1.
12	It was in Liquid PARAM. Dietary matrix influence was
13	not included in TIM Version 1, but it was included in
14	Liquid PARAM.
15	And there are a number of other possible
16	explanatory variables as well, because we did do
17	dietary residues quite differently, proportion time
18	foraging in the field and so on quite differently.
19	And even in TIM Version 2.0 which does have a
20	better time step, a quicker time step, 1 hour, because
21	they use quite different daily foraging behavior
22	patterns, something approaching gorge feeding, I would
23	argue that that also leads to higher predictions of
24	mortality than you would see with Liquid PARAM which
25	has the same time step.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 144 So, those are some of the reasons I believe
2	that TIM Version 1 and 2.0 over-predict risk.
3	A little bita little note on how we dealt
4	with uncertainty in Liquid PARAM. I think it's
5	apparent to anybody who'swho's been involved with
6	avian risk assessment of pesticides, there is limited
7	information for a number of the input parameters
8	thatthat we need toto estimate exposure and risk.
9	As I mentioned before, direct measures of the
10	proportion of diet obtained from treated fields by
11	individual birds is just not available for North
12	American bird species, at least the ones we're
13	interested in.
14	Toxicity data are not available for most
15	focal species, and what toxicity data are available
16	simulate gorge feeding, that bolus dose placed in the
17	crop of the bird or the esophagus of the bird. That is
18	not the typical feeding pattern inin the field. And
19	no matter which model you're considering, TIM Version
20	1, 2.0, 2.1 or Liquid PARAM, they're affected by these
21	sources of uncertainty. I think we need to be up front
22	about that.
23	Like I said, I hope five, ten years from now,
24	we're going to have better data and improved models as
25	a result of that.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 145
1	In this example when information was limited,
2	we took a number of steps to deal with that. The
3	preferred approach was to have studies conducted to
4	fill the data gaps, and you heard about those studies
5	from Keith.
6	To account for uncertainty where possible,
7	so, for example, the allometric model that was used for
8	food metabolic rate, that allometric model was a
9	regression model. It has an error term. We
10	incorporated that error term in our assessment and in
11	our model which was not done in TIM Version 1.
12	We partitioned variation between individuals
13	forfor dietary residues and proportion time foraging
14	in the field or between fields and within fields.
15	And failing all that, we used conservative
16	assumptions. For example, for brainfor recovery
17	from brain acetylcholinesterase inhibition, we used the
18	highest half-life that was from that study. You could,
19	in a refinement of the model, actually put the dose
20	dependence relationship between half-life and dose and
21	actually refine the model from there. That line only
22	had three points on it, so we're a little uneasy about
23	that and went with a conservative assumption instead,
24	but there's no reason why you couldn't refine the model
25	toto deal with that dose response relationship.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 146
1	Okay, thatthat's the part of my talk to do
2	with Liquid PARAM. Talk very briefly about other lines
3	of evidence. Yesterday, you heard from Melissa Panger
4	a list of deficiencies that have been associated with
5	state monitoring studies. There have been a number of
6	monitoring studies conducted by states where they go in
7	and look for dead birds following application of
8	carbofuran.
9	And there are deficiencies in a lot of the
10	monitoring studies, and we acknowledge that. For
11	example, the use of ATVs to go look for carcasses is
12	obviously an inappropriate way to go look for dead
13	birds. You wouldyou would miss a lot of dead birds.
14	But there were some studies that were well
15	conducted. There was kind of a broad brush used
16	approach yesterday, you know, oh, there was all these
17	deficiencies, and they apply to all state monitoring
18	studies. Well, that isn't true. It applies to some,
19	but there are some studies that have been well
20	conducted.
21	These studies have been reviewed by Smith,
22	1997. That report is in the public docket. It's quite
23	an extensive review of all the state monitoring
24	studies. And I'm just going to touch on a couple of
25	these studies that were better conducted studies and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 147
1	talk a little bit about the results that they got.
2	So, California, they undertook state
3	monitoring studies in 1995 and 1996. Searches were
4	conducted by foot of the perimeter and interior of the
5	field. All together, 153 miles were searched following
6	application of carbofuran, liquid carbofuran. Those
7	searches were conducted in zero to 3 days post
8	application. Searches included census counts for each
9	of the species observed in and around the fields.
10	I should further note that the searches that
11	are involved in that study were actually trained
12	searchers. They were trained by the California
13	Department of Fish and Game, I think. I just have the
14	abbreviation in front of me, but anyway, they were
15	trained by the state agency.
16	And what they found was they didn't find any
17	mortalities due to carbofuran in those 153 miles that
18	they searched. They did find 7 birds whichdead
19	birds which, when you did the residue analysis, it was
20	pretty clear that it was an organophosphate that caused
21	those mortalities. So, it wasn't a case of them
22	missing dead birds. They did find dead birds. They
23	just weren't due to carbofuran.
24	Oklahoma in 1995, 46 acres of edge and field
25	were searched by foot 2 days after treatment. Again,



- T	EPA MEETING 02/06/08 CCR# 15796-2 Page 148
1	census counts. Again, zero mortalities due to
2	carbofuran.
3	And just a clarification. In the RED report,
4	EPA 1996, it's claimed that ATVs were used in those
5	California searches. They were not.
6	Texas, I want to talk a little bit more about
7	Texas, because Texas has probably done the most
8	comprehensive state monitoring program for carbofuran.
9	In 1995 and '96, they surveyed 697 linear miles of
10	perimeter and edge habitat by foot 3 hours to 15 days
11	post treatment. They didn't do counts or abundance
12	determinations for each species of bird, but they did
13	note presence/absence of species, and no dead birds
14	were found.
15	1997, EPA requested that 30 acres be searched
16	on 30 randomly selected sites, that these be done 24
17	and 48 hours post treatment, that the transects be 6
18	feet wide in areas of wildlife use which would be
19	primarily the edge and border areas but also the field
20	interiors, and that the searches be done by walk at
21	less than 2 miles per hour. So, EPA had reviewed the
22	profile. This is what they asked for.
23	To the extent that the state could, they
24	complied with these requests. They searchall
25	together, they searched 273 acres. They did so 48



	EPA MEETING 02/06/08 CCR# 15796-2 Page 149
1	hours post treatment, because they were not allowed to
2	enter the field sooner than that. All together, 392
3	miles were searched at the pace requested by EPA.
4	These searchers were also trained researchers. They
5	were trained by state and federal wildlife agencies.
6	Numerous wild birds found in and around the
7	fields, and these were censussed. Zero mortalities due
8	to carbofuran.

Just to give you an idea of how intense these 9 searches were, there actually was a mourning dove nest 10 11 that was found in a treated cotton field. It was 12 detected 2 days post treatment, so during the first 13 search, and they actually went back repeatedly to find 14 out how that nest fared. The eggs did hatch. The 15 birds did fledge. That's...that's an ancillary 16 comment. It's nothing about whether there's risk in 17 this field or not. It just gives you an idea of how 18 involved the searchers were in searching these fields. A little bit about incidents. You heard a 19

20 lot about incidents yesterday. What I've got here is a 21 summary of the incident reports for liquid carbofuran 1998 to present. This is for birds. On the x axis are 22 23 a number of categories from abuse/misuse, unknown, 24 alfalfa, and then the five crops that are currently 25 included on the amended label.



EPA MEETING 02/06/08 CCR# 15796-2 Page 150 1 What has happened, if we look at number of 2 dead birds, there has been a tremendous number of dead 3 birds that have occurred due to misuse, and I'll come 4 back to this in a little while, a few due...due to 5 unknown use. There was a large number of birds killed 6 in one incident for alfalfa, and then very few birds 7 killed for the remaining crops...that have been killed 8 on the remaining crops. 9 If you look at number of incidents, there are 10 a large number of abuse and misuse incidents, a few 11 unknown, one for alfalfa, one for corn, nothing for all 12 the remaining crops. 13 The reason we picked this interval of 1998 to 14 present is that reflects the current label. John, in 15 his earlier presentation, noted that there were a 16 number of label changes in 1997. The influence of granular product on incidents has been removed at this 17 18 point. So, this is a...a more accurate picture of what 19 might be occurring in this time frame. 20 A little bit about this number here, 31,048. At least 27,000 of those birds is due to one incident. 21 22 And that incident was an Illinois baiting incident. 23 The farmer actually was quite annoyed by all the birds

25 actually...treated it with undiluted furidan, and then

24



that were foraging in his field. He took seed...grain,

	EPA MEETING 02/06/08 CCR# 15796-2 Page 151
1	broadcast that over the field. It's hard to argue that
2	that's a clear misuse, an off label use of the product.
3	He was charged as a result.
4	So, 27,000 of thosethose birds on there or
5	more were due to that particular incident.
6	Also included in that bar there is athe
7	cauliflowerColorado sunflower incident that you
8	heard about yesterday, that complicated scenario that
9	Melissa described. It was a large bird kill there.
10	The reason we've moved it from an unknown to the
11	misuseyesterday, EPA had it in the unknown
12	characategory, and we have it in the abuse/misuse
13	categoryis because that grower entered a guilty plea
14	with the Department of Justice January 3rd of this
15	year, admitting to deliberate misuse of the product.
16	It's called an off label use, and so, that does not
17	apply. That incident is not an unknown; it is a
18	misuse.
19	One other comment. You'll note here the
20	value that there was 803 waterfowl birds that were
21	killed in this one incident in alfalfa. In the figures
22	presented yesterday, it was 1200 birds in this
23	incident. I don't know where the discrepancy comes
24	from. All I can say is that that value that we use
25	here was based on a Freedom of Information request that



EPA MEETING 02/06/08 CCR# 15796-2 Page 152 1 the registrant submitted to the EPA, and EPA provided 2 this number to us as a result of that request. 3 Otherwise, I can't explain the discrepancy. A little bit about incidents in New York and 4 5 California. As you remember... 6 DR. HEERINGA: Dr. Moore, if you could, 7 try to push to wrap up in about ten minutes. 8 **DR. MOORE:** I am so close to wrapping 9 up. Okay. Are we into lunch or...all right. You have 10 no concept of time when you're up at the mike. 11 Very quickly, then, you noticed yesterday 12 that the vast majority of incidents that have been 13 reported by states since 1972 were in New York and 14 California. There's a reason for that. 29 of the 38 15 incidents from New York State actually occurred in the 16 city, and they represent a clear misuse, the baiting of 17 pigeons. 18 California, 50 of the 111 incidents were 19 related to application on grapes. That's a unique 20 application method. Doesn't apply to any other crop, 21 and as explained yesterday, it has since been 22 mitigated. 23 So, I think that partly explains why there's 24 a lot more incidents reported by New York and 25 California compared to other inci...states.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 153
1	So, to wrap up, which the chairman apparently
2	wants me to do, some final conclusions. We believe, as
3	a panel, an independent panel, that liquid carbofuran
4	poses minor risks to the field birds that forage in
5	treated row crop fields, such as corn, melons,
6	potatoes, and so on. That gorge feeding waterfowl may
7	be at high risk oror intermediate risk in treated
8	alfalfa fields if they happen to forage in those fields
9	shortly after application.
10	We believe that the results from Liquid PARAM
11	are at least consistent with controlled field studies,
12	the results of field monitoring studies and incident
13	reports.
14	And we would contend that it is unlikely that
15	expert field researchers, trained searchers, farmers,
16	growers' associations, government officials, and so on
17	would have missed, over a long period of time, EPA's
18	predicted mass mortalities associated with labeled uses
19	of flowable carbofuran. That just seems very unlikely.
20	And so, if that's what's predicted by EPA
21	with TIM Version 1 and subsequent versions, it suggests
22	to us that there are issues with regard to model
23	structure for TIM Versions 1 and 2.0 and 2.1, and so,
24	we would argue that questions regarding model structure
25	are critical in considering the risk of flowable



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 154
1	carbofuran to birds.
2	There no questions addressing model structure
3	in your charge, and we would respectfully request that
4	you, if you have time at least, to consider questions
5	regarding model structure. Some possible questions to
6	consider, are refinements to the model structure of TIM
7	Version 1 required to adequately understand the risk
8	posed by liquid carbofuran to birds?
9	Is it better to ignore critical, albeit
10	uncertain, variables or incorporate the available
11	knowledge about the variables? And the reason we pose
12	that question is the EPA had a number of questions
13	about the avoidance study, the acetylcholinesterase
14	study, and the dietary matrix study. They noted that
15	there's uncertainty about that, and so, rather than
16	deal with that uncertainty inin the confines of
17	their model, they would rather not include it in their
18	model at all.
19	I'm reminded of a famous quote by Charles
20	Babbage, errors using inadequate data are much less
21	than those using no data at all. We do have data here,
22	obviously, andthis is mymy own further
23	statementusing adequate data would be even better.
24	We obviously believe that the data from the
25	registrant's submitted studies are adequate, even if



	EPA MEETING 02/06/08 CCR# 15796-2 Page 155
1	there are uncertainties.
2	And, really, if you think about it, all
3	variables in the avian model are uncertain, and some of
4	them are really uncertain, such as proportion time
5	foraging in the field, and those variables were
6	included in TIM Version 1, 2.0, and 2.1, so that
7	argument doesn't hold for excluding some of the
8	variables that we've addressed in our studies.
9	We would like to see what the panel thinks
10	about Liquid PARAM. Is it a better model for assessing
11	avian risk? And as sort of a final grand question,
12	which of the EPA and registrant assessments represents
13	the best available science for characterizing the risk
14	of liquid carbofuran to birds?
15	We know you have a packed agenda with the
16	charge questions you already have, but we do hope that
17	there is time to address some of these more fundamental
18	questions regarding model structure.
19	And I thank you for your time and attention.
20	DR. HEERINGA: Thank you very much, Dr.
21	Moore and Dr. Solomon as well. A very detailed and
22	comprehensive presentation.
23	I would like to turn to the panelwe're
24	going to break for lunch shortly, butto see if there
25	are several key questions, particularly for those of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 156
1	you who have questions where you think that thein
2	regards to the environmental exposure and avian risk
3	assessments. Yes, Dr. Clark?
4	DR. CLARK: This gets to the field
5	studies' differences. In terms of the detection
6	efficiency and observer reliability, were those
7	estimates included in the model? Were they known?
8	DR. MOORE: They were included in
9	thesorry, Dwayne Moore. Those estimates of carcass
10	search efficiency andand loss rates from the fields
11	were done by the study authors for each plot. They
12	provided that data in those field reports, and we used
13	that information, then, in making our calculations
14	regarding percent mortality. We provided the raw data
15	as well as the corrections.
16	DR. CLARK: As a follow-up, then, in
17	terms of the population estimates as well in terms of
18	the authors were estimating what the population numbers
19	were in the area, were the same sorts of reliability
20	estimates andcalculated for that as well?
21	DR. MOORE: I'm going to turn this over
22	to Lou Best.
23	DR. CLARK: And detection efficiencies.
24	DR. MOORE: Yeah, Lou Best is actually
25	more of an expert, so I'll let him answer that



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 157
1	question.
2	DR. BEST: No, as was stated, theoh,
3	excuse me. I'm Lou Best. As was stated, they did make
4	a correction for disappearance rate andand
5	efficiency searching for the carcass. There was no
6	such correction made for bird observations during the
7	surveys which merely means that those bird counts were
8	actually under-representative of the total bird
9	community that was there, because no adjustment was
10	made for detectability of the birds.
11	DR. HEERINGA: Dr. MacDonald, then Dr.
12	McCarty.
13	Just for for the panel members, tooKen
14	asked for this questionI expect this period of
15	questioning to continue after lunch for a short period
16	of time, so you don't have to rush in, but I want to
17	take the proper time.
18	DR. MACDONALD: Yeah, I'd just like to
19	comment. I think we've had some extremely good
20	presentations, and I'm very impressed with the
21	description of thethe model, the Liquid PARAM, but I
22	think it's impossible for us to say which model is good
23	science, because we haven't had peer review of the
24	Liquid PARAM model. We haven't had EPA review of it.
25	We just have to take your word that it works asas



	EPA MEETING 02/06/08 CCR# 15796-2 Page 158
1	you describe.
2	DR. MOORE: Dwayne Moore. Yeah, I
3	agree. I mean, if it had gone to peer review, I think
4	that adds credibility. No doubt about it.
5	What we have provided, though, is a very
6	detailed description of the model and all of its
7	inputs. Every calculation was described in our report,
8	and we do have a number of avian experts around the
9	table who have experience. And so, I think the
10	information is there to actually do that peer review
11	that you think is important. And I agree it's
12	important.
13	DR. HEERINGA: Dr. McCarty?
14	DR. MCCARTY: Two quick questions. One,
15	a quick follow-up on the bird observations and the
16	census of what's out there. Were those unlimited
17	radius counts that you did?
18	DR. BEST: In the alfalfa study, they
19	were transect counts. I can't remember
20	DR. MCCARTY: Do you know the distance?
21	DR. BEST:the width, and I would
22	have to go back to the studies, but the studies do
23	describe the width of the transects and also the length
24	of the transects. And theywhat they did is made the
25	surveys on the perimeter of the field, so they were



EPA MEETING 02/06/08 CCR# 15796-2 Page 159 1 simultaneously counting birds on the field perimeter as 2 well as birds in the field edge. 3 DR. MCCARTY: But you don't remember the width and... 4 5 DR. BEST: I haven't recently looked at the study, no, but it is in the report. 6 7 DR. MCCARTY: And we don't... 8 **DR. MOORE:** We can get that information 9 for you after lunch. 10 DR. BEST: We can get that information 11 for you. 12 DR. MCCARTY: Okay, that would be good. 13 The second quick question is on page 18, 14 talking about the...the even daily feeding rates or 15 feeding rates through the day. I know some of those 16 studies, and I know at least some of them involved 17 feeding nestlings, and I'm wondering if the estimates 18 you...you use partition out the adults feeding 19 themselves versus adults going out foraging and 20 bringing food to the nestlings, because, of course, the 21 models, as far as I know, ignore nestlings, and they're 22 just focused on adults. 23 Do you know ... were you able to partition out 24 how the distribution of adults feeding themselves 25 looked?



	EPA MEETING 02/06/08 CCR# 15796-2 Page 160
1	DR. MOORE: Dwayne Moore. In the model,
2	no. Asas I understand it, those observations were
3	just counts of how many trips the bird took away from
4	the nest and returned, but I'll let Lou expand on that.
5	He'she was involved with some of those studies.
6	DR. BEST: That's correct. They were
7	simply frequency counts ofof bird forays from the
8	nest and then returning to the nest to feed the
9	nestlings. The assumption there would be that the
10	foraging pattern of adults wouldwould mirror the
11	foraging pattern for the young which I don't believe is
12	an unreasonable assumption in terms of the frequency of
13	forays, because much of the time they'rethey're
14	going to return to the nest they're spending brooding.
15	They would be actually at the nest itself. So, they
16	have to feed at the same time theythey go on a foray
17	to seek food for their young.
18	DR. HEERINGA: Yes, Dr. McCarty?
19	DR. MCCARTY: Would that apply, say, to,
20	then, you know, a recently arrived migrant in May,
21	small passerine crashing down in a fence row or
22	something or aa shore bird, say, a golden flubber
23	during migration in early May in a cornfield?
24	DR. BEST: Lou Best again. That's
25	certainly a valid question. There is, I think, an



	EPA MEETING 02/06/08 CCR# 15796-2 Page 161
1	important distinction to be made between waterfowl and
2	gallinaceous birds like bobwhite quail and passerines
3	in the fact that the passerines do not have a crop.
4	They do not have a storage organ which necessitates
5	them feeding more frequently throughout the day. So,
6	the comparison is confounded by that.
7	DR. HEERINGA: Dr. Sample and Dr.
8	Sparling have questions, but ifI'm going to ask them
9	to hold those till after the lunch.
10	Before we do break for lunch, II want to
11	just give you my synopsis of how things are moving
12	along. Clearly, we are behind schedule, and my deepest
13	apologies to public presenters who are here for a short
14	period of time to make theirtheir statements and
15	their presentations, but we have to stay with the order
16	of the agenda. It is floating, and these discussions
17	are absolutely critical to the scientific review.
18	So, my apologies, but I am going to proceed
19	with the careful review of this material.
20	Before we break for a one-hour lunchI want
21	everybody back at 1:30the Designated Federal
22	Official, Dr. Sharlene Matten, has a few comments to
23	make.
24	DR. MATTEN: Actually, Dr. Heeringa took
25	part of what I was going to say. The public



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 162
1	commenters, I understand that one or two may have to
2	fly back. If you would let me know what time you need
3	to fly back, with some adjustments with other public
4	speakers, we mightwe certainly don't want you to
5	have to pay \$1000 to reschedule your flight. That's
6	not what we intended. While we're floating, we are
7	certainly cognizant of people's time, and if you could
8	come see me if you have a 5:00 o'clock flight or 6:00
9	or 7:00, we may be able to make some adjustments.
10	Our usual process is to take the oral comment
11	requests in the order in which they come to me, and so,
12	if there's some flight concerns, please let me know,
13	and we'llDr. Heeringa and I willwe'll talk about
14	it and we'll letbecause FMC has several more hours
15	of presentations.
16	The other note I wanted to make is if you've
17	come to me with your scheduled time, please try
18	duringat least during the presentation to more or
19	less stick to the time in which you've at least given
20	me previously.
21	Thanks.
22	DR. HEERINGA: Thank you, everybody,
23	and we will break for lunch now. Again, we'll resume
24	at 1:30.
25	(WHEREUPON, Session B was concluded and a luncheon



	EPA MEETING 02/06/08 CCR# 15796-2 Page 163
1	recess was taken.)
2	DR. HEERINGA: As soon as we can get a
3	Designated Federal Official, we'll get under way.
4	We're still waiting a Designated Federal Official. I
5	can't start without either Sharlene or Steve. Can I
6	deputize somebody? I don't know.
7	In the process, we have entered a period of
8	public comment, and we are receiving presentations by
9	expert panels that have been assembled by the
10	registrant and have conducted various research and
11	developmentals and exploration activities. We have
12	heard the presentation on the avian risk assessment
13	additisupplemental studies and actual modeling
14	efforts with Liquid PARAM, and we are at a point now
15	where the panel is addressing questions of
16	clarification toto the presenters on this topic.
17	Dr. Matten, the DFO, reminded me, too, we
18	want to make sure we stay within reasonable time
19	constraints on all of our comments. That includes both
20	presentations and our questions, but, again, I'm going
21	to balance that to make sure that we get full
22	development and exploration onon these issues. So,
23	I'll try to manage that accordingly, but you know where
24	I'm going with things.
25	So, let'sat this point, let's return to



EPA MEETING 02/06/08 CCR# 15796-2 Page 164 1 questions of clarification. 2 DR. MOORE: All right, Dr. Heeringa, we 3 do have an answer to one of the questions posed before. 4 DR. HEERINGA: Yes, Dr. Moore, why don't 5 you provide that? 6 DR. MOORE: Well, actually, Lou Best 7 will provide an answer to that. That was with regards 8 to the field studies. 9 There...there were some DR. BEST: 10 questions asked about the...the length and width of 11 the...the nature of the transects. For the alfalfa 12 study, the transect width in the middle of the field was 50 meters wide on either side of the midline of the 13 14 transect. On the field edge, it was 25 meters on 15 either side of the midline. They were fixed width 16 transects. 17 In the cornfield study, it was a bit different there. They had a variable width transect 18 19 for the edge habitat, depending upon the extent of that 20 edge habitat, because they were dealing with, I think, 21 fence rows and so forth, and because of the difficulty 22 in making observations in tall corn, they actually did 23 their surveys from platforms. They were 24 positioned...they had two per field. They had three 25 surveys per week, and the radius that they surveyed



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 165
1	was, let's see, I think it was a 50-foot radius from
2	those50-yard radius from those platforms.
3	DR. MCCARTY: So, would I interpret from
4	that the variable width on the edge means they tried
5	tothey just count birds in what they were defining
6	as edge?
7	DR. BEST: Right. What you typically
8	will find isis something like a fence row or some
9	strip cover along the edge, and, basically, the width
10	is dictated by the width of that particular strip
11	cover.
12	DR. HEERINGA: Thank you very much, Dr.
13	Best.
14	Picking up where we left off before our lunch
15	break, I think Dr. Sample, Brad Sample, had a question.
16	DR. SAMPLE: Yeah, I was looking
17	throughor in the presentation, you were talking
18	about the application of thea factor to adjust for
19	food matrix. I noticed that you used a value of, I
20	guess it was, 3.8.
21	DR. MOORE: Yes.
22	DR. SAMPLE: And there werethat was
23	based on the quail study. There was also the data that
24	were based on the mallards which was a lower value, a
25	value of about 2, and I notice you did not use that in



	EPA MEETING 02/06/08 CCR# 15796-2 Page 166
1	your model and did not discuss it. Is there a
2	particular reason, and how does thathow did that
3	affect your modeling results?
4	DR. MOORE: That value of 2 for mallards
5	was the value devised by EPA. In our analysis of the
6	mallard dataand this is in ourour report as
7	wellwe calculated a worst case lowest value for the
8	mallard study for the adjustment factor and a best
9	case, and itthat range was from 2 to 4.6, depending
10	on what assumptions you made about slope of the curve
11	and so on, the probable slope. And that 2 to 4.6
12	actually brackets 3.8 in the middle. So, we felt that
13	3.8 was a reasonable factor to apply for all of our
14	analyses.
15	Obviously, that's aan uncertainty as to
16	whether the results for two bird species apply to all
17	other focal species, but asas a reasonable estimate
18	for both bobwhite quail and mallards, around the 3.8.
19	DR. SAMPLE: And you include that
20	parameter as aas a fixed value?
21	DR. MOORE: We did, and honestly, I
22	think if we had enough to actually put a distribution
23	around that, if we had more speciesI know where
24	you're going with thatI think we would treat that as
25	an uncertainty as well.



EPA MEETING 02/06/08 CCR# 15796-2 Page 167 1 DR. HEERINGA: Dr. Sparling had a 2 question. 3 DR. SPARLING: Actually, if I could, 4 I've got several questions, but I'm going to ask two, 5 if I could. 6 DR. HEERINGA: Certainly. 7 DR. SPARLING: Okay. The first question 8 is with regards to the food avoidance study. In the 9 Liquid PARAM model, did you try to examine what the 10 effects would be if you did not have food aversion 11 going on there? 12 DR. MOORE: Yes, we did. In our 13 sensitivity analyses, we ran set exposure scenarios. 14 There's two of them, a high number and a low number 15 scenario, and we ran them with avoidance turned off and 16 with avoidance turned on, and it makes quite a bit of 17 difference. 18 DR. SPARLING: And so, with avoidance 19 turned off, there would be substantially more 20 mor...mortality? 21 DR. MOORE: Yes, there would be. 22 DR. SPARLING: Okay. The second 23 question, then, deals with the...and I think this is 24 might...might be a follow-up on Dr. Sample's. In your 25 studies, your extra studies that you submitted, you



EPA MEETING 02/06/08 CCR# 15796-2 Page 168 1 indicated that the aqueous toxicity for the carbofuran 2 was inaccurate on a bolus, that it was far more toxic 3 than it was in a food bolus. 4 DR. MOORE: Mm-hmm. 5 DR. SPARLING: Okay. At the same time, it's my understanding in Liquid PARAM, you're able to 6 7 model uptake or exposure from puddles? 8 DR. MOORE: We...in the...Dwayne Moore. 9 In Liquid PARAM, you have options whether to...for 10 drinking water scenario whether to do puddles day of 11 application, puddles day after, or dew only throughout. 12 For the results that we presented in our risk 13 characterization, it was dew only, and that was to 14 mirror exactly what was done by EPA in their assessment 15 report. So, there was a dew only drinking water source in the...in our models. 16 17 **DR. SPARLING:** Okay. And then, when you looked at the effects and you made your decision yes, 18 19 there was an effect or no, there wasn't an effect, was 20 that based on food bolus LD50 or the aqueous LD50 or 21 neither? 2.2 DR. MOORE: It would be based on the 23 food bolus. So, what essentially, you're...I think, if I know where you're going...the dose response curves 24 25 were all moved three-fold to the right to account for



	EPA MEETING 02/06/08 CCR# 15796-2 Page 169
1	dietary matrix exposure, and we did not adjust that for
2	the drinking water part that would be coming in.
3	So, there's two dietaryor two routes of
4	exposure. There's a dietary, and there's an assumption
5	of dew.
6	Computationally, it would have beenI don't
7	even know how you would do it. It would be very
8	difficult to haveadjust that dose response curve for
9	how much they were getting from drinking water versus
10	diet. It would be an interesting exercise, albeit a
11	difficult one.
12	But what we found was that the contribution
13	that was coming from the dew drinking water sources was
14	relatively minor, and thisthis is corroborated by
15	EPA in their assessment. They found that that source
16	of exposure was relatively minor.
17	So, as our interim solution, I guess, we just
18	simply went with the dose response curve adjusted for
19	the dietary matrix.
20	DR. SPARLING: Okay. And one other
21	question. This is goinggoing right back to what
22	Imy first question. You said there was a
23	considerable difference between the food avoidance
24	calculation on mortality and without the food
25	avoidance. Are we talking about an order of magnitude?



	EPA MEETING 02/06/08 CCR# 15796-2 Page 170
1	Are we talking about a two-fold? Can you give me a
2	ball park figure?
3	DR. MOORE: I can give you a ball park
4	figure. Be easier if I can use the graph for you.
5	Give me two seconds. Almost there.
6	Okay, for horned larks which is a high
7	exposure scenario, if you look atat the results,
8	assuming high sensitivity for that species, we would
9	have predicted about 50 percent mortality if you do not
10	account for avoidance. If you account for avoidance,
11	assuming a 1-hour time lag in response, that drops down
12	to about 14 percent predicted mortality, and itif it
13	were instantaneous, which it isn't, it would drop down
14	to just a few percent.
15	That's our high exposure scenario assuming
16	high sensitivity. If you assume median sensitivity or
17	low sensitivity, it really doesn't matter, very low
18	mortality, and if you do a low exposure scenario,
19	avoidanceturning avoidance on or off doesn't really
20	matter, obviously. Very low predicted mortality.
21	So, it's really just in a high exposure
22	scenario with a bird species that gorges in the field a
23	lot that it can make that sort of two and a half-fold,
24	three-fold difference.
25	DR. SPARLING: Thank you.

COURT REPORTING

EPA MEETING 02/06/08 CCR# 15796-2 Page 171 1 And that's on, for anybody DR. MOORE: 2 looking at it, it's page 118 of the report, Moore, 3 et.al., 2007. 4 DR. HEERINGA: Thank you, Dr. Moore and 5 Dr. Sparling. Dr. Clark? 6 DR. CLARK: It's Larry Clark. I'm just 7 trying to get some clarification on the food avoidance 8 studies, so... I don't know if you had all this 9 information. So, how long were the...the birds down once they were exposed to their initial dose, inactive? 10 11 DR. MOORE: I think that's probably a 12 question for Larry, Larry Brewer. 13 DR. BREWER: Larry Brewer. In the food 14 avoidance study, we didn't have any birds that showed 15 any signs of exposure. 16 DR. CLARK: Okay. And...and then, two 17 other very simple questions is, were these studies run 18 over a standard work week? So, did they start on a 19 Monday and proceed through the Friday? 20 DR. BREWER: Not necessarily, no. Our 21 lab runs all week long, and there's someone there every 22 day of the week and usually a team of people. 23 DR. CLARK: Okay. I'm just trying to 24 understand, for example, the...you have a total daily 25 feed consumption data which is the...the food intake



	EPA MEETING 02/06/08 CCR# 15796-2 Page 172
1	adjusted for body weight over timer, and the controls
2	show a pattern as well. Were the birds visually
3	isolated?
4	DR. BREWER: From each other. I think
5	probably what we saw in that little pattern that you
6	saw in the control of the offering is ais something
7	we see in caged birds quite often. When you initiate a
8	study, there's a substantial amount of activity, and
9	itit has an influence on the birds. Ititin
10	the form of stress. In a few days, theythey get
11	used toespecially ducks. They get used to your
12	patterns. They relax a little bit. They become
13	moremore likely toto consume normal amounts of
14	food, and so you'll see that pattern.
15	And since it did happen in the controls,
16	everything we did with regard to comparisons, I'd say,
17	was back to the control, and so we felt that it was not
18	an issue.
19	DR. CLARK: Thank you.
20	DR. HEERINGA: Dr. Montgomery?
21	DR. MONTGOMERY: Cheryl Montgomery. I'd
22	like to follow up on the slide number 10 that's titled
23	Appropriately Conducted Study. I believe Dr. Solomon
24	presented this information. It says here there's no
25	learning of location of contaminated food. Feeder was



- Г	EPA MEETING 02/06/08 CCR# 15796-2 Page 173
1	switched each day.
2	And I was wondering ifI don't know if you
3	were present yesterday or not, but the EPA put up a
4	right and left side preference feeding for the birds,
5	and I was wondering if you would be willing to comment
6	on what EPA presented yesterday and how that reconciles
7	with this, if it does.
8	DR. SOLOMON: Keith Solomon. If I just
9	go to the next slide, perhaps, this illustrates the
10	distribution of left and right side preferences inin
11	the birds in the study. This is all of the 70 birds
12	that were used in the study, and we've color coded
13	thethe various groups there, and we saw nono bias
14	towards one side or the other. And this data,
15	obviously, we should probably do some more statistical
16	analysis of it. Because of the time, we couldn't do
17	that.
18	So, I will ask Larry Brewer who did the study
19	to perhaps explain in a little bit more detail the
20	points and how they were determined.
21	DR. MONTGOMERY: Well, may I just ask a
22	clarification? Did you see the presentation that EPA
23	made yesterday? I mean, I don't remember seeing your
24	faces in the audience, so you know the slides I'mI'm
25	referring to, the bar graphs with the left and right?



	EPA MEETING 02/06/08 CCR# 15796-2 Page 174
1	DR. SOLOMON: Yeah
2	DR. MONTGOMERY: For the preference
3	there?
4	DR. SOLOMON: Keith Solomon again. The
5	barthe bar graphs probably refer towell, some of
6	them consistently favored the right side, and there
7	were other animals that consistently favored thethe
8	left side, and those were the graphs you saw yesterday
9	which were the extreme ends of theof the
10	distribution, and the others were in between, and there
11	was no apparent bias inin ain the study that
12	theyand then, when we switched the feeders or
13	wewhen Larry's people switched the feeders every
14	second day or every day they switched them, theeven
15	though they preferred that feeder, they were then going
16	to a feeder that was different than the one they had
17	before.
18	So, we felt that controlswell, we believe
19	that that controls as far as wewhich we couldn't
20	avoid, and Larry Brewer can probably give you a little
21	more explanation on that.
22	DR. BREWER: Larry Brewer. Forfor
23	the purposes of thisof this slide, what this is, as
24	we repeated earlier, everything onon the right side
25	showsof the diagonal line shows birds that favored



	EPA MEETING 02/06/08 CCR# 15796-2 Page 175
1	the right side of the pen, and on the left side is the
2	birds that favored the left side of the pen. And so,
3	if you look at those, there's no real bias towards them
4	doing one or the other, and in thein thethe
5	example given yesterday, the presenter said we picked
6	anan extreme example, and this is what we're
7	hypothesizing about that extreme example.
8	And, again, because they would favor one side
9	of the pen or the otherand I have some ideas why
10	they do that. Some birds do. Some birds don't. I can
11	get into that if you want, but because, every day, we
12	switched the feeders from one side to the other
13	containing fresh food versus contaminated food, they
14	were getting the same exposure toto the food in
15	total number of hours throughout this day.
16	DR. MONTGOMERY: Was it fresh
17	contaminated food?
18	DR. BREWER: No, it was fresh food,
19	uncontaminated.
20	DR. MOORE: Right, uncontambut it was
21	fresh uncontaminated
22	DR. BREWER: Every day.
23	DR. MONTGOMERY: And then, but you took
24	the contaminated feed and switched it side to side, or
25	did you put fresh contaminated feed?



EPA MEETING 02/06/08 CCR# 15796-2 Page 176 1 They had fresh contaminated DR. BREWER: 2 feed every morning. 3 DR. MONTGOMERY: And fresh feed every 4 morning. 5 DR. BREWER: And fresh feed every 6 morning. 7 DR. MONTGOMERY: Okay. 8 DR. BREWER: And the next day, they had 9 the same thing in opposite positions. 10 DR. MONTGOMERY: Opposite sides, yes. 11 DR. BREWER: Yeah. And...and with 12 regard to what makes a duck lean to one side or the 13 other, we notice in mallards that they're 14 kept...they're kept sexes separate prior to the study. 15 DR. MONTGOMERY: Mm-hmm. 16 DR. BREWER: When you put them together, 17 even though they're in metal pens with metal dividers, 18 the female mallard is the vocal leader in the group, and the males can hear the females next to them if 19 20 they're totally randomly assigned to their cages, and 21 then the treatments randomly assigned to that, but if 22 they happen to be next to a female and they can hear 23 her, they're going to spend more time on that side of 24 the cage or if its' on the other side of the cage, and 25 this does show a random propensity towards the sides of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 177
1	the cage, and I really think that's the explanation.
2	DR. MONTGOMERY: Okay, thank you.
3	DR. HEERINGA: Just aa note to
4	everybody. I would like to terminate this questioning
5	at about 2:15, because wewe have three other topics
6	this afternoon to get to. So, we have about 15 or 20
7	minutes.
8	Dr. Edler and then Dr. Portier.
9	DR. EDLER: Just for a while on
10	thaton that slide here. There is a time behind
11	that. We have day 1 to 5, so which time actually
12	thisdoes this figure belong to? Because I think we
13	have a little bit of a problem here. We have that
14	statements, we have the figures, and then we have the
15	real data, and always see these threethese three
16	fields very bouncebounce around, and the figures, of
17	course, cannot show always the data. Sometimes we need
18	some more information.
19	DR. SOLOMON: Keith Solomon here, and
20	I'll justthethe raw data is available in theon
21	the CD that you've been supplied. We have all the
22	figure from that study all available if you want them,
23	and thisthis is a mean value for the study that you
24	see here. To put all of the individual days on here
25	would have made it look somewhat uninterpretable.



EPA MEETING 02/06/08 CCR# 15796-2 Page 178 1 I don't know if Dr. Brewer would 2 prefer...would like to add. 3 **DR. BREWER:** Just that that...these values are the total feed consumed from both sides per 4 5 bird for the...for the full exposure period. 6 DR. HEERINGA: At this point, Dr. Lu and then Dr. Portier. I know Dr. Portier has some detailed 7 8 questions, but Dr. Lu. 9 I have two DR. LU: Alex Lu. 10 fundamental questions regarding the Liquid PARAM model. 11 So, you mentioned that you...you found there is a dose 12 dependent half-life of recovery which struck me as a very shocking finding, because for all the 13 14 pharmacokinetic o pharmacodynamics parameters that you 15 estimate, the half-life is one of the few...it's not 16 the only one...that's independent from the dose. The 17 half-life effect by the route of administration will 18 have an effect by which phase are you talking about, 19 proportionately for inhalation, but in terms of dose 20 dependence, it's very difficult for me to understand 21 that there is a possibility that these two things will 22 have relationship. 23 So, if you look at your slide 20 and 21, 24 especially 20, the curve actually look really 25 identical. I mean the previous one. Yes, the previous



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 179
1	one. This one. If you plot these three curves on the
2	semi log paper and estimate a slope, that should give
3	you the same number, and that slope will represent the
4	half-life. So, I don't know how you calculate the
5	half-life. There's no number that I can base this on.
6	So, that leads you to the problem on slide 21
7	which I don't know how you calculate that the half-life
8	will lead to this linear relationship. Again, if you
9	can comment on why the half-life is dose dependent.
10	And the second question or you can comment on
11	this is that you using the half-life derived from the
12	cholinesterase enzyme recovery in the model to estimate
13	doseto estimate body burden. It seems to me that
14	you actually use the different and wrong parameter to
15	try to come up with a different measurement outcome
16	that has nothing to do with acetylcholinesterase
17	enzyme.
18	It seems to me likeI mean, if you are
19	going to use an estimate from the enzyme data, you are
20	using some sort of pharmacodynamic model, but they're
21	kind of like pairs, thethe parent compound and
22	metabolite relationship, but I think the Agency
23	presentation yesterday was talking about looking at the
24	chemical in the environment or in the bird and they
25	come up with the estimate half-life whichwhich I



	EPA MEETING 02/06/08 CCR# 15796-2 Page 180
1	think is reasonable, but in your approach, it struck me
2	as somewhat very novel. So, if you can comment on
3	this?
4	DR. SOLOMON: Dr. Lu, Keith Solomon. I
5	will initially talk to that, and then Dr. Moore may add
6	some comments to that. Thewhat we were looking at
7	in this particular relationship here isis not just
8	cholinesterase. That's what they're measuring as an
9	endpoint in vivo. So, we take these birds. We've
10	gavage dosed them, and then we, at various times, we
11	sacrifice them and measure the brain
12	acetylcholinesterase.
13	So, what we're seeing is a combination of
14	recovery of inhibited enzyme over time, but in addition
15	to that, if there are any remnants of the initial dose
16	of carbofuran still circulated in the body, they could
17	inhibit newly released enzyme, and this would slow down
18	the recovery rate.
19	So, it's a combination of cholinesterase and
20	metabolism that we're seeing here, and I think that's
21	why we see a slow recovery at higher dose. If I took
22	this into a test tube, as I recall doing as a grad
23	student, the recovery rate was always the same. It
24	doesn't matter, because you're dealing with pure enzyme
25	and nono metabolism going on.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 181
1	Thein that sense, we believe that
2	thisbecause we're measuring the toxic
3	endpointthis is what kills the birds, is inhibition
4	of cholinesterase. That is actually a very useful
5	endpoint from the point of view of a risk assessment,
6	because it is clearly related to mortality. It
7	integrates, in this case, metabolism once the chemical
8	is in the body and the recovery of the cholinesterase.
9	DR. LU: This is Alex Lu again. I think
10	I disagree with your interpretation of this slide. If
11	you look at
12	DR. HEERINGA: Dr. Lu, we might want
13	to
14	DR. LU: Okay.
15	DR. HEERINGA: Unless it gets to a point
16	of question. I mean, if it's really clarification on
17	this, then I'll permit it. Otherwiseplease, if you
18	feel that you need clarification, but just for
19	discussion at this point, I think we'd prefer to save
20	that for later.
21	DR. SOLOMON: Well, I can pick this up,
22	if that's permissible, Mr. Chairman, later on.
23	DR. HEERINGA: Yes, you certainly may
24	talk with Dr. Lu and come back to us. Very quickly, to
25	Dr. Grue and then to Dr. Portier.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 182
1	DR. GRUE: Chris Grue, University of
2	Washington. Was there a carrier used forin the
3	mallard study, the avoidance study?
4	DR. BREWER: Larry Brewer. In the
5	avoidance, they werewere dosed in athey were
6	nottherethere was no carrier with regard to in
7	the feed. They weren't dosed. They were, of
8	courseit was a dietary.
9	DR. GRUE: That's what I'm saying. Did
10	you use a carrier, though, in mixing thethe
11	pesticide into the waterI mean, into the feed?
12	DR. BREWER: No, it was put in neat.
13	It's a liquid. The product is liquid.
14	DR. GRUE: Okay. So, okay, so there's
15	nothere's no carrier involved. Okay.
16	Maybe I'll just ask a couple other points of
17	clarification?
18	DR. HEERINGA: Of course.
19	DR. GRUE: The time, the 1-hour time lag
20	for the avoidance workboth of these are directed to
21	Dr. Mooreand the 8-hour time step for the avoidance
22	results, could you just clarify those two for us?
23	DR. MOORE: I'll do my best. The 1-hour
24	time lag is the simple aspect of it. There
25	arebecause the birds aren't able to, as far as we



	EPA MEETING 02/06/08 CCR# 15796-2 Page 183
1	can tell, at field relevant concentrations, sense the
2	compound in any way through taste or smell, there is
3	not an immediate avoidance. Asas Keith talked about
4	in hishis presentation, what happens is they feel
5	symptoms from the exposure. They feel those symptoms
6	within about half an hour. If you look at that graph,
7	you'll see at half an hour is whenwhen the levels
8	are lowest for acetylcholinesterase.
9	So, it'sI think it's ourour hypothesis
10	is that the birds feel sick, they reduce their feeding,
11	and then as the exposure is removed, they increase
12	their feeding accordingly. So, that feeling of
13	symptoms and reduction of food intake rate happens
14	around half an hour.
15	So, because we have a 1-hour time step that's
16	either zero or 1, we make it more conservative and said
17	there's a 1-hour lag in the avoidance. It's certainly
18	not immediate. If it was immediate, it would be a
19	lower risk.
20	And what was the second?
21	DR. GRUE: Maybe just make a comment on
22	this first point. II think it's important that you
23	make a distinction between testing repellancy and a
24	pesticide-induced anorexia, and whatwhat you're
25	suggesting is that this is a pesticide-induced



EPA MEETING 02/06/08 CCR# 15796-2 Page 184 1 anorexia. 2 DR. MOORE: Yes. 3 And...and that...the DR. GRUE: 4 distinction is important, because it relates to the potential hazard in the field. 5 6 DR. MOORE: Yes. 7 DR. GRUE: And we can...we can talk 8 about that more later. 9 The second clarification was the 8-hour time 10 step from the avoidance results, then, into...into the 11 I wasn't...I wasn't clear about that. model. 12 DR. MOORE: Sure. In the original 13 study, food consumption was measured on a daily basis. 14 As I understand it from talking with...with Larry 15 Brewer, it's just not feasible to go in and measure on 16 an hourly basis, because that amount of intervention 17 would...would seriously disturb the birds. So, we have 18 a daily consumption rate. 19 The model, however, has an hourly time step, 20 so we had to get from those values in reduced food 21 consumption expressed on a daily basis to the hourly 22 time step. In the protocol for that study, it's...it's 23 clear that they had an 8-hour daylight throughout the 24 duration of that study. So, for mallards, it's a 25 reasonable assumption that they fed over that 8-hour



	EPA MEETING 02/06/08 CCR# 15796-2 Page 185
1	period but not during the 16-hour dark period.
2	And so, basically what we did is we took the
3	results expressed as daily divided by 8 to convert it
4	to the hours that we have in the model. Is that an
5	assumption? Absolutely, it's an assumption.
6	DR. GRUE: Okay, thank you.
7	DR. HEERINGA: Let's go to Dr. Portier
8	now who, I think, has some questions on the model
9	structure.
10	DR. PORTIER: Thank you. Slide 32. I
11	have a few clarification onon the methodology in the
12	model. So, starting on the left, the initial
13	concentrations in food and water, if I look at one
14	field, one of your 1000 fields in the simulation, all
15	20 birds are going to basically receive a time series
16	for food and a time series for water.
17	DR. MOORE: That's correct.
18	DR. PORTIER: In the slope of a K curve.
19	DR. MOORE: That's correct. Over time,
20	they'll receive that.
21	DR. PORTIER: Again, for that same
22	field, you've got one degradation rate for food and one
23	for water. Right?
24	DR. MOORE: Actually, we have separate
25	degradation rates for each of the parameters.



EPA MEETING 02/06/08 CCR# 15796-2 Page 186 1 DR. PORTIER: Okay. So, for the... 2 DR. MOORE: For the grass, forage, seeds, and insects. 3 4 DR. PORTIER: So, when...when you put 5 that together into concentrations in food and water 6 over time, essentially, you've got, for each field, a 7 time series. 8 DR. MOORE: That's correct. 9 DR. PORTIER: For each foray, a time 10 series for water. 11 DR. MOORE: Yes. 12 DR. PORTIER: All right? Okay. So, 13 you've got 1000 time series. So, that's that set. So, there is... 14 15 DR. MOORE: You know what? 16 DR. PORTIER: ... there's no bumpiness 17 over time. They're pretty much... 18 DR. MOORE: Well, it's smooth and... 19 DR. PORTIER: Smooth curve. Okay. 20 Foraging behavior is the one where I start to...to lose 21 it right there. 22 DR. MOORE: Okay. 23 DR. PORTIER: In foraging behavior, it 24 seems that there's two parts here. There's the how you 25 take the total daily intake, the TDI, of a particular



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 187
1	bird, and distribute it over the 14 feeding hours of
2	the day.
3	DR. MOORE: That's correct.
4	DR. PORTIER: So, that can be either for
5	ducks, two on each side orso, for a particular
6	birdwell, we'll skip the field that's on the left,
7	the bird's on the right. Right? For a particular
8	bird, do all of 20 birds in that field have the
9	sameof the same species have the same TDI
10	distribution to the day?
11	DR. MOORE: Yes, they would have the
12	exact same hourly intake rate per day.
13	DR. PORTIER: So, if we looked at your
14	slide 36 there, slide 36, there would just be one for
15	all 20 birds. Right?
16	DR. MOORE: That's correct.
17	DR. PORTIER: When I change to another
18	field, same species of bird, do I have the same
19	DR. MOORE: Same intake rate.
20	DR. PORTIER: Okay, so that's fixed for
21	a bird.
22	DR. MOORE: That's correct.
23	DR. PORTIER: For a bird species.
24	Right?
25	DR. MOORE: Yes.



EPA MEETING 02/06/08 CCR# 15796-2 Page 188 1 Okay. The other DR. PORTIER: 2 component, then, is the TDI for a bird. Is the TDI for 3 a bird distributed, or is that fixed to body weight? 4 DR. MOORE: The TDI is distributed, and 5 it's distributed based on the error term in the allometric models that we used to estimate a food 6 metabolic rate. 7 8 DR. PORTIER: Okay. So, related to body 9 weight or body size ... 10 DR. MOORE: Body weight, that's correct. 11 DR. PORTIER: ... and you're looking at a 12 distribution going in, and you distribute that. Okay. 13 So, where does this discussion on slides 40 and 42 come 14 in where you talk about field... 15 DR. MOORE: Ah, okay. 16 DR. PORTIER: ... distribution and 17 dietary residues distribution? 18 DR. MOORE: Okay. You...you are 19 completely clear in your understanding so far, so you 20 did... 21 DR. PORTIER: Well, that... I mean, 22 wasn't really sure. 23 DR. MOORE: That's great, and 24 this...this is a hard...this is the hardest part. So, the birds get a certain portion of their daily diet 25



	EPA MEETING 02/06/08 CCR# 15796-2 Page 189
1	each hour of that distribution, but where they get it
2	from still has to be decided. Do they get it from on
3	the field, or do they get it from off the field?
4	And that's what this parameter does. This
5	proportion time foraging in the field
6	DR. PORTIER: So, there's a binomial
7	proportion? Every hour, you flip a coin to decide if
8	it's on or off the field, depending on the bird?
9	DR. MOORE: No, wethat'sthat's a
10	TIM Version 1 approach.
11	DR. PORTIER: Okay.
12	DR. MOORE: In our model, they can be on
13	the field and off the field in the same hour. So, what
14	we do is through this process of once we partition the
15	variation between fields and within fields, we come up
16	with a distribution that represents the range in
17	proportion of time that theyeach individual spends
18	in the field, randomly draw thatfrom that
19	distribution.
20	And that's that bottom chart there on slide
21	40, and what we have is for that particular field, we
22	have a population for a group of 20 birds. Some will
23	haveonly spend a small amount of time foraging in
24	the field, and those would be the bars right around
25	0.25, 0.35. Other birds in that group will spend a



EPA MEETING 02/06/08 CCR# 15796-2 Page 190 1 large amount of time ever time step foraging in the field, and that would be to the right. Most of them 2 3 seem to be around 0.65 to 0.75. 4 DR. PORTIER: So...so, the bird gets one 5 draw, and they're a 0.25 bird... 6 DR. MOORE: That's a... 7 DR. PORTIER: ... and every hour, they're 8 a 25 percent, then, in the field. 9 DR. MOORE: That's right. I mean, if we 10 had data to distribute those variables, we would. We 11 don't, but if you think about, particularly in the case 12 of...of nesting passerines, they're going to 13 have...they're going to make a lot of foraging trips per hour, and so, there will be some consistency from 14 15 one time step to the next in where they spend their 16 time foraging, so it's not a perfect... 17 DR. PORTIER: But that...so that 18 fraction, the TDI, are going to be tied to the exposure 19 that the bird actually gets in any particular hour? 20 DR. MOORE: That...that's independent of 21 how much exposure they get. 22 DR. PORTIER: So, how does the exposure 23 come in? 24 DR. MOORE: Well, once you have a 25 concentration in all the dietary items...



	EPA MEETING 02/06/08 CCR# 15796-2 Page 191
1	DR. PORTIER: Right.
2	DR. MOORE: you know what the
3	ratethe intheir intake rate and how much they get
4	from the field. You have an hourly dose.
5	DR. PORTIER: Right.
6	DR. MOORE: The adjustment that's made
7	for preceding dose is the avoidance function. So, we
8	calculate an hourly dose, and then we look at how much
9	they've accumulated so far and figure out how much they
10	would reduce their food intake rate, and we reduce that
11	current time step exposure accordingly. And
12	thatthat's how previous exposure factors into
13	current exposure.
14	DR. PORTIER: Okay. Thethe
15	discussion onwhat was itfigure 42 which talked
16	aboutI wasn't quite sure what that slide had to do
17	with any of the other slides.
18	DR. MOORE: It wasit was really
19	addressing a comment from EPA. As you noted, the
20	concentrations, once we figure out the initial
21	concentration in the field, decay, and we assume no
22	intrafield variability. Thatnow, but EPA raised the
23	concern that there is, of course, intrafield
24	variability with dietary residues, and some of the
25	coefficients of variation are listed on that slide, but



	EPA MEETING 02/06/08 CCR# 15796-2 Page 192
1	what I wanted to make the point of is that it's not
2	that important once you account for bird foraging
3	behavior.
4	The birds spatially and temporally average
5	their exposures, because they are making multiple trips
6	into the field, and so, all I was trying to do with
7	this example, very simple example, is convey how the
8	importance of variability in dietary residue within a
9	field is reduced as a result of that spatial and
10	temporal average.
11	DR. PORTIER: I understand.
12	Slidereal quickly, please, slide 44 is your
13	avoidance behavior curve. Now, if I was aif I gave
14	this to a student statistician, they would put a
15	straight line through zero that would actually be
16	sharper than your line and would have uncertainty of
17	about plus or minus 25 percent at every dose. Right?
18	In yourin your model, you're not using any of the
19	uncertainty
20	DR. MOORE: No.
21	DR. PORTIER:and you're using a
22	curve which I don't believe fits the data.
23	DR. MOORE: Thatthat curve fits the
24	data. The statistics are discussed in ourour
25	report. It's a significant fit.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 193
1	DR. PORTIER: Just not
2	DR. MOORE: Yeah, is it messy?
3	Absolutely, it's messy. I would very much like to, in
4	a future iteration of the model, try to introduce the
5	uncertainty into that. Computationally, it's
6	difficult, because in each time step, you know, we have
7	to randomly figure out how much draws from thatso,
8	we figure out what the preceding dose was and then
9	randomly draw from the distribution to account for the
10	error and do that for each time step for each of 20,000
11	birds.
12	Even that is easy, but the problem here is
13	this noise represents variation between birds, not
14	between time steps within a bird. So, I would
15	actuallywhat I would suppose is that this curve is
16	different for every bird, and you would somehow have to
17	account for that in a model.
18	Thatthat's just an ordinary way of saying
19	computationally, it's a very difficult exercise.
20	Conceptually, I completely agree with you.
21	DR. PORTIER: And thethe last one is
22	45. And on this one, I understand how you've created
23	these three parallel lines, andand I talked with my
24	statistician colleague, and neither one of us believe
25	that thethat the 05 or the 95 percent lines would be



	EPA MEETING 02/06/08 CCR# 15796-2 Page 194
1	exactly parallel if youand thenand we're not
2	going to argue this, and we can talk about this on the
3	side, but I would have expected the line on the left to
4	be tilted more. The slope would change.
5	Because what you're assuming here is you're
6	just shifting the mean of the distribution. You're not
7	affecting the slope at all, and the slopethe slope
8	being the variants of the distribution. So, you're
9	saying the variants of the distribution of lower
10	percentiles is going to have the same variants as the
11	distribution of the median, and that's just not going
12	to be the case, but I understand how you did it.
13	DR. MOORE: Oh, II'm not sure I agree
14	with that. What the variants of any one of those
15	curves represents is variation in sensitivity of
16	individuals within a bird species, and I'm not sure why
16 17	individuals within a bird species, and I'm not sure why I would expect variation in sensitivity to be different
17	I would expect variation in sensitivity to be different
17 18	I would expect variation in sensitivity to be different fromin a systematic way from one species to the
17 18 19	I would expect variation in sensitivity to be different fromin a systematic way from one species to the next, but, you know, there's not enough data to answer
17 18 19 20	I would expect variation in sensitivity to be different fromin a systematic way from one species to the next, but, you know, there's not enough data to answer that.
17 18 19 20 21	I would expect variation in sensitivity to be different fromin a systematic way from one species to the next, but, you know, there's not enough data to answer that. DR. PORTIER: I was going to say if you
17 18 19 20 21 22	I would expect variation in sensitivity to be different fromin a systematic way from one species to the next, but, you know, there's not enough data to answer that. DR. PORTIER: I was going to say if you go back and you look at your slide 14, you actually see



	EPA MEETING 02/06/08 CCR# 15796-2 Page 195
1	insight into, I see variants changes, slope changes.
2	DR. MOORE: But if you go to the next
3	slideyou have that? Oh, no, we don't have. You may
4	have to make the plots with mallards andand bobwhite
5	quail, and actually, slopes don't look that different,
6	but, I mean, there are only a limited number of slopes
7	that have been reported in the literature. For
8	carbofuran for birds, they're all steep, and is there
9	variation in slope? Absolutely. Is it systematic
10	according to sensitivity of the birds? I'm not sure of
11	that. I'd have to look into the data.
12	But there isthey're all steep. They're
13	all fairly close together. So, that's why we made the
14	assumption ofof equal slopes for our three
15	hypothetical species.
16	And I would further note that this is the
17	exact same approach that's taken in TIM Version 1 and
18	2.
19	DR. PORTIER: I don't doubt that. The
20	other thing is if you shift those lines, you shift it
21	in 3.8x over, again, you have no data to show that the
22	slopes never vary, the slope of that line doesn't shift
23	as well.
24	DR. MOORE: You're right.
25	DR. PORTIER: Which means that you could



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 196
1	be sliding over, but some of the lower bound ones would
2	still beso, anyway, the point made.
3	DR. MOORE: Yeah, II can comment on
4	that one. For a bobwhite quail which is one
5	withwhere we have more treatments, we did do aa
6	pointed curve for the aqueous bolus treatment and the
7	food matrix bolus treatment, and once you do that, you
8	can calculate, say, an LC5, an LC50, and an LC95. It
9	varies from 3.84 at the low end to 3.94 at the high
10	end.
11	DR. PORTIER: Oh, okay, that helps.
12	DR. HEERINGA: Okay, I'm going to have
13	to draw the question and answer period on this
14	particular presentation to a close simply because we
15	have three more presentations to finish, I think,
16	today. I want to thank Dr. Solomon and Dr. Moore and
17	the panelists.
18	I think, panelists, if there are critical
19	items, and I know several of you are raising your
20	hands, I think that we can get them answered at the
21	break. Obviously, if you have a conversation, you need
22	to report it back here publicly in terms of any
23	findings that would influence your recommendation.
24	So, at this point in time, we're going to
25	make an exception in the agenda. We're goingI'm



	EPA MEETING 02/06/08 CCR# 15796-2 Page 197
1	going to ask Mr. Ray Youngand this has been approved
2	by the relevant partieswho is a farmer and crop
3	consultant with Young & Young Consultants, I believe
4	with his son. He has a short public presentation, and
5	then we will return to the sequence of presentations by
6	FMC.
7	Mr. Young?
8	MR. YOUNG: My name is Ray Young, and
9	I'd like to thank Dr. Matten for giving me the
10	opportunity to speak to this distinguished panel here
11	today. I'm an independent crop consultant and a farmer
12	in northeast Louisiana.
13	By independent, I mean that we deal with
14	individual growers and that our business is in no way
15	concerning with crop sales.
16	I grew up in the '30s with my family, farming
17	cotton. We plowed the mules, chopped the cotton, and
18	picked the cotton. In 1931, my two older brothers went
19	to the Navy, and I was left to farm by myself at a
20	pretty young age, but during that time, I like to say
21	that we used nicotine sulfate to control aphids, and we
22	used Paris green to control leaf worms. Pretty bad
23	combination when you shook it out with a cloth flour
24	sack behind and you're through it.
25	In 1939, I began scouting cotton. That was



	EPA MEETING 02/06/08 CCR# 15796-2 Page 198
1	the very beginning of agricultural consulting as a
2	profession asas we know it today. I received a
3	bachelor's degree from Louisiana Tech in agriculture in
4	1950. I served four years in the Navy as a carrier
5	pilot. I returned to civilian life, enrolled in LSU,
6	and received a master's degree in entomology in 1957.
7	I'm still actively involved in farming and
8	consulting with my son, Jesse. We give advice to
9	growers on every phase of crop production from seed
10	selection to harvest preparation. For the purpose of
11	my discussion today, I'll limit my remarks to our
12	dealing with insect control.
13	In our business, we're constantly on guard to
14	prevent insect resistance. This is a problem that
15	we've encountered through the years, and wewe deal
16	with this problem by alternating chemistry.
17	My first experience with insect resistance
18	was in 1955, cotton boll weevil that was living through
19	the chlorinated hydrocarbons. That was not a pretty
20	scene.
21	Since that time, we have seen resistance
22	develop in several classes of chemistry and several
23	insects, including the tobacco bollworm, the tobacco
24	bloodworm, tarnished plant bugs, and the cotton aphids.
25	There have been problems with aphids



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 199
1	sporadically throughout the cotton belt for many, many
2	years. It's sporadic occurrences, but you never know
3	when they'll show. Aphids develop resistance very
4	rapidly because of the frequency of generations. If
5	you look at figure 1, you'llyou'll see an
6	overlapping of generations.
7	Aphids develop through a process known as
8	parthenogenesis. That means that they give live birth
9	to fertilized females. Generations occur in 7 or less
10	days, depending upon temperatures.
11	So, you can see that these insects can very
12	quickly wrap up a whole plant, and when they do, they
13	damage that plant very quickly. These aphids excrete a
14	liquid called honeydew. That honeydew goes onto the
15	green leaves, setting on a fungus forms and grows and
16	interferes with photosynthesis. When that honeydew
17	gets on the lint as the lint begins to open, as the
18	bolls open, it causes a set of mold, and this
19	destroysdestroys quality and, hence, the price.
20	Over the years, many products haveaphids
21	have gotten resistant to many of the classes ofof
22	insecticides, the organochlorines, organophosphates,
23	synthetic pyrethroids, and some carbamates. Furidan is
24	a product that is effective. It has been effective
25	through the years. We've trusted it, and we return to



	EPA MEETING 02/06/08 CCR# 15796-2 Page 200
1	it for our worst case aphids.
2	For the past several years, we've had a new
3	type of chemistry called the neonicotinoids that have
4	worked quite well until the last couple of years, but
5	we are beginning to see a weakness, because they've
6	been applied to a good portion of the crop producing
7	area. As we lose these products, we'll lose control.
8	If you look at figures 5 and 6, look at
9	figure 5 first. That's in 2052005. You'll see that
10	all products at 7 days gave excellent control of
11	aphids, 70, 84, 80 percent control. And that's at a
12	half rate for Intruder and Synthra.
13	Now, look at figure 6, and you'll see that in
14	2006, these products, at full label rates, were less
15	than adequate control. You will note, however, that
16	Furidan stands out among the bunch as still being very
17	effective.
18	We had one failure a couple of years ago, and
19	in that failure, furidan was granted on section 18, and
20	it cleaned the aphids up very nicely. If we lose
21	furidan, we lose a very important resistance management
22	tool.
23	Cotton is a vital part of the production of
24	agricultural products across the southern United
25	States. Furidan is a vital product for managing



EPA MEETING 02/06/08 CCR# 15796-2 Page 201 1 insects in cotton. We don't need to lose this 2 important resistance management tool. 3 I feel very strongly about this testimony 4 because of my experience with insect resistance through 5 the years and my experience growing cotton for the past 6 67 years. 7 I thank you for your attention, and I 8 appreciate your working me into your busy schedule, Dr. 9 Matten. I would be happy to attempt to answer any 10 questions that you might have. 11 DR. HEERINGA: Thank you, Mr. Young. 12 Any questions for Mr. Young? 13 (No response.) 14 DR. HEERINGA: Thank you for that 15 presentation. 16 Thank you very much. MR. YOUNG: 17 DR. HEERINGA: An example of 18 conciseness. 19 I've been informed of the Designated 20 Federal...by the Designated Federal Official we need to 21 have a short administrative meeting of the panel in our 22 breakout room, so I'm going to call a break, and when 23 we return, we'll resume with the...the next of the 24 public presentations. Panel members, if you could just 25 join us here.



EPA MEETING 02/06/08 CCR# 15796-2 Page 202 1 (WHEREUPON, a brief recess was taken.) 2 DR. HEERINGA: As soon as we have a 3 Designated Federal Official, we'll get underway. Okay, 4 we're ready. Okay, we're...we're going to be ready to 5 resume, and before we begin with the next presentation, the Designated Federal Official, Sharlene Matten, has a 6 few clarifying comments. 7 8 DR. MATTEN: Yes, this is Sharlene 9 Matten. I...I just wanted to clarify a remark or a set 10 of remarks that were made this morning about the 11 Federal Advisory Committee Act and duplication of 12 efforts. 13 EPA has a longstanding policy of trying not 14 to do the exact same charge between two different 15 Federal Advisory Committees, one being the Human 16 Studies Review Board and the Scientific Advisory Panel. 17 After much discussion, a new light has been shed that 18 there...there may be some nuances in understanding of 19 different scientific questions that weren't addressed 20 specifically by the Human Studies Review Board that 21 could be available for some sort of discussion of those 22 very same studies that had a specific set of charge 23 questions related to them. 24 And so, the panel may have some discussion on 25 these studies related to those specific set of issues



	EPA MEETING 02/06/08 CCR# 15796-2 Page 203
1	that weren't previously addressed that wouldn't overlap
2	two difoverlap charges between two different federal
3	advisory committees. And, hopefully, that makes some
4	sense.
5	I'm a little overwhelmed by the number of
6	attorneys that have been advising over the last several
7	hours, but II hope that clarifies things just a
8	little bit. It doesn't completely clarify it for me,
9	butso, I think you can continue.
10	DR. HEERINGA: I think we will continue.
11	That'sthat's probably the bestbest step to take
12	at this point. And, again, just to reiterate, our
13	focus here is on full scientific exploration and
14	development of the issues at hand, and we're going to
15	do that, and we'll accommodate processes and legalities
16	and everything else as we go, and thank you very much.
17	And I apologize to the audience for the
18	abrupt recess there, but we're ready to move on now,
19	and we are, I think, to the next of the presentations,
20	and this is the worker risk presentation.
21	DR. LAMB: That's correct.
22	DR. HEERINGA: And Dr. James Lam of the
23	Weinberg Group, is going to be the leader.
24	DR. LAMB: That's me. I'm Jim Lam. I'm
25	with the Weinberg Group, and I was asked by FMC to



	EPA MEETING 02/06/08 CCR# 15796-2 Page 204
1	review the toxicology data, and in this presentation,
2	I'll talk for a very surprisingly short time about the
3	worker data on the toxicology relative to the worker
4	risk assessment, and then Dr. Jeffrey Driver will talk
5	about the exposure, occupational exposure assessment.
6	In the first slide is simply an outline of
7	the major issues that I will cover. The outline may
8	give you a sense this is longer than it really is. I
9	really think that this is going to be 15 minutes' worth
10	of touching on what to ask as the most important issue.
11	Ultimately, worker risk assessment is
12	evaluated by comparing the point of departure to
13	potential field exposures, and they look for margins of
14	exposure andI hope everybody can hear methe
15	margins of exposure generally need to be 100 or more.
16	Thethe bottom line comes to that EPA's calculations
17	in the Notice of Intent to Cancel and the interim red
18	have scenarios for the selection of point of departure
19	and exposure assessment that gets you to less than 1 to
20	about 50, so they are considered by EPA to be
21	unacceptable.
22	FMC's worker risk assessment actually
23	demonstrates that the occupational exposures are
24	acceptable with margins of exposures between 110 and
25	3400, and I will explain that as we go through.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 205
	But there are really two major issues. One
2	is the issue I will talk about, and the other is the
3	issue that Dr. Driver will talk about. First, EPA's
4	assessment, I think as you already know, doesn't use
5	the guideline dermal toxicology study. Instead, they
6	have taken an oral toxicology study.
7	Both look at brain acetylcholinesterase, and
8	then they take the oral study and adjust using the
9	dermal absorption factor from the Shaw study.
10	My position is that you should be relying on
11	the der21-day dermal study. No absorption factor is
12	necessary in this approach.
13	Dr. Driver will talk about that EPA's
14	position is relying more on older exposure assessment
15	tools, and he'll be talking about the new exposure
16	assessment methodology that isthat is being used by
17	EPA, but it's not being used yet by EPA in this
18	assessment.
19	There isvery quickly, because I know
20	you've heard all this stuff beforethe margin of
21	exposure is, basically, take the point of departure for
22	the critical adverse effect and divide it by exposure,
23	and we're looking for margins of exposure greater than
24	100 for acceptable uses. The EPA approach and the FMC
25	approach basically end up with numbers that differ by



	EPA MEETING 02/06/08 CCR# 15796-2 Page 206
1	two orders of magnitude so that if you took the same
2	exposure number which, in this example, is 0.016
3	mg/kg/day, that the two different points of departure,
4	you would end up with very different margins of
5	exposure.
6	Bottom line as a toxicologist is that the
7	point of departure, the selection of the point of
8	departure, the study that you're using to select that
9	point of departure is critical. Typically, EPA will
10	use dermal toxicology studies for pesticide mixers,
11	loaders, and applicators.
12	Just to make this really clear, the interest
13	here is adults, and it is dermal exposure. It is
14	usually done that they use a 21 or 28-day rat or rabbit
15	dermal toxicology study, and there are testing
16	guidelines that exist that describe the testing methods
17	and the endpoints that need to be evaluated.
18	These are examples of studies, carbamates and
19	organophosphates, where that approach has been taken.
20	Theand we will get atthis is simply to give you a
21	sense that this is not aan issue of first
22	impression.
23	EPA, though, in this particular case, has
24	used an oral point of departure of 0.02 mg/kg. It's
25	based on adult rat acetylcholinesterase inhibition, and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 207
1	it has to be, since it's an oral study and our concern
2	is primarily dermal exposure, it has to be adjusted for
3	dermal penetration.
4	The study that they have and have relied upon
5	for that is the Shaw study, and I think Dr. Shaw was up
6	here earlier today. They, like us, are looking for
7	margins of exposure that are actually greater than or
8	equal to 100, but typically, they only take this
9	approach when they lack valid dermal toxicology
10	studies.
11	Inin this case, they basically classified
12	a valid study as unacceptable and leads them back to
13	this position. They've rejected the use of the dermal
14	study, and I believe that is, in fact, an error.
15	The studies are thatthat the 21-day rat
16	dermal study was submitted. FMC has used this. Now,
17	this study was created in response tothere was
18	already a rabbit dermal study submitted to EPA. It's
19	my understanding that EPA was not satisfied with the
20	findings, that thethey didn't believe the no
21	observed adverse effect level could be that high, and
22	so that they asked for another study.
23	It's also my understanding that at that point
24	in time, they did not ask for pharmacokinetic data or
25	time to effect or time to peak response. They asked



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 208
1	for a dermal toxicology study.
2	There are also human dermal studies. I think
3	you've already heard a little bit about the issues in
4	these. I really don't see that the human studies play
5	much of a role in this case in any event.
6	But the review of the 21-day dermal study
7	does. In the EPA data evaluation record, basically,
8	they rejected the study specifically because the
9	information did not include time of onset, time of
10	peak, and time until recovery. That sort of
11	pharmacokinetic or pharmacodynamic information is not
12	in the guidelines for the dermal toxicology study, it
13	wasn't requested by EPA, and as far as I know, it
14	hasn't been used in a worker risk assessment.
15	I have an example where it was asked for, for
16	example, on carbaryl. It's not even clear it was used
17	even after they got those data, but I think, actually,
18	more important thanthan the administrative aspects
19	of this is whether or not the data are really needed.
20	The most appropriate study is the one done by
21	the same route of exposure. The toxicology study to
22	evaluate dermal risk, the best one is the dermal
23	toxicology study. They have a good study in their
24	file. It's the same as has been used or very similar
25	to those used for other carbamates and other



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 209
1	organophosphates.
2	We need to talk a little bit about some of
3	the specifics, because I'm afraid there may have been
4	some confusion about the study this morning. It was a
5	6-hour exposure. Now, my understanding of what I heard
6	this morning from EPA was they want now time to effect.
7	At the end of the 6 hours, they would want sequential
8	evaluations. That's what I heard.
9	This study was done with a protocol specified
10	that no sacrifice shouldshould be later than 6 hours
11	after the exposure ending. I have to admit that we
12	went back and looked at the time to collection. The
13	average was 6 minutes. So, they cleanthey dosed for
14	6 continuous hours.
15	Now, this is a product with a pretty fast
16	half-life. They dosed for 6 hours, and right at the
17	end of that, they cleaned the site, and within an
18	average of 6 minutes, 7 for females, 6.1 exactly for
19	males, theythe animals were killed, the samples were
20	collected.
21	Thethethere were 2 animals that were 12
22	minutes after sacrifice, 1 was 11. All the rest were
23	10 minutes or less.
24	There was not timemy opinion is that
25	it'sI have no data in the rat with carbofuran, but



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 210
1	if what they wanted was a 6-hour exposure and then we
2	start looking at response, itit's nearly implausible
3	to me that the response is going to go up after we've
4	cleaned the application site. And so, the rapid
5	sacrifice was considered important, and that's the way
6	the study was done.
7	Out of that study, brain acetylcholinesterase
8	was evaluated. The no observed adverse effect level in
9	that study was 50 mg/kg/day. There was significant
10	suppression at 250, the next highest dose level. There
11	are a couple of dose levels below this which confirm
12	the lack of inhibition of brain or RBC cholinesterase.
13	In our opinion, and we hope the SAP will
14	consider this very seriously, that this study should be
15	accepted and used in the risk assessment. This is the
16	best model, the best science that's available at this
17	point in time.
18	Now, the other points, in addition to the 6-
19	hour exposure giving time for the peak to occur and
20	then, according to typical guidelines, and sacrifice
21	pretty quickly, thethe only value that I would say
22	the human study might provideand I'm really not
23	going to push this very hard; I don't think it's that
24	importantis whether or notis basically the human
25	study does show somethat the peak did come on. It



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 211
1	came on slowly.
2	There's also a carbaryl absorption
3	disposition metabolism and excretion study. It's a
4	different carbamate. It's at relatively high dose
5	levels, but it does show that dermal penetration
6	continued in that study pretty much throughout the
7	study.
8	And there's not a whole lot else I can offer
9	you in the science.
10	The RBC data they listed as part of the
11	reason this study was rejected as well. The real focus
12	was the lack of pharmacokinetic data, but I wanted to
13	address the point of variability in the RBC data in
14	this study.
15	As you can see from these coefficients of
16	variationand youI will say, too, that the FMC
17	reports that you've seen to date typically show
18	standard deviations. EPA's show standard errors. So,
19	with group sizes that are generally 10, our bars are
20	going to be three times bigger than everybodythan
21	the EPA ones, and that really is more the reason you
22	see this variation. These were not group sizes of 2 or
23	3 animals. I just want to be really clear on that.
24	But the coefficients of variation in this
25	study are not remarkable. They're not huge.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 212
1	The weaknesses of the current approach
2	proposed by EPA is it's ignoring a valid study, a valid
3	dermal tox study. It calls for unnecessary
4	manipulation of the oral toxicology data. And they're
5	approach, in fact, does not address that very
6	pharmacokinetic information that they're asking that be
7	provided through the dermal study.
8	Also, the dermal study was not designed for
9	this purpose, so to be fair, it was done 20 years ago,
10	designed for a different purpose, and those data are
11	limited.
12	You don't have the raw data which, in our
13	case, of course, any FMC study goes to the Agency with
14	all the underlying raw data in considerable detail.
15	The approach that was taken was sampling
16	times of 2 hours and 24 hours andand afterwards as
17	well meant that the exposure continued all the way out
18	to 24 hours. Acetone was used as a vehicle. That has
19	a high likelihood that it would enhance absorption of
20	the material because of the breakdown of the skin.
21	They didn't clean the application site, as I
22	mentioned, and also, they did not, in that study,
23	because it was not designed for this purpose, they
24	didn't measure acetylcholinesterase or its inhibition.
25	Their approach, the EPA approach, frankly,



1does not improve the risk assessment. They don't model2the workday the way they developed it. The oral study3and the dermal penetration data together do not provide4information on dermal pharmacokinetics5The bethe preferred method is, frankly, the use of6the dermal toxicology study that's been provided.7These were 21 consecutive days of treatment. I think8you heard this morning it was 5 days a week, and that9really isn't correct, but I completely agree with10Ginger Moser that itit doesn't matter. The 1st day11is probably going to be pretty much the same as the1221st. So, I'mI don't think it makes any difference13whether it was 5 or 7. It was 7, and the sacrifice was14within minutes of the end of the treatment.15And bottom line is you should be using the1621-day dermal study. The point of departure should be17the BMDL of 50, that they shouldEPA should not be18rejecting the study on the basis of this19pharmacokinetic data requirement.20And with that, I'm going to pass the21microphone to Dr. Driver to move on to worker exposure22and then you can askit's up to you, Dr. Heeringa.23DR. HEERINGA: That's what I was going24to suggest, and I want to thank you for conciseness and		EPA MEETING 02/06/08 CCR# 15796-2 Page 213
and the dermal penetration data together do not provideinformation on dermal pharmacokinetics55566677777788999	1	does not improve the risk assessment. They don't model
 information on dermal pharmacokinetics The bethe preferred method is, frankly, the use of the dermal toxicology study that's been provided. These were 21 consecutive days of treatment. I think you heard this morning it was 5 days a week, and that really isn't correct, but I completely agree with Ginger Moser that itit doesn't matter. The 1st day is probably going to be pretty much the same as the 21st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going 	2	the workday the way they developed it. The oral study
5 The bethe preferred method is, frankly, the use of 6 the dermal toxicology study that's been provided. 7 These were 21 consecutive days of treatment. I think 8 you heard this morning it was 5 days a week, and that 9 really isn't correct, but I completely agree with 10 Ginger Moser that itit doesn't matter. The 1st day 11 is probably going to be pretty much the same as the 2 21st. So, I'mI don't think it makes any difference 13 whether it was 5 or 7. It was 7, and the sacrifice was 14 within minutes of the end of the treatment. 15 And bottom line is you should be using the 21-day dermal study. The point of departure should be 17 the EMDL of 50, that they shouldEPA should not be 18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	3	and the dermal penetration data together do not provide
6 the dermal toxicology study that's been provided. 7 These were 21 consecutive days of treatment. I think 8 you heard this morning it was 5 days a week, and that 9 really isn't correct, but I completely agree with 10 Ginger Moser that itit doesn't matter. The 1st day 11 is probably going to be pretty much the same as the 12 21st. So, I'mI don't think it makes any difference 13 whether it was 5 or 7. It was 7, and the sacrifice was 14 within minutes of the end of the treatment. 15 And bottom line is you should be using the 16 21-day dermal study. The point of departure should be 17 the BMDL of 50, that they shouldEPA should not be 18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 21 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	4	information on dermal pharmacokinetics
 These were 21 consecutive days of treatment. I think you heard this morning it was 5 days a week, and that really isn't correct, but I completely agree with Ginger Moser that itit doesn't matter. The 1st day is probably going to be pretty much the same as the 21st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going 	5	The bethe preferred method is, frankly, the use of
8 you heard this morning it was 5 days a week, and that 9 really isn't correct, but I completely agree with 10 Ginger Moser that itit doesn't matter. The 1st day 11 is probably going to be pretty much the same as the 22 lst. So, I'mI don't think it makes any difference 13 whether it was 5 or 7. It was 7, and the sacrifice was 14 within minutes of the end of the treatment. 15 And bottom line is you should be using the 21-day dermal study. The point of departure should be 17 the BMDL of 50, that they shouldEPA should not be 18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	6	the dermal toxicology study that's been provided.
 ¹ really isn't correct, but I completely agree with Ginger Moser that itit doesn't matter. The 1st day is probably going to be pretty much the same as the 21st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going 	7	These were 21 consecutive days of treatment. I think
10 Ginger Moser that itit doesn't matter. The 1st day 11 is probably going to be pretty much the same as the 21 21 st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. 15 And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. 20 And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	8	you heard this morning it was 5 days a week, and that
11 is probably going to be pretty much the same as the 2 21st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going	9	really isn't correct, but I completely agree with
12 21st. So, I'mI don't think it makes any difference whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going	10	Ginger Moser that itit doesn't matter. The 1st day
 whether it was 5 or 7. It was 7, and the sacrifice was within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going 	11	is probably going to be pretty much the same as the
 within minutes of the end of the treatment. And bottom line is you should be using the 21-day dermal study. The point of departure should be the BMDL of 50, that they shouldEPA should not be rejecting the study on the basis of this pharmacokinetic data requirement. And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going 	12	21st. So, I'mI don't think it makes any difference
15And bottom line is you should be using the1621-day dermal study. The point of departure should be17the BMDL of 50, that they shouldEPA should not be18rejecting the study on the basis of this19pharmacokinetic data requirement.20And with that, I'm going to pass the21microphone to Dr. Driver to move on to worker exposure22and then you can askit's up to you, Dr. Heeringa.23DR. HEERINGA: That's what I was going	13	whether it was 5 or 7. It was 7, and the sacrifice was
 16 21-day dermal study. The point of departure should be 17 the BMDL of 50, that they shouldEPA should not be 18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going 	14	within minutes of the end of the treatment.
17 the BMDL of 50, that they shouldEPA should not be 18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	15	And bottom line is you should be using the
18 rejecting the study on the basis of this 19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	16	21-day dermal study. The point of departure should be
19 pharmacokinetic data requirement. 20 And with that, I'm going to pass the 21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	17	the BMDL of 50, that they shouldEPA should not be
And with that, I'm going to pass the And with that, I'm going to pass the microphone to Dr. Driver to move on to worker exposure and then you can askit's up to you, Dr. Heeringa. DR. HEERINGA: That's what I was going	18	rejecting the study on the basis of this
21 microphone to Dr. Driver to move on to worker exposure 22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	19	pharmacokinetic data requirement.
22 and then you can askit's up to you, Dr. Heeringa. 23 DR. HEERINGA: That's what I was going	20	And with that, I'm going to pass the
23 DR. HEERINGA: That's what I was going	21	microphone to Dr. Driver to move on to worker exposure
	22	and then you can askit's up to you, Dr. Heeringa.
24 to suggest, and I want to thank you for conciseness and	23	DR. HEERINGA: That's what I was going
	24	to suggest, and I want to thank you for conciseness and
25 the base of your presentation.	25	the base of your presentation.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 214
1	DR. LAMB: No problem. Thank you.
2	DR. HEERINGA: Dr. Driver?
3	DR. DRIVER: Thank you very much. Thank
4	you, panel, for your continued endurance. I'd like to
5	briefly turn your attention to the carbaryl worker
6	exposure risk analysis.
7	SPEAKER: Carbofuran.
8	DR. DRIVER: Carbofuran. Sorry. Pardon
9	me. Thethe purpose of the impact ofor the
10	purpose of my presentation is to demonstrate the impact
11	of using what we propose is the appropriate toxicology
12	benchmarks, route-specific benchmarks, as well as the
13	best available exposure monitoring data.
14	My outline includes a brief overview,
15	contrasting EPA's assessment with what we're proposing.
16	I'd then like to, by way of background, just discuss
17	the routes of exposure and the more simplistic exposure
18	assessment algorithm that's used for tier 1
19	deterministic calculations in contrast to relevant
20	stochastic modeling you saw earlier, so I'll bring you
21	back to elementary school math, the exposure reduction
22	via closed systems that arethat are used by
23	carbofuran, and I comment on those engineering
24	controls, and also the exposure monitoring data that
25	are available to inform the exposure analysis, and then



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 215
1	my results and conclusions.
2	So, with respect to an overview, as we heard,
3	EPA's assessment did address both dermal and inhalation
4	routes for workers, appropriately. Inin both cases,
5	the toxicology benchmark was based on oral routes,
6	BMDL10, necessitating, in thein the case of the
7	dermal route, an absorption factor. As has been
8	pointed out, this inherently assumes, then, that the
9	dermal exposure results inin essentially an
10	instantaneous bolus of pure dose, if you will, via the
11	dermal route as it's compared, then, to an oral
12	benchmark dose.
13	The exposure estimates were, appropriately
14	for a tier 1 assessment, based on standardized
15	scenarios in the Pesticide Handler's Exposure Database
16	and associated assumptions. The resulting MOEs are
17	listed here at the bottom of the slide. Asas has
18	been mentioned, they range from approximately 1 to 50.
19	On the right-hand side, we see FMC's refined
20	assessment. In this case, as Jim had mentioned, we're
21	looking at the dermal toxicology studies, the basis for
22	the dermal benchmark.
23	In the case of the inhalation route, as is
24	commonly done in the absence of an inhalation study for
25	this compound, carbofuran, it's based on an oral point



	EPA MEETING 02/06/08 CCR# 15796-2 Page 216
1	of departure. In this case, a value was selected
2	representing that derived by EPA for children which
3	would be protective for adults as well.
4	In this case, no dermal absorption factor
5	would be necessary, of course. We're using applied
6	dose dermal NOEL to compare to external dermal exposure
7	on the workers as you estimate it.
8	The exposure estimates, then, as the next
9	bullet indicates are based on data specifically
10	selected to represent exposures for workers involved in
11	using engineering controls that are used for carbofuran
12	in liquid applications.
13	In addition, we made some respiration rate
14	adjustments that I'll talk about for activity level
15	specific tasks that workers are undertaking. The
16	contrasting MOEs are listed there, ranging from 110 to
17	3400.
18	This difference in the MOEs, in part,
19	obviously, is due to the difference in the toxicology
20	benchmark associated with the dermal route. These are
21	total MOEs, by the way, across both the inhalation and
22	dermal routes. So, the difference, obviously, is
23	largely, in part, related to the difference in the tox
24	benchmark but also inin terms of the exposure
25	estimates, as I will explain.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 217
1	By way of background, the primary route of
2	exposure inin most worker situations is the dermal
3	route, followed by inhalation. Engineering controls
4	can mitigate and, in both cases, reduce exposure
5	significantly. Carbofuran has very low vapor pressure,
6	so dermal route isis typically the largest exposure
7	route of interest.
8	The exposure algorithm, very simply stated
9	here, is a function of the amount handled, as far as
10	what we refer to as the unit exposure metric divided by
11	body weight. The amount handled is typically expressed
12	as pounds of active ingredient handled. The amount
13	handled often is assumed to be a maximum application
14	rate, maximum acreage treated, so we're biasing that
15	towards an upper end of the distribution. Wewe
16	intend to do that.
17	The unit exposure is typically expressed as
18	mg of exposure per lb of AI handled.
19	I'd like toto briefly inform you about
20	closed system technologies. The worker protection
21	standard developed by EPA has defined thethese
22	technologies, properly functioning systems that enclose
23	the pesticide, of course, and prevent it from
24	contacting handlers or other persons, and studies have
25	been done and summarized that demonstrate, in this



	EPA MEETING 02/06/08 CCR# 15796-2 Page 218
1	case, the mean reduction in exposure relative to
2	conventional open mixing and loading, 96.8 percent.
3	This was from five studies that the California's EPA's
4	Department of Pesticide Regulations had reviewed.
5	The systems specifically used with carbofuran
6	include the micromatic drum valve system. I have some
7	examples here, and this would be fit to a 110-gallon
8	mini bulk container or a 15-gallon returnable
9	container. There's also a smaller container, 2.5
10	gallon, that utilizes a secure LG system.
11	Just for purposes ofof reminding us, this
12	is a picture of an open mixing and loading system,
13	obviously. This is not what's used with
14	carbarylcarbofuran. Sorry. I'll get it right
15	eventually.
16	This diagram actually shows the micromatic
17	drum valve system, and it basically creates a drwhat
18	we refer to as a dry lock system that minimizes the
19	leakage. Technical specifications for this type of
20	system would be approximately 1 ml residue leaking or
21	less. Obviously, that's going to significantly reduce
22	operator exposure, and there are a variety of other
23	benefits that are mentioned here.
24	The schematic in the lower right-hand column,
25	if you can actually see that, just shows in black there



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 219
1	where these valves would be located at the top of the
2	container. We actually have a container here to your
3	right. Okay, I'll keep going.
4	So, what my friend, Dan O'Ryan, is now
5	picking up is the largerthis actually is the 25-
6	gallon containeror is that 15? 15, sorry, 15 gallon
7	container. The valve system is on the top, the
8	stainless steel valve system, so thatthat's
9	obviously dry locks. The hose, then, would be
10	connected to the top of that valve system, creating a
11	sealed container forthesethese containers
12	actually can be returned andand re-used after
13	appropriate rinsing.
14	There's a smaller container here at the
15	bottom here, too, that you can look at at your leisure.
16	Here's a picture of the secure NG closed
17	system for the 2.5-gallon. It's basically aa valve,
18	a top, you see, that screws on the container, again,
19	creating a secure system. There's some pictures on the
20	graph here and some more that you can read about if
21	you're interested.
22	In addition to closed mixing and loading
23	systems, open cabsor closedI'm sorryclosed cab
24	systems are another engineering control that's used
25	with carbofuran. This is an example of the open cab,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 220
1	in contrast, that a tractor operator obviouslyand
2	this happens to be air blast in an apple orchard. In
3	contrast, here's a picture of an enclosed cab ground
4	boom application rig.
5	As indicated in EPA's guidance, enclosed cabs
6	can result in up to 98 percent reduction in both dermal

7 and inhalation exposure. So, in the case of 8 carbofuran, we have these engineering controls that are 9 being used.

10 And so, it's important to use exposure 11 monitoring data, then, that were developed with workers 12 using these controls. So, our proposal is to...to 13 consider those more relevant data. They include data 14 submitted to EPA by the Agricultural Handlers' Exposure 15 Task Force. There also are some data relevant within 16 the Pesticide Handlers' Exposure Database that can be 17 subset and used in addition to...to the AHTTF data. 18 And, finally, I'd also mention that the

inhalation exposure data can be and should be adjusted...and this has been agreed upon through some harmonized discussions with regulatory agencies...task and activity level specific respiration rates. So, persons, for example, piloting an aircraft or driving a tractor would be breathing at a lower rate than someone with a lot of physical exertion.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 221
1	This, just quickly, gives you a map, if you
2	will, of the available exposure monitoring data that we
3	would propose for use. There are two studies from the
4	task force. They've been submitted to EPA, as
5	indicated by theirwhat are referred to as NRID
6	numbers. They provide a total of 22 monitoring units.
7	A monitoring unit can be thought of as a set of
8	measurements for eachfor a unique worker.
9	In addition, two studies have been provided
10	for closed cockpit aerial applicator exposures of
11	liquids.
12	There are also 9 monitoring units completed
13	thus far for a closed cab ground boom application of
14	liquids. However, they haven't been submitted.
15	There are data within the Pesticide
16	Handlers' Exposure Database that can be used, adjusted
17	for an appropriate respiration rate.
18	The next slide just simply provides
19	comparisons of the central tendency values, the unit
20	exposure values expressed, in this case, as g of
21	exposure per pound AI. So, on the left-hand column,
22	you have these three scenarios I've been mentioning,
23	closed system mixing and loading of liquids, fixed wing
24	aerial aircraft applicator exposures, and then the
25	ground boom tractor drivers in enclosed cabs.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 222
1	So, we have both the inhalation and dermal
2	routes and their respective unit exposures for either
3	the PHED data or a refined estimate that has been
4	adjusted based on respiration rate in the case of the
5	inhalation route, followed in the final column with the
6	AHTTF unit exposure values. I have bolded those values
7	that we're proposing for selection.
8	I've indicated the values shown here are
9	geometric means. The values listed here for PHED
10	depend on the best fit analysis within the database.
11	Typically, it's either a log normal or geometric mean,
12	a normal arithmetic mean, or an other categorization in
13	which a median value would be used.
14	The role ofof task force data and other
15	studies, too, that have been collected are going
16	forward and, in the recent past, have been, in fact,
17	the subject ofas well as the existing PHED data have
18	been aa subject of discussion at a recent, January,
19	2007, science advisory panel. Some of the panel
20	members here were involved in that. It was an
21	excellent discussion. Wewe allthere was
22	concurrence about the need to develop new data and a
23	lot of great discussion about how those data should be
24	collected, study design, sample size, and a variety of
25	other statistical considerations.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 223
1	In general, agreement was that additional
2	data would significantly improve the assessments. In
3	fact, the primary purpose of the task force, as you can
4	imagine, is to address some of the deficiencies in the
5	existing data.
6	For example, the upperupper left schematic
7	of the gingerbread man representsthe Os and Xs
8	represent locations of patches, patch dosimeters, small
9	square dosimeters that would be used atat located
10	throughoutacross the various body part areas of an
11	individual. This is sort of the historical method for
12	collecting dermal exposure monitoring data both for
13	outer and inner, outside being outside the clothing and
14	then underneath the clothing.
15	The lower right hand column represents the
16	preferred method which is a whole-body dosimeter. This
17	is an ininner dosimeter that a person would wear
18	underneath their work clothing.
19	There are a number of advantages to the
20	derthat use of the dermal passive dosimeter, in
21	part, for example, as this bullet indicates, in looking
22	at some of the limitations of existing data, including
23	the patch type monitoring, for example, as the first

25 number of measurements for one or more body areas, in

24 bullet indicates, you may often have an inadequate



	EPA MEETING 02/06/08 CCR# 15796-2 Page 224
1	other words, missing patches, so that one would have to
2	extrapolate from another body part area toto
3	estimate a value.
4	There were limitations, skipping down a few
5	bullets, ofof censored data, many values being below
6	the detection limit, particularly with inner
7	dosimeters, and there are some other limitations
8	mentioned here that you could read at your leisure.
9	So, the role ofof collecting data such as
10	those represented by AHTTF are probably obvious, but
11	let me just highlight a few things here for you. The
12	data, as I've mentioned, exist. The data, AHTTF data,
13	do exist for carbofuran representative of closed mixing
14	and loading systems and aerial application. There are
15	examples recently where EPA has also selected those
16	appropriate studies, aldicarb, carbaryl, and I think
17	they could be used here. Those studies were all
18	conducted under good laboratory practices. So many of
19	the historical data sets were not.
20	The limits of quantitation, as you can
21	imagine, analytical sensitivities were lower, so we
22	have a lessa lower proportion of censored data, the
23	use of full-body dosimeters, and, very importantly,
24	joint regulatory committees, EPA, PMRA, California EPA
25	have been involved, staff have been involved in the



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 225
1	design of these studies.
2	Another important aspect is that, from an
3	allometric standpoint, body surface areas are
4	proportionate to the subjects' body weights. I had
5	mentioned respiration rates that are task specific so
6	that non-physiological rates aren't used for low
7	activity tasks.
8	And the data represent full workdays in terms
9	of the monitoring period that they represent.
10	So, these studies can be used preferentially
11	for occupational assessments for liquid pesticides such
12	as carbofuran.
13	As Jim had mentioned, the toxicology endpoint
14	selection is critical. Preferentially, if route-
15	specific data are available that are considered valid,
16	theythey would be used. The dermal assessment can
17	be based, we think in this case, on the dermal 21-day
18	study, and as I had mentioned, the oral point of
19	departure can be used and has been routinely for the
20	inhalation risk assessment.
21	This just provides you with a sampling of
22	total margins of exposure across both routes for three
23	scenarios. The unit exposures used, the acres treated
24	assumed, and the resulting MOEs, cornthese are for
25	corn application scenarios which happens to be the



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 226
1	worst case scenario for carbofuran. Thethe details
2	of our assessment are provided in written materials
3	submitted to the panel, to EPA.
4	And, finally, in conclusion, we would propose
5	consideration of the route-specific toxicology data,
6	the refined exposure monitoring data that would be
7	available, and using those data demonstrates acceptable
8	risks in the case of carbofuran occupational scenarios.
9	Thank you.
10	DR. HEERINGA: Thank you, Dr. Lamb and
11	Dr. Driver.
12	DR. DRIVER: I do have one last slide.
13	I'm sorry.
14	DR. HEERINGA: Sure.
15	DR. DRIVER: Thesethis is just
16	prompts, some questions for the panel to consider
17	whichwhich, I think, are obvious, but, you know, use
18	of the 21-day dermal study in contrast to an oral study
19	and the uncertainties that that may introduce, and,
20	secondly, use of the exposure monitoring data.
21	Thank you.
22	DR. HEERINGA: Thank you very much.
23	Questions for Dr. Lamb or Dr. Driver? Dr. Hattis,
24	okay.
25	DR. HATTIS: Yes, I have two questions.



EPA MEETING 02/06/08 CCR# 15796-2 Page 227 1 You've got geometric means here. What are 2 the associated geometric standard deviations? 3 DR. DRIVER: I don't...I could provide I don't have that with me. 4 that to you. 5 DR. HATTIS: It's not in your written 6 materials or anything? 7 DR. DRIVER: I don't think it is, but I 8 can provide them to you. 9 DR. HATTIS: All right. And then, 10 second, do you have any surveys of actually uses of 11 carbofuran to see how...how often these wonderful new 12 procedures are actually employed? 13 DR. LAMB: Don, do you? 14 DR. HEERINGA: Be sure to introduce you, 15 I think, Dr. Carlson. 16 DR. CARLSON: Yes, my name is Dr. Donald 17 Carlson. I'm with FMC Corporation. 18 Actual surveys, we do not have actual 19 surveys. The equipment itself, as it's been 20 demonstrated, is the only equipment that is available. 21 It is sold only in these types of containers. In the 22 2.5 size, all of it is in 2.5 with the Sotera link G 23 with the exception of California. California requires puncture box systems, and in that case, it goes into a 24 25 puncture box system.



EPA MEETING 02/06/08 CCR# 15796-2 Page 228 1 We do have, obviously, data which is 2 collected by the 6A2 reporting in order to go and look 3 at whether there are affected work incidents of any type, and that is available if you would like to look 4 5 at it. 6 **DR. HEERINGA:** Dr. Brimijoin and then 7 Dr. Edler. 8 DR. BRIMIJOIN: Just a quick one. So, 9 your assessment of the...which...which includes lines 10 on the 21-day rate dermal test study indicates that, in 11 some cases, there are large NOEs and, in other cases, 12 sort of in the...at the border of acceptable, on...on 13 the good side but close. 14 So, what happens to this effect if EPA were 15 to accept the 21-day dermal toxicology study, but given 16 that it has already determined that, in general, the 17 RBC is more sensitive than the brain and has already 18 determined that your RBC data from that study are 19 in...are not acceptable, what...what will that do to 20 your NOEs? 21 DR. LAMB: First, let me make it clear 22 that...and I do actually make it clear in the 23 discussion of the oral study. RBC in adults, EPA even 24 says, is not more sensitive, despite the chart they 25 keep throwing up. That...there's a data point that's



	EPA MEETING 02/06/08 CCR# 15796-2 Page 229
1	in error there, and they have concluded, and I think
2	it's even in the issue paper that you've received, that
3	RBC is not more sensitive than brain.
4	I'll also, in the next presentationbut I
5	can't miss the opportunitywill mention that,
6	obviously, it's very valuable for certain studies, but
7	EPA andand I agreeEPA has said and I agree, it's
8	a surrogate measure. The adverse effect is brain
9	acetylcholinesterase activity, and the inhibition of
10	that activity is the adverse effect.
11	DR. HEERINGA: Dr. Lamb, you should
12	touch off that microphone right next to you.
13	DR. LAMB: I'm sorry.
14	DR. HEERINGA: Other questions? Dr.
15	Edler and then Dr. Lu.
16	DR. EDLER: Lutz Edler, German Cancer
17	Center. I have just a question, Dr. Lamb, about the
18	NOE calculation at 50 mg/kg. I think we have very nice
19	dose response data in this case, so I was wondering if
20	somebody has actually calculated a benchmark dose with
21	these data.
22	DR. LAMB: I don't know that anyone has
23	donewe have not done a benchmark dose calculation.
24	The datathe data, though, show clear inhibition at
25	the five-fold higher dose level of 250 and not



EPA MEETING 02/06/08 CCR# 15796-2 Page 230 1 inhibition at the 50 for brain acetylcholinesterase 2 inhibition. 3 **DR. DRIVER:** And just a correction. In our written report, we did provide a benchmark dose 4 5 calculation for the dermal route. 6 DR. LAMB: I don't think so. 7 **DR. DRIVER:** We didn't? 8 DR. LAMB: No. 9 DR. DRIVER: Okay. Sorry, okay, I...I 10 stand corrected. 11 DR. LAMB: I don't think it's there. 12 4.7. DR. DRIVER: 13 DR. LAMB: He's just causing trouble. Ι 14 don't think it's there. 15 DR. DRIVER: That must have been for 16 carbaryl. I thought we did. 17 DR. LAMB: No, as far as I know, it 18 doesn't...it has not been calculated. So, I thought 19 the NOAEL worked pretty clearly, and, you know... 20 DR. HEERINGA: Dr. Lu and then Dr. 21 Morton. 22 DR. LU: I think you...your points are 23 well taken, and you have addressed most of the concern 24 that EPA raised in their presentation yesterday, but, 25 apparently, you omitted one point which I think is



	EPA MEETING 02/06/08 CCR# 15796-2 Page 231
1	critical. It's the performance of the contractor lab
2	on the samples. Can you comment on that?
3	Because what I'm getting by reading thethe
4	documentation and EPA's presentation is that there are
5	some issues associated with the analytical protocol
6	that actually introduce this continuing reactivation of
7	the enzyme activity. So, the resulting data look like
8	there's no inhibition at all, but the question is, is
9	that truly inhibition? The moment you collect the
10	sample from thethe rat, and then, is that
11	reactivated continuously?
12	And if that's the case, then, my opinion,
13	without how good the study was designed, the data is
14	notcannot be used, and, you know, that's probably
15	the case. Or you can comment on this.
16	DR. LAMB: Thank you. Theit's really
17	important we separate these out. One is that the issue
18	is exclusively RBC cholinesterase inhibition or RBC
19	cholinesterase activity assays at a particular
20	laboratory. Brain acetylcholinesterase is really the
21	critical adverse effect that's being monimodeled in
22	this 21-day dermal study. It's the correct point of
23	departure.
24	There are no questions about or issues that
25	I've heard about the brain acetylcholinesterase



	EPA MEETING 02/06/08 CCR# 15796-2 Page 232
1	activity. So, it's almost likeEPA has talked a lot
2	about the RBC issue, andand my view is we should
3	basicallywe can remove that from consideration in
4	this case.
5	And in this particular study, the brain
6	acetylcholinesterase activity responds very quickly.
7	It respondsit recovers quickly. It is certainly
8	aan example of an effect on the central nervous
9	system. It, in factand I'll go into this in my next
10	talk as wellthe brain appears to be, in adults, the
11	first endpoint that responds even in the EPA studies.
12	For example, the McDaniel study, I believe,
13	at 0.1 mg/kg/day, the brain responds in the
14	EPAthat's an EPA lab, different assay. It's not
15	until 0.3 mg/kg that RBC and motor activity start to
16	respond.
17	So, in the adult, theif anything, the
18	brain appears to be not only the most relevant but also
19	the most sensitive endpoint and should be usedand
20	should be completely valid inin this particular 21-
21	day dermal study.
22	I hope that answers your question.
23	DR. LU: This is Alex Lu again. I guess
24	mymylet me put my question this way. Say you are
25	able to split thethe blood sample. Doesn't matter



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 233 if it's brain tissue or red blood cells. And you have
2	your contract lab analyze for cholinesterase enzyme
3	activity, and then you send it to EPA. Would you
4	expect thisthe number from this blood sample will
5	come in agreement?
6	It look like that it won't, because, I mean,
7	there are many problems that I canI can, you know,
8	envision associated with the protocol that your
9	contract lab used, and one of the most critical points
10	is that the sample was collected and sit on the ice for
11	an hour. So, if you think that the reactivation of the
12	enzyme activity inhibit by a carbamate or, in this
13	case, carbofuran was so dramatic, so rapid, then that
14	1-hour window of time will wipe out all information
15	resulting from dermal exposures.
16	Do you agree?
17	DR. HEERINGA: I was waiting for the
18	question mark, Dr. Lu.
19	DR. LAMB: I was, too. No, I don't
20	agree, because I don't believe you're really looking at
21	the correct critical effect. I think it really needs
22	to be the brain acetylcholinesterase inhibition where
23	you don't have the same issues.
24	DR. HEERINGA: Questions of
25	clarification? I'm going to go now to Dr. Bunge and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 234
1	then to Dr. Chambers.
2	DR. BUNGE: On
3	SPEAKER: Your mike went out.
4	DR. BUNGE: Thank you. I'm a specialist
5	in dermal absorption but not cholinesterase inhibition,
6	so I may be asking as naive question, but one of the
7	issuethe analysis method, the modified Elman's
8	reagent method, was used for both the red blood cell
9	and the brain tissue.
10	Is the problem that EPA has discussed
11	potentially occurring with the red blood cell, would it
12	not occur in the analysis of the brain tissue? In
13	other words, iswhat's different about the two
14	tissues?
15	DR. LAMB: Right, right. I think that
16	the most significant issue with the red blood cell was
17	probably the dilution or rinsing of the red blood cells
18	which was not done with the brain. So, I do think that
19	the assaysthere's a reason one is responding
20	andand appears reliable and the reason the other
21	does not.
22	DR. HEERINGA: Thank you.
23	DR. CHAMBERS: Jan Chambers. The last
24	chart you had there with the NOEs that you calculated,
25	just clarify for me, did you use the AHTTF values for



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 235
1	that then?
2	DR. LAMB: Yes, right.
3	DR. CHAMBERS: All right.
4	DR. HEERINGA: Dr. Bunge?
5	DR. BUNGE: Annette Bunge again. Could
6	I have some clarification on how you establish the no
7	effect, no observable adverse effect level at 50? When
8	I look at the study report, at least in terms of the
9	means, and I did go through a statistical analysis, if
10	I look at the mean values of the cholinesterase levels
11	in the brain, I see they're reduced at lower doses than
12	the 50. Can you explain the decision to choose 50?
13	DR. LAMB: Thethe selection of 50 was
14	the study authors' selection, but I really think it's
15	based on a combination of statistical significance and
16	the degree of cholinesterase inhibition. Itit's not
17	articulated in the report. I think it'sif it's not
18	50, it's real close.
19	DR. BUNGE: The report doesn't discuss
20	the NOAEL at all, andand we have, at least as near
21	as I can tellI think I've gone through all of my
22	piles of papers and electronic filestheir report
23	describe how you took the data to determine the no
24	effect level. Maybe I'm mistaken. If we have a
25	document about that or if we can get one, it would be



EPA MEETING 02/06/08 CCR# 15796-2 Page 236 1 helpful. 2 DR. LAMB: Okay, what we can do is look 3 at that and provide you something probably later today or in the morning. 4 5 DR. HEERINGA: We'd like to have a reference or if it requires a separate justification, 6 7 to provide it, that would be very helpful. 8 DR. LAMB: Sure. 9 DR. BUNGE: Actually, I had a few more, 10 but I'll ask one more and then let other people have a 11 chance. Now I've forgotten what I was going to ask. 12 Oh, yes, back to the issue of the...the timing and 13 maybe we should ask the EPA folks again, but I think 14 the issue wasn't a pharmacokinetic issue. It was the 15 issue of the sample handling. So, the samples were 16 collected more or less immediately, but then, they 17 could be held on ice for up to an hour, according to the protocol. 18 19 And so, the question is, what about that one 20 hour on ice? What effect might that have had on the 21 measurement? 22 DR. LAMB: I had the impression from 23 what EPA has written and said that it...it was both in that the problem, one, it...the understanding that EPA 24 25 had was that it sounded like they didn't think the



	EPA MEETING 02/06/08 CCR# 15796-2 Page 237
1	analysis waseven the sample collection was likely to
2	happen for an hour after theafter the cleaning of
3	the site. That's, as I mentioned in my talk, that's
4	not correct.
5	But itit really sounded to me like they
6	were looking for data in a time course, much as you
7	have the data in the time course for the oral study
8	where they looked over a period of time and, as they
9	described it, from the time the dosing ends, they would
10	then look for whether the peakwhen the peak comes,
11	what the time is to the peak, whether that changes.
12	So, it's my understanding, from what they've
13	written and said, that's what they want, but you might
14	be right, that we maybe need to ask them, because it's
15	not fair for me to say much about that.
16	DR. BUNGE: If I can follow up, then
17	let's assume that youyou did have the samples
18	collected almost immediately following the end of
19	exposure, but they could be held as long as an hour on
20	ice, according to the protocol. What effect would that
21	have on the data, the results?
22	DR. LAMB: Well, it's ait's a fair
23	question that I don't have the answer to. It'sand
24	Ijust as I havejust as I asked for how long did
25	we really have the animals there for an hour, the



	EPA MEETING 02/06/08 CCR# 15796-2 Page 238
1	answer was no, it was 6 minutes. I don't have the data
2	as to when they analyzed the samples compared to that
3	point in time, and I don't even know if they exist, but
4	we could check and see if they do.
5	That's the best I can do on that one, and I
6	really don't know that that's going to answer your
7	question, because that sort of time course was not
8	done. That's sort of
9	DR. HEERINGA: Yes, Dr. Stinchcomb?
10	DR. STINCHCOMB: Audra Stinchcomb,
11	University of Kentucky. Could you describe the
12	application procedure in the dermal tox studies and how
13	it's better than or different from the acetone
14	deposition study?
15	DR. LAMB: I really think one of the
16	biggest differences inis that the acetone deposition
17	study created a slurry with acetone as the vehicle, and
18	itit's my understanding from people who worked in
19	this area that that is likely to degrade skin and
20	facilitate absorption beyond what you'd normally
21	expect, whereas the dermal toxicology study is not
22	using an acetone slurry. It's using the product either
23	as a formulation or diluted in water and then applied
24	to the skin.
25	DR. STINCHCOMB: It was applied in both



EPA MEETING 02/06/08 CCR# 15796-2 Page 239 1 ways or ... 2 DR. LAMB: I'm told it was...no, I'm sorry. I'm told... I was hedging. I'm told it was 3 technical material in water, diluted in water, as a... 4 5 DR. STINCHCOMB: As a solution or a 6 slurry? 7 DR. LAMB: Slurry. 8 DR. STINCHCOMB: Is that typical of 9 other studies of this type, to put it in a slurry or 10 not? 11 DR. LAMB: Yes. 12 **DR. HEERINGA:** Dr. Montgomery? 13 DR. MONTGOMERY: I thought this 14 compound...this is Cheryl Montgomery. I thought this 15 compound was insoluble in water? 16 DR. LAMB: That's why it was a slurry. 17 DR. MONTGOMERY: I understand that, but 18 if it's in a slurry and it's in water...oh, I guess I'm 19 ... I'm obviously confused. I understand it's a slurry 20 in water. You're saying that this...this is basically 21 an active ingredient... 22 DR. LAMB: That's essen... 23 DR. MONTGOMERY: It's insoluble in 24 water, so it's not in a...not. 25 DR. LAMB: And that is how it's used.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 240
1	When it's enteredput in these tanks, water is added,
2	and Jeff knows more about this than me, but that'sit
3	ends up being used, actually, and the worker exposure
4	actually is to a slurry in water. So, that is a clear
5	reflection of the product as a worker is going toif
6	a worker comes in contact with it, that's what they'll
7	come in contact with.
8	DR. MONTGOMERY: Is this part no-liquid
9	formulation?
10	DR. LAMB: Don Carlson will answer that
11	one.
12	DR. MONTGOMERY: And it comes in drums.
13	Typically
14	DR. HEERINGA: Dr. Carlson?
15	DR. MONTGOMERY: chemicals that come
16	in drums are in liquid formulation, and if this
17	compound is insoluble in water, it must have
18	surfactants added to keep it suspended so that it can
19	stay in the solution.
20	DR. CARLSON: Don Carlson, FMC
21	Corporation again. First off, let me address the
22	question of the water solubility. The water solubility
23	of carbofuran varies anywhere, in the figures that have
24	been made available, from about 340 ppm to 600 ppm, so
25	it's not aa relatively insoluble material.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 241
1	In regard to the formulation, the technical
2	material for the furidan flowable was very finely
3	ground. It is put on a very finely ground clay
4	carrier, and then, that is suspended in water. The
5	water is about 40 percent of the formulation, and there
6	are suspending agents in thethe formulation that
7	help to keep it in suspension.
8	DR. MONTGOMERY: I'm going to think on
9	this.
10	DR. HATTIS: Was there suspending agents
11	also in the technical material that was used for the
12	experiments?
13	DR. CARLSON: The experiment was done on
14	technical material. There was a slurry of the
15	technical material which was pasted on or, you know,
16	applied to the skin, spread on the skin.
17	DR. HATTIS: It did have the suspending
18	agents. Is that right?
19	DR. CARLSON: No.
20	DR. HEERINGA: Dr. Carlson answered
21	that.
22	DR. CARLSON: The answer was no.
23	DR. HATTIS: Thank you.
24	DR. CARLSON: You're welcome.
1	



EPA MEETING 02/06/08 CCR# 15796-2 Page 242 1 just add? 2 DR. HEERINGA: Dr. Cummings, sure. 3 DR. CUMMINGS: Just for ... just for 4 clarification, the...the guideline study from the USEPA 5 is to use... is to use technical material and not 6 formulated product. 7 DR. CARLSON: If I may, to further 8 clarify... 9 DR. HEERINGA: Sure, Don Carlson. 10 DR. CARLSON: ... in relation to Dr. 11 Hattis' question, what was used in the study was the 12 technical material in a slurry, and what the guidelines 13 specify is the technical material to be used in the 14 study. 15 DR. HEERINGA: Thank you. At this 16 point, we have, with the presentation by FMC and the 17 worker exposure assessment, there is supporting papers 18 and reports that we've received. Any additional 19 questions of clarification before we move on? 20 (No response.) 21 DR. HEERINGA: Not seeing any...one 22 more. 23 DR. BUNGE: Annette Bunge. One of the issues that's been raised was that other 21 or 28-day 24 25 dermal tox studies for other carbamates or...or



	EPA MEETING 02/06/08 CCR# 15796-2 Page 243
1	organophosphates have been used, but what the Agency
2	has said about this pesticide is that it has this very
3	rapid recovery, and so, that's my question. On these
4	other pesticides that havewhere studies have been
5	accepted, was the recovery asas similarly rapid?
6	Because it's not just a combinationit's a
7	combination also of how quickly the body is able to
8	clear them.
9	DR. LAMB: I think it would not be true
10	for the organophosphates, because the binding is
11	typically irreversible, but for the carbamates, it
12	would be, but they typically have much shorter half-
13	lives, and, in fact, I think EPA talked about that
14	earlier this morning as far as thethe range of half-
15	lives for the N-methyl carbamates.
16	DR. HEERINGA: Okay. Well, thank you
17	very much, Dr. Lamb and Dr. Driver. Stick around. You
18	may be up here again shortly, I believe.
19	At this point, I'll turn back to Dr.
20	Cummings. I think we're up for the presentation on the
21	human health and dietary risk assessment.
22	DR. CUMMINGS: It will just be a moment
23	while we switch
24	DR. HEERINGA: Absolutely. Before we
25	begin, I want tojust a small administrative matter.



- Г	EPA MEETING 02/06/08 CCR# 15796-2 Page 244
1	Mr. Larry Kleingartner, if you would be willing to,
2	speak to Sharlene at some point.
3	Thank you very much for your patience, and at
4	this point, we'd like to begin, and, Dr. Lamb, if you
5	could begin and introduce your colleagues, as
6	appropriate.
7	DR. LAMB: You bet. With me
8	todayagain, I'm Jim Lam of the Weinberg Group. I
9	have Dr. Robert Sielken who will be speaking after me,
10	and then I'll speak again, and then Dr. Morris from FMC
11	will speak on the dietary exposure model. So, you're
12	going to get four relatively short presentations.
13	We're trying to help you get through the lunch down and
14	keep things rolling along. How is that?
15	I will start with the oral risk assessment.
16	Some of these points we may have already covered. If
17	we have, I'll move along as quickly as possible to try
18	to help you get towards schedule.
19	The outline of our presentations, initially,
20	I'll talk about how FMC and EPA have done their risk
21	assessment generally and the selection of a point of
22	departure and past practice. Then, Dr. Sielken will
23	speak to the mathematical and statistical issues. I'll
24	talk again on some of the specific toxicological points
25	and conclude this section, and then Dr. Morris will



	EPA MEETING 02/06/08 CCR# 15796-2 Page 245
1	talk about the dietary exposure assessment that ties
2	the risk assessment together.
3	I think you all know that the Food Quality
4	Protection Act controls the presence of pesticides on
5	foods. Both EPA and FDAFMC have carefully estimated
6	dietary exposure using various data and models.
7	But one of the key concepts in this is a
8	discussion of the risk cup, the methodand it was
9	mentioned yesterday. It's ait's a model or aa
10	target that was developed under the Food Quality
11	Protection Act that is a calculated allowable intake of
12	pesticide in food andand other sources, food,
13	drinking water, for example.
14	One of the first steps and key steps in
15	determining the risk cup is the selection of the point
16	of departure. I am going to make your lives much
17	simpler today by not arguing much about the point of
18	departure.
19	You can do this from oral studies, whether
20	they're gavage or dietary. You can do it with one
21	study; you can do it with multiple studies.
22	Ultimately, you're trying to get a level that
23	represents no to a low response. And whether this is a
24	LOAEL or a NOAEL or some version of a benchmark dose,
25	as you heard yesterday, the EPA policy, when they use



	EPA MEETING 02/06/08 CCR# 15796-2 Page 246
1	the benchmark dose, is to use the BMDL10 which is the
2	95 percent lower confidence limit on the BMD10.
3	The risk cup is a calculated allowable
4	takeintake, because the calculation comes in once
5	you have the point of departure, you divide it by
6	various factors. There's the interspecies uncertainty
7	factor, the intraspecies uncertainty factor, and the
8	default values for those are 10. And there are the
9	regulatorilythe legislatively mandated FQPA factor
10	that begins at 10 and can be reduced if there's
11	sufficient data to protect children.
12	EPA, for carbofuran, has selected a point of
13	departure of 0.3 mg/kg based on postnatal day 11 rat
14	brain acetylcholinesterase. Those are the data upon
15	which they're relying on, but they have a concern
16	about, obviously, acetylcholinesterase inhibition.
17	That is one of the major issues that we will be talking
18	about, because that, in turn, leads to differences in
19	uncertainty factors.
20	Theythe 10 and 10 standard interspecies
21	and intraspecies uncertainty factors are used, but they
22	drop the 10-fold FQPA to 5 instead of what we think
23	should be 1, and you'll hear me and EPA talk about the
24	risk cup. We're referring often to this acute
25	population-adjusted dose that Jack Housenger mentioned



	EPA MEETING 02/06/08 CCR# 15796-2 Page 247
1	yesterday or an adjusted reference dose, adjusted by
2	the FQPA factor.
3	What are the differences? Well, the
4	differences are, actually, substantial, and they really
5	come down to a couple of issues. There's no argument
6	about leaving the intraspecies factors at 10. There is
7	somegoing to be some discussion about the
8	interspecies, whether it should remain at 10 or might
9	be dropped to 3. There is major issue about the Food
10	Quality Protection Act factor which, currently, EPA has
11	at 5 and we strongly believe should be at 1.
12	And in the end, that leads to differences
13	using exactly the same brain PND11 acetylcholinesterase
14	endpoint for us and for EPA. Thethe risk cup for
15	EPA is 0.00006 mg/kg/day, and the way we do the
16	calculation with an uncertainty factor of 300, it would
17	be 0.001. If you used 100, it would be 0.003. I'm
18	sorry, 30 or 100 are the two uncertainty factors we
19	think areareit's going to be somewhereit ought
20	to be somewhere in that range.
21	As I mentioned, to me, it takes a lot of
22	theit should solve some of the discussion we've had
23	for this. For the purposes of this study, of this
24	evaluation, the brain acetylcholinesterase from PND11
25	of 0.03 is the number that FMC is using for the risk



	EPA MEETING 02/06/08 CCR# 15796-2 Page 248
1	assessment. It's the uncertainty factors that matter,
2	because it shrinks the risk cup down by to 5 to 16.7-
3	fold.
4	With EPA's factors, nearly every use of
5	carbofuran is precluded, and without them, the risk cup
6	allows the continued use of carbofuran with the
7	labadjusted label, as we've already discussed.
8	So, that additional risk factor or
9	uncertainty factor is very significant. If you use the
10	smallest uncertainty factor, you get the largest risk
11	cup. The 100-fold gets you another, and the 500
12	shrinks it down quite a bit, and I can't tell you
13	whether these are quantitatively correct cuts or not.
14	I'm sure they are, in fact, though.
15	We're using the pup brain
16	acetylcholinesterase endpoint, and EPA has expressed
17	the concern that I know you've heard that RBC
18	acetylcholinesterase is up to 5 times more sensitive
19	than brain. Wewethey've used the BMD50
20	calculations to make that comparison of sensitivity
21	rather than individual animal data.
22	The details on that calculation are not
23	apparent to us. The assumptions, the calculations, the
24	data, we can't find the in the Notice of Intent to
25	Cancel. We can't find them within other Agency



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 249
1	documents.
2	I know that you've already heard that the
3	number has changed a bit with a recalculation. We
4	don't know how that calculation was done, either, but I
5	think we're getting closer to understanding the
6	numbers.
7	Bottom line is we believe that the use of pup
8	brain acetylcholinesterase as the point of departure is
9	the appropriate. It is anwe are talking about an
10	acute effect. We are talking about aan acute
11	response, not a chronic risk.
12	As EPA indicated yesterday, you don't have
13	issues of carcinogenicity, reproductive, developmental
14	and neurotox. The brain acetylcholinesterase, again as
15	mentioned yesterday, is the adverse effect. This is an
16	effect that's been measured in juvenile animals, and it
17	models nervous system responses.
18	The biological basis for some of these issues
19	I'm going to talk about after Dr. Sielken gets through,
20	butbut you should go into this knowing that we agree
21	on one uncertainty factor. We're closer on a second,
22	the interspecies factor being in the range of 3 to 10.
23	We completely disagree on the FQPA factor being 5 and
24	think it should be closer to 1, itin fact, it should
25	be 1.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 250
1	So, the uncertainty factor really belongs in
2	that range of 30 to 100, not 500, and we're going to
3	talk about each of these in more detail.
4	One point I want to make that I alluded to
5	earlier is this chart that we've seen several times in
6	this point as the origin of the 5-fold FQPA factor.
7	These are data from adults. These are data that were
8	shown in the MMC cumulative risk assessment, and this
9	particular data point that's circled is the one that,
10	actually, FMC had identified that as erroneous.
11	The waywe believe that number is low
12	simply because it's an artifact of a combination of
13	studies, and, ultimately, in the SAP issue paper,
14	basically, EPA says, and we agree, that the BMD10s for
15	adult RBC and brain acetylcholinesterase are similar,
16	and they don't support the 5x factor used for adults
17	that usedbased on the adult data in the 2006 risk
18	assessment.
19	That isthat is how they say it started,
20	but we agree that thenit started with a concern that
21	adults were different, and it turns out they're not.
22	And this is the position with EPA is agreeing with in
23	the document.
24	So, I think it's important to clarify,
25	because I'm fearful you may have misunderstood



	EPA MEETING 02/06/08 CCR# 15796-2 Page 251
1	thethe point of that N-methyl carbamate slide and
2	comparing aldicarb to carbofuran and other N-methyl
3	carbamates.
4	So, now I'm going to move to the math. The
5	bottom line here, though, is that the 5-fold FQPA
6	factor is being applied because of the lack of RBC
7	acetylcholinesterase data in juvenile animals at the
8	low end of the dose response curve.
9	I'm going to put the pots aside for now and
10	let you listen to Dr. Sielken in the meantime and the
11	mathematical points.
12	Thank you. And, as usual, hold questions
13	till we're all done.
14	DR. HEERINGA: Yes. Dr. Sielken?
15	DR. SIELKEN: All right. This is Bob
16	Sielken, and I was asked to do a statistical comparison
17	of acetylcholinesterase inhibitions in RBC and brain in
18	rats exposed to carbofuran, and as Dr. Lamb has
19	indicated, we're going to be talking about the juvenile
20	rates, the PND11 in the EPA study, the PND17 in the
21	other EPA ORD study. So, we're going to be looking at
22	those juvenile rats, and we're going to be looking at
23	the relevancy of sensitivity of RBC to brain.
24	And when we come back, Dr. Lamb will go back
25	to the issue about well, we probably don't even need to



	EPA MEETING 02/06/08 CCR# 15796-2 Page 252
1	be looking at RBC, because brain is the relevant
2	endpoint. But because this issue of the 5x has come up
3	about the relative sensitivity, then let me try and
4	address that and really put that to bed, because there
5	really isn't a substantial difference in sensitivity
6	between RBC and brain in those juvenile rats.
7	EPA's methodology for comparing these
8	cholinesterase values is indicated in their issue paper
9	as being derived from table 5, and this is a
10	reproduction of table 5 shown here on this slide, and
11	in table 5, they actually tabled BMD50 values for PND11
12	in brain, 0.23; BMDBMD50 in PND11 rats at 0.05 for
13	RBC.
14	Then they took the ratio of those two
15	numbers, 0.23 divided by 0.05, 4.6. Did the same thing
16	for PND17 animals, and said that on this basis, they're
17	going to conclude that RBC isthe juvenile rats are 3
18	to 5 times more sensitive to RBC inhibition than they
19	are to brain inhibition.
20	There are a couple of issues that I'd like to
21	talk about concerning their methodology. The first is
22	the derivation of the numerical values in that table 5.
23	It's not transparent. The numbers cannot be confirmed,
24	and in fact, yesterday, EPA said they've changed at the
25	last minute.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 253
1	So, II do want toto look at those
2	numbers. I think the more important issue, though,
3	isis not where those PMD50s came from, although we
4	can't reproduce them in the table as it is. The more
5	important issue is that you have better data for
6	looking at relative sensitivity than those BMD50s.
7	BMD50s might be used if you didn't have better data,
8	but here, you really do have better data.
9	You, in fact, observed RBC and brain
10	inhibitions in the same animal at the same time. So, I
11	mean, you have individual animal data. That's being
12	ignored, the simultaneous availability of RBC and brain
13	in the same animal that's ignored in the BMD
14	calculation, and, really, you can use it directly to
15	get a better idea of relative inhibition.
16	And that would be insympathetic to the
17	comment we heard earlier from EPA that there is a high
18	degree of intra-animal correlation, that within an
19	animal brain and RBC are correlated. That correlation
20	is lost when you igignore the individual animal and
21	you just spread the RBC values in one calculation and
22	the brain values in a different calculation. Okay.
23	Most of you, in fact, all of you probably
24	know what a BMD50 is. Here, since we're looking at a
25	continuous endpoint, cholinesterase inhibition, we're



	EPA MEETING 02/06/08 CCR# 15796-2 Page 254
1	starting with a curve where we've got 100 percent of
2	the acetylcholinesterase level in the controls, and
3	we're looking for how that level decreases as the dose
4	increases. And the point where the
5	acetylcholinesterase level is decreased 50 percent, the
6	dose corresponding to that is the BMD50. Simple idea.
7	If you look at the PND11 values from the EPA
8	ORD study, Moser, in 2007, and you plot that data as I
9	have done here, the diamonds, if you will, in this plot
10	indicate the sample means. I could have put on here
11	sample standard deviations as well, but for the
12	purposes of this talk, the means will be fine. They're
13	showing the mean inhibition atat the experimentat
14	the five experimental doses.
15	And you'll notice thatand this is for RBC.
16	And you'll notice that for RBC, the point where you
17	have a 50 percent inhibition happens to correspond to
18	that lowest experimental dose, 0.1 mg/kg/day. So,
19	regardless of the modeling or anything else that's done
20	with this data, if you're looking for the point where
21	there's 50 percent inhibition, you can go directly to
22	the experimental data, and it should be 0.1. Anything
23	else is, you know, not reflecting the experimental
24	data.
25	EPA got 0.05 initially. They got a different



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 255
1	number yesterday, but they got 0.05 in their report,
2	perhaps suggesting that you need to look at the data
3	itself, not just reported numbers supposedly related to
4	the data.
5	For PND17, the top curve here which is blue
6	but it's on top, is brain. The one underneath is RBC.
7	And this is, again, a plot of experimental data. You
8	can see, again, for RBC, that there's 50 percent
9	inhibition at the lowest experimental dose. So, again,
10	the BMD ought to be around 0.1. EPA got 0.07 in their
11	calculations initially.
12	You look at brain. Well, it's almost down to
13	50 percent at the second dose, 0.3, so maybe the BMD is
14	just a little bit bigger than 0.3. It's certainly not
15	0.2, as was in EPA's table 5.
16	This discrepancies between the data
17	andbetween the experimental data and the numbers in
18	EPA's table 5 made it hard to reconcile what was EPA
19	doing to actually get those values and come to their
20	conclusion. Okay.
21	Again, with the idea of emphasizing looking
22	at the experimental data, if you just look at the two
23	lowest experimental doses in this study, EPA's study in
24	the PND11 pups, at the lowest dose, 0.1, the ratio
25	between the reduction in RBC and the reduction in brain



	EPA MEETING 02/06/08 CCR# 15796-2 Page 256
1	at that lowest dose is 1.3, not 5. It's 1.3.
2	You look also at the ratio of the percent
3	reductions at 0.3, the second lowest dose, and the
4	ratio is 1.2, again, not 5.
5	If you want to do dose response modeling
6	hereand I am a dose response modeler by trade, so
7	beingbeing a little disparaging about the dose
8	response modeling comes from one who does it all the
9	time, too, but I never do it without looking at the
10	data. Okay? So, if I go back to that PND11 data for
11	brain in the Moser study, the data points are here.
12	A fit of the exponential model with the power
13	in the model being 1 or a fit of the HAIR model which
14	is like a McCayliss-Menton model, those models, either
15	one of them, fit this data reasonably well. The same
16	thing could be said for the RBC data, particularly when
17	you're looking at the lower end.
18	I've done a piece-wise linear plot, but I'm
19	really trying to emphasize here that at the points
20	where you have data, these fitted curves go close to
21	the experimental data, and you can pick any of
22	theeither of those two models.
23	If you want to go with a BMD approachand,
24	again, I don't think that that's the best
25	approachyou can take either one of these fitted



	EPA MEETING 02/06/08 CCR# 15796-2 Page 257
1	models, the fitted exponential or the fitted HAIR
2	model. both of which fit the data reasonably, and look
3	at BMD10s, BMD20s, BMD30s, BMD40s, just depending on
4	how far back towards zero you want to do your
5	extrapolation. Or you can do it linearly which is
6	probably the closest thing to the data.
7	And any of those numbers, comparisons of
8	BMD10s, 20s, 30s, 40s, using linear extrapolation
9	fitted exponential, fitted Hill models, those ratios of
10	relative sensitivity in dosesin the dose metric come
11	out to be all numbers less than 2. Certainly, well
12	less than 5.
13	Okay, I indicated in the beginning that there
14	was an issue with how EPA derived its numbers and it
15	was hard to replicate, et cetera. If you go ahead and
16	take their approach, you do show, if you enter it
17	correctly, that regardless of which model you take,
18	you're looking at relative sensitivity less than 2-
19	fold, more like 1.5-fold. All right?
20	And I also indicated at the start that there
21	was a better approach. You've got data on RBC and
22	brain in the same animal. So, why not use that data?
23	And that's true not only of the Moser
24	studies; it's true of the FMC studies as well. We
25	might debate about whether their RBC values are usable



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 258
1	or not in those FMC studies, but it's always there.
2	That's the protocol, is to observe both of these things
3	in the same animal.
4	Having this information in the same animal
5	allows for a direct comparison. You can do awe can
6	take advantage of or not distort the analyses by the
7	fact that these observations on RBC and brain
8	inhibition in the same animal are highly correlated.
9	Use of the individual rats as unit of
10	analysis invoyavoids issues of variability between
11	the animals in their response, differences in dose
12	administration, absorption, time from dose
13	administration to observation. So, all of those
14	differences between animals are kind of eliminated or,
15	at least, better taken account of by looking within the
16	same animal.
17	You don't have to make any unvalidated
18	assumptions about the shape of the dose response
19	models, and you don't have to dissociate the RBC data
20	from the brain data. You don't have to treat those
21	data sets as separate data sets.
22	And although this figure is a little hard to
23	read, as a statistician, I feel compelled to show how I
24	did my calculations, and this is an excerpt from the
25	Moser data on PND11 pups. We have the individual



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 259
1	animal data, as shown by the ID numbers down the left-
2	hand side, and for each animal at each dose level, I've
3	got a separate reading for brain and RBC cholinesterase
4	inhibition.
5	For the controls, I can take an average value
6	to give me a reference point when I look at inhibition
7	relative to controls.
8	For each of the animals, individual animals,
9	pups, at each of the doses, I get an observation on
10	both brain and RBC, and I can take these individual
11	values, compare them to the control average, and get a
12	percent reduction in, first of all, brain in that
13	animal. And we do the calculation again comparing the
14	animal's value to the average in controls to get a
15	percent reduction for RBC.
16	I can compare those 2 percent reductions and
17	get a relative sensitivity of RBC to brain. And I do
18	that calculation for each of the individual animals.
19	If I do that, I get the averages of these individual
20	animal measurements of relative sensitivity to be these
21	numbers at the four doses in that experiment, an
22	overall average of around 1.2.
23	The specific number doesn't really matter.
24	The numbthe important thing here is that it's really
25	close to 1. It's certainly not 5.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 260
1	I did the same calculation for the PND17 rat
2	pups. Again, that's the other EPA pup study. And the
3	average there is around 1.56, again, certainly less
4	than 2, considerably less than 5.
5	Now, EPA raised the issue last night in the
6	waning hours of the day thatthat I wasand they
7	knew from my advance submission that I was going to
8	talk about this, and they were trying to find an
9	argument against it or, at least, the scientific
10	critique, however you want to phrase that, and they
11	werewanted to say that well, I'm looking at relative
12	acetylcholinesterase values and not relative doses.
13	Well, my contention would beand we have
14	thought about this in the beginningsis that as long
15	as the dose response relationships are linearand
16	most non-threshold dose response relationships are at
17	least approximately linear, in general approximations
18	in the low dose region, that as long as you have
19	roughly linearity in the low dose region, the relative
20	reduction in the acetylcholinesterase values and the
21	relative magnitudes of BMDs are equal.
22	And I'm a mathematician, so I like to do it
23	one way, but I thought the easiest thing for my clients
24	and probably the panel was just to do a hypothetical
25	example that was some pictures. And so, I did.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 261
1	Here's the acetylcholinesterase values for
2	brain in blue and in red is RBC. Other than the fact
3	that brain was usually bigger than RBC, thethat's a
4	hypothetical example. They have different slopes in
5	those linear relationships.
6	If I put that back and draw the picture in
7	terms of fractional reduction, you'll notice that when
8	I did my calculations, I did it not on fractional
9	reductions but acetylcholinesterase values, but if I
10	draw the pictures in terms of fractional reduction, I
11	get that picture.
12	And if I go ahead and do the comparison of
13	BMD50s, say, if I just, you know, come over from 50
14	percent and identify the two BMD50s, 2.3 and 3, take
15	the ratio of those, that ratio in this picture is about
16	1.3.
17	If I do theif I look at it the other way,
18	that is, I look at a dose and look at the relative
19	acetylcholinesterase values, then that's what I get in
20	this picture. But if I take a dose of, say, 0.3I
21	mean, 3and these are an arbitrary dose scale3 and
22	go up, the fractional reduction for RBC is about 0.65.
23	The fractional reduction for brain is about a half.
24	The ratio if those two reductions is 1.3.
25	So, whether you want to look at this in terms



	EPA MEETING 02/06/08 CCR# 15796-2 Page 262
1	of acetylcholinesterase values or BMDs in the low dose
2	region, the comparison is the same or equivalent.
3	For those of you who like algebra better than
4	pictures, your slide sets show that this equivalence
5	holds from an algebraic point of view as well as a
6	pictorial point of view, but I'll skip those slides for
7	everyone's benefit and just go right to my conclusions.
8	And the conclusions are that comparisons of
9	RBC and brain sensitivity to inhibition are
10	scientifically and statistically most valid when done
11	on an individual pup basis when that data is available,
12	and it is available here. EPA's approach of relying on
13	the BMD50s and basing the comparisons on these
14	artificial constructs requires unnecessary assumptions
15	about the dose response, and it loses the commonality
16	of RBC and brain within the same animal.
17	The average ratio of RBC to brain in the
18	PND11 pups which is our target, PND11 pups, is 1.22
19	which really is not a biologically significant
20	difference, as being told to me by my biological
21	colleagues. So, you're really looking at 1.22. You're
22	not looking at 5. You're not even looking at 2. The
23	FQPA safety factor really should be 1, and that's the
24	bottom line.
25	DR. LAMB: As promised, I'llthis is



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 263
1	Jim Lam of the Weinberg Group. I'll move on to
2	theimmediately to the toxicological issues andand
3	then pass over to Dr. Robert Morris.
4	First of all, we need to make the point that
5	brain acetylcholinesterase is, in fact, the more
6	relevant endpoint. It is more reliable statistically.
7	The levels are higher in brain by, typically, an order
8	of magnitude compared to red blood cells. It's more
9	relevant toxicologically.
10	The brain has basically been used as the
11	point of departure in numerous other risk assessments,
12	and the comparison of a value of brain
13	acetylcholinesterase to red blood cell
14	acetylcholinesterase has been reviewed by the science
15	advisory panel in the past.
16	I'm not going to read this whole slide, but
17	thethe bottom line in the review with respect to the
18	cumulative risk assessment was brain provide a health
19	protective endpoint for central and peripheral nervous
20	system and represents a direct measure of a common
21	mechanism of toxicity as opposed to using surrogate
22	measures which is a term that I think we've all used in
23	describing red blood cell. It is an absolute necessity
24	in a human study; it is not such a necessity in the
25	rodent studies as they've been designed.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 264
1	Also, within the N-methyl carbamate
2	cumulative risk assessment, EPA's position was that
3	brain cholinesterase is equally sensitive or more
4	sensitive compared to RBC, and it is a health
5	protective endpoint for both the CNS and peripheral
6	nervous system.
7	It is representative of the adverse effect.
8	It isit is a sign of neurotoxicity. It's not a
9	biomarker which is really what RBC may serve for. It
10	is a functional response. RBC may or may not be aa
11	synch as far as a function, but it certainly is not a
12	direct measure of neurotoxicity.
13	Another point made in the McDaniel study
14	which is an ORD study published in Toxicological
15	Sciencesand I know all these studies may be running
16	together in your head, and I know, by now, they're
17	actually running together in my head, but in this
18	study, she had reviewed a number of different
19	compounds, and in the ultimate sentence, final sentence
20	of the document, indicated that current data
21	supportedthis is a 3007 papersupport the use of
22	brain cholinesterase over RBC when evaluating
23	neurotoxicity for these chemicals, and carbofuran was
24	one of these chemicals.
25	RBC is variable. It's variable in EPA's



	EPA MEETING 02/06/08 CCR# 15796-2 Page 265
1	studies. It's variable in FMC studies, and this is
2	putting aside the issue of the quality of the assay.
3	It is much more variable than brain
4	cholinesteraseacetylcholinesterase.
5	And it's less reliable. You're talking, as I
6	said, at lower levels in red blood cells than brain.
7	Brain acetylcholinesterase activity represents the CNS
8	directly, and I think it better represents the
9	peripheral nervous system than red blood cell values
10	do.
11	It'stoxicologically, it is relevant. It
12	is, in the case of carbofuran, you get a rapid
13	response. We are talking peak responses beginning at
14	15 to 30 minutes. The blood-brain barrier does not
15	seem to slow this compound down a lot once it's
16	absorbed in the body.
17	The peripheral and central nervous system
18	responses are both in nerve cell endings. They're not
19	in circulating RBCs. As I say, one of the best uses
20	for red blood cell is in human studies where brain is
21	not an accessible endpoint or peripheral nervous system
22	to map accessible endpoints.
23	So, in our hands, with animal toxicology
24	studies especially, this is the best model for
25	potential neurotoxicity. And if it is used, if RBC is



	EPA MEETING 02/06/08 CCR# 15796-2 Page 266
1	used in the risk assessment, you really need to
2	consider the potential response at the low end of the
3	dose response curve where you have a BMD50 comparison,
4	but that involves unnecessary data manipulation, and
5	it's really valid if those dose response curves are, in
6	fact, parallel from the BMD50 to the BMD10.
7	The responses at the lowest levels are really
8	the ones that are most important, and we have valid
9	brain pup acetylcholinesterase data available at the
10	low end of the dose response curve which is why we
11	agree on the critical effect and point of departure.
12	So, in thethat same McDaniel study, the
13	lowest dose of carbofuranthe low dose first
14	inhibited brain acetylcholinesterase. The 0.1 mg/kg
15	dose level, that was the one endpoint that responded.
16	This is in adult rats.
17	Red blood cell and motor activity responded
18	later. I've heard discussions of the correlation of
19	these endpoints, but the fact is that red blood cell
20	motor activity, brain, all tend to move together, but
21	in these studies on carbofuran, brain moved first.
22	Now, we talked some already about aldicarb.
23	You guys talked yesterday a little bit about aldicarb
24	and urban legends. This particular exampleand
25	there's a chart over here to theto the side



	EPA MEETING 02/06/08 CCR# 15796-2 Page 267
1	thatthat is actually, it's the next slide in the
2	package. Soso, you've got this slide, all this
3	thing up here, but initicomparing aldicarb in the
4	lab to carbofuran in the rat, what you see are BMDL10s
5	that are somewhat different, showing that there is a
6	couple of fold, two or three-fold difference in potency
7	based on the BMDL10s for brain, rat brain
8	acetylcholinesterase. And I'm leaving the human and
9	the oxamyl out at this point.
10	So, the potency factors for the cumulative
11	risk assessment were in that range with a little less
12	than a two-fold difference between aldicarb and
13	acetylcholinesterase, but when you count the zeros, you
14	can see that aldicarbs, APAD or risk cup is actually
15	much larger than carbofurans.
16	And this chart over to the side or the one I
17	can show up here on the top, if you put various
18	elements at unity for carbofuranand this is purely
19	for the comparisonand look at adult rat brain, human
20	RBC, BMD10, and juvenile rat brain BMD10 and compare
21	these, aldicarb is more toxic, relative toxicity,
22	greater toxicity, not dose. Toxicologists like me have
23	trouble with these charts, but the toxicity of aldicarb
24	was higher than carbofuran in every case. Oxamyl was
25	lower, but the carbofuran's APAD is, in fact, higher



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 268
1	than the other two.
2	Another important point, talking about the
3	uncertainty factors. If you were to take the 10 for
4	interspecies and 10 for intraspecies, they are 100-fold
5	results in a very conservative dietary risk assessment.
6	We believe that for certain purposes, you
7	actually should consider the human study, and I realize
8	that I may have folks throw rocks at me about this one,
9	but the fact is the HSRB did notyou are not
10	repeating the task that the HRB undertook. They never
11	considered the full weight of the scientific evidence.
12	They basically received a limited weight of evidence
13	that has been substantially updated since the time it
14	was presented to them.
15	I really believe you need to be looking at
16	the full weight of the evidence and the human studies
17	in context. The dermal study can be set aside, but the
18	oral study was not excluded by the HSRB based on
19	ethical issues. They had concerns about it
20	scientifically which I've talked about.
21	Thethey did BMDLactually, EPA, I guess,
22	did BMDL10 calculations for the human study. They are
23	very close toin risk assessment, close to means
24	within an order of magnitude. They are very close to,
25	in fact, a lot closer than that, to the 0.03 point of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 269
1	departure we're talking about or effect level we're
2	talking about for brain cholinesterase. This is a
3	human study. Of course, this is based on the RBC
4	cholinesterase.
5	Peak response was at an hour. The study was
6	peer reviewed by several scientists who felt it was
7	appropriate to use it to develop a reference dose.
8	And, in fact, EPA proposed using the human
9	BMDL10 with uncertainty factor of 1 for interspecies
10	and 10 for intraspecies, and that's what was presented
11	to the HSRB, but the design of this study was limited.
12	It was a single oral dose. It had a small sample size.
13	There were 9 people, 2 per group. Really, the math
14	does work.
15	It'sthere are three dose levels. There
16	was one control person, but each individual served also
17	as their own control, because there was a pre-dosing
18	evaluation was well. And the top dose was treated
19	twice.
20	And then there are multiple time pre and
21	post-dosing assessments. Bottom line is RBC
22	cholinesterase was decreased inin the control, oddly
23	enough, but it wasit was decreased 11 and 22 percent
24	at 1 hour and back to normal within 3 hours. 0.05
25	mg/kg did not show symptoms. And these are the data



	EPA MEETING 02/06/08 CCR# 15796-2 Page 270
1	that EPA used to develop the BMDL10.
2	I've already mentioned that the HSRB did not
3	quethey were concerned about the study sample sizes
4	especially, and I see that. That'sbut, in fact, the
5	response was very similar to the animals. You are
6	seeing a lot of animal data, and these extensive animal
7	studies should increase confidence in the human
8	findings or vice versa. They, if nothing else, they
9	reinforce that we are in the correct range for
10	response.
11	You're seeing all of the data. We don't
12	believe these human studies should be used to select a
13	point of departure, but we do believe they can support
14	a reduction in the interspecies uncertainty factor from
15	10 to 3.
16	Now, if you look at the dietary risk
17	assessments, these are three different versions. The
18	first column is the version that EPA is presenting in
19	the Notice of Intent to Cancel. The bottom line is the
20	acute population adjusted dose is four zeros and a 6,
21	0.00006, with an FQPA factor of 5 and an interspecies
22	factor of 10.
23	If you did the human study, the EPA didwas
24	silent on whether or not they would stick with 5, go to
25	1, or use 10, so Ibut I put 1 for comparative



	EPA MEETING 02/06/08 CCR# 15796-2 Page 271
1	purposes. That's my number, to be clear.
2	The number for the acute POD, though, would
3	be 0.0026. The approach that we're presenting is the
4	same point of departure, 0.03, based on rat brain
5	acetylcholinesterase inhibition. Same intraspecies
6	uncertainty factor. Different interspecies uncertainty
7	factor which has, often in this talk, been expressed as
8	a range of 3 to 10, but the FQPA safety factor of 1 for
9	a number of 0.001 mg/kg/day.
10	So, conclusions, the data converge on the
11	BMDL10 of 0.03. Pup brain acetylcholinesterase data
12	are reliable and, actually, in these first two bullets,
13	I think, are entirely consistent with EPA's position.
14	Where, I guess, we really disagree on is the additional
15	5x uncertainty factor based on purported sensitivity of
16	RBC which is a surrogate measure, not an endpoint of
17	toxicity. The brain acetylcholinesterase is the
18	endpoint that reflects an adverse effect.
19	The 3x uncertainty factor based on the human
20	data, and that the total uncertainty factors basically
21	should be in the range of 30 to 100, not 500 as
22	proposed by EPA, and that, basically, thatthat risk
23	assessment is much more conservative than for other
24	carbamates or than it needs to be for carbofuran.
25	These are some charge questions that we have



	EPA MEETING 02/06/08 CCR# 15796-2 Page 272
1	in the toxicology. Is brain the preferred endpoint
2	over RBC toxicologically? Do the available data
3	support the conclusion or not that RBC
4	acetylcholinesterase in PND11 pups is 3 to 5 times or
5	that there's this uncertainty that it's 3 to 5 times
6	more sensitive than brain acetylcholinesterase?
7	Do they support the imposition or failure to
8	reduce the 5x FQPA factor? This is a juvenile
9	endpoint, not an adult endpoint, and do the data
10	support reducing the interspecies uncertainty factor to
11	3?
12	With that, we now move on to the diet, the
13	last of this series, the dietary exposure assessment,
14	Dr. Robert Morris from FMC.
15	DR. HEERINGA: Thank you, Dr. Lamb.
16	DR. LAMB: Thank you.
17	DR. HEERINGA: Dr. Morris?
18	DR. MORRIS: Thank you, Dr. Lamb. Good
19	afternoon. I'm Robert Morris. I'm a risk assessment
20	specialist with FMC Corporation, and I'll be discussing
21	the exposure portion of the dietary risk analysis.
22	II will not bore you with what a risk cup
23	is, because I think you've heard it more than enough.
24	So, I'm going to move on to the exposure level and how
25	it's calculated using the dietary evaldietary



	EPA MEETING 02/06/08 CCR# 15796-2 Page 273
1	evaluation exposure model, the DEEM model and what that
2	means to the actual percent of food within the dietary
3	risk cup.
4	There are three critical differences between
5	EPA and FMC's APAD calculations. This is a depiction
6	of the two dietary risk analyses that you've been
7	reviewing. The EPA's dietary risk analysis is a
8	refined tier 3 analysis very similar to FMC's. The
9	drastic difference is on the hazard side which is what
10	you'll be determining on whether the 5x is appropriate
11	in the FQPA side or if it should be removed and whether
12	the 3x that Dr. Lamb is proposing is appropriate to
13	result in an uncertainty factor of anywhere between 30
14	and 100.
15	In addition, there are a few exposure
16	elements that would result in slight decreases in APAD
17	that I would like to discuss. Some of them include the
18	crops that are considered in the dietary risk analysis,
19	and, also, there's a rather major difference between
20	the way EPA has performed the dietary risk analysis for
21	potatoes and residues associated with that from the PDP
22	program and the way FMC has done it, and I will go into
23	more detail on that.

As you've already seen, EPA considers with their dietary risk cup for their...the foods to fill



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 274
1	the cup overbasically overfills the risk cup, and
2	this demonstration shows that with around 300 percent
3	of the APAD taken up.
4	However, just doing one simple correction by
5	removing the 5x uncertainty factor which has been
6	supported by Dr. Lamb and Dr. Sielken, now the risk cup
7	itself has plenty of room to consider not just the food
8	but also consider rattle. So, this is an important
9	decision that you will have to make on what is the
10	appropriate uncertainty factor to apply.
11	This makes thethe decision that's facing
12	you a very, very difficult one, and wewe really hope
13	you get good consideration of this.
14	If you take only the EPA's assumptionsand
15	this does not include any of FMC's dietary risk
16	assumptionsand make this change, you now notice that
17	the risk cup, which is overfilled with the EPA's
18	assumptions, now is around 50 to 60 percent of the
19	APAD.
20	As I mentioned to you earlier, the
21	exposurethethe crops that were actually
22	considered in the exposure assessment for the Notice of
23	Intent to Cancel document by EPA has additional crops
24	that we didn't consider and forwe just considered
25	the amended label. The amended label includes the



	EPA MEETING 02/06/08 CCR# 15796-2 Page 275
1	following crops, many of which are the exact same
2	assumptions for residues that the EPA has. There are a
3	couple of exceptions. Potato I'll go into in more
4	detail, but there are a few other small slight
5	differences between the 4F application to melons and
6	the 15G application to cucurbit vegetables which is the
7	way we calculate it.
8	The milk itself that was discussed in detail
9	yesterday, we have the exact same assumptions that EPA
10	has.
11	For potatoes, FMC has looked at a large
12	amount of the PDP data that's available. There's
13	nearly 3000 samples that have been collected since
14	1995. This is in thethis is USDA's PDP program.
15	Thetheit's only until you get to the recent data,
16	which is the 2006 data, though, that you see a lower
17	detection limit.
18	If this lower detection limit is applied to
19	the potato residues, it makes a drastic difference in
20	thethe actual APAD predictions. In EPA's dietary
21	assessment, they relied on the 2002 to 2003 LOD which
22	is nearly an order of magnitude higher. So, when you
23	use the EPA's practice of half the LOD, it makes a
24	major difference in the risk assessment.
25	The fact that no residues have been detected



	EPA MEETING 02/06/08 CCR# 15796-2 Page 276
1	and the observation that therethere hasthere are
2	valid new samples of over 700 that have been collected
3	makes FMC believe you should be using the most current
4	LOD in your calculations and you shouldn't be impacting
5	your APAD calculations on, basically, nono residues
6	detected.
7	So, if you do these corrections, you'll now
8	see that the APAD predictions in the risk cupand
9	this is just 100x illustration for uncertainty
10	factorsis in theabout a third of the cup now has
11	been taken up byby food contributions. This
12	includes the most sensitive populations, similar to
13	what EPA has considered.
14	If one were to take the food and then add
15	water to it, you can see that there's room. About two-
16	thirds of the cup is available for drinking water, and
17	we think that once you start considering drinking
18	water, this isthis is an area that needs a lot of
19	consideration, because it doesn't seem like EPA put a
20	whole lot of thought into whatwhat would happen if
21	the risk cup was open and what is the relevant
22	concentrations that should be in drinking water.
23	This shows, as Dr. Lamb has presented, the
24	300x uncertainty factor assumption, and there's even
25	more room available for water, in this case, around 90



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 277
1	percent for all the dietary sensitive populations.
2	So, when one looks at those 100x uncertainty
3	factor assumptions and the 30x uncertainty assumptions,
4	one can do a drinking water level of comparison
5	approach and see what that translates to in drinking
6	water concentrations. Thisthese values that have
7	been calculated come to between 1 and 4.4 ppb if you
8	consider either then 100x uncertainty factor or the 30x
9	uncertainty factor in the risk cup.
10	So, in conclusion, the dietary contributions
11	from the amended label are the crops considered on the
12	amended label, the NPORE tolerances, and the mini
13	granminimal granular use all fit within the FQPA
14	risk cup. Remaining risk cup space was then allotted
15	for drinking water and calculated using the DWLOC
16	approach, resulting in estimated drinking water
17	concentrations that I mentioned that were approximately
18	1 to 4.4 ppb.
19	These numbers are actually higher than what
20	you'll see in true concentrations found in water
21	samples, and that will be talked about by the water
22	panel, you know, just following this presentation.
23	And I have one question to pose to the panel
24	for your consideration, and that's about when you have
25	an ND situation like we do for potatoes and the ND has



	EPA MEETING 02/06/08 CCR# 15796-2 Page 278
1	changed because of new analytical capabilities, should
2	the EPA be applying the new detection limit for our
3	potato commodities, or should beshould they be using
4	the older data?
5	Thank you.
6	DR. HEERINGA: Thank you very much. And
7	at this point, I'd like to open it up for questions
8	from the panel for Dr. Lamb and Dr. Sielken or Dr.
9	Moore. Yes, I'll start with Dr. Edler.
10	DR. EDLER: Lutz Edler, German Cancer
11	Center. I thinkwith problems with the time, but
12	only two short questions, I think.
13	One question toto Dr. Sielken. The
14	calculations you showed of the original data where you
15	got these factors, 1.2, 1.3 and so on, did you also
16	consider the variability of the controls which is
17	actually used for normalizing these data? Did
18	youdid you do some calculations? Because if you
19	calculate these ratios, they get a lot of variability
20	which are not ininin the point figure actually.
21	DR. MORRIS: The individual animal data
22	is there, of course, for the controls. I did not look
23	at percent inhibitions relative to the control mean
24	minus the standard deviation. I could have done that.
25	That would have affectedwould have



	EPA MEETING 02/06/08 CCR# 15796-2 Page 279
1	affected both the percent inhibition for brain as well
2	as the percent inhibition for RBC. I don't know how
3	much of an effect that would have for the ratio.
4	DR. EDLER: May I just follow up?
5	That's a totally different question which I have in
6	mind for a while. Are there specific reasons that in
7	these newer studies, the radiometricradiometric
8	method for the RBC and the brain conconcentrations
9	were not used? Because II'm asking this also
10	because in the 2005 SAP, there had been a discussion
11	about that usage of these methods, and my question is
12	simply what's the reason that one stayed with a
13	modified Elman method?
14	DR. SIELKEN: This is Bob Sielken,
15	again, to respond. Thethe calculations that I
16	showed for relative inhibition of LDC in brain being
17	less than two-fold was all based on EPA'sEPA ORD
18	studies, and it's my understanding that they used the
19	radiometric method, but there was no problem in
20	theirtheir analysis. That was all EPA
21	DR. HEERINGA: Dr. Lamb? Sorry, Dr.
22	Sielken.
23	DR. LAMB: Yeah, with regard to the
24	Elman assay that is the one that typically is done in
25	these guideline studies. TheI don't know that I



	EPA MEETING 02/06/08 CCR# 15796-2 Page 280
1	want to go out on a limb as to whetheryou guys would
2	probably know better than Ias to whether that is the
3	method thatthe method, only method required or
4	mentioned.
5	DR. HEERINGA: We maybe could have
6	yourJane to respond. Have her come up and say what
7	she said to you.
8	DR. MCCARTY: My name is Jane McCarty.
9	I'm a toxicologist with FMC Corporation and was
10	responsible for monitoring the studies that were done
11	by FMC.
12	The reason that the contract laboratories
13	that most industry goes to to do these kinds of studies
14	aren't done using the radiometric method is that most
15	of these laboratories do not have licenses for handling
16	the radio-labeled material that's required in that
17	process, so they don't have that method available to do
18	these large studies.
19	DR. HEERINGA: Thank you. Dr.
20	Handwerger?
21	DR. HANDWERGER: I'm just a small town
22	pediatrician, and II'm really very surprised
23	that neither you or the EPA have mentioned pregnancy,
24	fetuses, or risk of pesticides to pregnant women.
25	You know, I think of the paper last year on



	EPA MEETING 02/06/08 CCR# 15796-2 Page 281
1	diabetes care from NIEHS, another part of the
2	government, where Seldona and his colleagues showing an
3	increased incidence of gestational diabetes in women
4	exposed to a number of pesticides, including
5	carbofuran, circumstantial evidence of an increased
6	risk in some studies of breast cancer to women who've
7	been exposed to carbofuran, and so forth, but we've not
8	talked about any ofof these kinds of issues.
9	You know, I love birds, and I love rats and
10	mice, but, you know, II happen to work more with
11	people, andand II really am somewhat surprised
12	that we haven't really talked about that. We've talked
13	about atrazine and, you know, its potential dangers for
14	prostate cancer and so forth, but I'm also concerned
15	about things like gestational diabetes, because, you
16	know, itit's said that these pesticides are not
17	teratogens, but diabetes in pregnancy is a teratogen,
18	andand, clearly, women with gestational diabetes
19	have aa marked increased risk of having infants with
20	congenital abnormalities and so forth.
21	And I know that we're not here to discuss
22	this issue, but I just wish, when we talk about the
23	health effects, that wewe go and look at the
24	literature and think about what is there aboutabout
25	humans and about pregnancy and about fetuses and with



	EPA MEETING 02/06/08 CCR# 15796-2 Page 282
1	possible effects ofof carbofuran on sperm counts in
2	workers. There have been reports about decreased sperm
3	counts on workers, but we're not talking about that
4	here today.
5	I mean, of course, I don't know why we're not
6	talking about this today, but I'd just like tofor us
7	just to keep that in perspective.
8	DR. HEERINGA: I think, Dr. Lamb, if you
9	want to address that question, you may. Otherwise, I
10	think it's one appropriately put to the EPA, too,
11	because I think the statements have been made to
12	essentially set aside some of these other effects that
13	Dr. Handwerger is really alluding to.
14	DR. LAMB: I think I think it's the
15	disadvantage of where you are in this process which is
16	the process that involves hundreds of other
17	toxicological and exposure studies andand these
18	issues haveare not ignored. They are addressed at
19	other studies along the way, both in the initial
20	registration, re-registration, and as other questions
21	come up.
22	And what's happened is we're to the point
23	that we'rewe're at what iswhat is typically
24	referred in risk assessment as the critical effect.
25	And so, these other endpoints have been addressed



	EPA MEETING 02/06/08 CCR# 15796-2 Page 283
1	either through animal toxicology studiesI mean, if
2	something comes up in the literature, I can tell you
3	that if it's problematic regarding a pesticide, EPA is
4	aware of it, and we, ifif it's a product for which
5	we're responsible, the companies respond, and I think
6	EPA would say the same thing.
7	But this iswe're to the point that this is
8	the most sensitive effect, most sensitive species.
9	This is what we think should be used for risk
10	assessment, and if you protect from this, you should,
11	at the same time, be protecting from the other concerns
12	that youyou're raising.
13	At the same time, I can't respond to every
14	epidemiological observation that may be raised without
15	some specifics. So, I'd stop there.
16	DR. HEERINGA: Thank you, Dr. Lamb. Dr.
17	Portier and Dr. Chambers.
18	DR. PORTIER: Dr. Sielken, you fit an
19	exponential model to your data, and if I remember
20	correctly, EPA fit an exponential power model to the
21	same data. Did you fit the power models, and is the
22	power different than 1?
23	DR. SIELKEN: Yes, I did hear that
24	comment from EPA yesterday. I did hear Dr. Setzer say
25	that for the brain data, when he fit the power, it was



	EPA MEETING 02/06/08 CCR# 15796-2 Page 284
1	1 or close to 1, sowhich is the same power that I
2	was using.
3	My experience with the power model which ends
4	up being four parameters and five data points is that
5	that power is very volatile, variablepick oneand
6	hence, the results are very problematical for
7	interpretation.
8	The ones that I used werewas simple
9	exponential as well as the simple 1 model.
10	DR. PORTIER: But you get great fit.
11	Right?
12	DR. SIELKEN: Sufficient for BMD
13	calculations, yes.
14	SPEAKER: Well, I guess I have a similar
15	question
16	DR. HEERINGA: Whoa, whoa.
17	SPEAKER: Oh, I'm sorry.
18	DR. HEERINGA: Dr. Lu?
19	DR. LU: Alex Lu. I had a similar
20	question. If we can go back to slide 21, okay, so try
21	to make sense of this graph. When there's no dose,
22	there's no inhibition, but when there's a dose 1 which
23	is highest dose, inhibition is actually the lowest.
24	So, there's some sort ofam I interpreting
25	this graph differently than you? I look at this



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 285
1	DR. SIELKEN: Well, okay, maybe
2	yourthe label up there is percent inhibition
3	relative to controls is a slightly misleading. It's a
4	scale from zero to 1. At zero, there is no
5	inhibitionthere is not 100 percent inhibition, so
6	you might want to label that as 100 minus the percent
7	inhibition.
8	So, yes, clearly, at dose 0, there's no
9	inhibition relative to controls, and at the highest
10	dose which is the right-hand side of the figure,
11	there's
12	DR. HEERINGA: You want to fit the y
13	label on there.
14	DR. SIELKEN: Yeah.
15	DR. LU: I've got a second question
16	that's kind of related to what Dr. Portier just asked,
17	is if we try hard to do a semi log plot, it's similar
18	to one of the plot that EPA gave yesterday, the
19	relationship between dose and response become very
20	linear which sort of like you agree that the dose and
21	response in this case should be linear. So, if you
22	calculate BMD10 or 50 places on the curve that you
23	present here, so my question is that, will that
24	bewill the outcome of the calculation be the same
25	when you convert a graph to some more linear scale and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 286
1	then you can do the comparison?
2	So, I mean, you don't have to answer the
3	question right now, but I suspect that there is going
4	to be some differences, and the differences will
5	probably be in between your calculation and the
6	Agency's calculation.
7	DR. SIELKEN: I don't think so. I think
8	you're point isis a good one aboutabout scales
9	and models, but I get the same relative sensitivity
10	whether I'm doingdirectly looking at the
11	experimental data at the doses that were observed of
12	1.3, for example, as a relative sensitivity at 0.1, the
13	experimental dose, no modeling involved versus if I do
14	extrapolations to the low dose region and whether I go
15	down to a BMD10, 20, 30, 40you know, obviously, 40
16	is less extrapolation, but over that whole range of 40,
17	30, 20, 10, I'm still getting the same ratios of BMDs
18	in the neighborhood of 1.5.
19	DR. HEERINGA: Dr. Edoh, Dr. Lu, a
20	follow-up?
21	DR. LU: I do have a follow-up. I guess
22	based on my experience with acetylcholinesterase
23	inhibition is you don't need to get a linear response,
24	because you always seeespecially for a carbamate is
25	that you always see a quick inhibition and then you pot



	EPA MEETING 02/06/08 CCR# 15796-2 Page 287
1	belly, and that'sthat's sort of the data that kind
2	of common out there.
3	If you don't put it in a somewhat, a semi-log
4	scale, then you never get the linear range that you got
5	to forward, and theI think that the down side of not
6	using the semi-log is that you ignore the effect if the
7	dose is very low, and I think EPA has approached it
8	sort of like a method by the area and do the
9	calculation of the ratio, but I think my suggestion is
10	that for you to go back and come updo the semi
11	calculation that EPA used and see whether there are
12	some differences in terms of a numerical value, and
13	you'll be surprised thatnow, we're talking about
14	ratio between 1.5 to somewhere, that 4 point something
15	that EPA used, but I think the ratio will be very
16	DR. SIELKEN: I disagree that I would
17	get any number close to the number that 5 per EPA. I
18	mean, I'm running the same models that they're running,
19	andand I just don't get anything like their ratio.
20	And the data itself aren't suggesting that ratio.
21	Your other point about the quick recovery and
22	how long it takes, that relates to the time course, and
23	here we're looking at a fixed time which is mainly 40
24	minutes in the ORD. So, I don't have that time issue,
25	because it's a fixed time.



EPA MEETING 02/06/08 CCR# 15796-2 Page 288 1 DR. LU: Thank you. 2 DR. HEERINGA: Thank you, Dr. Sielken. 3 Dr. Edler? 4 DR. EDLER: No, thank you. 5 DR. HEERINGA: Okay. Dr. MacDonald and 6 then Dr. Chambers. 7 DR. MACDONALD: Yeah, I have been 8 puzzling over these same graphs as Dr. Lu has been, and 9 just one further question. You had together a 10 hypothetical example that you got linearity on linear-11 linear scales, yet most of the graphs like this I think 12 we have seen of the experimental data, we've got a log 13 linear plot. So, how do you justify getting the 14 straight line on linear-linear? 15 DR. SIELKEN: This is Dr. Sielken in 16 response. I did the... I did the approach both ways. 17 In other words, I did it on the dose scale by...by 18 looking at the Hill models, the exponential models, and 19 looking at it on that scale. On the relative values of 20 the acetylcholinesterase inhibition, the inhibition 21 scale, if you will, then those two are equivalent when 22 I have linearity. They're not equivalent when I don't 23 have linearity. 24 My contention was that line...and...and 25 that's all that these pictures were, was to show that



	EPA MEETING 02/06/08 CCR# 15796-2 Page 289
1	when you have linearity, looking at it on the dose axis
2	or on the response axis, you get the same ratio. That
3	was the only purpose of these pictures. So, I mean,
4	that's why these pictures were put up there this way.
5	I also made the comment that if we had
6	approximately low dose linearityand we are dealing
7	with low doses in the risk assessment, not these doses.
8	We're dealing with much lower dosesthat at those
9	low doses, the changes are going to be roughly linear.
10	And so, I'm talking about the right units for
11	that type of dose scale.
12	Thank you.
13	DR. HEERINGA: Dr. Chambers?
14	DR. CHAMBERS: Clarification for Dr.
15	Morris, please. This is Jan Chambers.
16	When you're talking about the LODs changing
17	because of the newer technology, and you talked about
18	the number of samples, were you just looking at the
19	more recent samples since the technology got more
20	precise?
21	DR. MORRIS: Robert Morris in response.
22	I was looking at all the data, but I was applying the
23	limit of detection from the new analytical
24	capabilities, the 2006 data.
25	DR. CHAMBERS: But applying that to even



EPA MEETING 02/06/08 CCR# 15796-2 Page 290 1 the older data that might have used the older 2 technology? 3 DR. MORRIS: That's right, because you...you can't...when you do the residue definition 4 5 files, you can't have mixed amounts in your...in the 6 file.. You have to have one or the other for LOD. 7 DR. HEERINGA: Yes, Dr. Stinchcomb? 8 DR. STINCHCOMB: If it's not 9 inappropriate, can I ask one more question about the 10 dermal study or not? 11 DR. HEERINGA: Why don't you...because 12 we're going to turn to water next and... 13 DR. STINCHCOMB: Okay. 14 DR. HEERINGA: ... I think let's go ahead 15 and get your question in. 16 DR. STINCHCOMB: So, when the slurry was 17 applied to the skin in the dermal tox study, is there 18 significant water that's still remaining, or is the 19 water all rubbed in and there was just dried particles 20 on the skin? And then, what happens at 6 hours when 21 the occlusion covering was removed? 22 DR. LAMB: I think that originally, it's 23 It's...it's placed there and that, there as a slurry. 24 over time, I think, with most of these studies... I am 25 not familiar with this...what they saw in this



	EPA MEETING 02/06/08 CCR# 15796-2 Page 291
1	particular case, but in most of these studies, the
2	application site dries, and that at the end of the
3	application period, this is why you then clean out that
4	site, and I think they used Ivory soap and water,
5	basically, to clean the site and then immediately
6	sacrificed the animals.
7	So, it's put on wet, but it has access to
8	air, so my expectation is it would dry over time.
9	DR. CHAMBERS: This states that there
10	was occlusion. Is that not true?
11	DR. LAMB: I thought it was semi-
12	occlusion. Let me check with Dr. McLean. Semi
13	occlusion, meaning it has access to air, but the animal
14	can't reach it.
15	DR. CHAMBERS: So the water evaporates
16	and you have dried particles?
17	DR. LAMB: That's my guess, yes.
18	DR. CHAMBERS: Do we know the particle
19	size of the chemical?
20	DR. LAMB: I don't. Somebody might, but
21	I don't.
22	DR. HEERINGA: We can probably get that
23	for you.
24	DR. LAMB: Yeah.
25	DR. HEERINGA: Yes, Dr. Bunge?



	EPA MEETING 02/06/08 CCR# 15796-2 Page 292
1	DR. BUNGE: Can I just make one follow-
2	up question?
3	DR. HEERINGA: Sure.
4	DR. BUNGE: So, the tape that's used, is
5	it non-occlusive? That's the two 3M tapes that are
6	talked about, are theycan water go through them?
7	DR. MCCARTY: Jane McCarty from FMC.
8	The tape that they used to cover the site, first they
9	put, I think, gauze on, and then they put vet wrap
10	which is aa semi-elastic, semi-occlusive wrap. It
11	was not a totally occlusive wrap.
12	Even though I think the EPA DER described it
13	as an occlusive covering, it was not totally occlusive.
14	It was always semi-occlusive.
15	DR. HEERINGA: Dr. Reed?
16	DR. REED: Withexcuse me. With all
17	the questions that, the follow-up questions that we
18	have, I guess we're, at least we are, curious about the
19	concept ofof the entire amount that is applied to
20	the skin in terms ofof how much isisis it in
21	contact with the skin. Is it the entire amount whether
22	it's inin a solid form oror wetable? I think
23	there was mention about solubility.
24	So, can you give us an estimate in terms of
25	how much was in contact with the skin that was in the



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 293
1	wet stuff?
2	DR. LAMB: What I can do is provide for
3	you the area that was treated on the back of the animal
4	thatthat will answer that question. It is in the
5	report, and we can pull it out so that you know, and
6	the, basically, the volume of the material so we can
7	calculate that.
8	So, is that in respondoes that answer your
9	question?
10	DR. MCCARTY: I can answer the area.
11	The area is
12	DR. HEERINGA: Dr. McCarty?
13	DR. MCCARTY: Dr. Jane McCarty. The
14	area that the material is applied to 5 by 8 cm, and the
15	material was prepared. It was a slurry. The water was
16	added to the weighed material, and that slurry was
17	applied and spread over that 5 by 8 cm area.
18	DR. REED: As a follow-upthis is Ruby
19	Reed again. And so, I guess the curious question
20	isis how much is taken up by the gauze and then, you
21	know, dry up at what point so that how much of the
22	chemical is in contact with the skin after 6 hours.
23	Does that make sense in terms of
24	DR. MCCARTY: Yeah, I don'tI don't
25	have any way of measuring that. I don't know.



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 294
1	DR. HEERINGA: Okay. What I'd like to
2	do at this point, here is my proposal which I'm going
3	to follow. It'schance to vote was yesterday, I
4	guess, and I'm sorry about this, but I feel it's very
5	important to finish this series of presentations this
6	evening.
7	What I'd like to do is I'd like to call for a
8	10-minute break, and then, as a service, we're going to
9	have Larry Kleingartner from the Sunflower Growers is
10	going to do a short presentation, and then we will move
11	to a full consideration of thethe water presentation
12	by SMFMC. So, is that okay?
13	I anticipate wrapping up by 7:00. The only
14	thing that we have to make sure of is that I'm told at
15	6:00 p.m., these doors lock out here, so if youif
16	you want to use the facilities, you're going to need
17	aa hall monitor to let you back in.
18	(WHEREUPON, Session C was concluded and a brief recess
19	was taken.)
20	DR. FAWCETT: My name is Richard
21	Fawcett, and I am one of the panel of 3 that FMC
22	convened to conduct a refined risk assessment for
23	Carbofuran in drinking water, and to also recommend
24	mitigation measures to protect ground and surface
25	water. The other members of the panel are Burnie Engel



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 295
1	and Dr. Engel, and Martin Williams. Robert Morris is
2	also with us here from FMC, and may be able to answer
3	some questions.
4	I want to start with just a little cheat-
5	sheet here with some acronym definitions. We may use
6	these, and hopefully we'll define them the first time
7	that time that we get to them, but if not, you'll have
8	this in the materials you can refer back to. I want
9	to introduce this topic by very briefly summarizing
10	EPA's methods and conclusions on drinking water
11	exposure, and contrast those with those from the panel
12	that we have here, that will be speaking to you this
13	afternoon. In their tier 2 modeling process EPA used
14	their typical procedure of the index resovoir modeling,
15	using Prism's exams.
16	But some important assumptions that were made
17	is that 100 $\%$ of the crop or in some cases all of the
18	agricultural land was treated with Carbofuran. So that
19	meant that up to 87 $\%$ of the watershed received
20	Carbofuran. Using those modeling techniques, they
21	calculated acute estimated drinking water at
22	concentrations of from 19 to 49 part per billion. In
23	their ground water assessments the estimated exposure
24	by scaling results from a shallow ground water
25	perspective study in Maryland to reflect all crops



	EPA MEETING 02/06/08 CCR# 15796-2 Page 296
1	specific application rates in all uses across the
2	country.
3	Using that technique, their 90 day average
4	estimated drinking water concentrations were from 1.4
5	to as much as 110 part per billion. Now I am sure you
6	are all familiar with the EPA's tiered approach in risk
7	assessment. Where they begin with a screening level,
8	and then may go to higher tier, more detailed
9	assessments, if that's deemed appropriate or necessary.
10	EPA stopped at the tier 2, and one of the reasons they
11	did is because as you've seen in EPA's calculations,
12	the risk cup was full with their dietary assessment.
13	There was not room for drinking water, so it
14	was deemed not necessary to carry forward with some
15	higher-tier assessments. However, they do in their
16	procedures allow for this, and the quote on the bottom
17	of the screen simply says, "failing a tier however,
18	does not necessarily mean that the chemical is likely
19	to cause health or environmental problems, but rather
20	there is a need to move to a higher tier, and conduct a
21	more refined assessment."
22	And because, with the material you have seen
23	presented by FMC would indicate that there is room in
24	that risk cup, then we think it is very appropriate
25	that we need to have the best assessment possible to



	EPA MEETING 02/06/08 CCR# 15796-2 Page 297
1	know what that drinking water contribution would be, to
2	see if there is room in that risk cup. And we would
3	argue that there is room, as you'll see from our
4	calculations. So we will be giving you the results
5	from that higher tier, a some refined assessment, this
6	afternoon.
7	We have already heard - and I am going to try
8	to be as brief as I can - You have heard how the use of
9	Carbofuran has changed over the years, due to market
10	forces and changes in label directions and eliminations

of some crops. The slide on the left shows 1992 us of

Carbofuran going from the lighter colors through green

to blue is the highest use. In 2005, you can see how

is no longer on the label, the 2005 data has been

adjusted for that. If you were to consider a pre-

emergent herbicide such as Atrogene, which is used on

80% of corn acres, or may a post-emergent herbicide

like Glyphocate that is used on over 90% of the soy

of the crop is treated with that product. But for

something like Carbofuran, when less than 1 % of the

crop area is treated, that really is not appropriate.

And it's an important concept that we're going to be

beans, then it is very appropriate to assume that 100 %

the use has declined considerably. And because alfalfa

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25 talking about, considering that percent of crop



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 298
1	treated. Just to very quickly summarize what you'll
2	hear about our surface water assessments, FMC in their
3	tier 3 modeling, a higher tier modeling, considered the
4	actual percent treated for Carbofuran from sales
5	figures. And for the watersheds a model that was
6	anywhere that was form 0.41 percent of the crop area
7	treated.
8	And that translated into from 0 to 0.7 $\%$ of
9	the watershed treated with Carbofuran. In that
10	modeling you'll see the results that presented later,
11	that shows that the estimated drinking water
12	concentrations were less than 1 part per billion.
13	EPA, as it turns out, has also used that tier 3
14	approach and they have used the percent crop treated
15	approach, in the cumulative methyl carbonate
16	assessment, using that procedure they came out with as
17	well with concentrations below one part per billion.
18	For ground water, the FMC's tier 3 modeling
19	analysis also showed that Carbofuran's concentrations
20	would be expected to be below 1 part per billion.
21	And the monitoring data that we'll be showing are also
22	supportive of that tier 3 modeling estimate. I would
23	like to turn the slides over to Dr. Engel, who will be
24	reporting on some of the surface water assessments
25	we've conducted.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 299
1	DR. ENGEL: Hi, I am Doctor Engel, I
2	have extensive research experience with hydro logic
3	water quality modeling, and large spacial data sets to
4	support those analysis. I'll spend about 10 minutes
5	talking about a portion of the surface water
6	assessment, initially looking at some of the work that
7	we did with resovoir based systems, and then pass the
8	slides to Marty Williams, who will talk about the
9	flowing water assessment.
10	For the surface water assessment, we looked
11	as resovoirs within Indiana, used the Prism Exams
12	Model - for which I'll provide a couple of more details
13	in a couple of moments - and a key point that here is
14	that we used actual Carbofuran use within those
15	watersheds and those assessments, and you'll see the
16	impact that has. We then looked at a national
17	resovoir assessment to understand what the potential
18	vulnerability may be for resovoirs nationally to
19	Carbofuran use, and considered the community water
20	system characteristics in that analysis. And finally,
21	as I said, Marty Williams will talk about the flowing
22	water assessment, the rivers that may be used for
23	community water systems, and used, monitoring data used
24	the warp model that he'll describe briefly and some
25	statistical analysis in that exploration.



EPA MEETING 02/06/08 CCR# 15796-2 Page 300 1 First, let me do a quick overview of a couple 2 of key concepts in setting up this resovoir modeling 3 approach that we have used, and that EPA has used as well. As you are probably aware, there is some 4 5 watershed area that would contribute run-off to a 6 resovoir, so that might be depicted here, and would be 7 called the drainage area. So this is going to be the 8 area on which materials may be applied, so therefore 9 this represents a potential capacity to deliver materials to a resovoir. 10

11 Run off from that area might enter a resovoir 12 so that would have some capacity. So depending on the 13 size of that capacity, larger would be more potential 14 for dilution. So sizes on these are going to matter. Not all this watershed is likely to be treated. 15 As 16 many of you flew across the country to get here, you 17 probably noticed that even within the corn belt not 18 everything is low cropped agriculture, that there are 19 non-agricultural land uses in the watershed. So the 20 green here depicts some percentage crop area within 21 this watershed, and not all that area is likely to be 22 treated with a particular product, especially a product 23 like Carbofuran. 24 So some percentage of that crop may be

25 treated, and that would ultimately provide some percent



	EPA MEETING 02/06/08 CCR# 15796-2 Page 301
1	area treated for the overall watershed. An important
2	concept as we look at an analysis within Indiana and
3	then scaled this nationally, was to examine this ratio
4	of percentage area treated with Carbofuran multiplied
5	by the drainage area of the watershed, divided by the
6	normal capacity of the resovoir. So this combination
7	identifies areas that would have potential for high
8	exposure to Carbofuran or applied to other products,
9	could be used in a similar fashion. So we'll see this
10	again in a couple of moments.
11	Within Indiana, we looked at 15 actual
12	resovoir based systems. Indiana being in the corn belt
13	is fairly typical of land uses, soils, management
14	practices, Carbofuran use, but importantly to us, the
1 -	

15 community water system data was available in a very 16 timely fashion, so that we could take advantage, and 17 use that in the Prism Exams modeling. Using the same 18 model that EPA used in their tier 2 assessment, here 19 though we took advantage again of actual data within 20 Indiana, with the actual community water system and 21 watershed data to conduct those analyses. Another 22 important distinction here is that we used actual 23 Carbofuran use that was experienced within this area on 24 a county by county basis, between 2002, 2004. 25 What did we find? Interestingly, only 3 of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 302
1	the 15 community water systems experienced Carbofuran
2	use in that period. The percentage of application of
3	crop areas within that was quite low, as you've heard
4	about already, and the range of expected Carbofuran
5	concentrations in those resovoirs ranged from .01 to
6	0.13 parts per billion. Contrast that to what EPA
7	would predict with their tier 2 approach, in that same
8	location one would get 19 to 49 parts per billion,
9	quite a stark contrast.
10	I know this is a little bit complicated,
11	so let me slow down and put some of these ratios in
12	perspective then and explain and hopefully help you
13	understand that some Indiana resovoirs were more
14	potentially vulnerable to Carbofuran than the index
15	resovoir. But at the end of the day, when we consider
16	the percentage crop treated, that that vulnerability
17	goes away. So let me step through this: So if we look
18	at this top line, this is the ratio of drainage area to
19	normal capacity for all the resovoirs within Indiana,
20	and it ranges from about 236 as depicted here in the
21	table, to about 2.
22	In contrast, the Shipman Index Resovoir that
23	EPA has used for tier 2 assessments is about 12. So we
24	have about half the Indiana systems being potentially

25 more vulnerable and about half less vulnerable. If we



	EPA MEETING 02/06/08 CCR# 15796-2 Page 303
1	now modify that, and consider the percentage cropped
2	area within those, that's going to be the second line
3	here, we see that values reduced correspondingly and
4	where does the index resovoir fall? It falls more at
5	the upper end now.

6 If we take that one step further, and 7 consider Carbofuran use in the watersheds now, for Indiana, since the percentages were quite low, this 8 9 relationship hugs this bottom line, whereas the index 10 resovoir remains at a value of 5.5 or 10.4, depending 11 on the particular run that EPA was making with that. 12 So to summarize the slide, so within Indiana, many 13 resovoirs potentially more vulnerable, but when one considers the actual use of the Carbofuran product, 14 15 they become much less vulnerable.

16 Again, as Doctor Williams pointed out, the 17 EPA has in the past, in the NMC Cumulative Assessment, 18 used a comparable sort of a concept. A watershed, some of that watershed agricultural land uses. Some of 19 20 that watershed treated, some of those crop uses treated 21 with Carbonates, and yet a smaller subset treated with 22 Carbofuran. And if fact, Carbofuran percentages on the 23 order of magnitude that we were using for our 24 assessments within Indiana. When EPA did that, they 25 found that their estimates with the index resovoir sort



	EPA MEETING 02/06/08 CCR# 15796-2 Page 304
1	of approach for Carbofuran in resovoir based systems
2	range from .002 parts per billion, to about .82 parts
3	per billion, that upper end being in Florida. FMC has
4	proposed that that be removed from the label, so it we
5	adjust that, concentrations would be actually quite
6	close to what we found for Indiana, .002 to .35 parts
7	per billion. And just quickly, EPA has used that
8	concept as percent crop treated approach on other
9	occasions.

M = = = 1

10 Moving to the national assessment to 11 understand the vulnerability or potential vulnerability 12 of community water systems, we took the Carbofuran use 13 between 1998 and 2003, actually we took the maximum use experienced in any county in any of those years, used 14 the natural break method to divide this into 4 use 15 classes, and then we go to the next slide, we use this 16 17 to identify every single resovoir based systems within 18 these class one to class four use tiers , or use 19 categories.

We identified the potentially vulnerable community water systems in these, based on the use intensity of Carbofuran, so based on our experience in Indiana , if use intensity was more than 2.1 pounds of active ingredient per acre we put that in the potentially vulnerable category, we also looked at the



	EPA MEETING 02/06/08 CCR# 15796-2 Page 305
1	resovoir watershed property, this drainage area by
2	percentage area treated divided by normal capacity
3	ratio, and again based on Indiana sensitivity analysis,
4	if that value exceeded .037, that was a good indicator
5	that there was potential to have Carbofuran in the
6	resovoir, above .5 parts per billion.
7	So we put those in the potentially vulnerable
8	category as well, and then as one might expect,
9	following some concerns about security of drinking
10	water systems, we were unable to get data for
11	Pennsylvania, and parts of North Carolina in a timely
12	fashion. So systems for which we lacked information,
13	we put those in the potentially vulnerable category as
14	well.
15	So what are the results of that? So we found
16	that 20 or the 30 states that we examined didn't have
17	community water systems that were resovoir-based that
18	werethat met any of these vulnerability criteria's,
19	so those could be assumed to be quite safe. In the 10
20	remaining states we found 65 reservoir-based systems
21	that could potentially be vulnerable, 15 based on the
22	characteristics of Carbofuran use, or the ratio that I
23	talked about. And again, 50 of those we were unable to
24	obtain data. So to be conservative we placed those in
25	this vulnerability category. You heard earlier in the



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 306
1	morning that FMC has proposed mitigation measures, we
2	would propose mitigation measures for these counties in
3	which these 65 systems would be located. At this point
4	let me pass the slides to Marty Williams to continue
5	the flowing water assessment.
6	MR. WILLIAMS: Good afternoon, or I
7	should say good evening, at this point. My name is
8	Marty Williams, I am with Waterborne Environmental Inc.
9	My background is in hydrology and water quality and for
10	the past 20 years my work has focused on the patent
11	transport of pesticides in the environment. To address
12	flowing water systems, we kind of took a stab at it in
13	three different areas.
14	The first one was looking at the U.S.G.S.
15	N.W.Q.A. database. N.W.Q.A. stands for the National
16	Water Quality Analysis. It's a monitoring program
17	developed by the U.S. Geological Survey to assess the
18	status of waters in the country. N.W.Q.A. includes
19	ground water and surface water data, there are study
20	units that are not primarily agriculture, there are
21	others that are more urban. The frequency of sampling
22	varies. Some states cites are sampled extremely
23	frequently, on the order of several day intervals for
24	periods. Others are more relaxed.
25	That always brings people - including the



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 307
1	EPA- to say "was the peak concentration missed in that
2	kind of study?". But when you look at it all together,
3	we've got over 20,000 Carbofuran records, and that
4	encompasses many many many site years, equivalence of
5	data. So it is a very large data set to work with.
6	Carbofuran, being an agriculture pesticide, you know
7	the monitoring and analysis for that is geared mostly
8	towards the ag type environments and the sample
9	frequency is more geared more towards the spring and
10	summer. So one would argue that the data on Carbofuran
11	is bias toward where you would find Carbofuran
12	detections. In that data there are over 20,000 records
13	for Carbofuran, but only 71 of those samples have
14	concentrations exceeding 0.5 ppb.
15	That's only 0.2 percent out of the data. The
16	maximum concentration in that data set was 32.2 part
17	per billion. EPA is aware of that sampling location,
18	but it also is a very, very unique condition, it was a
19	nursery environment with somewhere on the order of 10
20	pounds per acre application. That type of application
21	is no longer labeled and allowed, and the receiving
22	water was a very small ditch, which is not
23	representative of a community water supply. Since
24	community water supplies by nature have to supply
25	sufficient water to service their population, you don't



	EPA MEETING 02/06/08 CCR# 15796-2 Page 308
1	see it on small streams, they are geared toward larger
2	river systems.
3	To try to make a more, drinking water type of
4	assessment, we took a subset of that data where we
5	removed ditches, streams, impoundments in order to try
6	to come up with a representative data set that was more
7	applicable to a farm water community, water supply, and
8	that's shown in this bottom box here. From that we
9	still had a large number of Carbofuran records, because
10	the N.W.Q.A. program was mostly geared towards water
11	systems, but we only saw 29 samples greater than 0.5
12	ppb, and the max concentration in there was 5.82 ppb
13	which was the Trinity River Basin in Texas, and there
14	were only 2 or three other samples above 1 ppb, and
15	they range from 1.0 to 2.0. This Trinity River Basin
16	data set has been investigated by FMC in the past and,
17	you know, if you have questions on that, Donald
18	Carlson from FMC can come in to address it, but it also
19	is a very unique situation.
20	This map shows you in the lower left the 2005
21	usage patterns for Carbofuran, just so you can kind of
22	put that into context. This is the data, those are our
23	detections. I can't see the colors from here because
24	of my eyesightbutit's still hard to see the
25	colors in there. You'll find that there is very very



	EPA MEETING 02/06/08 CCR# 15796-2 Page 309
1	few points greater than 1.0 part per billion in that
2	data set. This overlay is the non-detects, just to
3	give you an idea of where that sampling has occurred.
4	The second analysis we performed was to use
5	the U.S. Geological W.A.R.P. model, which was a
6	watershed regression profess, which is what that
7	acronym stands for. EPA has been looking at that as a
8	kind of a candidate tool for addressing drinking
9	water's exposure for pesticides And what W.A.R.P. is,
10	is a series of regression equations developed initially
11	for Atrazine, they later adapted it to be used for
12	other chemicals by allowing chemical specific use
13	intensities, half lives, and soil absorption
14	coefficients to be used in that model, for it to be
15	used for other chemicals.
16	It involves a number of spatial parameters.
17	I'm not going to go over them in detail here, but they
18	are using the equations because they were found them to
19	be sensitive during their analysis in regression
20	development. The most important one is Carbofuran use,
21	and when you integrate those together, you get the
22	prediction of concentrations spatially within a
23	watershed. This shows the results of our analysis
24	using warp.
25	We focused on the 4 states in the corn belt,



	EPA MEETING 02/06/08 CCR# 15796-2 Page 310
1	because they represented high areas of Carbofuran use.
2	We did the analysis at what is called the Hot Twelve
3	Scale watershed, which is a relatively small watershed
4	classification is USGS's hierarchy scheme, and it's on
5	the order of 2,500 acres in size generally. For
6	example in Illinois there is thousands of hot twelves.
7	So these are really, really small basins that we did
8	the analysis on, so we are probably predicting
9	concentrations on the high end. The colors range again
10	from yellow low concentrations to dark blue higher
11	concentrations.
12	You can see the variability in that area.
13	The highest concentration was predicted for Illinois,
14	and that was 0.68 parts per billion. In the past few
15	weeks we did another analysis because EPA has expressed
16	concern - not just for this product, but for other
17	situations - that monitoring data does not capture a
18	peak, and that W.A.R.P. is then giving you the range of
19	high exposure concentrations that you might see in the
20	typical year, rather than after some extreme events.
21	So we wanted to try to determine if there was
22	a way to better estimate when an extreme event
23	concentration could be, and to do that we did a
24	statistical extrapolation. We took those 13,000 data
25	points that I showed you for the river/bay systems,



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 311
1	filtered, they were filtered to remove the ditches and
2	you know small streams, and canals and those sorts of
3	systems, and we also removed all concentrations less
4	than 0.5 ppb in order to get us that upper range of the
5	curve of detections to fit a regression line.
6	We developed a best-fit distribution, and
7	used that to extrapolate, to understand the probability
8	of high exposure events. The red points in here are
9	the individual detections of Carbofuran from that data
10	set. The middle blue lines flowing from the lower left
11	to the upper right is "best bet" line.
12	The outer blue lines are the 95th percentile
13	confidence intervals. The probabilities associated
14	with this tip were then re-adjusted to bring in the
15	data set of interest, which is you know the 13,000
16	points the whole the river system, and the
17	results of that analysis is provided here. So we are
18	showing concentrations from the table of 0.5 ppb all
19	the way up to 20 ppb, the probability of occurrence.
20	The probability of one PPB was up there at
21	the 99.93 percentile, and that equates to really the
22	equivalent of being equal to or exceeded .07 percent of
23	the time. That's 7 out of 10,000 chance of occurring.
24	If you look at theour W.A.R.P. prediction of 0.68
25	that's a 0.2 % probability of occurring, and maximum in



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 312
1	the N.W.Q.A. data set of 5.82 was 2 in 100,000. So we
2	feel that the probability analysis confirmed that we
3	are getting high probability exposure values from, you
4	know, out of the N.W.Q.A. data, and the W.A.R.P.
5	monitoring.
6	In summary, from all of our surface water
7	studies, with the same crop treated, the P.C.Y. is
8	critically important for an accurate prediction of
9	exposure for niche products like Carbofuran, and the
10	weight of evidence of our analysis has really shown.
11	Estimated drinking water concentrations in the subpart
12	per billion level and more toward an upper end level of
13	one part per billion. At this point Dr. Fawcett will
14	take over and provide an overview of the ground water
15	assessment.
16	DR. FAWCETT: When I was first
17	contacted by FMC to see if I had interest in
18	participating in a project to try to define the risk of
19	Carbofuran reaching ground and surface water I was at
20	first a little surprised by the concern. Because to my
21	knowledge of the monitoring literature Carbofuran had
22	been really a very rare detect, in either ground or
23	surface water, especially in the major areas of its
24	use. I was of course aware that back in the late 70's
25	early 80's that Carbofuran was detected in wells on



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 313
1	Long Island New York, along with some other pesticides,
2	where it had been used at relatively high rates on the
3	sandy soils in potato production. And for that reason,
4	use on Long Island was then prohibited on a label.
5	So there were some localities where
6	detections had occurred, but there were other
7	localities where detections were very rare. So it was
8	an interesting discrepancy to try to understand and
9	explain, but it's a very important discrepancy, because
10	as you have seen, EPA used a perspective study
11	conducted in Maryland to calculate their estimated
12	drinking water concentrations for all localities and
13	cropping systems. And that site in Maryland was chosen
14	to try to replicate the Long Island conditions.
15	So why might we have more detections in some
16	areas than others? Or maybe fewer detections today
17	than in some older historical monitoring studies? One
18	of the factors is the reduced use. We've seen how it's
19	become a niche use product, used on less than one
20	percent often of the acres.
21	So when we look at some of the older
22	monitoring studies, maybe done in the 80's, it was
23	used on at least ten times as many acres. So if we are
24	going to use those older studies to interpret for
25	today, we can of have a ten-fold safety margin there.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 314
1	But also there are specific vulnerability factors. We
2	really need to have all these together: Sandy soils,
3	coarse soil, shallow groundwater, but also have acidic
4	soils and acidic groundwater. We need all of those
5	factors together to get that vulnerability. And we
6	also need to keep in mind that there have been a number
7	of previous label changes.
8	Some of it you have heard about already; that
9	have reduced or prohibited use in vulnerable areas.
10	Use was prohibited in Long Island, New York, in 1984.
11	A groundwater advisory was added to the label in 1985,
12	advising against use where soils were coarse and
13	groundwater was shallow. And then there were some
14	specific changes addressing the more vulnerable
15	regions, due to soil type or groundwater depth.
16	Sequential treatments were not allowed on
17	those vulnerable soils in 1997. So you could only
18	apply the product once, not twice. And significantly,
19	the potato rate was reduced from 6 pound per acre -
20	which is probably what they were using on Long Island
21	when they got into trouble - from 6 pound down to one
22	pound per acre in those vulnerable soil areas. Again

EPA's tier 2 assessment, they based it the perspective groundwater study in Maryland. And that site is very unique, again selected to try to mimic Long Island.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 315
1	It has a sand soil texture, not a loamy sand
2	or sandy loam, but a true sand with greater than 90%
3	sand particles. This soil was very acidic, with a pH
4	of less than 5.8 for all measurements, and often far
5	below that. The ground water is also acidic, all
6	measurements were less than 6 and many below that, and
7	of course being a monitoring study, it had a relatively
8	shallow well depth of 13 to 14 feet.
9	Why is pH important? pH is very important to
10	Carbofuran persistence, and therefore the leaching
11	potential. The longer it lasts in the soil, the
12	greater the chance that it might move through the soil
13	to reach wells, and once it reaches water, the lower
14	the pH, the longer it will last and the greater the
15	chance that it may show up in that well.
16	We have seen some earlier numbers, the half
17	life depends upon the experimental conditions, but here
18	is a study that looked at soil half life, at pH 7 the
19	half life was 23 days, reducing the PH to 6.6 increased
20	that persistence to 43 days. Similarly in water, at a
21	pH of 9 Carbofuran has a half life of 12 hours. We
22	don't want to mix Carbofuran in alkaline water in the
23	spray tank, because it breaks down in the sprayer too
24	quickly to get the activity. If we look at pH 7, the
25	half life is 28 days and down to pH 5 it becomes



	EPA MEETING 02/06/08 CCR# 15796-2 Page 316
1	stable. So low pH's make Carbofuran more persistent,
2	and more likely to reach ground water.
3	We began our analysis, and really we did it
4	in 2 stages, we first concentrated on those green
5	states, essentially the corn belt, the higher use areas
6	for Carbofuran. Corn belt and 3 specific states in the
7	Pacific Northwest where it is used on potatoes.
8	We then conducted a separate analysis
9	essentially of all the states east of the Mississippi
10	that we had not previously analyzed. This included
11	areas that we assumed to be more vulnerable. Where we
12	had more sandy soils and where that Maryland site of
13	course is. But they were lower use areas. The first
14	thing we did was to try to find all of the monitoring
15	studies that we could find in the literature. And EPA
16	did identify many of these areas and they summarized
17	them in their document, but we were able to find some
18	additional monitoring studies, and partly some large
19	ones in the heart of the corn belt.
20	Those studies were done anywhere from 1983 to
21	2005, and an important source of data for us was that
22	National Water Quality Assessment. And those studies
23	were done anywhere from 1993 to about the present. So
24	it gives us a little more recent data set, and a very
25	high quality extensive study. Soil texture, we wanted



	EPA MEETING 02/06/08 CCR# 15796-2 Page 317
1	to identify those high sand soils and used the Statsco
2	Database to get at that. Water pH, we got from either
3	published studies, or surveys in states or databases or
4	in some cases we used the N.W.Q.A. data set for water
5	pH. Soil pH, rather than use a database, to try to
6	eliminate the complication of non-agricultural soils,
7	we contacted state soil specialists in each state, and
8	got their professional opinion of the typical ranges of
9	surface soil pH's as well as subsoil pH's.
10	Vulnerability, including aspects such as
11	groundwater depth, we ended up using EPA's County
12	Drastic Database, and I'll say a little bit about
13	drastic in a minute. And we also tried to get
14	Carbofuran use survey's to try to match the time
15	periods that these monitoring studies were done. For
16	many of the earliest studies we used state pesticide
17	surveys, kind of the mid ranges, we used the mass of
18	the National Agriculture Statistics service numbers,
19	and for recent use we accessed FMC's sales figures.
20	Many of you may be familiar with or heard of
21	Drastic before. It's a tool to measure the relative
22	vulnerability of groundwater. I won't read through
23	what all of what the acronym stands for, but you can
24	see the many factors that go into that, into that
25	calculation. When you apply Drastic you end up with a



	EPA MEETING 02/06/08 CCR# 15796-2 Page 318
1	score or a number. The higher the score, the more
2	vulnerable that site. For example, Wicomico Maryland,
3	that's the county in which the perspective study was
4	done, the score for that county is 185.
5	Undoubtedly if you calculated a score for the
6	study site, it would be a higher number, because it was
7	selected for it's vulnerability. But the county
8	average score for that county is 185. That's an
9	important number, because we'll use that as a benchmark
10	later.
11	To look at some other vulnerable areas,
12	Suffolk County, New York on Long Island, the score for
13	that county is 195. For comparison purposes, to look
14	at some higher use areas to the west, just to see what
15	the numbers would be. Cedar County, Iowa, that's where
16	my home farm is, the score for that county is 137.
17	Washington County, Mississippi, down in the Delta, the
18	score for that county is 144. Polk County, Oregon, is
19	out in the Willamette Valley, the score there was 122.
20	We chose to use Drastic as a tool, in a
21	tiered approach to try to identify potentially
22	vulnerable areas. And we use that 185 as a benchmark,
23	that Wicomico County, Maryland. This map shows all the
24	counties in the United States that had a score of 185
25	or more. And you can see that its almost all centered



$\Delta \Delta A = \Delta $	EPA N	MEETING	02/06/08	CCR#	15796-2	Page 319
--	-------	---------	----------	------	---------	----------

1	over here on the eastern seaboard and down through
2	Florida, with very few other counties scattered across
3	the country.

4 We then took an overlaid Carbofuran use data 5 on those high grassy scored counties to see if we had 6 both vulnerability and use. This shows for 1992, the 7 highest use is in red, but even there, that's 5 pounds 8 per square mile, even there, low use compared to other 9 pesticides. This shows use in 2005. What we did then, 10 was by using this, even those we'll see in a minute; 11 the detections of Carbofuran in that region have been 12 very low in the N.W.Q.A. data since 1993. But to make 13 sure that there was really no question about, worries 14 about contamination. We recommended..the amended label 15 has a number of geographical prohibitions. Florida, 16 North and South Carolina, the DELMARVA Peninsula, are 17 all prohibited from use. And those other scattered 18 counties are addressed, as well set backs, which I 19 think you heard about earlier.

Let's look at the monitoring results. We've got this divided into 2 sides, a left hand side of the slide are the major use areas, the kind of corn belt and potato states. On the right side and slide, are those states on the east of the Mississippi. Looking first on the left, there were 9,431 private, public and



	EPA MEETING 02/06/08 CCR# 15796-2 Page 320
1	monitoring wells in that universe of data. It's
2	important that there were private wells, because EPA is
3	rightly concerned, that if you for example simply look
4	at safe drinking water monitoring data that you'll miss
5	the private wells. There were many private wells in
6	the surveys.
7	There were also a lot of monitoring wells.
8	An important part of the N.W.Q.A. data set are shallow
9	monitoring wells on the edge of agricultural fields.
10	So we should have some of those worst case scenarios in
11	the data set. Looking at those western wells, I think
12	there were a total of 18 detects for a $.19$ % detection
13	rate. So really very rarely detected. And whenever we
14	talk about detection rates we need to consider
15	detection limits. N.W.Q.A. has very low detection
16	limits of .028 or .003, depending on the method used.
17	And while there were a few studies in the 80's that had
18	higher detection limits, most all the other studies had
19	detection limits of about .5 or less.
20	Looking at the highest concentration found in
21	those western states, that was one part per billion.
22	Found a well in Iowa. So there were no wells that came
23	anywhere close to approaching EPA's estimate of 17 part
24	per billion for their corn scenario. That well in
25	Iowa, I am very familiar with, because I made a



	EPA MEETING 02/06/08 CCR# 15796-2 Page 321
1	personal investigation back in the 80's. And it did
2	have a commercial mixing, loading, disposal site very
3	close to that well without any documented containment
4	in those years. At least it was my opinion it was
5	probably effected by that point source.
6	We shift to the right side of the slide, we
7	contrast to the states to the east. About 7,000 wells
8	in that data, and you can see the detection data was
9	higher; 2.56 % detection rate. Important, if we look
10	at the N.W.Q.A. data, and again that's 1993 onward.
11	It was about half the detection rate, despite the very
12	low detection limit, detections were lower in those
13	more recent years. Maximum detection it that was 36.6
14	part per billion back in '85, in a Massachusetts well,
15	we really don't have the details to say whether it was
16	a point source or something else, but that was the
17	highest number in the data set. But it's important to
18	consider that most of the detections, in fact all of
19	the detections above 1 part per billion occurred in the
20	1980's.
21	Before those label changes that reduced use
22	or prohibited use in vulnerable areas. Since 1993, in
23	that N.W.Q.A. data set there was only one N.W.Q.A. well

24 that had a concentration above 1 part per billion, and 25 that was 1.3 part per billion in a Connecticut well.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 322
1	Just to give you an idea of where the monitoring is
2	done, these are the N.W.Q.A. watersheds we don't report
3	on in those far southwest states, this shows where all
4	the N.W.Q.A. watersheds are. And here we have overlain
5	the locations of those additional studies we've
6	located. Often times they were just a few counties and
7	states that were aimed at vulnerable areas, but you can
8	see there in the heart of the corn belt they were
9	statistically designed statewide surveys for Nebraska,
10	Minnesota, Iowa and Illinois; an important use area.
11	Let's look at where we have the N.W.Q.A. detects,
12	because we have geo-referencing for all of those wells,
13	we can show you where the detections were, and where
14	the non-detects were.
15	These are the detections for Carbofuran in
16	the N.W.Q.A. wells. This just shows detection remember
17	all those except one were below one part per billion,
18	and about 99 $\%$ of them were at a tenth of a part per
19	billion or less, so usually very low concentrations.
20	That shows you where the detections were. This shows
21	you where the non-detects were. So you can see exactly
22	where the monitoring was conducted. And I have here on
23	the lower left, we show that the Carbofuran use map.
24	It's very important, because if you look
25	this, this is kind of one of the higher of use. It



	EPA MEETING 02/06/08 CCR# 15796-2 Page 323
1	just matches very closely, this area of higher
2	monitoring. Also in the Northwest we have monitoring
3	going on where there is the highest level of use. Also
4	important to note; here along the Eastern Seaboard,
5	very intensive monitoring in those vulnerable areas.
6	So the N.W.Q.A. gives us intensive monitoring both
7	where Carbofuran is used and in the more vulnerable
8	areas.

9 What are the factors that may explain the 10 discrepancy of the more detections in the East? At least in those early years of monitoring in particular. 11 12 Again, looking here on the left side of the slide we 13 are looking at those more vulnerable eastern states. Sand texture was greater than 5% of the surface soils 14 15 for 12 states. If we go over and look on the right for 16 the corn belt and the Northwest, it was less than 5 % 17 for all states except for Michigan and Nebraska. And 18 talking to soil specialists, those sandy soils in 19 Michigan and Nebraska were not real crop soils. Look 20 at Drastic.

For the states to the east the Drastic scores above 185, the county scores range from 0 to 88 %, but there were 7 states that had greater than 10% of soils, or counties having a Drastic score of 185. To the west, there was only a single county in Minnesota that



	EPA MEETING 02/06/08 CCR# 15796-2 Page 324
1	had a Drastic score of 185 or more. Far, it's rare to
2	find those vulnerable counties in those major use
3	states. Water pH's, in the east, generally low, they
4	were below 7. The mean pH for all the wells in the
5	data we analyzed, below 7 for 14 states. In the west,
6	they are above seven for all states, the mean pH.
7	In fact, there are only a few wells, single
8	wells in Texas, that had a pH as low as that Maryland
9	site. Soil pH's are a similar story, much lower in the
10	East. In particular the sandy soils and humid areas,
11	it's not uncommon to find low pH soils, often as low as
12	5.5, and in the subsoils as low as 4.5. It's kind of
13	the opposite as you go west, the farther west you go,
14	the higher the pH soils are. Often 6 to 7 for many
15	corn belt states, 7 to 8 as you get to Nebraska, west.
16	And in contrast with the East, subsoils tend to be
17	higher in pH, because of the presence of calcareous
18	porent materials or other reasons, so we have in the
19	East, lower pH's, and in the West, higher pH's.
20	So from that monitoring analysis, we are
21	confident that present use of Carbofuran results in a
22	very low risk of groundwater contamination. And in
23	fact in 99.9 percent of those N.W.Q.A. wells analyzed
24	since 1993; 99.9 percent were equal to or less than .17
25	part per billion, so far below one part per billion.



1	EPA MEETING 02/06/08 CCR# 15796-2 Page 325
1	But we wanted to carry the analysis farther,
2	and look really at a more national scale. EPA agrees
3	that Drastic is a useful tool to find vulnerable areas,
4	but there may be other tools that are also concerned
5	that the monitoring might have missed vulnerable sites.
6	So Waterborne conducted a national Carbofuran leaching
7	assessment, where they uses Prism, the Prism model to
8	simulate all agricultural soils, the entire U.S.,
9	64,000 soils. Assumed 30 years of consecutive use of
10	Carbofuran, in that model, and to measure the leaching
11	concentration at 5 meters below the soil's surface.
12	It was then loaded into an Aquifer model to
13	predict concentrations of Carbofuran in shallow ground
14	water. Both simulations were conducted either with or
15	without the geographic and soil restrictions that you
16	have heard about. And calculating maximum daily
17	concentrations, 95th percentile, or 90th percentile for
18	each of those runs. I am going to very briefly in the
19	interest of time just show you a snap shot of the
20	results of that nationwide analysis. Again, assuming
21	Carbofuran was used on every acre in the United States.
22	Again, this is the results from the amended label, that
23	has those geographical and soil type restrictions.
24	Across the top you have the spatial, less than 1
25	percent of acreage, less than 5 percent, and less than



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 326
1	10 percent of acreage.
2	Over on the left you have either the maximum
3	concentration that was predicted, or the 95th
4	percentile predicted. And you see that those are all
5	low numbers, nearly all except for that one maximum
6	value, less than a part per billion. To kind of put it
7	in words for the non-statisticians like myself, if all
8	eligible were treated at the one pound rate per acre
9	for every year for 30 years, and all the acreage had a
10	ground water depth of 5 meters, or about 15 feet, and
11	of course many areas don't have that shallow ground
12	water.
13	Then a concentration of .22 part per billion
14	would be expected to be equal or exceeded 5 % of the

00D# 1E700

 $M = = = 1 \times 10^{\circ}$

14 would be expected to be equal or exceeded 5 % of the 15 time on less than 1 % of the acres. So it does confirm 16 that the expected concentrations really are low. Less 17 than the 1 part per billion that we have been talking 18 about.

In conclusion, on the ground water, expect drinking water concentrations in ground water due to Carbofuran use are expected to be less than a part per billion. Or there is room in that risk cup for that amount. This is shown by the modeling in the National Prism Assessment, as well as that monitoring data. Ninety nine point nine percent of the almost 9,000



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 327
1	N.W.Q.A. wells since 1993 had a concentration of equal
2	to or less than .17 part per billion.
3	We also believe that the potential for ground
4	water contamination can be mitigated through labels
5	changes, and being conservative to remove some of those
6	worries about potential contamination. The amended
7	label that went in has useall the old prohibitions
8	are still therethings like Long Island, the things
9	you have heard about earlier.
10	But new prohibitions include all of Florida,
11	all of North Carolina, all of South Carolina, and all
12	the DELMARVA peninsula are prohibited from Carbofuran
13	applications. For some of those few other scattered
14	counties in other states, there is a well set back of
15	feet 50 feet required in those specified counties.
16	There is a new prohibit, a new label addition that
17	prohibits the mixing and loading and disposal
18	activities within 50 feet of a well, unless you have an
19	impervious pad.
20	To address the surface water concerns for
21	some of those counties you heard about, identified in
22	Illinois, Louisiana, and New Mexico, and all of Texas
23	and Pennsylvania, the label now calls for 66 foot
24	buffers adjacent to streams. I'm sure where many of
25	the panel members wonder where that 66 feet comes from.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 328
1	It's of course to both to be protected and compatible
2	with government farm programs. In order to get paid,
3	farmer to be paid, to seed down those buffers with a
4	conservation reserve program, they need to be at least
5	66 feet. On my farm, we have several miles of buffers,
6	along all the streams and many of these buffers were
7	already there, with help, with things like the
8	conservation reserve program.
9	I want to end with some quick acknowledgments
10	of some of the other scientists involved in these
11	studies, particularly monitoring and modeling. And we
12	have a few key questions like some of the other
13	speakers have had, that really relate to what we have
14	talked about here, I'll just leave them on the screen
15	for a minute.
16	I want to turn it over now to Keith Solomon,
17	and I know he'll be brief. I know he has a plane to
18	catch, but I think he has 3 slides on aquatic
19	toxicology, we have of course been dealing with the
20	drinking water aspects.
21	DR. HEERINGA: Dr. Solomon, then
22	we'll take questions.
23	DR. SOLOMON: Mr. Chairman, panel
24	members, I just had actually 3 data slides, and 1 title
25	slide, and it covers a large area. In terms of aquatic



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 329
1	risks, this was not a charge question to the SAP, and
2	it was mentioned yesterday by EPA. There are 2
3	documents that are being provided to the panel that
4	overview both the aquatic and the mammalian risks. And
5	just to briefly cover the aquatic, we obtained toxicity
6	values for aquatic organisms from the US EPA's ecotox
7	data base.

8 We also used microcosm based, this is 9 experimental ecosystem based no observed effect concentrations from Theo Broxworth in the Netherlands, 10 11 and Bartoningen and then we looked and compared these 12 two exposures, calculated by EPA in the IRED, also 13 using the N.W.Q.A. data that has been discussed 14 previously, although we did test a hypothesis that 15 there were changes in the pre 2000 and the post 2000 16 data, and we also used the one part per billion maximum 17 concentration that was talked about in the presentation 18 just given. So this starts off with a guick species 19 sensitivity distribution survey.

In the hollow points, the fish data the fish are less sensitive to Carbofuran that the arthropods and the solid points, and this just indicates the range of susceptibility to Carbofuran in these organisms. Now if you overlay on top of this the estimated concentrations from the IRED, you will see that fish



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 330
1	are still above the maximum concentration that they
2	estimated, but obviously there is some overlap with the
3	arthropod concentration.
4	However it you look at this in the context of
5	the Brock microcosm studies, which really show the low
6	observed adverse effect concentrations for microcosms,
7	which integrate many different species and interactions
8	between them. What you see is, this actually is very
9	close to the lower limit of the concentrations
10	estimated by EPA, and it still obviously exceeds some
11	of the toxicity values for the arthropods.
12	The reason for this is that the LC 50 testing
13	in the laboratory probably maximizes exposure which
14	does not occur in the real world. If you then place on
15	top of that the water concentration for the
16	presentation you just heard, you will see that somewhat
17	lower risks would be even less, lower from the Brock
18	microcosm reviews. I took the N.W.Q.A. data. I can't
19	show the individual data points, there are too many of
20	them, and it ceases the system up. These are the
21	regression lines, and you can see here that the
22	intercepts that some of these values on the basis of
23	some fairly high concentrations from places like Zonner
24	Creek, that we talked about earlier, in excess of 99 to
25	99.9 percent, so a very small probability that these



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 331
1	very high concentrations will occur and that adverse,
2	threshold adverse effects would be seen.
3	In terms of mammals, one slide. Mammals are
4	less sensitive than birds. And I am going to rely on
5	Dwayne Moore's modeling here. The mouse is the most
6	sensitive of the mammals, from the IRED 2 mg per kg and
7	the least sensitive mammal that I saw was the dog at
8	15. But in many instances these, in situations outside
9	of misuse and baiting, there would be similar exposure
10	reductions that we talked about in the avian risk
11	assessment, and in all likelihood they would have a
12	lower risk than for birds. And this I think is
13	consistent with the incident data, which excludes
14	misuse. If you look at the data, flowable uses are
15	only a very few incidences associated with mammalian
16	mortalities. There were more on the granular material,
17	but of course that's no longer in use, so thank you
18	very much Mr. Chairman.
19	DR. HEERINGA: Dr. Solomon, Dr
20	Fawcett, Dr O'Neil. Questions from the panel? With
21	regard to the presentations on water. Dr Sparling.
22	DR. SPARLING: Don Sparling for
23	Southern Illinois University. With the, I'm not
24	familiar with the Drastic score system. Why was 185
25	chosen? And how high do values go for Drastic?



	EPA MEETING 02/06/08 CCR# 15796-2 Page 332
1	DR. FAWCETT: One eighty five was
2	chosen because it was the value that was associated
3	with that Maryland prospective ground water monitoring
4	study, and I think values generally ranged maybe up as
5	high as 240. That would be like up in Broward County
6	Maryland, I mean Florida is in that sort of ballpark.
7	Maybe higher than that, 247, or something like that,
8	it's a relative index in its approach to relative
9	vulnerability. Mr Williams.
10	DR. HEERINGA: Other questions on the
11	presentation on the ground water or flowing water?
12	Okay, I want to thank you very much, again, for your
13	concise clear presentation. We have final, Mr.
14	Kleingartener, we have one more presentation left to go
15	before, I think. Mr. We have one more presentation
16	from FMC, just a wrap up that Dr. Cummings will do. We
17	are going to finish out after Dr. Cummings' summary
18	presentation. We are going to go to Mr. Kleingartner
19	and Mr. Engel from, representing the National Sunflower
20	Association, the sunflower growers. But let's continue
21	with the final presentation from FMC.
22	DR. CUMMINGS: Thank you Dr.
23	Heeringa. I only have about 3 or 4 slides, it
24	shouldn't take much more than an hour and a half. So
25	we should be in pretty good shape. I am pretty sure I



-	EPA MEETING 02/06/08 CCR# 15796-2 Page 333
1	am not going to get questions, so Real briefly, I
2	just wanted to summarize after, I was going to save my
3	thanks for the end, but I think I do want to thank the
4	chair as well as the entire panel for their patience,
5	endurance, level of participation. Certainly their
6	attention throughout the it's been a long day, and
7	we certainly appreciate the registrant having the
8	opportunity to present our scientific position to the
9	panel, and for their consideration.
10	Just real quickly, what I would like to do is
11	just summarize from a risk perspective what you've
12	heard in these scientific presentations today. And
13	hopefully what you've heard is that a reasonable set of
14	assumptions have been presented, scientifically
15	justified, and they support the conclusion that from an
16	F.Q.P.A. risk perspective, all of the crops that F.M.S.
17	is proposing to move forward with, that is the import
18	tolerances, the phase out crops, which will be phased
19	out over the next 3 to 4 years, as well as the 5
20	critically important crops, do meet the F.T.P.A.
21	standard, and fit within the risk cup. Now just to
22	reiterate this one slide very quickly, you saw it
23	earlier, it's not quite as neat and clean, I think it
24	is actually shown up on the side over here in a little
25	bit different form, but essentially if the F.T.P.A.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 334
1	safety factor is reduced to 1 - as is our position - as
2	well as reducing the inner species safety factor from,
3	well either maintaining it at 10, or reducing it to 3,
4	and maintaining the intra species safety factor.
5	There is, the food exposures do fit within
6	the risk cup and leave ample room for water
7	contributions. Basically to conclude there, is that
8	also we hope you've heard in the water segment of the
9	discussions is that there really is negligible
10	contribution to surface, from surface and ground water
11	to the risk cup.
12	Generally low to minimal avian risk. There
13	have been mitigation measures to alleviate any
14	concerns of avian risks, of higher risk, and that there
15	are acceptable margins of safety for workers. And in
16	addition, what you have heard along these critical and
17	important uses is that the benefits essentially do
18	outweigh the risks associated with the use of the
19	product. And I am not going to go through this, but
20	just, it's in your packet and these are the, just kind
21	of a re-cap of the scientific questions that the
22	registrant would feel that the SAP. should consider, if
23	they feel appropriate. So I'll go through those
24	quickly. Finally, I think to reiterate my comments,
25	earlier today, I guess much earlier today now, we do



	EPA MEETING 02/06/08 CCR# 15796-2 Page 335
1	feel based on sound science that the science does
2	support continued registration of Carbofuran in the
3	United States, based on the amended label. I would
4	like to thank the panel again for their attention.
5	DR. HEERINGA: Thank you Dr.
6	Cummings. Questions for Dr. Cummings in the wrap up
7	from the panel members? Okay, Dr. Cummings and your
8	team, thank you very much for your all of your
9	presentations; and panel members, thank you for your
10	questions and your patience. In case anybody is
11	wondering, this is not the latest a science advisory
12	panel has ever gone. I understand that genetically
13	modified corn went on almost until midnight on one of
14	it's days. Charlene was there, so we will no
15	pizzas.
16	Okay, returning to the program, we are going
17	to have 2 public commenters this evening, to do them
18	the favor of allowing them to get out. The first Mr.
19	Larry Kleingartner, who is representing the National
20	Sunflower Association, Mr Kleingartner.
21	MR. KLEINGARTNER: Thank you, Mr.
22	Chairman and members of the committee, for
23	accommodating us and I appreciate your work on this
24	subject. We just want to give you a little background.
25	You have heard obviously lots of laboratory kinds of



	EPA MEETING 02/06/08 CCR# 15796-2 Page 336
1	things, and we want to take you to the actual
2	production field and talk about one crop that would be
3	impacted in the absence of Carbofuran. Just some quick
4	sunflower basics. Sunflower is really a fairly minor
5	crop in the United States, several million acres, but
6	the product is very important in terms of demand, in
7	terms of nutrition.
8	It has, it is a naturally stable oil;
9	sunflower oil is. So it doesn't have to go through the
10	hydrogenation process, which results in trans-fatty
11	acids. So the potatochip companies in the United
12	States, a lot of snack food companies see this oil as a
13	very, very primary oil in the production of their
14	products. And it is also very low in saturated fats.
15	So it really is a preferred oil. We also produce
16	confection sunflower seeds, and if you are a baseball
17	fan, you'll notice that a number of baseball players
18	love to chew and spit sunflowers in absence of chewing
19	tobacco.
20	So I'm hitting all the health events here.
21	And it's also very high in folic acid and vitamin E,
22	and we can go on and on, 'cause you are going to hear
23	this from the potato people tomorrow. Here are just a
24	few of the products you know that, Frito Lay has
25	really become a major, major customer, they are the



	EPA MEETING 02/06/08 CCR# 15796-2 Page 337
1	largest snack food company in the U.S., and they
2	switched a majority of their products to sunflower oil,
3	to eliminate trans, and to lower saturates. I found a
4	Jim Beam up there.
5	Even though it's more Miller time right now,
6	for you Jim Beam people, there are sunflower seeds that
7	are soaked in Jim Beam, and you can get a little, you
8	can get just a little kick from that as well. I didn't
9	bring any samples, I didn't think I could get them
10	through the process out front. But let me get on to
11	serious stuff here.
12	The sunflower plant is a native species plant
13	in North America, and with that we've got some fairly
14	significant and native insects, and they've been here
15	for centuries, and once we throw up a 200 acre
16	sunflower field with nice big juicy heads and stalks
17	these native insects just have an absolute field day,
18	like kids in a candy shop. Because we are a native
19	species crop, the G.M.O., the Genetically Modified
20	Option is not possible for us at this point in time in
21	the regulatory phase, because of the potential of
22	outflow of the genes to the wild species. So, as far
23	as "quick fixes" for some of these production issues,
24	the G.M.O. is not an option. This is just kind of a
25	"look-see" of where the production is at.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 338
1	Let me get my laser here, this is where we
2	really have more of our insect problems, related to the
3	insect that we are talking about here, that we need
4	Carbofuran for. It's really in the Colorado, Kansas
5	area, and you see it's a fairly concentrated production
6	region. And again, it's a native insect that has been
7	with us, and this is it, the Adult Stem Weevil, it's a
8	very difficult insect to scout for, and I have a
9	producer, Mr. Unruh, who is sitting beside me and he'll
10	talk about that in just a minute.
11	It's a very cyclical population, as most
12	insects are, and Carbofuran really is the only
13	effective control. We're not using a lot of this
14	problem, I mean a lot of this product. But in this
15	particular area of the United States this insect is
16	rampant, and is there every year. And to produce this
17	crop successfully this is really the only product we
18	can use. In this area of Eastern Colorado, Western
19	Kansas, there is about \$ 200,000,000 worth of
20	infrastructure in place for processing this crop, so it
21	is a center of production.
22	The Stem Weevil basically impacts the stem,
23	it lays eggs, the larvae burrow into the stem, they
24	float up and down that stem all season long. We've
25	counted as many as 100 larvae in a stem, the stem is



	EPA MEETING 02/06/08 CCR# 15796-2 Page 339
1	weakened when there is that kind of pressure. You've
2	got a heavy head on the top side, with a weak stem on
3	the bottom side. You get a little breeze, which we
4	have quite a bit of, in Eastern Colorado and Kansas,
5	and you can see what happens when in that bottom photo.
6	They just basically tip over at the base. We
7	also have some secondary diseases that the Stem Weevil
8	is a vector for, and in essence, the hole in the stem
9	creates the pathway for these pathogens. And that's
10	the Charcoal Stem rot, and the Phoma Black Stem. And
11	those are fairly significant diseases when we get this
12	kind of pressure. Our response, we have been testing
13	genetic material in Western Kansas for the last 5
14	years. When I say "we", it's a combination of state
15	universities, and the U.S.D.A.'s Agricultural Research
16	Service.
17	We have found good segregation in populations
18	of wild species, and other you know, further refined
19	stocks of genetics. We have recently as an
20	organization, funded a poll stock, to take this
21	research and move it to the next level and try to get
22	this resistant material into hybrids as soon as
23	possible. We look at that as a 6 year process before
24	we really get into commercialization, so we need this
25	lead time. And as you can well recognize, insect



	EPA MEETING 02/06/08 CCR# 15796-2 Page 340
1	resistant research is a fairly high risk kind of
2	research.
3	In summary, Furodan is an important product
4	for the production of sunflowers in this key region of
5	Eastern Colorado, and Western Kansas. We don't have
6	any alternatives. I'm not aware of any pesticide
7	alternatives in the pipeline. We are working on hybrid
8	resistance, and Furodan really becomes an important
9	product for us with this kind of demand that we have in
10	place.
11	We really can't afford to lose any acreage.
12	Again, our demand is so strong we are importing
13	sunflower oil to make up for the lack of domestic
14	production, so an insect driving production out of this
15	country would certainly impact domestic users, and
16	certainly producers as well. So with that Mr. Chairman
17	I will give the chair to Bruce, and we'll be happy to
18	answer your questions.
19	DR. HEERINGA: Thank you very much Mr.
20	Kleingartner. Before we turn to Mr. Unruh, I will ask
21	if there are any questions from the panel. Yes, Dr.
22	Hattis.
23	DR. HATTIS: What is the basis for your
24	assessment that it is a unique product, that other
25	pesticides, either Carbonates or phosphates, or from



	EPA MEETING 02/06/08 CCR# 15796-2 Page 341
1	other insect classes would not do the job?
2	MR. KLEINGARTNER: Yeah, the uniqueness
3	of the product is that it translocates into the stem,
4	and so the larvae then, as they are chewing the
5	material, die. Other insecticides would all be contact
6	insecticides to kill the adult, and the adult is laying
7	eggs over a significant, I mean a fairly long period of
8	time. And that's what makes it unique.
9	DR. HEERINGA: Dr. Lu.
10	DR. LU: Quick question, this is sort
11	of a personal education question. So how do sunflower
12	farmers apply pesticides like Carbofuran to such an
13	enormous land?
14	MR. KLEINGARTNER: If I could let Mr.
15	Unruh answer that question, because he actually does
16	the, does the-
17	DR. LU: Okay, second question is, has
18	the trade group ever measured say, Carbofuran residue
19	in sunflower seed oil?
20	MR. KLEINGARTNER: Yes, all of that is
21	in place since early in the process of the plant
22	development. To my knowledge residue is not an issue
23	at all. If it were, we would be out of, we would not
24	be using this product.
25	DR. CARLSON: Mr. Chairman.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 342
1	DR. HEERINGA: I have to stay with, Mr.
2	Carlson, I have to stay with, if you have some
3	clarification that can be passed with the other public
4	speakers, I have to stay with this at this point.
5	Bruce Unruh, I guess we have answered the question
6	about application, and-
7	MR. UNRUH: I'll touch on that in mine
8	in a little bit. We're pretty much over that. My name
9	is Bruce Unruh, and I farm at Burnett Colorado. That's
10	East/Central Colorado, about 14 miles from the Kansas
11	border, and I raise wheat, corn and sunflowers. Our
12	average rainfall is 17 inches, so water to us is a
13	precious commodity. I use Furodan on the sunflowers
14	for Stem Weevil and on corn for Root Worm control.
15	Without the use, sunflowers I have had up to
16	a 30% loss. Because of the Stem Weevil, I have seen
17	neighbors that have had losses even greater than that.
18	When this thing hits and the wind blows, we have had
19	straight line winds before harvest at 60 miles per hour
20	and it blows everything over.
21	If Furodan were banned I would no longer be
22	able to grow sunflowers, because Furodan is the only
23	labeled product right now on the market for use with
24	Stem Weevils. So It's like, if we can't put that on we
25	would be off label and where I grow confectionary



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 343
1	flowers, they are very critical with the residue,
2	because you eat them, and so there are only certain
3	periods. As far as putting it on, I use a half pound
4	of actual ingredient at planting with the seeds, so it
5	is put approximately 2 inches in the ground and covered
6	up.
7	The other stage, if it doesn't go on then,
8	would be at approximately a B7, 8 stage, which would be
9	a little bit under knee high, and it be over the top,
10	and still at the same half pound of active ingredient,
11	so it's not a heavy rate we're using, just enough to
12	knock this thing down, and keep it held down.
13	On my farm, like I say, 2,200 pound flowers,
14	248 acres, 30 cents a pound, 30% loss, would be \$
15	47,000, which you only stand that about one or two
16	years, and then you are looking for another occupation.
17	On the next page is pictures that Larry showed, and he
18	talked about the Stem Weevil bores into the stalk.
19	When the wind blows at harvest that's why it falls
20	over. The other thing is to go down low, we go down
21	low with like snouts on the combine. As you start
22	picking things up, you pick up a lot more stalks. You
23	get docked at the elevator, they don't want all the
24	trash, so you can't separate it with the combine. Like
25	Larry said, when you've got a heavy and a short stalk



	EPA MEETING 02/06/08 CCR# 15796-2 Page 344
1	the stalk sticks up, and you get the stalk for free.
2	Because of the increased loss of sunflower heads there
3	is also another problem that develops, it's volunteer
4	sunflowers the next year, and if hybrid sunflowers get
5	tough to grow, volunteers will grow fantastically, and
6	they'll come up 2 or 3 times a year, which causes us
7	another chemical operation, plus a loss of moisture the
8	next year.
9	So, it kind of, as the ball rolls, you start
10	creating more problems because of this. On the next
11	page there it talks about Kansas State University's
12	. what their estimated cost of raising flowers is, and
13	where I arrived at my numbers. For lack of time I
14	won't go through that.
15	Basically without this, I am looking at a
16	\$96, at least, loss per acre. So why am I going to
17	continue to raise the crop? With the direct cost of
18	losing Furodan would be over 52,000 on the total acres,
19	the total cost to operate my farm would be much
20	greater. More importantly, sunflowers are an integral
21	part of my crop rotation, so it's not like I put
22	Furodan on every acre every year. This would be like a
23	3 or 4 year, so it gives time for the soil and
24	everything to digest it, and it wouldn't be like the
25	water issue, or anything of that nature. Integrated



	EPA MEETING 02/06/08 CCR# 15796-2 Page 345
1	pest management; I have observed neighbors who have
2	been in flowers for 4 years, not used Furodan and have
3	had some major losses.
4	Last year I watched a neighbor lose, I know
5	he was at 30%, I didn't go out and look much closer,
6	but you could tell it was bad. Later planting dates,
7	where we're at, doesn't seem to help. Also we start
8	losing yield at that stage of the game. Other
9	chemicals, like I say, there is nothing else labeled.
10	So there is no other product. You grow them and hope
11	for the best, which that doesn't always work.
12	The lower annual rain fall in my area limits
13	the alternate crops that we can go to, so it takes my
14	rotation and changes that picture completely. Like I
15	say, without Furodan, I don't think I'll be able to
16	grow sunflowers, so I just appreciate your studying
17	into it, looking at everything with a very open mind,
18	and I just thank you for your time and effort.
19	DR. HEERINGA: Thank you very much, Mr.
20	Unruh. Questions from the panel? Yes, Dr. Kehrer.
21	DR. KEHRER: Jim Kehrer. Mr.
22	Kleingartner said that the weevil problem was cyclical,
23	but it sounds like you treat the sunflowers every year
24	with Furodan, is that true?
25	MR. UNRUH: When I grow sunflowers I



_	EPA MEETING 02/06/08 CCR# 15796-2 Page 346
1	treat them every year, because to scout them, when you
2	walk out there in that period they drop to the ground,
3	and because of the color they look like the ground.
4	All the consultants that I know will not even scout for
5	them. They just say at a certain stage you have just
6	got to put it on, or you are going to lose them, so
7	they come up every year.
8	MR. KLEINGARTNER: If I could clarify,
9	they are cyclical in other parts of the country, but in
10	that region where Mr. Unruh lives they are consistent,
11	yeah. But up in the Dakotas and Minnesota we may see
12	them every 6 years or so, but not to the volume that we
13	see consistently in this area of Eastern Colorado,
14	Western Kansas, and that's why we are doing all the
15	resistence testing there. Because we have a continuous
16	cycle or a continuous population of the insect.
17	DR. LU: So you forgot to tell us how
18	you apply the Carbofuran on the sunflowers.
19	MR. UNRUH: I apply it at planting, at
20	the half pound of active ingredient with the seed, with
21	the starter fertilizer at the time. So it is put in,
22	in the furrow. The other time is approximately like a
23	B7, B8, about knee high, and then we come over the top
24	of the ground grade.
25	DR. LU: So it's like an aerial spray,



1	EPA MEETING 02/06/08 CCR# 15/96-2 Page 54/
1	or-
2	MR. UNRUH: No, it's for the ground
3	grade. Like just a close sprayer.
4	DR. LU: Okay.
5	DR. HEERINGA: Dr. Sparling.
6	DR. SPARLING: Don Sparling, Southern
7	Illinois University. I know the sample says there is
8	only one farm, but after application of Carbofuran,
9	have you ever found dead birds in your sunflowers?
10	MR. UNRUH: I have not found dead birds
11	around Furodan since granules have been gone.
12	DR. SPARLING: Have you looked?
13	MR. UNRUH: Yes, yes, I walked the
14	fields and looked for other pests because a little bit
15	after this we are going to come into head moth, and
16	other pests start showing up. And these are on
17	sprinklers, which we have to go out and check everyday,
18	so I have driven around and walked and have not found
19	any birds.
20	MR. KLEINGARTNER: Mr. Chairman, if I
21	might, on the back of my presentation there is a copy
22	of a news release from the Department of Justice, which
23	deals with the issue of the Colorado producer who was
24	found to mis-apply. If you notice in the second
25	paragraph, the second sentence, he relates to the mis-



. [EPA MEETING 02/06/08 CCR# 15796-2 Page 348
1	application of the chemical. To our knowledge in the
2	sunflower industry, this is only time we have heard of
3	any bird kill related to this product.
4	DR. HEERINGA: Since I have opened it
5	up for you, Dr Carlson, did you have something related
6	to the detection of sunflower oil?
7	DR. CARLSON: Yes. Don Carlson, with
8	FMC Corporation. There was a question raised relative
9	to, would there be residues in sunflower oil?
10	Virtually all oils, whether they come from sunflower or
11	any other oil seed crops go through a process for
12	processing the oil. In the stage going from raw oil to
13	refined oil it is usually treated with a very alkaline
14	treatment, and in that step as a result of a the highly
15	alkaline treatment, all residues of Carbofuran, either
16	Carbofuran or 3 Hydroxy Carbofuran would be completely
17	destroyed. And the EPA has verified that, and agreed
18	to that conclusion. Thank you.
19	DR. HEERINGA: Thank you Dr. Carlson.
20	You answered my question about why these bugs don't
21	show up in the Dakotas. Because that's where my
22	mother's family is from.
23	MR. UNRUH: Fortunately we have
24	different bugs there. But we have alternatives to
25	Furodan.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 349
1	DR. HEERINGA: But the wind never
2	blows.
3	MR. UNRUH: The wind never blows.
4	DR. HEERINGA: Okay, with that, I think
5	I would like to draw today's proceedings to a close.
6	Before I do close, I want to thank everybody for their
7	patience today. We will resume first thing tomorrow
8	morning at 8:30 with a continuation of the public
9	speakers who have registered to speak. Again, if you
10	are in the audience and have not had an opportunity to
11	speak but wish to speak, please see Dr. Matten, to
12	register for a 5 minute presentation, and Dr. Matten
13	has a few closing comments before we break.
14	DR. MATTEN: Right, I think it was this
15	morning still, the health effects divisions personnel,
16	they gave a number of clarification slides in the
17	morning in they have made printouts of those slides,
18	plus they answered Dr. MacDonald, maybe, about the
19	sourcing of various materials, data in the matrix table
20	and so that is also provided. And then after that meet
21	next door.
22	DR. HEERINGA: Panel members if we can
23	meet briefly in the break out room, thank you everybody
24	for your participation today. See you tomorrow.
25	(WHEREUPON, the session was concluded at 6:33 p.m.



	EPA MEETING 02/06/08 CCR# 15796-2 Page 350
1	CAPTION
2	
3	The foregoing matter was taken on the date, and
4	at the time and place set out on the Title page
5	hereof.
6	
7	It was requested that the matter be taken by
8	the reporter and that the same be reduced to
9	typewritten form.
10	
11	Further, as relates to depositions, it was
12	agreed by and between counsel and the parties that
13	the reading and signing of the transcript, be and
14	the same is hereby waived.
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	



- 1	EPA MEETING 02/06/08 CCR# 15796-2 Page 351
1	CERTIFICATE OF REPORTER
2	COMMONWEALTH OF VIRGINIA
3	AT LARGE:
4	I do hereby certify that the witness in the
5	foregoing transcript was taken on the date, and at
6	the time and place set out on the Title page hereof
7	by me after first being duly sworn to testify the
8	truth, the whole truth, and nothing but the truth;
9	and that the said matter was recorded
10	stenographically and mechanically by me and then
11	reduced to typewritten form under my direction, and
12	constitutes a true record of the transcript as
13	taken, all to the best of my skill and ability.
14	I further certify that the inspection, reading
15	and signing of said deposition were waived by
16	counsel for the respective parties and by the
17	witness.
18	I certify that I am not a relative or employee
19	of either counsel, and that I am in no way
20	interested financially, directly or indirectly, in
21	this action.
22	
23	
24	CHARLES DAVID HOFFMAN, COURT REPORTER / NOTARY
25	SUBMITTED ON FEBRUARY 6, 2008



0	0004 4:1	262:23 269:1, 24
0 285:1 298:1 323:22	0005 5:1	270:25, 25 271:1
0.00006 247:15		277:1, 18 283:22
270:21	0007 7:1	284:1, 1, 1, 22
0.001 247:17 271:1	0008 8·1	285:1 297:22
0.0026 271:1	0009 9:1	298:12, 20
0.003 247:17	002 304:1, 1	308:14 321:19,
0.016 206:1	003 320:16	24 325:24
0.02 206:24	01 101:1 201:1 301:1	326:15, 17
		328:24 334:1
271.1 11	$02 \cdot 1 \\ 202 \cdot 1 \\ 202 \cdot 1 \\ 302 \cdot$	1-hour 85:12 96:19
271:1, 11 0.05 252:12, 15	302:1 02 102:1 202:1 302:1 028 320:16	97:1 104:14, 19
254:25 255:1	020 320.10	105:1 107:12
269:24	037 305:1	116:1, 1 118:1, 11
0.07 255:10		170:11 182:19,
0.08 115:19	04 104:1 204:1 304:1	23 183:15, 17
0.1 232:13 254:18,	05 105:1 193:25	233:14
	205:1 305:1	1.0 308:15 309:1
22 255:10, 24 266:14 286:12	06 106:1 206:1 306:1	1.2 256:1 259:22
0.119 80:1 119:1	07 107:1 207:1 307:1	
0.13 302:1	311:22	
0.2 255:15 307:15	08 108:1 115:21 208:1 308:1	1.3 256:1, 1 261:16,
311:25	09 109:1 209:1 309:1	24 278:15 286:12
0.23 115:21	09 109:1 209:1 309:1	
252:12, 15	1	1.4 296:1
		1.5 286:18 287:14
10 25 189·25 190·1	1 7/•16 10 78•12	
0.25 189:25 190:1 0 26 130:1	1 74:16, 19 78:12 88:1 89:23 92:12	1.5-fold 257:19
0.26 130:1	88:1 89:23 92:12	1.56 260:1
0.26 130:1 0.3 130:1 232:15	88:1 89:23 92:12 93:20 94:16, 19	1.56 260:1 10 10:1 40:1 59:17
0.26 130:1 0.3 130:1 232:15 246:13 255:13,	88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1	88:1 89:23 92:12 93:20 94:16, 19	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20	88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20,</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20	88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1,</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11,</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21,</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16 0.88 129:21</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 19:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16 189:10 195:17</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23 10-fold 246:22</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16 0.88 129:21 0.93 115:19, 21</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23 10-fold 246:22 10-minute 294:1</pre>
0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16 0.88 129:21 0.93 115:19, 21 116:12, 21	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16 189:10 195:17 199:1 204:19 209:22 214:18</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23 10-fold 246:22 10-minute 294:1 10.4 303:10</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16 0.88 129:21 0.93 115:19, 21</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16 189:10 195:17 199:1 204:19</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23 10-fold 246:22 10-minute 294:1 10.4 303:10 100 134:22, 24</pre>
<pre>0.26 130:1 0.3 130:1 232:15 246:13 255:13, 14 256:1 0.3i 261:20 0.33 130:20 0.35 189:25 0.41 298:1 0.5 109:1 307:14 308:11 311:1, 18 0.6 120:1 0.65 190:1 261:22 0.68 310:14 311:24 0.69 129:24 0.7 298:1 0.71 115:22 0.75 109:15 190:1 0.78 130:16 0.88 129:21 0.93 115:19, 21 116:12, 21 00 100:1 200:1 300:1</pre>	<pre>88:1 89:23 92:12 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 16, 24 97:16 98:14 100:10 103:18 104:1 107:1 109:24 110:1 112:1, 11 113:20 114:1, 23 117:21 119:25 121:11 124:1 129:1, 18 131:13, 16 132:1 136:1 139:11 141:12, 16, 22 142:24, 25 143:11, 13, 20 144:1, 20 145:11 153:21, 23 154:1 155:1 177:11 183:16 189:10 195:17 199:1 204:19 209:22 214:18 215:14, 18</pre>	<pre>1.56 260:1 10 10:1 40:1 59:17 61:1 110:1 132:16 133:1, 11 134:1, 1, 20, 22, 23, 24, 25 135:1 137:1 172:22 209:23 210:1 211:19 246:1, 10, 20, 20 247:1, 1 249:22 268:1, 1 269:10 270:15, 22, 25 271:1 286:17 299:1 305:19 307:19 310:1 326:1 334:1 10% 323:23 10,000 99:23 116:24 311:23 10-fold 246:22 10-minute 294:1 10.4 303:10</pre>



205:24 207:1 247:17, 18 250:1 254:1 271:21 273:14 285:1, 1 295:17 297:20 338:25 **100,000** 312:1 **100-fold** 248:11

 208:1
 16 16:1 28:20, 21
 1:30...the

 1000 95:24 103:13
 16:1 119:22 216:1
 1st 213:10

 129:1 185:14
 316:1
 316:1

 186:13 **100x** 276:1 277:1, 1 **16.7** 248:1 1, 11, 12 111:1 209:22 211:1 246:13 269:23 311:1 **110** 204:24 216:16 296:1 110-gallon 218:1 111 152:18
118 171:1
11s 50:12

 11s
 50:12
 219:1
 295:22
 302:1
 2,200
 343:13

 12
 12:1
 30:24
 65:1
 319:1
 320:12
 2,500
 60:20
 310:1

 87:1
 96:15
 1931
 197:18
 2.0
 96:19
 107:1,

 103:18
 112:1
 143:1
 1939
 197:25
 12
 121:11
 143:19

 209:21
 212:1
 195 318:13

 302:23
 312:1
 1950 198:1

 302:23 312:1 315:21 323:15

 97:11
 104:13,

 18, 22, 24
 1957

 107
 107

 12-hour 96:22

 18, 22, 24
 1972 152:13

 107:10 114:1 116:1
 1980's 321:20

 1200 151:22 **122** 318:19
13 13:1
 65:1
 66:18
 1985 314:11

 113:1
 213:1
 1989 125:1, 1

 313:1
 315:1
 1991 60:23

 12th 91:16

 313:1
 315:1
 1991
 60:23
 2.64
 84:16

 13,000
 310:24
 311:15
 210:1
 20
 20:1
 63:13

 137 318:16 **14** 14:1 114:1 170:12

 187:1
 194:22
 214:1
 321:10, 22

 314:1
 315:1
 324:24
 327:1

 314:1 315:1 324:1 342:10 **144** 318:18

 142:21
 204:15
 15 15:1
 148:10
 275:14

 15-gallon 210.1 **153** 147:1, 17 **15g** 275:1 **16-hour** 185:1 317:1 320:23 324:24 327:1 342:12 342**:**12 **18**18:1118:1159:13262:22269:13200:19218:1318:1295:13296:10320:12301:18302:1, **19** 19:1 119:1 **1955** 198:18 **1983** 316:20 **1984** 314:10 319:1 **1993** 316:23 319:12

177:1 204:11996 147:1 148:1215:1 219:1, 1,1997 146:22 148:151 265:14 301:11150:16 314:17 302:1305:21315:1**1998**149:22150:13326:10331:1304:13**15-gallon**218:1**19th**91:20 **1:30** 162:24 1:30...the 161:21 2 **2** 74:24 109:14

 10:00 56:1
 166 136:17
 124:1, 1 125:1, 18

 11 11:1 14:24
 166 136:17
 134:1 135:1 147:25

 39:24 47:24
 49:16, 17 51:1, 1,
 165:25 166:1, 1,

 48:1, 1 49:22,
 117:1 217:1
 11 105:18 209:21

 24 50:19 51:1,
 317:1 320:23
 211:22 210:15

 257:11, 18 259:16 260:1
185 318:1, 1, 22, 24
 21, 23 308:14

 323:22, 24 324:1
 312:1 314:23 316:1

 331:24
 319:21 329:1 331:1

 335:17 343:1 344:1 12 121:11 143:19 144:1, 20 153:23 155:1 308:15 **2.1** 75:1 91:23 92:1, 11 96:20 107:12 121:11 124:1 144:20 153:23 155:1 304:23 **2.3** 261:14 **2.4** 105:1 **2.5** 218:1 227:22, 22 2.5-gallon 219:17
2.56 321:1 95:23 103:11 113:1 120:1 132:25 133:10, 15 134:1, 1 139:18
1995 60:1
 66:1, 1
 177:1
 178:23, 24

 147:1, 24
 148:1
 185:15
 187:1, 15



 189:22
 212:1
 220:1
 223:1
 315:19
 323:1
 3.3
 142:10

 286:15, 17
 236
 302:20
 3.4
 121:19

 305:16
 306:10
 24
 24:1
 41:24
 3.8
 84:23
 121:13

 311:19
 320:1
 101:1
 124:1
 148:16
 123:14
 165:20

 20,000
 103:14
 193:10
 324:1
 324:1
 3.84
 196:1

 200 337:15 **200,000,000** 338:19 **247** 332:1 2000 329:15, 15 **2001** 76:1 89:25 90:16, 25 93:22 96:14 96:14 2002275:21301:24225:1325:1200378:20275:21250104:15210:10 304:13

 2004
 76:1
 90:1
 2500
 60:20
 66:23
 330:1
 343:14

 107:17
 301:24
 26
 26:1
 126:1
 30%
 342:16
 343:14

 2005
 16:16, 19
 226:1
 326:1
 30%
 342:16
 343:14

 2005
 16:16, 19
 226:1
 326:1
 30%
 342:16
 343:14

 2005
 16:16, 19
 226:1
 326:1
 30%
 342:16
 343:14

 279:10
 297:13,
 127:1
 136:20
 300
 247:16
 274:1

 15
 308:20
 316:21
 142:1, 1, 1
 300,000
 60:10
 61:1

 319:1
 277:1
 327:1
 3000
 275:13
 3007
 264:21

 1.
 1
 59:22
 273
 148:25
 200**
 276:24

 1, 1 59:22
 273 148:25
 300x 276:24

 62:18, 18 74:13
 28 28:1 100:1, 1
 30s 197:16 25

 200:14 250:17
 101:1 128:1 141:25
 30x 277:1, 1

 275:16 289:24
 142:1 228:1 315:25
 31 31:1 131:1

 2007 17:1 46:12
 328:1
 231:1 331:1

 89:13 91:17, 18,
 29 29:1 129:1 152:14
 31,048 150:20

 254·1
 200:1 200:1 200:1
 200:1 200:1

 254:1 2007/08 46:1 **2008** 2:1 74:13

 205...2005 200:1
 3
 33 33:1 133:1

 208 136:12, 17, 20
 3 80:1 89:19
 34 34:1 134:1

 137:1, 1
 109:1, 1 113:14
 234:1 334:1

 205 257:1
 115:1 116:13, 22
 340 240:24

 21 21:1 54:21
 147:1 148:10
 3400 204:25 216:17

 121:1 178:23 179:1
 211:23 247:1
 25 35:1 120:1

 206:14 213:1 221:1
 249:22 252:17
 35 35:1 120:1

 232:20 242:24
 261:14 269:24
 304:1 335:1

 207:15 208:1
 272:1, 1, 11 273:1
 36 36:1 136:1

 207:15 208:1
 294:21 298:1,
 336:1

 213:16 225:17
 13, 18, 22
 36:1

 226:18 228:10,
 301:25 316:1
 37 37:1 137:1

 21st 213:12
 322:23 333:19
 348:16

 322:1 326:13
 3...and 261:21
 39 39:1 131:18 139:1

 323 23:1 123:1
 3.1 104:1
 239:1 339:1

 205...2005 200:1

240 332:1 229**:**25 229:1 308:11 329:1 **2:15** 177:1 3_____

3.8x 195:21 **3.94** 196:1 **30** 30:1 118:14 130:1 130:20 00 **25** 25:1 35:23139:20, 22 148:15,44:16 125:1 164:1416 230:1 247:18190:1 192:17 219:1250:1 265:14 271:21 273:13 286:15, 17 305:16 325:1 326:1 330:1 343:14 **30%** 342:16 343:14 **30s** 197:16 257:1 **31** 31:1 131:1 231:1 331:1 **31,048** 150:20 **32** 32:1 132:1 185:10 232:1 332:1 **32.2** 307:16 **33** 33:1 133:1



392 149:1	133:21, 21 137:1	E.00 162.1
3m 292:1	139:19 177:11	5th 102:17 120:18,
3rd 151:14	200:1, 1 213:1, 13 246:22 247:11 248:1, 18 249:23	24 139:15, 15
3x 271:19 273:12	246:22 247:11	5x 250:16 252:1
	248:1, 18 249:23	271:15 272:1
4	252:1, 10, 11, 18,	273:10 274:1
4 89:20 111:25	22 255:15, 18	
	256:1, 1 257:12	6
112:1, 1, 10, 14	259:25 260:1	-
113:1, 1 116:1	262:22 270:21,	6 2:1, 19 59:22
287:14 304:15	24 272:1, 1 287:17	109:13 148:17
309:25 332:23		200:1, 13 209:1,
333:19 344:23	293:14, 17 305:1	10, 13, 14, 16, 18
345:1	315:25 319:1	210:18 238:1
4.4 88:1 104:1	320:19 323:16	270:20 290:20
122:24 277:1, 18	325:11, 25 326:10,	293.22 314.19
	14 333:19 339:13	21 315:1 324:14
4.5 324:12	349:12	339:23 346:12
4.6 166:1, 11 252:15		
4.7 230:12	5-fold 250.1 251.1	6(b 56:12
40 40:1 70:1, 12, 19	5-fold 250:1 251:1 5.23 104:24	6-nour 209:1 210:1
131:16 140:1		6.1 209:18
188:13 189:21		6.6 315:19
240.1 241.1	5.8 315:1	60 60:1 113:1
286:15, 16	5.82 308:12 312:1	160:1 260:1 274:18
287:23 340:1	50 40:10 50:1 112:14	342:19
207.23 340.1	100 11 100 11	600 240:24
40you 286:15 40s 257:1		
40s 25/:1	1 - 0 . 1 1 - 0 . 1 0	600,000 59:23 60:18
41 41:1 141:1	164:13 170:1	61 61:1 161:1 261:1
241:1 341:1	001 00 010 1	62 62:1 162:1 262:1
42 42:1 142:1 188:13	213:17 215:18	63 63:1 163:1 263:1
191:15 242:1 342:1	$Z \perp J \cdot \perp I Z \perp J \cdot \perp O$	64 64:1 164:1 264:1
43 43:1 143:1	229:18 230:1	64.000 325:1
243:1 315:20 343:1	235:1, 12, 12, 13,	65 65:1 165:1 265:1 305:20 306:1 65 8 137:1
44 44:1 144:1 192:12	18 250:1 254:1,	265.1 205.20 206.1
244:1 344:1	17, 21 255:1, 13	
	261:13 274:18	05.0 137.1
45 45:1 88:23	285:22 305:23	66 66:1 166:1
145:1 193:22 245:1	327:15, 18 330:12	266:1 327:23, 25
345:1	50-foot 165:1	328:1
46 46:1 146:1 147:24	500 248:11 250:1	67 67:1 141:22 167:1
246:1 346:1	271:21	201:1 267:1
47 47:1 147:1		68 68:1 168:1 268:1
247:1 347:1	50th 102:18	680 101:1
47,000 343:15	120:18, 24	
48 48:1 148:1, 17,	51 51:1 151:1 251:1	69 69:1 169:1 269:1
	52 52:1 152:1 252:1	697 148:1
25 248:1 348:1	52,000 344:18	6:00 106:15 162:1
49 49:1 149:1	53 53:1 153:1 253:1	294:15
249:1 295:22 302:1	54 54:1 154:1 254:1	6:33 349:25
349:1	55 55:1 155:1 255:1	6a2 228:1
4f 275:1		
	56 56:1 156:1 256:1	7
5	57 57:1 157:1 257:1	7 18:10 19:1
5 18:1 89:21 104:1	58 58:1 158:1 258:1	
	59 59:1 159:1 259:1	147:18 199:1
	0	

COURT REPORTING

F		
200:10 209:18	186:1 286:1	219:17 222:18
		$240 \cdot 25$ $245 \cdot 1$
213:13, 13	8/ 8/:1 18/:1	Z4U:Z5 Z45:1
311:23 315:18,	287:1 295:19	264:10 281:19
21 222.22 221.1	00, 00, 1, 100, 1	202.10 204.17
24 323.23 324.1,	87 87:1 187:1 287:1 295:19 88 88:1 188:1 288:1 323:22 89 89:1 189:1 289:1	292.10 294.17
1, 14, 15	288:1 323:22	aan 58:20
7 000 321.1	00 00.1 100.1 200.1	166.15 206.21
	69 09:1 109:1 209:1	100.15 200.21
70 70:1 170:1 173:11	8:30 349:1	232:1 249:10
200:11 270:1	8:30 349:1 8th 75:1	aas 166:20
701-010-04		- if 100-10
70's 312:24		aif 192:13
700 276:1 70s 59:15, 19	9	ain 78:1 98:1
70 = E0.1E 10	• 10 11 001 10	174:11
/08 59:15, 19	9 18:11 221:12	\perp / \pm • \perp \perp
71 71:1 171:1	269:13 315:21	ais 172 : 1
271.1 307.13	0 000 226.25	a itle 237.22
2/1.1 50/.15	9,000 320.23	
72 72:1 172:1 272:1	9,431 319:25	245:1
73 73.1 173.1 273.1	0 1 100.05	anot 239:24
	269:13 315:21 9,000 326:25 9,431 319:25 9.4 122:25	1 - 1 - 1
	90 90:1 190:1 2/6:25	
75 75:1 113:1	290:1 296.1	athev 182:1
	290:1 296:1 90% 297:19 315:1	
	90% 29/:19 315:1	athrough 60:22
76 76:1 176:1 276:1	90th 325:17	awe 258:1
	91 91:1 191:1 291:1	aWIIat 134:1
77.4 137:1	92 92:1 192:1 292:1	abas 140:22
70 70.1 170.1 270.1	93 93:1 193:1 293:1	abbrariated 80.1
10 10.1 110.1 210.1	93 93:1 193:1 293:1	appreviated 00.1
79 79:1 179:1 279:1	94 94:1 194:1 294:1 95 87:1 95:1 137:1	abbreviation 147:14
7.00 162.1 294.13	OF 07.1 05.1 127.1	a m 56·1 106·15
	99 07.1 95.1 157.1	
7th 91:18	142:20 193:25	ability 126:1
	195•1 246•1 295•1	able $27.22 74.11$
0	95.2 136:23 95th 102:19 120:18, 24 311:12 325:17 326:1 96 96:1 148:1	
<u> </u>	95.2 136:23	/5:1 /9:1 82:16
8 117:16 119:21,	95th 102:19	94:1 115:1
21 120.1 125.1 18	120.18 24	119.14 123.22
	120.10, 24	
139:22 185:1	311:12 325:17	126:14 159:23
293:14, 17	326:1	162:1 168:1 182:25
321.15 313.1	0 = 0 = 1 + 1 + 0 + 1	232.25 2/3.1 295.1
524.15 545.1	96 96:1 148:1	
 8-hour 182:21 184:1,	196:1 296:1	316:17 342:22
23, 25	96.8 218:1	345:15
		accept 228:15
8.8 40:24 41:1	97 97:1 197:1 297:1	-
80 80:1 180:1 200:11	98 98:1 198:1	acceptable 61:23
280:1		133:1 204:24
	220:1 298:1	
80% 297:18	99 60:17 99:1	205:24 226:1
80's 312:25 313:22	199:1 299:1 322:18	228:12, 19 334:15
		accepted 210:15
320:17 321:1	330:24	
803 151:20	99.4 136:19	243:1
		access 291:1, 13
80s 59:15, 19	99.5 136:23	
81 81:1 181:1 281:1	99.9 324:23, 24	accessed 317:19
82 82:1 182:1	330:25	accessible 265:21,
		22
282:1 304:1	99.93 311:21	
83 83:1 183:1 283:1		accommodate 203:15
	A	accommodating 335:23
84 84:1 184:1 200:11		-
284:1	aa 65:17 79:1	accompanying
85 85:1 185:1	80:13 96:24	91:15, 19
285:1 321:14	117:1 141:1 150:18	
86 86:1 142:1	160:22 177:1 196:1	135:21 139:1
	0	



195:10 210:20 236:17 237:20 accordingly 163:23 183:12 191:11 **account** 10:13 18:10 95:11 99:1 117:1 121:13 125:23 138:1 145:1 168:25 170:10, 10 192:1 193:1, 17 258:15 accounted 64:22 accounting 60:20 accumulated 191:1 accumulative 15:1 16:19 17:25 52:10 accurate 51:1 80:18 150:18 312:1 abnormalities 281:20 **about...about** 281:24 286:1 **about...i** 191:16 acerbic 43:24, 24 **acetone** 212:18 238:13, 16, 17, 22 acetylcholinesterase 86:22 98:20 103:22 104:1 143:1 145:17 154:13 179:16 180:12 183:1 205:1 206:25 210:1 212:24 229:1 230:1 231:20, 25 232:1 233:22 246:14, 16 247:13, 24 248:16, 18 249:1, 14 250:15 251:1, 17 254:1, 1 260:12, 20 261:1, 1, 19 262:1 263:1, 13, 14 265:1 266:1, 14 267:1, 13 271:1, 11, 17 272:1, 1 286:22 288:20 **abrupt** 203:18 **acid** 20:1 336:21 acidic 314:1, 1 315:1, 1 **acids** 336:11 **absence** 140:23 215:24 336:1, 18

absolute 35:1 263:23 337:17 absolutely 161:17 185:1 193:1 195:1 243:24 **absorb** 132:22 **absorbed** 44:1, 11 45:14 265:16 absorption 5:1 6:1 26:20 27:14, 17 40:23 41:1, 1, 15 42:1 43:1 44:22, 23 45:1, 1, 12 77:18 82:19 85:14 99:1 205:1, 11 211:1 212:19 215:1 216:1 234:1 238:20 258:12 309:13 absorptions 41:18 abundance 132:23 148:11 **abuse** 150:10 abuse/misuse 149:23 151:12 acknowledge 146:10 acknowledgments 328:1 adapted 309:11 **add** 19:11 51:22 66:17 116:14 178:1 180:1 242:1 276:14 added 71:1 93:1 94:1, 1 136:1 240:1, 18 293:16 314:11 adding 8:1, 15 66:1 additi... supplemental 163:13 addition 8:13, 16 55:20 70:19 180:14 210:18 216:13 219:22 220:17 221:1 273:15 327:16 334:16 additional 20:1 65:11 69:1 70:17 73:24 94:1 223:1 242:18 248:1 271:14 274:23 316:18 322:1

additive 78:1 address 2:24 22:17 63:1 67:1, 24 68:1 71:20 78:13 82:18 155:17 211:13 212:1 215:1 223:1 240:21 252:1 282:1 306:11 308:18 327:20 addressed 155:1 202:19 203:1 230:23 282:18, 25 319:18 addresses 78:12 addressing 2:17 70:1 154:1 163:15 191:19 309:1 314:14 adds 158:1 adequate 22:11 23:1 72:23 73:1 154:23, 25 200:15 adequately 154:1 **acre** 129:1 139:12 141:13 304:24 307:20 314:19, 22 325:21 326:1 337:15 344:16, 22 **acreage** 217:14 325:25 326:1, 1 340:11 acres 147:24 148:15, 25 225:23 297:18 310:1 313:20, 23 326:15 336:1 343:14 344:18 **acronym** 295:1 309:1 317:23 across 10:1 15:1, 17, 19 34:10 86:11 102:20, 21 119:10 128:13 129:1, 1 130:16 131:17 139:17, 21 142:1 200:24 216:21 225:22 296:1 300:16 319:1 325:24 **act** 34:25 55:1 90:1 202:11 245:1, 11 247:10 acting 4:1

COURT REPORTING

action 2:19 56:12	161:24 164:1, 22	178:17 258:12, 13
57:16	166:12, 22 167:1	administrative
active 59:18, 24	177:11 178:24	201:21 208:18
60:21 61:1 98:18	179:14 181:1	243:25
105:24 129:1	185:24 190:19	admit 209:11
139:12 141:12	192:15 194:22	admitting 151:15
217:12 239:21	195:1 204:22 207:1	adult 14:1, 1
304:24 343:10	208:17 218:16,	35:23 41:18
346:20	25 219:1, 1, 12	42:1, 18, 24
actively 198:1	227:10, 12	44:1 45:1 47:21
activities 47:17	228:22 229:20	206:25 232:17
163:11 327:18	231:1 236:1 240:1,	250:15, 17
activity 29:16 30:1,	1 247:1 250:10	266:16 267:19
1, 15 34:1, 12	252:11 255:19	272:1 338:1 341:1,
40:1 43:22 47:1,	264:17 267:1, 14	1
10, 12, 19, 24	268:1 271:12	adults 14:21
48:11, 17 50:1	274:21 277:19	15:13, 18 16:1
51:1 53:1 86:25	278:17, 20	34:12 49:14 51:1
138:1 172:1 216:14	284:23 304:1, 13	105:24 159:18, 19,
220:22 225:1	328:24 330:1	22, 24 160:10
229:1, 10 231:1,	333:24 341:15	206:13 216:1
19 232:1, 1, 15	actuallyindicates	228:23 232:10
233:1, 12 265:1	119:1	250:1, 16, 21
266:17, 20 315:24	actuallytreated	advance 260:1
actual 33:1, 1,	150:25	advantage 91:1 258:1
12, 19 34:1 35:1	actuallywhat	301:16, 19
41:22 43:11, 19	193:15	advantages 223:19
80:24 111:1 135:13	acute 13:1 29:1 31:1	adverse 70:15 78:1
163:13 227:18,	62:20 78:17	83:20, 21 87:22
18 273:1 275:20	83:17 85:16 99:1	205:22 207:21
298:1 299:14	121:15 246:24	210:1 229:1, 10
301:11, 19, 20, 22	249:10, 10	231:21 235:1
303:14 336:1 343:1	270:20 271:1 295:21	249:15 264:1
actually 21:12 27:13		271:18 330:1
35:1, 17 38:1	adjacent 327:24	331:1, 1
40:15, 24 41:21,	adjust 165:18	adverse
23 42:1, 10	169:1 205:1 304:1	unreasonable 70:14
43:18 47:1	adjusted 79:16	advice 76:1 198:1
48:12, 24 52:17,	169:18 172:1 207:1	advise 62:21
18, 19 53:1	221:16 222:1	advised 73:24
71:1, 18 93:24 107:23 109:12	247:1, 1 270:20 297:16	advising 203:1
117:1 118:14	adjustedand	314:12
124:25 128:23	220:20	advisorthe 96:14
130:1 131:1 138:1,	adjustment 85:19	advisory 2:1, 17, 23
1, 17, 18, 19	94:1 123:1, 11,	55:1, 1, 11, 11
140:11 145:19,	13, 21 157:1 166:1	56:11 62:1 68:1,
21 147:11	191:1	14, 25 69:1 75:1
149:10, 13		
149.10, IJ		89:25 90:10, 24
150:23 152:15	adjustments 162:1, 1	91:10 94:1 96:1,
	adjustments 162:1, 1 216:14	91:10 94:1 96:1, 14 107:17
150:23 152:15	adjustments 162:1, 1	91:10 94:1 96:1,



263:15 314:11 335:11 **affect** 44:19 133:1 166:1 affected 77:18 141:15 144:20 228:1 279:1 affected...would 278:25 affecting 132:23 194:1 affects 51:1 **affixed** 40:14 **afford** 340:11 aerial 221:10, 24 224:14 346:25 **aerobic** 18:15 **aα** 307:1 **against** 51:18 76:25 86:24 92:20 260:1 314:12 **age** 34:17 47:15 49:19 197:20 agencies 149:1 agencies...task 220:21 agency 2:1 4:1 5:1 8:1, 14 60:1, 16, 23 62:1, 13, 22 63:16 66:1, 12, 18, 20 67:16 70:1 91:16, 18, 20 147:15 179:22 212:13 243:1 248:25 agency's 2:19 8:19 9:1 10:10, 24 55:15 56:12 286:1 agency...or 69:1 agenda 6:10, 12, 14, 24 55:21 57:15 155:15 161:16 196:25 agents 241:1, 10, 18 ages 34:11 **afraid** 209:1 aggression 49:1 afternoon 12:1, 1 31:1 85:24 177:1 272:19 295:13 297:1 306:1

afterwards 212:16 **ah** 188:15 **ago** 48:22 92:25 200:18 212:1 **ahead** 12:19 121:1 257:15 261:12 290:14 **agree...epa** 229:1 agreed 220:20 348:17 agreeing 250:22 agreement 223:1 233:1 agricultural 61:15 198:1 200:24 220:14 295:18 303:19 320:1 325:1 339:15 agriculture 198:1 300:18 306:20 307:1 317:18 **ai** 217:18 221:21 **ahttf** 220:17 222:1 224:10, 12 234:25 **aimed** 322:1 **air** 78:18 220:1 291:1, 13 **aircraft** 220:23 221:24 **albeit** 154:1 169:10 **aldicarb** 14:1, 18 16:23 17:1, 12 224:16 251:1 266:22, 23 267:1, 12, 21, 23 aldicarbs 267:14 **alex** 5:13 178:1 181:1 232:23 284:19 **alfalfa** 9:22 10:1, 1 68:12, 12, 15 72:13 75:18 94:1, 17 109:10, 11, 12 113:18 125:1 126:24 129:1, 12, 17 130:1, 13, 20 131:18, 24, 25 132:1 135:17 137:1, 10, 25 138:1, 1, 10, 23 140:17 149:24 150:1, 11 151:21

153:1 158:18 164:11 297:14 **algebra** 262:1 algebraic 262:1 algorithm 214:18 217:1 **alight** 106:1 138:1 **align** 139:1 aligning 73:1 **alkaline** 315:22 348:13, 15 **all...there** 222:21 **alleviate** 334:13 allometric 95:13 145:1, 1 188:1 225:1 **allotted** 277:14 **allow** 86:1 296:16 **allowable** 245:11 246:1 **allowed** 126:18 128:25 135:21 149:1 307:21 314:16 allowing 57:14 309:12 335:18 **allows** 90:1 101:1 103:1 248:1 258:1 **alluded** 99:13 134:20 250:1 **alluding** 282:13 am 2:21, 22 4:11, 19 30:1 73:21 152:1 161:18 245:16 256:1 281:11 290:24 294:21 296:1 297:1 299:1 306:1 320:25 325:18 331:1 332:25 333:1 334:19 344:15, 16 **alone** 74:23 **amended** 72:11 94:1 135:17 149:25 274:25, 25 277:11, 12 319:14 325:22 327:1 335:1 **america** 337:13 american 3:14 122:1 138:12 144:12

COURT REPORTING

already 44:13, 15 55:14 64:20 86:1 91:1 101:14 155:16 205:1 207:18 208:1 228:16, 17 244:16 248:1 249:1 266:22 270:1 273:24 297:1 302:1 314:1 328:1 **alternate** 345:13 alternating 198:16 alternatives 59:21 61:1 62:12 72:1, 23 73:1 340:1, 1 348:24 **an...a** 111:24 **an...an** 175:1 **an...we** 249:1 analogous 132:1 141:18 analyses 107:1 121:20 122:11 123:22 132:1 141:1 166:14 167:13 258:1 273:1 301:21 analysis 10:1 33:11, 22 35:10, 15, 22 46:14 48:10 49:1 50:13, 21 54:1 69:22 94:14 105:1 121:18 122:10 123:25 133:10 141:16 147:19 166:1 173:16 214:1, 25 222:10 234:1, 12 235:1 237:1 258:10 272:21 273:1, 1, 18, 20 279:20 298:19 299:1, 20, 25 301:1 305:1 306:16 307:1 309:1, 19, 23 310:1, 1, 15 311:17 312:1, 10 316:1, 1 324:20 325:1, 20 analytical 224:21 231:1 278:1 289:23 analyze 233:1 analyzed 238:1 316:10 324:1, 23

ancillary 149:15 **among** 200:16 **amount** 38:1 42:1 58:1 87:13 119:1 132:21 172:1 184:16 189:23 190:1 217:1, 11, 12 275:12 292:19, 21 326:23 **amounts** 79:17 172:13 290:1 **and-a** 15:1 **and...and** 64:20 81:24 82:1 83:16 90:21, 22 108:1 110:15, 17 133:1 156:10 157:1 171:16 176:11 184:1 193:23 195:1 212:16 219:12 229:1 232:1 234:20 235:20 245:12 263:1 281:11, 18 282:17 287:19 and...and...and 59:21 60:1 97:1 and...between 255:17 and...calculated 156:20 and...i 204:14 and...this 154:22 **ample** 334:1 **animal** 30:17 32:1 41:14 49:13 50:19 51:12 77:1, 13, 21 85:1 86:14 87:20 248:21 253:10, 11, 13, 19, 20 257:22 258:1, 1, 1, 16 259:1, 1, 13, 20 262:16 265:23 270:1, 1 278:21 283:1 291:13 293:1 **animal's** 259:14 animals 29:15, 17, 18 30:1, 15, 17 31:24 34:11 48:1, 1 49:15, 17 50:15, 22 51:1, 1, 1, 20 79:1,

1, 1, 12, 16 82:1 83:1, 1 84:1, 1, 10 86:20 174:1 209:19, 21 211:23 237:25 249:16 251:1 252:16 258:11, 14 259:1, 1, 18 270:1 291:1 **animals...or** 83:25 **anna** 12:1 **annette** 6:1 20:1 46:1 235:1 242:23 **annoyed** 150:23 **annual** 345:12 **anorexia** 183:24 184:1 **answer** 30:23 32:1 51:22 72:1 74:1 92:23 156:25 164:1, 1 194:19 196:13 201:1 237:23 238:1, 1 240:10 241:22 286:1 293:1, 1, 10 295:1 340:18 341:15 answered 28:1 196:20 241:20 342:1 348:20 349:18 **answers** 31:15 50:23 232:22 anticipate 6:23 7:1 294:13 **anticipated** 6:15 anticipation 81:1 **apad** 267:14, 25 273:1, 16 274:1, 19 275:20 276:1, 1 **any...one** 242:21 anybody 93:1 144:1 171:1 335:10 **anybody's** 75:24 **anyhow** 131:1 anymore 46:1 anyone 28:1 57:1 229:22 **anything** 45:23 49:11 71:15 85:1 132:12 227:1 232:17 254:19, 22 287:19 344:25



anyway 49:13 82:1 85:11 147:14 196:1 **anywhere** 41:19 240:23 273:13 298:1 316:20, 23 320:23 aphids 66:1 197:21 198:24, 25 199:1, 1, 13 200:1, 11, 20 apologies 74:10 161:13, 18 apologize 20:1 81:15 203:17 **apparent** 124:24 144:1 174:11 248:23 apparently 23:1 130:22 153:1 230:25 **appear** 78:1 appearing 45:1 appears 232:10, 18 234:20 appendices 136:10 **apple** 220:1 **apples** 16:12, 12 17:1, 1 applicable 82:1 308:1 application 9:25 10:1, 1, 1 11:13 63:22, 24 81:1 94:19 100:1, 1 102:1 104:15 115:1 118:1, 1, 1 121:23, 24 124:22 125:1 129:13, 20 130:1 135:18, 20 137:24 139:1, 11 141:12 142:13 146:1 147:1, 1 152:19, 20 153:1 165:18 168:11 210:1 212:21 217:13 220:1 221:13 224:14 225:25 238:12 275:1, 1 291:1, 1 296:1 302:1 307:20, 20 342:1

347:1 348:1 applications 67:22 68:1 100:11 104:20 135:21 216:12 327:13 applicator 221:10, 24 applicators 206:11 **applied** 5:12 10:1 122:1 126:22 127:1, 1, 23 135:20 200:1 216:1 238:23, 25 241:16 251:1 275:18 290:17 292:19 293:14, 17 300:1 301:1 **applies** 146:18 **apply** 120:1 125:12 146:17 151:17 152:20 160:19 166:13, 16 274:10 314:18 317:25 341:12 346:18, 19 apply...applicable 115:1 applying 278:1 289:22, 25 appreciable 15:15 appreciate 21:22 201:1 333:1 335:23 345:16 appreciatively 15:12 **approach** 78:15 95:10 96:22 121:1 128:1, 1 141:1 145:1 146:16 180:1 189:10 195:17 205:12, 24, 25 206:19 207:1 212:1, 1, 15, 25, 25 257:16, 21 262:12 271:1 277:1, 16 288:16 296:1 298:14, 15 300:1 302:1 304:1, 1 318:21 332:1 approach...and 256:23 approach...you 256:25

approached 287:1 approaches 108:1 approaching 108:14 143:22 320:23 appropriate 6:22 54:10 59:1 69:14 74:23 81:1 83:13 85:12 110:16 126:18 127:18 208:20 214:11 219:13 221:17 224:16 244:1 249:1 269:1 273:10, 12 274:10 296:1, 24 297:20, 23 334:23 appropriately 80:14 172:23 215:1, 13 282:10 **approved** 197:1 approximate 40:1 approximately 14:12 215:18 218:20 260:17 277:17 289:1 343:1, 1 346:22 approximations 260:17 **arbitrary** 261:21 are...are...it's 247:19 **are...because** 182:25 are...liquid 64:1 **are...that** 214:22 **are...these** 64:1 76:1 **are...we** 61:22 66:15 area 3:1, 20 4:1, 12, 25 5:1 131:24 134:17, 18 138:22 139:1 140:1, 18 156:19 200:1 224:1 238:19 276:18 287:1 293:1, 10, 11, 14, 17 297:23 298:1 300:1, 1, 1, 11, 20, 21 301:1, 1, 1, 23 302:18 303:1 305:1, 1 310:12 322:10 323:1 328:25 338:1, 15, 18 345:12



346:13
areas 3:24 49:1
62:20 63:19
65:12 67:1, 21, 24
72:22 73:1 97:1
109:19, 22 148:18,
19 223:10, 25
225:1 301:1
302:1 306:13 310:1
312:23 313:16
314:1, 22 316:1,
11, 13, 16 318:11, 14, 22 319:22
14, 22 319:22
321:22 322:1 323:1, 1 324:10
325:1, 1 324:10
aren't 16:24 33:1
35:1 37:1 95:1
182:25 225:1
280:14 287:20
argue 142:25
143:23 151:1
153:24 194:1 297:1
307:10
arguing 245:17
argument 92:10
130:12 155:1 247:1
260:1
arguments 103:16
126:14
arise 60:25 109:16
arithmetic 222:12
aquatic 3:20 328:18,
25 329:1, 1, 1
aqueous 168:1, 20
196:1
aquifer 325:12
asas 88:20 119:13
157:25 160:1 166:17 183:1 198:1
243:1
aswe 128:1
asas 215:17
ascending 13:1, 1
arose 54:1, 1, 1
aroundtyp
typical 59:17
arranging 14:16
arrival 57:1
arrived 60:22 160:20
344:13

arrows...some 78:1 **aside** 22:25 24:15 251:1 265:1 268:17 282:12 arthropod 330:1 arthropods 329:21 330:11 **article** 41:19 articulated 235:17 **artifact** 250:12 artificial 262:14 ask...it's 213:22 **at...after** 82:1 at...and 87:1 at...at 82:1 170:1 223:1 254:13 at...times 141:1 at..this 206:20 **atb** 23:1 **ate** 82:1 **aspect** 182:24 225:1 **aspects** 9:1 208:18 317:10 328:20 assay 20:14, 17 24:14, 22 232:14 265:1 279:24 **assays** 231:19 assays...there's 234:19 assembled 62:19 63:1 163:1 **assess** 62:22 306:17 assessed 86:24 assessing 10:18, 22 155:10 assessment 4:1, 20 5:1 6:1, 1 8:1 9:17, 18, 21 10:1, 1, 15 13:1 16:19, 22 17:1, 23, 25 21:1 22:1, 22 23:22 27:20 43:1 44:11, 19, 21 45:1, 11 46:1, 1, 1, 1 58:23 62:22 63:1 64:10, 22 68:16 69:16 73:24 75:1, 10, 15 76:1, 24 86:18 88:22

89:1, 12, 18 90:1, 14, 17 91:13, 16, 18, 25 92:1 93:18, 19 99:13 104:12 113:14, 15 121:19 128:15 143:1 144:1 145:10 163:12 168:14 169:15 181:1 204:1, 1, 11, 19, 22 205:1, 14, 16, 18 208:14 210:15 213:1 214:15, 18 215:1, 14, 20 225:16, 20 226:1 228:1 242:17 243:21 244:15, 21 245:1, 1 248:1 250:1, 18 263:18 264:1 266:1 267:11 268:1, 23 271:23 272:13, 19 274:22 275:21, 24 282:24 283:10 289:1 294:22 296:1, 12, 21, 25 297:1 298:16 299:1, 1, 10, 17, 22 301:18 303:17 304:10 306:1 308:1 312:15 314:23 316:22 325:1 326:24 331:11 340:24 assessments 8:25 58:11 62:1 63:1 67:14 68:11 69:24 70:1, 18 74:21 155:12 156:1 223:1 225:11 263:11 269:21 270:17 295:23 296:1, 15 298:1, 24 299:15 302:23 303:24 assessor 4:22 assigned 97:1 176:20, 21 assignment 74:10 assimilated 95:1



assist 88:21 92:22 93:13 126:1 assistant 3:23 assoc...associated 136:1 **associate** 5:1 associated 2:18, 25 56:11 95:13 96:17 100:22 103:21 131:1 135:15 137:1, 1 146:1 153:18 215:16 216:20 227:1 231:1 233:1 273:21 311:13 331:15 332:1 334:18 associates 4:19 association 332:20 335:20 associations 153:16 assume 22:23 32:10 37:1 47:21 98:1 104:1, 1, 1 107:1 112:10 115:12 116:12, 21 120:18 138:1 139:14 140:1 170:16 191:21 237:17 297:20 **assume...if** 140:1 **assumed** 45:1, 14 106:24 107:1 112:1 137:19 138:11 217:13 225:24 305:19 316:11 325:1 assumes 215:1 assuming 29:25 44:1, 24 51:1, 1 53:1 111:20 112:1 120:12 123:1, 10 170:1, 11, 15 194:1 325:20 assump...conclusions 64:24 assumption 45:12 51:18 97:13 110:24, 24 118:15 145:23 160:1, 12 169:1 184:25 185:1, 1

195:14 276:24 assumptions 62:23 74:18 108:1 124:1 138:12 145:16 166:10 215:16 248:23 258:18 262:14 274:18 275:1, 1 277:1, 1 295:16 333:14 assumptions...and 274:14, 16 **atlanta** 3:15 audience 38:21 57:1 173:24 203:17 349:10 **audra** 5:1 238:10 **atrazine** 281:13 309:11 **atrogene** 297:17 **august** 62:18 **attempt** 54:1 201:1 **attend** 74:11 attention 155:19 201:1 214:1 333:1 335:1 attorneys 203:1 attractive 109:20, 22 138:1 attractiveness 109:17 availability 84:10 253:12 **available** 17:22 58:1 61:1 91:1 102:11 144:11, 14, 15 154:10 155:13 177:20, 22 202:21 210:16 214:13, 25 221:1 225:15 226:1 227:20 228:1 240:24 262:11, 12 266:1 272:1 275:12 276:16, 25 280:17 301:15 **atvs** 146:11 148:1 **average** 30:13 97:23 98:1 102:20 109:1, 1, 15 110:1, 11 111:18 116:1, 23

118:23 121:1 192:1, 10 209:13, 18 259:1, 11, 14, 22 260:1 262:17 296:1 318:1 342:12 averaged 121:1 **averages** 259:19 averaging 116:16 **aversion** 167:10 avian 59:1 62:20 68:1, 1, 14, 19, 20 69:1, 1 73:23 74:15 75:1 77:1 88:21 90:14, 17 91:15 93:18 99:12 124:23 127:14 144:1 155:1, 11 156:1 158:1 163:12 331:10 334:12, 14 **author** 43:11 **authors** 125:13 128:1, 1 156:11, 18 235:14 aware 283:1 300:1 307:17 312:24 340:1 away 131:1 160:1 302:17 **avoid** 174:20 avoidance 76:13 78:16 80:1, 1, 12 81:24 94:1 103:23 105:1 118:1, 10 123:1 143:11 154:13 167:1, 15, 16, 18 169:23, 25 170:10, 10, 19 171:1, 14 182:1, 1, 20, 21 183:1, 17 184:10 191:1 192:13 avoidance... **turning** 170:19 **ax...x** 120:1 **axes** 135:11 **axis** 33:25 34:1 80:1, 1 86:25 87:25, 25 104:14, 16

COURT REPORTING

106:14 107:1 111:1 116:18 118:23, 24 120:1, 20 121:12 123:1 129:11, 12 134:15, 16 141:13, 14 142:1, 1 149:22 289:1, 1 В **babbage** 154:20 bachelor's 198:1 background 34:20 36:1 37:1 89:22 214:16 217:1 306:1 335:24 **backgrounds** 35:1 **backs** 319:18 backwards 93:1 bad 130:23 197:22 345:1 badly 92:18, 19 bailey 6:1, 1 28:17, 19, 23 29:1, 1, 11, 19, 22 30:1, 22 31:1 32:14 33:24 34:1 **baiting** 150:22 152:16 331:1 **balance** 163:21 **ball** 93:1 131:1, 11 170:1, 1 344:1 ballpark 332:1 **band** 39:14 **banded** 94:20 115:1 141:11 **banned** 342:21 **bar** 151:1 173:25 174:1 **bar...the** 174:1 **barely** 112:24 **barrier** 265:14 **bars** 29:23 189:24 211:19 bartoningen 329:11 **base** 46:10 179:1 213:25 329:1 339:1 **baseball** 336:16, 17 **based** 7:1 39:24 40:1 45:13 53:1, 1 60:14 61:17 67:1 **be...dr** 69:1

68:14 70:11 74:14, 17 75:1 76:1 88:1 104:1, 10 107:15 108:1, 22 114:15 116:1 123:25 142:23 143:1, 1 151:25 165:23, 24 168:20, 22 188:1 206:25 215:1, 14, 25 216:1 222:1 225:17 235:15 246:13 267:1 268:18 269:1 271:1, 15, 19 279:17 286:22 299:1 301:12 304:1, 17, 21, 22 305:1, 21 314:23 329:1, 1 335:1, 1 **baseline** 82:16 **bases** 14:14 **basic** 33:1 **basically** 44:23 45:1 49:1 50:25 79:1 81:13 82:21 84:10 115:12 120:12, 20 140:1 165:1 185:1, 15 205:21, 25 207:11 208:1 210:24 218:17 219:17 239:20 250:14 263:10 268:12 271:20, 22 276:1 291:1 293:1 334:1 338:22 339:1 344:15 basically...we 232:1 **basics** 13:1 336:1 **basin** 308:13, 15 **basing** 52:20 262:13 **basins** 310:1 **basis** 32:24 54:1 119:15, 16 184:13, 16, 21 213:18 215:21 249:18 252:16 262:11 301:24 330:22 340:23 **be...and** 260:13

be...should 278:1 **be...so** 196:1 be...the 213:1 **be...will** 69:1 285:24 **beam** 337:1, 1, 1 **beans** 297:20 **beast** 99:24 132:1 became 87:1 124:24 **become** 30:19 140:22 172:12 285:19 303:15 313:19 336:25 becomes 77:1 315:25 340:1 **bed** 252:1 been...i 169:1 **been...that's** 64:23 **before...the** 205:20 begin 6:1 56:21 106:15 202:1 243:25 244:1, 1 296:1 beginning 3:1 21:13 198:1 200:1 257:13 265:13 beginnings...is 260:14 begins 118:14 199:17 246:10 **behalf** 69:1 118:13 behavior 53:1 97:22, 23 98:1 99:1 100:25 103:23 105:1, 10 107:14 108:1 113:11 118:1, 10 123:1 124:1 138:1 143:21 186:20, 23 192:1, 13 behavior... particularly 106:1 behavioral 53:1 **behaviors** 98:1 106:13 111:13, 18 **behind** 6:14, 24 38:12 161:12 177:10 197:24 being...being 256:1 being...wanting



115:1	16 214:13 222:10	biology 3:1, 12,
believe 7:18 8:1, 18	238:1 256:24	25 4:15
11:21 12:17 25:1	265:19, 24	biomarker 264:1
29:1 31:20 32:1	296:25 311:11	biomarkers 5:15
56:20 58:13	345:11	
70:18 80:14, 25	best-fit 311:1	bird 77:1 94:10,
		21 95:19 97:1
84:24 91:21 128:21	bestbest 203:11	102:1, 24 103:1,
144:1 153:1, 10	bet 244:1 311:11	10 104:1 105:1,
154:24 160:11	better 13:20 25:1	16, 19 106:18
172:23 174:18	49:10 89:1 90:22	107:1 108:1, 22
181:1 192:22	99:1 105:12 143:20	109:1 110:21
193:24 197:1	144:24 146:25	113:1, 1 116:21
207:14, 20	154:1, 23 155:10	122:1, 1, 15
232:12 233:20	238:13 253:1, 1,	123:17 125:1, 15
243:18 247:11	1, 15 257:21	126:1, 1, 15
249:1 250:11	258:15 262:1 265:1	
268:1, 15	280:1 310:22	130:17 131:17
270:12, 13 276:1	beyond 238:20	140:14 141:13
327:1	b7 343:1 346:23	142:19, 20 144:12,
believers 61:14	b8 346:23	17, 17 148:12
believes 90:1 115:16		151:1 157:1, 1,
belly 287:1	bias 81:1 173:13	1 158:15 160:1, 1,
belong 177:12	174:11 175:1	22 166:16 170:22
-	307:11	178:1 179:24
belongs 250:1	biased 81:18, 20	187:1, 1, 18,
belowzero 79:24	biasing 217:14	21, 23 188:1, 1
belt 199:1 300:17	bigger 211:20 255:14	189:1 190:1, 1, 19
301:12 309:25	261:1	192:1 193:14, 16
316:1, 1, 19	biggest 238:16	
319:22 322:1	bill 53:18	194:16 348:1
323:16 324:15	billion 19:21 295:22	bird's 187:1
benchmark 215:1, 12,	296:1 298:12,	birdwell 187:1
22 216:20, 24	17, 20 302:1, 1	birds 4:17 10:1, 14,
229:20, 23 230:1	304:1, 1, 1	18 74:17 77:15
245:24 246:1	305:1 307:17 309:1	80:22, 25 81:1,
318:1, 22	310:14 312:12,	11, 15, 17 82:14
benchmarks 214:12,	13 320:21, 24	83:19 85:10
12	321:14, 19, 24, 25	95:1, 24 96:23
benefit 262:1	322:17, 19 324:25,	97:1 98:1, 24
benefits 62:1 63:1	25 326:1, 13,	99:1, 1 101:11
218:23 334:17	17, 22 327:1	103:12, 14
beside 338:1	329:16	105:1, 10, 18
best 25:1 67:1	bimodal 106:19 107:1	107:19 108:18, 20,
69:1 74:1, 1, 1	binding 82:21 243:10	23 109:1, 1, 1,
90:1 108:24	_	11, 14, 14, 23
111:1 155:13	binomial 96:25 189:1	111:10, 21
156:22, 24	bio-statistics 5:23	113:1, 1 116:1,
157:1, 1 158:18,	biological 12:24	1 117:1 125:20
21 159:1, 10	32:17 34:22, 23	126:1, 1 127:1,
160:1, 24, 24	62:1, 14 79:20	1 128:1, 10, 13
164:1, 1 165:1, 13	100:21 249:18	129:21, 23 136:1
166:1 182:23	262:20	138:21 139:1 141:1
208:22 210:16,	biologically 262:19	144:11 146:1,
200.22 210.10,	biologists 33:1	



Page 3	366
--------	-----

13, 13 147:18, 19, 22, 22 148:13 149:1, 15, 22 150:1, 1, 1, 1, 21, 23 151:1, 20, 22 153:1 154:1, 1 155:14 157:10 159:1, 1 161:1 165:1 171:1, 14 172:1, 1, 1 173:1, 11, 11 174:25 175:1, 10, 10 180:1 181:1 182:25 183:10 184:17 185:15 187:1, 15 188:25 189:22, 25 192:1 193:11, 13 195:1, 10 281:1 331:1, 12 347:1, 10, 19 **birth** 199:1 **bit** 14:1 34:16 39:12 48:14 53:1, 19 59:1 60:12 62:1 65:14 75:1 88:1, 24 89:22 99:19 103:15 106:1, 22 109:1 114:1 117:17 134:1 137:16 142:21 147:1 148:1 149:19 150:20 152:1 164:17 167:16 172:12 173:19 177:13 194:25 203:1 208:1 209:1 248:12 249:1 255:14 266:23 302:10 317:12 333:25 339:1 342:1 343:1 347:14 bit...a 103:15 144:1 **black** 107:1 218:25 339:10 blackbirds 102:10 **blast** 220:1 **blood** 9:1 20:13 22:1, 1, 23 24:13, 22 33:18 39:25 40:19 48:13, 16 49:1, 1, 1 77:24 232:25 233:1, 1

234:1, 11, 16, 17 263:1, 13, 23 265:1, 1, 20 266:17, 19 **blood-brain** 265:14 **bloodworm** 198:24 **blows** 342:18, 20 343:19 349:1, 1 **bmd** 46:14, 20 253:13 255:10, 13 256:23 284:12 **bmd...bmd50** 252:12 **bmd10** 246:1 266:1 267:20, 20 285:22 286:15 bmd10s 250:14 257:1, 1 **bmd20s** 257:1 **bmd30s** 257:1 **bmd40s** 257:1 **bmd50** 248:19 252:11 253:24 254:1 266:1, 1 bmd50s 253:1, 1 261:13, 14 262:13 **bmdl** 46:22 213:17 bmdl...actually 268:21 bmdl10 215:1 246:1 268:22 269:1 270:1 271:11 bmdl10s 267:1, 1 **bmds** 46:15 260:21 262:1 286:17 **blue** 17:1 40:20, 20 104:17 116:18 134:17 140:11 141:19 255:1 261:1 297:13 310:10 311:10, 12 **bnd** 40:1, 10 **board** 13:1 55:14 202:16, 20 **bob** 69:21 251:15 279:14 bobwhite 83:23 84:1, 13 122:1 161:1 166:18 195:1 196:1 bobwhites 102:1 **bodies** 65:13 body 44:17, 24 77:22

80:1 82:24 83:1 84:14 87:13 88:1 94:24 98:20 101:12, 15, 19, 23 102:1 104:1, 16, 17, 22, 24, 25 105:1 118:1 119:1 120:1, 21 143:1 172:1 179:13 180:16 181:1 188:1, 1, 1, 10 217:11 223:10, 25 224:1 225:1, 1 243:1 265:16 **boiled** 133:24 **boiling** 136:10 **bold** 136:1 **bolded** 222:1 **boll** 198:18 **bolls** 199:18 **bollworm** 198:23 bolus 44:11, 16, 25 45:1, 10 78:18, 18 83:1, 1, 11, 11, 14, 17, 24 84:15 85:17, 17 121:15 144:16 168:1, 1, 20, 23 196:1, 1 215:10 **boluses** 83:15 boom 220:1 221:13, 25 **booth** 125:1 **border** 148:19 228:12 342:11 **bore** 272:22 **bores** 343:18 both...vulnerable 67**:**20 **bottom** 49:1 189:20 204:16 206:1 213:15 215:17 219:15 249:1 251:1 262:24 263:17 269:21 270:19 296:16 303:1 308:1 339:1, 1 bottom-line 27:21 bounce...bounce 177:16 bound 19:1 43:17, 23 44:1 196:1



bowers 114:24 **box** 227:24, 25 308:1 **brackets** 166:12 **brad** 4:21 165:15 **bradbury** 7:10, 12 11:1, 19 65:25 99:13 brain 9:1 10:14 14:1, 24 17:1, 12 22:11, 24 23:1, 1 24:1, 16 26:1 33:16, 17 34:11 39:25 40:1, 19 47:17, 19, 25 48:10 49:1 86:22, 25 87:21 104:1 143:1 145:17 180:11 205:1 210:1, 12 228:17 229:1, 1 230:1 231:20, 25 232:1, 10, 13, 18 233:1, 22 234:1, 12, 18 235:11 246:14 247:13, 24 248:15, 19 249:1, 14 250:15 251:17, 23 252:1, 1, 12, 19 253:1, 12, 19, 22 255:1, 12, 25 256:11 257:22 258:1, 20 259:1, 10, 12, 17 261:1, 1, 23 262:1, 16, 17 263:1, 1, 10, 12, 18 264:1, 22 265:1, 1, 1, 20 266:1, 14, 20, 21 267:1, 1, 19, 20 269:1 271:1, 11, 17 272:1, 1 279:1, 1, 16 283:25 brain...for 145:16 **brain...from** 143:1 **break** 37:10 39:1 56:1, 1, 1 57:1 155:24 161:10, 20 162:23 165:15 196:21 201:22

294:1 304:15 349:13, 23 breakdown 212:20 **breakout** 201:22 breaks 315:23 **breast** 281:1 breathing 220:24 **breeze** 339:1 brewer 69:1 74:1, 1 79:1 171:12, 13, 13, 20 172:1 173:18 174:20, 22, 22 175:18, 22 176:1, 1, 1, 11, 16 178:1, 1 182:1, 1, 12 184:15 brief 57:18 202:1 214:14 294:18 297:1 328:17 briefly 7:22 59:1 65:1, 23 69:10 74:1 88:24 96:10 146:1 214:1 217:19 295:1 299:24 325:18 329:1 333:1 349:23 bright...in 112:1 brimijoin 11:1, 10 26:23, 24 28:1, 1 45:19 71:1, 1 228:1, 1 bring 214:20 311:14 337:1 bringing 41:1 159:20 **brings** 306:25 broad 72:19 73:1 146:15 broadcast 94:20 151:1 brochures 64:15 **brock** 330:1, 17 **brooding** 160:14 **brothers** 197:18 **broward** 332:1 **broxworth** 329:10 **bruce** 340:17 342:1, 1 **brush** 146:15 **bubble** 106:1 **buckets** 73:10 **buffers** 67:23 327:24

328:1, 1, 1 **bugs** 198:24 348:20, 24 **build** 35:1 **bulk** 218:1 **bullet** 63:15 64:1 216:1 223:21, 24 bullets 224:1 271:12 bumpiness 186:16 **bunch** 200:16 bunge 6:1, 1 12:1 20:1, 1, 1, 21, 25 21:14, 17, 22 22:10, 13, 15, 20 23:1, 12, 19 24:12, 21, 25 25:1, 20, 23 26:10, 19 42:16, 17, 20, 25 43:1 44:1 45:1, 19, 24, 25 46:1, 17, 20 55:1, 1 233:25 234:1, 1 235:1, 1, 1, 19 236:1 237:16 242:23, 23 291:25 292:1, 1 burden 101:15, 20, 23 102:1 104:16, 22, 24, 25 105:1 118:1 119:1 179:13 **burnett** 342:1 **burnie** 294:25 **burrow** 338:23 **business** 197:14 198:13 **busy** 201:1 **but...but** 249:20 but...so 203:1 but...to 155:24 **by...by** 276:11 288:17 by...submitted 69:1 С cab 219:23, 25 220:1 221:13 **cabs** 220:1 221:25 **cabs...or** 219:23 cage 176:24, 24 177**:**1

caged 172:1

COURT REPORTING

cages 80:22 85:1	204:17 248:25
176:20	270:19 274:23
calcareous 324:17	canceled 70:21
calculate 40:15	cancellation 11:12
87:16 128:20	cancelled 11:22, 23
129:16, 18	cancer 3:1, 14
134:22 179:1, 1	5:22 229:16 278:10
191:1 196:1 275:1 278:19	281:1, 14
285:22 293:1	candidate 309:1
313:11	candy 337:18
calculated 166:1	capabilities 278:1
229:20 230:18	289:24
234:24 245:11	capacity 300:1,
246:1 272:25	12, 13 301:1 302:19 305:1
277:1, 15 295:21	capture 310:17
318:1 329:12	-
calculating 325:16	captured 78:16 captures 110:1, 17
calculation 39:17	carbamate 4:13 21:19
44:22 46:20 128:19	28:14 67:12
158:1 169:24	74:21 211:1 233:12
229:18, 23 230:1	251:1 264:1 286:24
246:1 247:16	carbamates 13:1,
248:22 249:1	18 15:1 16:20
253:14, 21, 22	25:13, 16 53:12
259:13, 18 260:1	67:11 86:10, 11
285:24 286:1, 1	88:1 199:23 206:18
287:1, 11 317:25	208:25 242:25
calculations 115:1 128:14 129:1	243:11, 15 251:1
156:13 204:16	271:24
214:19 248:20,	carbamyl 86:1
23 255:11 258:24	carbaryl 15:20
261:1 268:22 273:1	208:16 211:1 214:1
276:1, 1 278:14,	224:16 230:16
18 279:15 284:13	carbaryl
296:11 297:1	carbofuran 218:14
california 3:19	carbofuran 2:1, 20
5:1 147:1, 12	8:23 9:1 10:1,
148:1 152:1, 14,	1, 12, 16, 18 13:1 15:11, 20, 23
18, 25 224:24	16:23 17:1, 1,
227:23, 23	1, 12 18:24
california's 218:1	19:1, 1 20:23
can'twhen 290:1	27:15 29:1, 1 31:1
canas 68:1	54:11, 17 56:13
cani 233:1	57:11 58:1, 14, 21
canwe 184:1	59:14 61:1, 20
canada 4:1 5:11	63:19 67:1 70:1,
88:20 138:14	12, 20 72:1, 12
canals 311:1	74:13 75:13 77:1
cancel 2:20 11:12	81:1 82:19 83:24
56:13 66:1 74:12	84:14 85:14

87:14 88:22 90:1 96:18 100:1 103:21 104:1 105:1 124:22 125:12 127:1, 11 137:20, 21 142:16 146:1 147:1, 1, 17, 23 148:1, 1 149:1, 21 153:1, 19 154:1, 1 155:14 168:1 180:16 195:1 209:25 214:1, 1, 23 215:25 216:11 217:1 218:1 219:25 220:1 224:13 225:12 226:1, 1 227:11 233:13 240:23 246:12 248:1, 1 251:1, 18 264:23 265:12 266:21 267:1, 24 271:24 281:1, 1 282:1 294:23 295:18, 20 297:1, 12, 22 298:1, 1 299:14, 19 300:23 301:1, 1, 14, 23 302:1, 1, 14 303:1, 14, 22, 22 304:1, 12, 22 305:1, 22 307:1, 1, 10, 11, 13 308:1, 21 309:20 310:1 311:1 312:1, 19, 21, 25 315:10, 21, 22 316:1, 1 317:14 319:1, 11 322:15, 23 323:1 324:21 325:1, 10, 13, 21 326:21 327:12 329:21, 23 335:1 336:1 338:1, 12 341:12, 18 346:18 347:1 348:15, 16, 16 carbofuran's 267:25 298:19 carbofurancontaining 64:1 carbofuran...and 267:18



carbofuranthe
266:13
carbofurans 267:15
carbomanated 78:1
86:1
carbon 20:1
carbonate 298:15
carbonates 303:21
340:25
carcass 126:1, 1
156:1 157:1
carcasses 146:11
carcinogenicity
249:13
care 34:1 35:1 126:1
281:1
careful 35:14 85:1
161:19
carefully 79:1 245:1
carlson 71:19, 21,
21, 23, 24, 24
227:15, 16, 17
$2/10 \cdot 10^{-1} 1/1 20 20^{-1}$
240:10, 14, 20, 20 241:13, 19, 20, 22, 24 242:1, 1,
22, 24 242:1, 1,
10 308:18 341:25
342:1 348:1, 1, 1,
19
carolina 40:20
305:11 319:16
327:11, 11
carried 11:12 101:22
carrier 182:1, 1,
10, 15 198:1 241:1
carry 101:11
296:14 325:1
case 32:1 39:1
84:1 113:22 116:10
117:1 129:24 130:1
136:13 143:1 147:21 166:1, 1
181:1 190:11
194:12 200:1
206:23 207:11
208:1 212:13
215:1, 20, 23
216:1, 1 218:1
220:1 221:20 222:1
225:17 226:1, 1
227:24 229:19
231:12, 15 232:1
233:13 265:12

267:24 276:25 285:21 291:1 320:10 335:10 **cases** 31:17, 23 67:23 72:24 73:1 93:1 111:22 215:1 217:1 228:11, 11 295:17 317:1 **catch** 20:17 87:12 328:18 **categories** 72:17, 19 73:1 132:14 134:1 139:1 149:23 304:19 categorization 132:1 222:12 categorize 133:1 categorized 132:1 135:11 140:1 **category** 304:25 305:1, 13, 25 category...is 151:13 cauliflower... **colorado** 151:1 **cause** 296:19 336:22 **caused** 147:20 causes 199:18 344:1 causing 83:20 230:13 caution 92:1, 1 110:19 cca 20:23 22:1, 12 23:1 46:12 **caveat** 16:1 52:15 **cd** 42:1 75:22 177:21 **ceases** 330:20 **cedar** 318:15 cell 3:1 20:13 22:1, 1, 23 24:14, 22 39:25 48:13, 16 49:1 234:1, 11, 16 263:13, 23 265:1, 18, 20 266:17, 19 **cells** 9:1 33:19 40:19 233:1 234:17 263:1 265:1 **censored** 224:1, 22 **census** 97:25 111:1 147:1 148:1 158:16 censussed 149:1

center 3:24 5:23 81:18 229:17 278:11 338:21 **centered** 318:25 **central** 78:1 221:19 232:1 263:19 265:17 centrality 117:1 **cents** 343:14 **centuries** 337:15 certain 19:1, 25 42:1 67:22 68:1 110:22 119:1 132:21 188:25 229:1 268:1 343:1 346:1 certainly 9:1 12:1 17:20 35:1 37:23 38:1 39:1, 1 52:11 58:1 60:1 61:11, 18, 21 95:10 99:20 108:15 130:17 131:11 140:25 160:25 162:1, 1 167:1 181:23 183:17 232:1 255:14 257:11 259:25 260:1 264:11 333:1, 1 340:15, 16 cessation 82:1 cetera 85:1 257:15 chair 2:22 8:22 52:1 59:1 333:1 340:17 chairman 73:20 88:17 153:1 181:22 328:23 331:18 335:22 340:16 341:25 347:20 challenging 118:19 **chambers** 3:1, 1, 1 234:1, 23, 23 235:1 283:17 288:1 289:13, 14, 15, 25 291:1, 15, 18 **chance** 56:1 93:15 96:25 97:1 112:21, 23 114:1, 1, 11 236:11 311:23 315:12, 15 change 9:10 10:21 32:21, 23 33:1, 1,



1, 20 34:21 35:1, 16 77:16 79:1 100:14 119:1 129:25 187:17 194:1 274:16 **changed** 249:1 252:24 278:1 297:1 changeover 79:11 changes 7:23 8:1, 12 30:1 32:12 35:1 51:1, 1 60:15 64:20 150:16 194:24 195:1, 1 237:11 289:1 297:10 314:1, 14 321:21 327:1 329:15 345:14 changing 87:11 289:16 chapter 89:19, 20, 21 113:14 115:1 chara...category 151:12 characteristic 30:1 characteristics 52:14 299:20 305:22 characterization 89:1 168:13 characterize 112:1 116:17 characterizing 155:13 **charcoal** 339:10 charge 2:25 8:18 10:25 36:1, 10 37:14 53:23 154:1 155:16 202:14, 22 271:25 329:1 **charged** 90:1 92:1 151:1 charges 203:1 **charlene** 335:14 **charles** 154:19 **chart** 18:1 41:22 189:20 228:24 234:24 250:1 266:25 267:16 **charts** 267:23 **cheat** 295:1

check 238:1 291:12 347:17 **checked** 93:11 **chemical** 6:1 13:17 27:1 30:19 52:12, 15, 19 61:16 80:24 82:23 83:1 86:14, 16 179:24 181:1 291:19 293:22 296:18 309:12 344:1 348:1 chemicals 15:20 47:20 240:15 264:23, 24 309:12, 15 345**:**1 chemist 4:20 **chemistry** 198:16, 22 200:1 **cheryl** 4:18 72:1 172:21 239:14 **chew** 336:18 **chewing** 336:18 341:1 chickens 88:1 children 216:1 246:11 **china** 74:10 chlorinated 198:19 chlorpyriphos 126:24 127:1 130:11 chlorpyrophos 48:24 **choice** 78:23 cholinergic 50:1, 1 cholinesterase 9:1, 11 10:14 13:16 20:13 21:1 27:20, 23 29:17 40:15 47:1, 1, 17, 19 48:1, 1, 11 49:1, 1, 11 50:13, 22 51:1, 15, 19 52:25 53:1, 10, 11 76:15 78:1 83:1 85:1, 23 86:1, 22, 25 87:10, 18, 21 88:10 179:12 180:1, 19 181:1, 1 210:12 231:18, 19 233:1 234:1 235:10, 16 252:1 253:25 259:1 264:1, 22 269:1,

1, 22 cholinesterase... acetylcholinestera **se** 265:1 cholinsterase 23:1 33:16, 17 34:12 **choose** 100:23 112:10 235:12 **chooses** 59:1 **chopped** 197:17 **chose** 88:1 112:1 318:20 **chosen** 112:1 117:15 313:13 331:25 332:1 chris 4:1 182:1 christmas 81:16 christopher 101:10 127:22 137:1 **chronic** 249:11 cincinnati 3:10 **circled** 250:1 circulated 180:16 circulating 265:19 circumstantial 281:1 citations 108:10 116:1 **cite** 40:25 **cited** 54:20 **cites** 306:22 **city** 152:16 **civilian** 198:1 claimed 82:1 148:1 clarification 6:16, 23 20:1, 1, 12 21:1 36:11 45:17 51:23 55:1 65:24 66:1 70:25 148:1 163:16 164:1 171:1 173:22 181:16, 18 182:17 184:1 185:11 233:25 235:1 242:1, 19 289:14 342:1 349:16 clarifications 20:1 clarifies 203:1 **clarify** 24:12 42:17 182:22 202:1 203:1 234:25 242:1



250:24 346:1 **clarifying** 7:18 11:1 59:1 202:1 **clark** 3:22, 22 5:19 156:1, 1, 16, 23 171:1, 1, 1, 16, 23 172:19 **class** 15:17, 19 52:10 62:19 304:18, 18 **classes** 52:12 198:22 199:21 304:16 341:1 classification 310:1 classified 207:11 **clay** 241:1 **clean** 212:21 291:1, 1 333:23 **clean...they** 209:13 **cleaned** 200:20 209:17 210:1 cleaning 237:1 **clear** 19:1 21:18 50:1 140:22 147:20 151:1 152:16 184:11, 23 188:19 206:12 208:16 211:23 228:21, 22 229:24 240:1 243:1 271:1 332:13 **clearly** 137:12 161:12 181:1 230:19 281:18 285:1 **clients** 260:23 clinical 5:25 13:14, 15, 19 55:1 **cm** 293:14, 17 **close** 131:1 152:1 195:13 196:14 228:13 235:18 256:20 259:25 268:23, 23, 24 284:1 287:17 304:1 320:23 321:1 330:1 347:1 349:1, 1 **closed** 64:1 214:22 217:20 219:16, 22 221:10, 13, 23 224:13 **closed...i'm** 219:23

closely 63:1 323:1 **closer** 249:1, 21, 24 268:25 345:1 **closest** 257:1 **closing** 349:13 **cloth** 197:23 clothing 223:13, 14, 18 **cloud** 40:1 **clouds** 40:10 **cmsm** 4:21 co-authors 111:1 coarse 314:1, 12 cockpit 221:10 **code** 38:11 93:15 **coded** 81:15 173:12 coefficient 48:14 116:11, 15, 20 coefficients 52:19 115:18, 22 191:25 211:15, 24 309:14 cognizant 162:1 **coin** 189:1 **cns** 264:1 265:1 colleague 193:24 colleagues 244:1 262:21 281:1 **collect** 231:1 collected 111:1 126:17 209:20 222:15, 24 228:1 233:10 236:16 237:18 275:13 276:1 collecting 223:12 224:1 collection 209:12 237:1 college 3:1, 10 5:1, 17 **color** 81:15 173:12 346:1 colorado 6:1 338:1, 18 339:1 340:1 342:1, 10 346:13 347:23 **colors** 297:12 308:23, 25 310:1 **column** 117:19 218:24 221:21 222:1

223:15 270:18 combination 86:13 87:11 180:13, 19 197:23 235:15 243:1 250:12 301:1 339:14 combination...it's 243:1 combinations 136:12 **combine** 100:16 343:21, 24 **combined** 103:14 112:1 129:1 **comes** 45:23 48:21 101:16 116:22 151:23 204:16 237:10 240:1, 12 246:1 256:1 283:1 327:25 comfortable 43:1 coming 26:1 74:15 169:1, 13 comment 6:18, 19 19:11 28:11 33:24 40:23 44:21 52:1 55:19, 20 56:15, 15 58:1 71:16 76:12 114:21 149:16 151:19 157:19 162:10 163:1 173:1 179:1, 10 180:1 183:21 191:19 196:1 214:23 231:1, 15 253:17 283:24 289:1 **commented** 96:1, 21 commenter 57:1 commenters 57:1 162:1 335:17 comments 7:11 52:20 56:1 57:20, 22, 23 70:1 92:1 96:1, 13 103:16 125:23 161:22 163:19 180:1 202:1 334:24 349:13 commercial 321:1 commercialization 339:24



commissioned 75:1 91:1, 11, 14 98:21 committee 55:1, 11 202:11 335:22 committee's 55:11 committees 55:1 202:15 203:1 224:24 commodities 63:1 278:1 commodity 63:1 342:13 common 83:1 94:23 142:13, 16 263:20 287:1 commonality 262:15 commonly 97:1 215:24 communicate 132:1, 1 communication 132:11 135:12 community 19:15, 19, 21 141:1 157:1 299:19, 23 301:15, 20 302:1 304:12, 21 305:17 307:23, 24 308:1 community...at 141:1 companies 283:1 336:11, 12 **company** 11:13 61:11 337:1 comparable 14:22 130:18, 21 303:18 comparative 20:19 33:14 38:1 270:25 compare 17:1 33:21 55:1 79:21 122:19 130:19 216:1 259:11, 16 267:20 compared 48:1 83:1 152:25 215:11 238:1 263:1 264:1 319:1 329:11 comparing 16:12 204:12 251:1 252:1 259:13 **comparison** 14:1 37:1 161:1 248:20 251:16 258:1 261:12 262:1 263:12 266:1 277:1

286:1 318:13 comparison...and 267:19 comparisons 172:16 221:19 257:1 262:1, 13 compartment 23:1 24:1 compatible 93:1 328:1 compelled 258:23 complete 137:1 completed 91:1 221:12 completely 31:18 97:11, 12 188:19 193:20 203:1 213:1 232:20 249:23 345:14 348:16 completing 92:21 complex...so 141:1 complicated 27:13, 17 151:1 302:10 complication 317:1 **complied** 148:24 **comply** 70:1 component 95:16, 19 99:25 121:10 188:1 components 94:1 96:12 composition 94:24 compound 17:1 19:10 99:1 114:1 179:21 183:1 215:25 239:15 240:17 265:15 compound...this 239:14 **compounds** 14:1, 14 96:18 264:19 comprehensive 148:1 155:22 computationally 118:19 169:1 193:1, 19 **compute** 29:12 computers 75:1 con...concentrations 279:1 conceivable 131:19

concentrated 316:1 338:1 concentration 80:1 82:11 84:1 104:1 116:18 117:21 190:25 191:21 307:1, 16 308:12 310:13, 23 320:20 321:24 325:11 326:1, 13 327:1 329:17 330:1, 1, 15 concentrations 67:15 81:25 84:1 95:1 100:1, 14, 18, 19 114:1 115:10 183:1 185:13 186:1 191:20 276:22 277:1, 17, 20 295:22 296:1 298:12, 17, 19 302:1 304:1 307:14 309:22 310:1, 10, 11, 19 311:1, 18 312:11 313:12 322:19 325:13, 17 326:16, 20 329:10, 25 330:1, 1, 23 331:1 **concept** 97:20 99:14 152:10 292:19 297:24 301:1 303:18 304:1 concepts 133:1 245:1 300:1 conceptually 12:24 193:20 concern 19:12, 20, 24 32:14 67:16 98:10 191:23 207:1 230:23 246:15 248:17 250:20 310:16 312:20 concerned 32:21 51:1 270:1 281:14 320:1 325:1 concerning 90:1 197:15 252:21 concerns 9:1 22:1 54:1 58:25 63:18 68:1 162:12 268:19 283:11 305:1



327:20 334:14 **concise** 332:13 conciseness 201:18 213:24 **conclude** 58:12 244:25 252:17 334:1 **concluded** 56:1 74:13 75:13 132:25 162:25 229:1 294:18 349:25 concluding 40:24 70:1 conclusion 41:15 74:15 226:1 255:20 272:1 277:10 326:19 333:15 348:18 conclusion... concluding 70:1 conclusions 52:14 89:1 91:25 153:1 215:1 262:1, 1 271:10 295:10 **concur** 141:1 concurrence 222:22 condition 307:18 conditional 7:22 conditions 313:14 315:17 **conduct** 23:15 131:24 294:22 296:20 301:21 conducted 33:12, 23 74:1 75:1 80:15 94:15 99:1, 1 115:18 118:12 121:20 125:1 126:16 128:1 131:20 145:1 146:1, 15, 20, 25 147:1, 1 163:10 172:23 224:18 298:25 313:11 316:1 322:22 325:1, 14 confection 336:16 confectionary 342:25 confidence 14:1, 15, 18 15:1 23:1 87:1 246:1 270:1 311:13

confident 70:11 324:21 **confines** 154:16 **confirm** 73:18 210:11 326:15 confirmed 252:23 312:1 confounded 161:1 confused 239:19 confusing 47:15 confusion 209:1 congenital 281:20 conjunction 84:21 connected 219:10 connecticut 321:25 consecutive 213:1 325:1 conservation 71:10 72:1 328:1, 1 conservative 44:1 64:24 67:1, 14 68:10 74:18 88:1, 1 111:20, 23 118:15 145:15, 23 183:16 268:1 271:23 305:24 327:1 consider 27:1 54:21 58:1 60:1 76:1 89:1, 11, 16, 17 103:22, 25 107:13 116:1 124:14 127:12 130:12 133:17 154:1, 1 210:14 220:13 226:16 266:1 268:1 274:1, 1, 24 277:1 278:16 297:16 302:15 303:1, 1 320:14 321:18 334:22 considerable 169:23 212:14 considerably 260:1 297:14 consideration 54:15 59:25 107:10, 17 108:20 226:1 232:1 274:13 276:19 277:24 294:11 333:1

considerations 222:25 considered 22:1, 11, 23, 25 24:1 26:16 43:18 44:1 75:15 80:1 105:1 133:16 204:20 210:1 225:15 268:11 273:18 274:22, 24 276:13 277:11 298:1 299:19 considering 108:1 144:19 153:25 276:17 297:25 considers 136:1 273:24 303:14 consistency 190:14 consistent 24:16 30:19 67:1, 11 79:1 81:1 82:11 86:11 153:11 271:13 331:13 346:10 consistently 81:19 174:1, 1 346:13 **constant** 122:19 constantly 198:13 constitute 90:1 constitutes 92:13 constraints 163:19 constructs 262:14 consultant 4:19 197:1, 11 consultants 197:1 346:1 consulting 198:1, 1 **consume** 79:17 109:12 172:13 consumed 77:21 178:1 consumption 79:1, 19 119:15 171:25 184:13, 18, 21 **contact** 240:1, 1 292:21, 25 293:22 341:1 contacted 93:1 312:17 317:1 contacting 217:24 container 218:1, 1, 1 219:1, 1,



1, 11, 14, 18 container...or 219:1 containers 219:11 227:21 containing 175:13 containment 321:1 contaminated 78:23 81:1 172:25 175:13, 17, 24, 25 176:1 contamination 319:14 324:22 327:1, 1 **contend** 153:14 contention 260:13 288:24 context 8:24 13:1 52:1 53:19 59:1 62:1 138:16 268:17 308:22 330:1 contingent 8:12 continuation 7:1 56:1 349:1 continue 2:10, 12 7:18 56:1 61:13 75:14 90:12 106:16 120:1 157:15 203:1, 10 306:1 332:20 344:17 continued 45:1 58:13 82:1 90:19, 20 211:1 212:17 214:1 248:1 335:1 continues 100:1 continuing 8:1 112:25 231:1 continuous 209:14 253:25 346:15, 16 continuously 231:11 contract 233:1, 1 280:12 contractor 231:1 contrast 107:1 214:19 220:1, 1 226:18 295:11 302:1, 1, 22 321:1 324:16 contrasting 214:15 216:16 contribute 32:1 300:1 contribution

169:12 297:1 334:10 contributions 56:16 276:11 277:10 334:1 control 30:14 33:13, 15 34:10, 19 66:1 72:1 79:21 81:22 83:13, 18, 21 86:24 87:1, 20 125:1, 10, 21 126:20, 21, 23, 25 127:1, 15, 16, 17 129:1, 20, 24 130:1, 1, 1, 11, 13 172:1, 17 197:21, 22 198:12 200:1, 10, 11, 15 219:24 259:11 269:16, 17, 22 278:23 338:13 342:14 control...with 79:24 **control...you** 83:12 control/treatment 125:17 controlled 30:12 81:13 131:22 153:11 controls 30:12 79:1, 13, 19 83:13 87:1, 1 172:1, 15 174:19 214:24 216:11 217:1 220:1, 12 245:1 254:1 259:1, 1, 14 278:16, 22 285:1, 1 controls...well 174:18 **convened** 294:22 convention 26:15 conventional 218:1 **converge** 271:10 conversation 196:21 conversations 12:22 16:17 **convert** 119:1 128:11 185:1 285:25 converted 120:1 **convey** 192:1 convince 11:17

convulsions 50:10 cooperative 4:1, 24 coordination 2:1 **copies** 17:20 **copy** 42:1, 1 75:21, 22, 24 347:21 **corn** 9:22 10:1 62:1 65:21 94:17 125:1 126:23 129:1, 12, 17, 19, 25 130:16 131:16 139:10 140:1, 15 141:12 142:16 150:11 153:1 164:22 225:25 297:18 300:17 301:12 309:25 316:1, 1, 19 319:22 320:24 322:1 323:16 324:15 335:13 342:11, 14 **corn...these** 225:24 cornfield 160:23 164:17 corporation 57:10 71:25 73:23 227:17 240:21 272:20 280:1 348:1 correct 19:22 21:11, 16 22:1, 1, 12 23:10 28:1 29:1, 10 43:1 45:14, 15 80:1 120:1 127:17 129:22 130:1, 1, 1, 1 160:1 185:17, 19 186:1 187:1, 16, 22 188:10 203:21 213:1 231:22 233:21 237:1 248:13 270:1 corrected 126:1, 12, 15 127:16 230:10 correction 129:19 130:13, 19 157:1, 1 230:1 274:1 corrections 156:15 276:1 correctly 37:1



44:1 257:17 283:20 correlated 48:17 49:10, 12 253:19 258:1 correlation 47:1, 1, 10, 11 48:14 52:23 253:18, 19 266:18 correlations 35:14 50:21 52:24 correspond 254:17 corresponding 48:20 254:1 correspondingly 303:1 corroborated 108:1 169:14 **cost** 344:12, 17, 19 cotton 8:1, 16 11:16 62:1 65:22 66:1, 1, 1, 15 71:1 94:17 121:25 140:15 149:11 197:17, 17, 18, 25 198:18, 24 199:1 200:23 201:1, 1 count 165:1 267:13 **counted** 338:25 counterintuitive 114:1 counties 67:23 68:1 306:1 318:24 319:1, 1, 18 322:1 323:24 324:1 327:14, 15, 21 counting 159:1 country 296:1 300:16 306:18 319:1 340:15 346:1 counts 98:1 147:1 148:1, 11 157:1 158:17, 19 160:1, 1 282:1, 1 county 301:24, 24 304:14 317:11 318:1, 1, 1, 1, 12, 13, 15, 16, 17, 18, 18, 23 323:22, 25 332:1 couple 7:14, 21, 24 12:10 20:1 57:21 70:1 113:1

136:10 146:24 182:16 200:1, 18 210:11 247:1 252:20 267:1 275:1 299:12, 13 300:1 301:10 course 11:17 13:12 21:24 22:17, 25 23:1, 23, 25 24:1, 18 25:1, 1, 11, 14 27:22 28:15, 15, 16 30:20 31:1, 12, 23 32:1 43:1 53:1 77:1 82:25 85:10 104:23 105:11 159:20 177:17 182:18 191:23 212:13 216:1 217:23 237:1, 1 238:1 269:1 278:22 282:1 287:22 312:24 315:1 316:13 326:11 328:1, 19 331:17 course...it 182:1 covariance 40:13 cover 7:17 54:1 64:18 165:1, 11 204:1 292:1 329:1 covered 244:16 343:1 covering 290:21 292:13 **covers** 328:25 crashing 160:21 **created** 121:21 193:22 207:17 238:17 creates 218:17 339:1 creating 219:10, 19 344:10 credibility 158:1 **creek** 330:24 criteria's 305:18 criterion 134:21 critical 23:1 61:1, 25 62:1 65:1 68:11, 13, 19 72:24 94:1 99:13 124:1 153:25 154:1 161:17 196:18 205:22 206:1

225:14 231:1, 21 233:1, 21 266:11 273:1 282:24 334:16 343:1 critically 122:18 124:1 312:1 333:20 criticized 130:25 131:1 **critique** 260:10 **crop** 100:1, 23 109:10, 11 111:15 144:17 152:20 153:1 161:1 197:1, 11, 15 198:1 200:1 295:17 297:21, 23, 25 298:1, 14 300:20, 24 302:1, 16 303:20 304:1 312:1 323:19 336:1, 1 337:19 338:17, 20 344:17, 21 cropped 300:18 303:1 cropping 313:13 crops 10:1, 1 59:15 66:20 68:19 75:14 94:1, 11, 17 109:10 111:1 113:17, 18 129:12 135:15, 22, 24 138:1 140:14 149:24 150:1, 12 273:18 274:21, 23 275:1 277:11 295:25 297:11 333:16, 18, 20 345:13 348:11 **crops...that** 150:1 crossed 135:1, 1 **crp** 71:17 crux-point 23:21 crystal 93:1 **cucurbit** 275:1 cummings 57:1, 12, 13 70:25 71:1, 1, 12, 18 72:21 73:12 241:25 242:1, 1 243:20, 22 332:16, 17, 22 335:1, 1, 1

COURT REPORTING

cumulative 250:1	cut 53:20	111:1, 22 113:23
263:18 264:1	cuts 248:13	126:19 128:16,
267:10 298:15	cycle 346:16	17 136:15, 22
303:17	cyclical 338:11	140:23 144:14, 15,
cup 245:1, 15 246:1,	345:22 346:1	24 145:1 154:20,
24 247:14 248:1,	510.22 510.1	21, 21, 23, 24
1, 11 267:14	D	156:12, 14
272:22 273:1, 25	daily 105:1, 13	165:23 171:25
274:1, 1, 1, 17	107:1, 11, 13	173:14 177:15, 17,
276:10, 16, 21	108:1, 17 119:16	20 179:19 190:10
277:1, 14, 14	124:1 143:21	192:22, 24 194:19,
296:12, 24 297:1	159:14 171:24	25 195:11, 21
326:22 333:21	184:13, 18, 21	204:1, 1 207:24
334:1, 11	185:1 186:25	208:1, 17, 19
cupand 276:1	188:25 325:16	209:25 211:10, 12,
curious 29:22	dakotas 346:11	13 212:1, 10, 12, 14 213:1, 19
31:13 292:18	348:21	214:13, 24 216:1
293:19	dale 5:19	220:11, 13, 13,
current 7:1 8:12	damage 199:13	15, 17, 19
47:18 62:22 64:1, 22 65:1 72:1	dan 3:17 46:24 219:1	221:1, 15 222:1,
101:15, 18	dangers 281:13	14, 17, 22, 23
118:11 119:12	dark 119:22, 23	223:1, 1, 12, 22
120:1 150:14	185:1 310:10	224:1, 1, 12,
191:11, 13 212:1	dash 116:19	12, 12, 19, 22
264:20 276:1	dator 113:11	225:1, 15 226:1,
currently 4:1 6:12	data 10:16 11:17	1, 1, 20 228:1,
8:17 58:1 60:11,	13:1 14:14	18, 25 229:19, 21,
18 67:10 149:24	15:15, 19 17:1	24 231:1, 13
247:10	18:14 22:1, 1, 11, 16, 23, 24 23:1	235:23 237:1, 1,
curve 102:11 103:1	24:16 25:1, 1 26:1	21 238:1 245:1 246:11, 14 248:21,
104:17, 18	30:1 31:1, 18, 22,	24 250:1, 1, 1, 1, 17
119:10 120:1 121:1	25 32:1, 16	251:1 253:1, 1, 1,
134:18 135:1, 1,	33:12 34:1, 1,	11 254:1, 20,
1, 1 136:1	17 35:10 36:18	22, 24 255:1, 1,
139:25 141:19	38:21 39:24	1, 16, 17, 22
142:12 166:10	40:14 43:1, 25	256:10, 10, 11,
169:1, 18 178:24 185:18 186:19	44:12 45:1, 10	15, 16, 20, 21
192:13, 22, 23	46:13, 13, 15,	257:1, 1, 21, 22
193:15 196:1 251:1	22 47:18, 25	258:19, 20, 21,
254:1 255:1 266:1,	48:13, 16, 22	21, 25 259:1
10 285:22 311:1	50:20 58:1, 10	262:11 264:20
curves 9:1 40:10	60:1 62:24 67:1	266:1, 1 269:25
95:18 102:23	69:22 70:17 75:1 12 76:1	270:1, 11
112:19 121:12	75:1, 12 76:1, 23 77:1 79:25	271:10, 11, 20 272:1, 1 275:12,
132:1 136:1, 23	81:12 83:22	15, 16 278:1,
139:13, 24 140:15,	84:16 88:1 92:20	14, 17, 21 283:19,
16, 20 168:24	95:12 97:25, 25	21, 25 284:1
179:1 194:15	102:1, 1, 14	286:11 287:1, 20
256:20 266:1	108:10, 21, 22	288:12 289:22,
customer 336:25	110:16, 17, 18	24 290:1 297:15



298:21 299:1, 23	232:21 246:13
301:15, 19, 21	260:1 296:1 302:15
305:10, 24	306:23 333:1
306:19 307:1, 1,	337 : 17
10, 12, 15, 16	daylight 184:23
308:1, 1, 16, 22	days 6:13, 13 9:16
309:1 310:17, 24	-
	18:11, 18, 19
311:1, 15 312:1, 1	49:18 100:1, 1
316:21, 24 317:1	
	101:1 104:1 147:1,
319:1, 12 320:1,	25 148:10 149:12
1, 1, 11 321:1, 1,	
	172:10 177:24
10, 17, 23 324:1	199:10 200:10
326:24 328:24	213:1, 1 315:19,
329:1, 13, 16,	20, 25 335:14
20 330:18, 19	
	de 68:19 132:10
331:13, 14 349:19	133:19 134:12
·	
dataand 84:13	135:1, 11
166:1	136:16, 18 137:18,
datathe 229:24	20 139:1 140:1
database 29:1 31:1	dead 126:15 128:11
215:15 220:16	146:1, 12, 13
221:16 222:10	147:22, 22
306:15 317:1, 1,	148:13 150:1, 1
12	347:1, 10
databases 317:1	deal 8:15 18:21
date 211:17	35:15 145:1, 25
	JJ.IJ IHJ.I, ZJ
dates 345:1	154:16 197:13
datum 109:1	198:15
datum 109:1	198:15
datum 109:1 dave 18:1	198:15 dealing 164:20
datum 109:1	198:15 dealing 164:20 180:24 198:12
datum 109:1 dave 18:1 david 12:17	198:15 dealing 164:20
datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19
datum 109:1 dave 18:1 david 12:17	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1 174:14, 14 175:11,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23 decision 21:1 22:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1 174:14, 14 175:11, 15, 22 176:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23 decision 21:1 22:1
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1 174:14, 14 175:11, 15, 22 176:1 177:11 187:1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23 decision 21:1 22:1 23:10, 21 24:22
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1 174:14, 14 175:11, 15, 22 176:1</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23 decision 21:1 22:1 23:10, 21 24:22 54:1, 1, 19
<pre>datum 109:1 dave 18:1 david 12:17 day 2:1, 16 7:14 9:14 13:14 18:1 19:1 21:10, 15, 20, 20, 25 22:1, 1 54:22 56:10 59:1 61:19 65:1 79:18 81:1, 13 95:1, 1 96:15 101:1, 1, 1 104:1 105:11, 20, 21 106:1, 1, 1, 17, 23 107:1, 20, 24 108:1 110:22 118:1 119:21 120:1, 1, 13 122:18, 20 159:15 161:1 168:10, 11 171:22 173:1 174:14, 14 175:11, 15, 22 176:1 177:11 187:1,</pre>	198:15 dealing 164:20 180:24 198:12 289:1, 1 328:19 deals 72:11 167:23 347:23 dealt 124:12, 13 144:1 dean 5:16 death 50:10 debate 257:25 debbie 7:10 11:20 decades 142:13, 17 decay 103:23 114:1 191:21 decayed 117:23 december 66:11, 12 decent 14:1 decide 189:1 decided 24:13 189:1 deciding 43:23 decision 21:1 22:1 23:10, 21 24:22

168:18 235:12 274:1, 11 decisions 61:16 **decline** 76:12 104:23 declined 59:22 297:14 **declines** 115:11 decreased 254:1 269:22, 23 282:1 decreases 254:1 273:16 decreasing 103:18 **deem** 273:1 **deemed** 24:14 127:25 296:1, 14 **deepest** 161:12 **default** 246:1 deficiencies 146:1, 1, 17 223:1 deficiency 66:14 deficits 53:1 **define** 26:1 100:1 295:1 312:18 define...to 76:1 **defined** 134:10 217:21 defining 165:1 definitely 18:1 88:1 definition 290:1 definitions 295:1 definitive 76:1 degradation 18:1, 1 95:15 100:16, 17 115:12 117:24 143:1 185:22, 25 degrade 18:23 19:1 238:19 **degree** 57:24 198:1, 1 235:16 253:18 **degrees** 18:12 **delay** 85:1 **deliberate** 151:15 deliberations 9:15 **deliver** 300:1 **delmarva** 319:16 327:12 **delorme** 4:1, 1 **delta** 318:17 **demand** 336:1 340:1, 12

COURT REPORTING

demands 105:23 demonstrate 214:10 217:25 demonstrated 106:11 227:20 demonstrates 204:23 226:1 demonstration 274:1 **density** 132:20 **department** 3:18 4:24 5:24 6:1 147:13 151:14 218:1 347:22 departure 23:17 69:20 204:12, 18 205:21 206:1, 1, 1, 1, 24 213:16 216:1 225:19 231:23 244:22 245:16, 18 246:1, 13 249:1 263:11 266:11 269:1 270:13 271:1 depend 50:16 222:10 dependance 16:1 dependant 9:13 dependence 126:1 132:21 145:20 178:20 dependent 15:1 18:1 31:21 86:1 178:12 179:1 depending 14:11 43:21 77:14 97:1 129:15 130:18 164:19 166:1 189:1 199:10 257:1 300:12 303:10 320:16 **depends** 315:17 depicted 300:1 302:20 depiction 273:1 **depicts** 300:20 deposition 238:14, 16 depth 314:15 315:1 317:11 326:10 deputize 163:1 der 292:12 der...21-day 205:11

der...that 223:20 derivation 16:21 252:22 **derive** 40:1 derived 40:13 179:11 216:1 252:1 257:14 dermal 5:1 6:1 9:1 20:15, 22 22:1, 14, 16 23:22 24:1 25:16 26:1, 20 27:11, 12, 14, 20 40:23 41:1, 1, 15 43:1 46:1, 11 54:1, 11, 12, 17, 22 55:1, 1 69:13 205:1, 1, 11 206:10, 13, 15 207:1, 1, 1, 13, 16, 18 208:1, 1, 1, 12, 22, 22 211:1 212:1, 1, 1 213:1, 1, 1, 16 215:1, 1, 1, 11, 21, 22 216:1, 1, 1, 20, 22 217:1, 1 220:1 222:1 223:12, 20 225:16, 17 226:18 228:10, 15 230:1 231:22 232:21 233:15 234:1 238:12, 21 242:25 268:17 290:10, 17 dermal-tox 21:1 22:21 25:1 26:21 27:1 43:1, 1 **describe** 98:1 134:12 158:1, 23 206:16 235:23 238:11 299:24 described 89:11, 18, 20, 21 99:1 101:10 102:1, 15 104:11 118:1 121:18 151:1 158:1 237:1 292:12 describing 263:23 description 157:21 158:1 **design** 125:1 222:24 225:1

269:11 **designated** 2:1 56:17 161:21 163:1, 1 201:19, 20 202:1, 1 designed 212:1, 10, 23 231:13 263:25 322:1 **despite** 228:24 321:11 destroyed 348:17 destroys... **destroys** 199:19 detail 39:17 59:1, 1, 11 65:14 67:18 68:10, 20 72:16 79:1 89:12 96:12 99:21 115:1 128:15 173:19 212:14 250:1 273:23 275:1, 1 309:17 **detailed** 39:1 155:21 158:1 178:1 296:1 **details** 99:22 226:1 248:22 299:12 321:15 **detect** 312:22 detectability 157:10 **detected** 149:12 275:25 276:1 312:25 320:13 detection 156:1, 23 224:1 275:17, 18 278:1 289:23 320:12, 14, 15, 15, 18, 19 321:1, 1, 11, 12, 13 322:16 348:1 detections 307:12 308:23 311:1, 1 313:1, 1, 15, 16 319:11 321:12, 18, 19 322:13, 15, 20 323:10 **detects** 320:12 322:11 determinations 148:12 determine 99:1 105:1, 13 110:11



115:10, 18 119:14 126:11 235:23 310:21 determined 54:18 105:17, 17 120:23 125:1 126:1 128:10 129:1 173:20 228:16, 18 determines 95:23 100:1 101:1 110:1 118:10 determines...i'm 110:1 determining 58:1 102:1 245:15 273:10 deterministic 214:19 **develop** 6:21 78:22 91:12 198:22 199:1, 1 222:22 269:1 270:1 **developed** 50:1 51:14 52:1 62:24 75:1 76:1 89:24 90:16 93:1, 19 110:1 115:1 132:1 136:1 213:1 217:21 220:11 245:10 306:17 309:10 311:1 developing 96:10 development 7:1 32:13 51:15 72:1 88:25 90:13, 19, 20 91:1, 1 99:12 163:22 203:14 309:20 341:22 developmental 3:12 51:17 249:13 developmentals 163**:**11 develops 344:1 deviation 115:20 278:24 deviations 211:18 227:1 254:11 **devised** 166:1 **dew** 95:1, 1 168:11, 13, 15 169:1, 13 **dfo** 163:17 diabetes 281:1, 1,

15, 17, 18 **diagonal** 106:20 174:25 **diagram** 218:16 diamonds 254:1 **diaphragm** 47:1 49:1 **dick** 12:20 dickcissel 111:1, 1 **dictated** 165:10 did...was 270:23 **did...you** 121:1 **die** 129:23 341:1 dies 102:1 103:1 105:1 **diet** 79:25 80:1, 1 110:23 144:10 169:10 188:25 272:12 dietary 8:1 9:1 59:1 62:20 69:19, 24 76:14 81:25 85:19 94:1, 23 95:1 98:11, 12, 12 99:1, 1 101:1 104:1 113:19, 24 114:1 117:13 121:16 123:1, 12, 13 124:12 143:12, 17 145:13 154:14 169:1, 1, 19 182:1 188:17 190:25 191:24 192:1 243:21 244:11 245:1, 1, 20 268:1 270:16 272:13, 21, 25 273:1, 1, 1, 18, 20, 25 274:15 275:20 277:1, 10 296:12 **dietary...or** 169:1 **dif...overlap** 203:1 **differ** 205:25 differed 114:23 **difference** 17:10, 13 33:15 46:15, 18 83:10 120:17 121:1 122:16, 25 123:1, 1 167:17 169:23 170:24 213:12 216:18, 19, 22, 23 252:1

262:20 267:1, 12 273:1, 19 275:19, 24 differences 12:25 32:1 34:1 104:20 109:16 114:17, 19 121:14 124:1, 10, 15, 17 142:11 156:1 238:16 246:18 247:1, 1, 12 258:11, 14 273:1 275:1 286:1, 1 287:12 different 9:10 14:1 15:12 16:24 20:20 29:23, 24 31:1, 11 34:16, 17 35:1 38:10, 14, 18 40:1 47:15 48:25 49:1, 1 51:1 77:12 79:16, 17 81:22 84:17 88:1 90:1 94:11, 25 97:22 106:1, 13 108:1 109:11 112:19 122:1, 12 124:1 128:1 131:14 136:15 138:1, 1 143:21 164:18 174:16 179:14, 15 193:16 194:17 195:1 202:14, 19 203:1 206:1, 1 211:1 212:10 232:14 234:13 238:13 250:21 253:22 254:25 261:1 264:18 267:1 270:17 271:1 279:1 283:22 306:13 330:1 333:25 348:24 differently 143:17, 18 284:25 **difficult** 13:15 33:21 34:1 49:21 50:1 80:17 169:1, 11 178:20 193:1, 19 274:12 338:1

difficulties 93:1



difficulty 164:21	d
diffusion 27:16	_
82:23	d
digest 344:24	d
diluted 238:23 239:1	
dilution 234:17	d
300:14	d
diminishing 78:1, 1 direct 144:1 258:1	d
263:20 264:12	d
344:17	Ŭ
directed 21:1 182:20	d
directions 297:10	d
directly 80:16 86:16	
88:11 138:1 253:14	
254:21 265:1	d
director 3:14, 23	d
4:1, 1	d
disadvantage 282:15	d
disagree 181:10	d
249:23 271:14	_
287:16	d
disappearance 126:1, 13 157:1	
disappointed 93:1	d
discrepancies 255:16	
discrepancy 151:23	
152:1 313:1, 1	
323:10	
discuss 8:25 55:12	
166:1 214:16	
166:1 214:16 235:19 273:17	
166:1 214:16 235:19 273:17 281:21	
166:1 214:16 235:19 273:17 281:21 discussed 9:18	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1	
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1	d
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15	đ
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21,	đ
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21,	-
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21, 23 228:23 245:1	d
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21, 23 228:23 245:1 247:1, 22 279:10	d
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21, 23 228:23 245:1 247:1, 22 279:10 discussions 2:10, 13	d
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21, 23 228:23 245:1 247:1, 22 279:10 discussions 2:10, 13 7:14 75:20	d d d d
166:1 214:16 235:19 273:17 281:21 discussed 9:18 59:1 65:1 69:10 192:24 234:10 248:1 275:1 329:13 discussing 272:20 discussion 36:1, 1 54:1 62:17 81:1 83:12 89:1 118:1 137:16 181:19 188:13 191:15 198:11 202:17, 21, 24 222:18, 21, 23 228:23 245:1 247:1, 22 279:10 discussions 2:10, 13	d

diseases 4:1 339:1, 11 **lisparaging** 256:1 dispersion 116:19 117:1 disposal 321:1 327:17 disposition 211:1 dissociate 258:19 distance 67:22 68:1 158:20 **listinct** 55:10 distinction 161:1 183:23 184:1 301:22 distinguish 109:24 distinguished 197:10 **listort** 258:1 distorts 81:1 distribute 187:1 188:12 190:10 distributed 76:17 188:1, 1, 1 distribution 40:12, 15, 16 81:14 95:17 96:24 97:1, 21, 23 98:1 102:15 107:1 110:1 111:17, 19 112:1, 1, 12 113:1 114:1 115:1 116:17, 24 117:1, 1 120:15, 22 159:24 166:22 173:10 174:10 187:10 188:12, 16, 17 189:1, 16, 19 193:1 194:1, 1, 1, 11 217:15 311:1 329:19 distributions 40:18 108:1, 12 113:15, 16, 21 114:14 distrustful 36:25 **listurb** 184:17 disturbance 80:22 **litch** 307:22 ditches 308:1 311:1 **livide** 205:22

246:1 304:15 divided 185:1 217:10 252:15 301:1 305:1 319:21 **dividers** 176:17 **dividing** 135:1 **divisions** 349:15 **docked** 343:23 **docket** 146:22 doctor 299:1 303:16 document 17:17, 19 40:25 115:1 235:25 250:23 264:20 274:23 316:17 document...we 116:1 documentation 231:1 documented 321:1 documents 71:13 75:19 91:21 115:14 249:1 329:1 doesn't...it 230:18 dnrs 31:17 32:12 **dog** 331:1 dogs 126:1, 1 doing...directly 286:10 domestic 340:13, 15 don 4:23 71:21, 24 227:13 240:10, 20 242:1 331:22 347:1 348:1 don't...i 227:1 293:24 don't...they 126:1 donald 227:16 308:17 **done** 9:20 18:16 19:14 21:1 26:1 47:1, 13 55:21 68:10 78:21 98:1 110:14 113:1 119:16 121:10, 15 145:11 148:1, 16, 20 156:11 168:14 206:14 208:20 209:1 210:1 212:1 215:24 217:25 229:23 234:18 238:1 241:13 244:20 249:1 251:13 254:1, 19 256:18



262:10 273:22 278:24 279:24 280:10, 14 313:22 316:20, 23 317:15 318:1 322:1 done...we 229:23 **door** 349:21 doors 294:15 dose 9:1 15:1 16:1 22:1 24:17 29:16, 18 30:17, 18 39:24 40:1 42:1 43:19 44:1, 1, 1 51:1 77:12, 13 83:1 84:13 85:11 87:1, 1, 25 101:1, 1, 14, 16, 17, 18, 19, 23 102:1, 11, 22 103:1, 1 104:17 118:23 119:1, 1, 1, 10, 25 120:1, 20 121:1, 15 144:16 145:19, 20, 25 168:24 169:1, 18 171:10 178:11, 16, 19 179:1 180:15, 21 191:1, 1, 1 192:17 193:1 210:10, 11 211:1 215:10, 12 216:1 229:19, 20, 23, 25 230:1 245:24 246:1, 25 247:1 251:1 254:1, 1, 18 255:1, 13, 24 256:1, 1, 1, 1, 1 257:10 258:11, 12, 18 259:1 260:15, 16, 18, 19 261:18, 20, 21 262:1, 15 266:1, 1, 10, 13, 13, 15 267:22 269:1, 12, 15, 18 270:20 284:21, 22, 23 285:1, 10, 19, 20 286:13, 14 287:1 288:17 289:1, 1, 11 dose...to 179:13

dosed 84:1 86:21 180:10 182:1, 1 209:13, 16 doses 13:1 30:1, 1, 11 81:22 83:24 84:1, 1 101:12 119:1 235:11 254:14 255:23 259:1, 21 260:12 286:11 289:1, 1, 1 doses....that 289:1 doses...in 257:10 dosimeter 223:16, 17, 20 dosimeters 223:1, 1 224:1, 23 dosing 54:16 83:15 86:23 237:1 dots 17:1 29:1 111:1 **double** 104:25 doubt 158:1 195:19 **dove** 149:10 dr 2:1, 10, 12, 15 3:1, 1, 1, 13, 17, 22 4:1, 1, 11, 14, 18, 21, 23 5:1, 1, 1, 13, 16, 19, 22 6:1, 1, 1 7:10, 12, 12 11:1, 1, 1, 10, 19 12:1, 10, 12, 13, 15, 17, 19, 20, 23, 24 13:22, 25 15:14, 24 16:1, 1, 1, 1, 1, 10, 11, 14, 18 17:16, 16, 19, 21, 22, 24, 25 18:1, 1, 1 19:17, 23 20:1, 1, 1, 18, 21, 22, 25 21:11, 14, 16, 17, 18, 22 22:1, 10, 12, 13, 14, 15, 19, 20 23:1, 1, 1, 11, 12, 13, 19, 24 24:12, 19, 21, 24, 25 25:1, 1, 12, 20, 22, 23, 25 26:10, 13, 19, 23, 23, 24 27:1, 24

28:1, 1, 1, 11, 17, 17, 17, 19, 23, 25 29:1, 1, 1, 10, 11, 13, 19, 20, 22, 25 30:1, 1, 22 31:1, 1, 15 32:1, 1, 14 33:10, 24 34:1, 1, 1, 13, 13, 14 35:19, 19, 20, 21 36:11, 14, 17, 20, 23 37:1, 16, 16, 19, 23, 25 38:1, 1, 1, 15, 15, 17, 19 39:1, 1, 10, 10, 11, 13, 21 40:21, 21, 22 41:1, 1, 1, 11, 13, 14, 20 42:1, 1, 10, 12, 14, 16, 16, 17, 19, 20, 22, 25 43:1, 1, 10, 13, 15 44:1 45:1, 1, 15, 16, 16, 19, 19, 24, 24, 25 46:1, 17, 19, 20, 21, 23, 23, 24 48:1 50:24 51:1, 21, 22, 24 52:1, 1, 1, 1, 17, 21, 21, 22 53:1, 16, 16, 17, 21, 23, 25, 25 55:1, 1, 1, 17 56:1, 19 57:1, 1, 11, 13, 13 58:19 69:1, 1, 1, 1, 1, 12, 15, 21, 23 70:1, 1, 24, 24, 25 71:1, 1, 1, 1, 1, 1, 1, 12, 13, 18, 19, 21, 22, 23, 24 72:1, 1, 1, 21 73:11, 11, 14, 15, 17, 20 74:1 75:1 76:19 85:19 88:12, 14, 14, 15, 16 96:1 99:13 118:15 152:1, 1, 1 155:20, 20, 21 156:1, 1, 1, 16, 21, 23, 24



157:1, 11, 11, 11,	194:13, 21	1, 1, 1, 10, 13,
18 158:1, 13,	195:1, 19, 24,	21 279:1, 14,
13, 14, 18, 20, 21	25 196:1, 11,	21, 21, 21, 23
159:1, 1, 1, 1,	12, 16, 16 197:1	280:1, 1, 19,
10, 12 160:1, 1,	201:1, 11, 14,	19, 21 282:1, 1,
18, 18, 19, 24	17 202:1, 1	13, 14 283:16, 16,
161:1, 1, 1, 22,	203:10, 21, 22,	16, 17, 18, 18,
24, 24 162:22	22, 24 204:1	23, 24 284:10, 12,
163:1, 17 164:1,	205:1, 13 207:1	16, 18, 18, 19
1, 1, 1, 1, 1	213:21, 22, 23	285:1, 12, 14, 15,
165:1, 1, 12,	214:1, 1, 1, 1,	16 286:1, 19,
12, 15, 16, 21, 22	1 226:10, 10,	19, 19, 21
166:1, 19, 21	11, 12, 14, 15,	287:16 288:1, 1,
167:1, 1, 1, 1, 1,	22, 23, 23, 23, 25	1, 1, 1, 1, 1,
12, 18, 21, 22, 24	227:1, 1, 1, 1,	1, 1, 1, 15, 15
168:1, 1, 1, 17,	13, 14, 15, 16, 16	289:13, 13, 14,
22 169:20 170:1,	228:1, 1, 1, 1, 21	14, 21, 25
25 171:1, 1, 1, 1,	229:11, 11, 13,	290:1, 1, 1, 1,
1, 1, 11, 13,	14, 14, 15, 16,	11, 13, 14, 16, 22
16, 20, 23	17, 22 230:1, 1,	291:1, 11, 12, 15,
172:1, 19, 20, 20,	1, 1, 1, 11, 12,	17, 18, 20, 22,
21, 23 173:1, 21	13, 15, 17, 20,	24, 25, 25
174:1, 1, 1, 22	20, 20, 22	292:1, 1, 1, 1,
175:16, 18, 20,	231:16 232:23	15, 15, 16
22, 23 176:1, 1,	233:17, 18, 19,	293:1, 10, 12, 12,
1, 1, 1, 10, 11,	24, 25 234:1, 1,	13, 13, 18, 24
15, 16 177:1, 1,	1, 15, 22, 23	294:1, 20 295:1
1, 1, 1, 19 178:1,	235:1, 1, 1, 1, 1, 1,	298:23 299:1
1, 1, 1, 1, 1,	13, 19 236:1, 1,	312:13, 16 328:21,
1, 1 180:1, 1, 1	1, 1, 22 237:16,	21, 23 331:19, 19,
181:1, 12, 12, 14,	22 238:1, 1, 10,	19, 20, 21, 22
15, 21, 23, 24,	15, 25 239:1, 1,	332:1, 10, 16, 17,
25, 25 182:1, 1,	1, 1, 11, 12,	22, 22 335:1, 1,
1, 12, 14, 18, 19,	12, 13, 16, 17,	1, 1 340:19, 21,
21, 23 183:21	22, 23, 25	23 341:1, 1, 10,
184:1, 1, 1, 1, 12	240:1, 10, 12, 14,	17, 25 342:1
185:1, 1, 1, 10,	14, 15, 20	345:19, 20, 21
17, 18, 19, 21, 24	241:1, 10, 13, 17,	346:17, 25
186:1, 1, 1, 1, 1,	19, 20, 20, 22,	347:1, 1, 1, 1, 12
11, 12, 15, 16,	23, 24, 25, 25	348:1, 1, 1, 19,
18, 19, 22, 23		
	242:1, 1, 1, 1, 1, 1,	
187:1, 1, 11,		12, 14, 18, 22
13, 16, 17, 19,		drdr 69:19
20, 22, 23, 25	19, 22, 24	drwhat 218:17
188:1, 1, 1, 10,	244:1, 1, 1, 10,	draft 32:20 78:20
11, 15, 16, 18,	22, 25 249:19	
		drainage 300:1 301:1
	251:10, 14, 14,	302:18 305:1
11, 12 190:1, 1,	15, 18, 24	dramatic 122:14
1, 1, 17, 20,	262:25 263:1	124:16 142:10,
22, 24 191:1, 1,	272:14, 15, 15,	
1, 1, 14, 18	16, 17, 17, 18, 18	15 233:13
		dramatically
192:11, 20, 21, 23	273:12 274:1, 1	116:25 131:14
193:1, 1, 21	276:23 278:1, 1,	
	0	



142:25 drastic 273:1 275:19 317:12, 13, 21, 25 318:20 323:20, 21, 24 324:1 325:1 331:24, 25 draw 96:24 113:1 189:18 190:1 193:1 196:13 261:1, 10 349:1 **drawing** 40:11 drawn 103:1 draws 40:16, 18 193:1 **dreap** 127:23 128:1, 20 dried 290:19 291:16 dries 291:1 drinking 7:17 18:1 19:11 67:15 95:1, 1 168:10, 15 169:1, 1, 13 245:13 276:16, 17, 22 277:1, 1, 15, 16 294:23 295:10, 21 296:1, 13 297:1 298:11 305:1 308:1 309:1 312:11 313:12 320:1 326:20 328:20 driven 18:1 347:18 **driver** 69:15 204:1 205:1, 13 213:21 214:1, 1, 1 226:11, 12, 15, 23 227:1, 1 230:1, 1, 1, 12, 15 243:17 **drivers** 221:25 **driving** 220:23 340:14 **drop** 170:13 246:22 346:1 dropped 247:1 **drops** 129:22 130:1 170:11 **drum** 218:1, 17 drums 240:12, 16 dry 218:18 219:1 291:1 293:21 **duck** 176:12 ducks 172:11 187:1

due 59:20 115:11 128:1 147:17, 23 148:1 149:1 150:1, 21 151:1 216:19 297:1 314:15 326:20 due...due 150:1 duplication 202:11 **duration** 184:24 during 31:12 55:13 57:1 97:12 105:11, 19 106:1 116:1 128:23 131:24 138:1 149:12 157:1 160:23 162:18 185:1 197:20 309:19 during...at 162:18 dwayne 69:1, 1 73:15 74:1 88:18 156:1 158:1 160:1 331:1 **dwloc** 277:15 Ε each...for 221:1 **earlier** 41:12 54:1 76:1 124:1 150:15 174:24 207:1 214:20 243:14 250:1 253:17 274:20 305:25 315:16 319:19 327:1 330:24 333:23 334:25, 25 **earlier...was** 75:16 **earliest** 317:16 **early** 59:15, 19 66:11 99:11 105:21 106:1 107:1, 25 160:23 312:25 323:11 341:21 **easer** 37:1 **easier** 170:1 **easiest** 260:23 **east** 316:1 319:24 321:1 323:10, 21 324:1, 10, 16, 19 east/central 342:10 eastern 319:1 323:1, 13 338:18 339:1 340:1 346:13

easy 93:12 193:12 **eat** 82:1 343:1 ec...economic 61:13 echo 57:21 58:1 ed 101:10 120:1 **ed...oh** 286:19 ecological 4:22 8:1, 20 9:17, 21 76:23 92:1 132:14 ecologically 132:17 ecologist 4:16 **ecology** 4:16 economic 61:11 62:1, 1, 13 economically 68:13 ecosystem 329:1 **ecotox** 329:1 edge 109:19 127:1 147:24 148:10, 19 159:1 164:14, 19, 20 165:1, 1, 1 320:1 **edler** 5:22, 22 177:1, 1 228:1 229:15, 16, 16 278:1, 10, 10 279:1 288:1, 1 education 64:15 341:11 edwards 7:10 **efed** 18:1 141:1 **effect** 30:18 34:22, 23 35:1 76:14 81:16 83:1 86:17, 21 87:23 99:1 118:25 133:1, 1, 11, 15, 21, 22 134:1, 1, 1, 23, 24 168:19, 19 178:17, 18 205:22 207:21, 25 209:1 210:1 228:14 229:1, 10 231:21 232:1 233:21 235:1, 1, 24 236:20 237:20 249:10, 15, 16 264:1 266:11 269:1 271:18 279:1 282:24 283:1 287:1 329:1 330:1 effected 321:1



effective 199:24, 24 200:17 338:13 effectively 113:1 effects 10:12 48:20, 21 68:1, 14 69:1, 1 70:15 74:14 75:1 77:1 78:1 83:20, 21 84:1 85:1 89:19 95:16 102:1 103:1, 10 121:10 132:16, 25 135:10 167:10 168:18 281:23 282:1, 12 331:1 349:15 efficiencies 126:13 156:23 efficiency 94:25 126:1 156:1, 10 157:1 effort 63:18 345:18 efforts 163:14 202:12 eggs 84:19 149:14 338:23 341:1 eight 26:11, 16 32:1 41:17, 18, 24 42:23 **eighty** 332:1 **either** 40:1 48:17 50:1 82:15 92:17 163:1 164:13, 15 183:16 187:1 222:1, 11 238:22 249:1 256:14, 25 277:1 283:1 312:22 317:1 325:14 326:1 334:1 340:25 348:15 electronic 235:22 elementary 214:21 elements 59:22 60:1 267:18 273:16 **elevator** 343:23 **eleven** 49:18 elicited 55:1 eligibility 62:18 eligible 326:1 eliminate 317:1 337:1 eliminated 44:1

258:14 elimination 88:1 98:21 143:1 eliminations 297:10 **elissa** 12:1 **elman** 279:13, 24 **elman's** 234:1 elmans 20:14, 19 emergent 297:17 **else** 41:1 45:23 49:11 122:19 203:16 211:1 254:19, 23 270:1 321:16 345:1 **enclose** 217:22 **enclosed** 220:1, 1 221:25 encompasses 307:1 encountered 198:15 encouragement 90:12 encouraging 90:25 93:22 **elwood** 4:11 **emory** 5:14 **end-up** 30:10 end...and 111:11 endangered 132:19 **endings** 265:18 endocrinologist 3:11 endorsement 90:1, 11 endpoint 180:1 181:1 225:13 232:11, 19 247:14 248:16 252:1 253:25 263:1, 19 264:1 265:21 266:15 271:16, 18 272:1, 1, 1 endpoint...this 181:1 endpoints 69:15 206:17 265:22 266:19 282:25 endurance 214:1 333:1 **energy** 94:24 138:1 emphasize 256:19 emphasizing 255:21 employed 227:12 **engel** 70:1 294:25 295:1 298:23

299:1, 1 332:19 engineering 6:1 214:23 216:11 217:1 219:24 220:1 **enhance** 212:19 **enormous** 341:13 enrolled 198:1 **enter** 55:18 149:1 257:16 300:11 entered 96:25 151:13 163:1 entered...put 240:1 enters 77:16 83:1 **entire** 112:22 137:14 141:1 292:19, 21 325:1 333:1 **entirely** 97:1, 1 271:13 entitled 35:22 entomology 198:1 **epa** 6:17 11:17 20:1 31:1 34:15 35:22 43:19 46:13 54:14, 20, 25 63:11 64:22 66:1, 1, 13 73:21 74:15 76:11 89:24 90:1 91:23 92:22 93:13, 14 102:22 103:1, 17 107:16 114:23, 24 115:15 116:12 120:1 121:1 122:25 124:10 125:23, 23 128:19 132:1 133:1 136:1 141:17 143:1 148:1, 15, 21 149:1 151:11 152:1, 1 153:20 154:12 155:12 157:24 166:1 168:14 169:15 173:1, 1, 22 191:19, 22 202:13 204:20 205:17, 17, 24 206:1, 23 207:18, 19 208:1, 13 209:1 211:21 212:1, 25 216:1 217:21



Page 385

220:14 221:1 224:15, 24, 24 226:1 228:14, 23 229:1 230:24 232:11, 14 233:1 234:10 236:13, 23, 24 243:13 244:20 245:1, 25 246:12, 23 247:10, 14, 15 248:16 249:12 250:14, 22 251:20, 21 252:24 253:17 254:1, 25 255:10, 18 257:14 260:1, 1 268:21 269:1 270:1, 18, 23 271:22 273:1, 20, 24 274:23 275:1, 1 276:13, 19 278:1 279:20 280:23 282:10 283:1, 1, 20, 24 285:18 287:1, 11, 15, 17 292:12 295:13 296:10 298:13 300:1 301:18 302:1, 23 303:11, 17, 24 304:1 307:1, 17 309:1 310:15 313:10 316:15 320:1 325:1 329:1, 12 330:10 348:17 **epa's** 54:1 57:21 58:1 88:1 153:17 204:16 205:1, 13 211:18 214:15 215:1 218:1 220:1 231:1 248:1 252:1 255:15, 18, 23 262:12 264:1, 25 271:13 273:1 274:14, 17 275:20, 23 295:10 296:1, 11 314:23 317:11 320:23 329:1 **epa's...epa** 279:17 epa...that's 232:14 environment 19:25

58:1 70:15 74:14 80:17 179:24 306:11 307:19 environmental 2:1 3:18 4:1 5:1 18:1 88:19 156:1 296:19 306:1 environments 19:1 307:1 **envision** 233:1 **enzyme** 34:24 47:11 78:1 86:1, 1 87:13 179:12, 17, 19 180:14, 17, 24 231:1 233:1, 12 epidemiological 283:14 ergonomic 49:1 equal 135:1 195:14 207:1 260:21 311:22 324:24 326:14 327:1 **equally** 264:1 **equate** 110:23 equates 311:21 equations 95:1, 11, 13 99:22, 23 309:10, 18 equipment 227:19, 20 equivalence 262:1 307:1 equivalent 84:15 262:1 288:21, 22 311:22 **erroneous** 250:10 **error** 32:1 95:12 118:17 124:14 145:1, 10 188:1 193:10 207:14 229:1 errors 29:21 31:21 93:14 154:20 211:18 **et** 85:1 257:15 **et.al** 89:13 114:14, 15 125:1, 1 171:1 **etcetera** 27:1 39:1 esophagus 144:17 especially 21:1 34:10 178:24

194:24 265:24 270:1 300:22 312:23 **ethical** 268:19 **essen** 239:22 **essence** 339:1 essentially 17:1 28:1 61:1 65:1, 12 67:19 84:1 95:22 98:1 106:25 110:10 125:11 168:23 186:1 215:1 282:12 316:1, 1 333:25 334:17 establish 235:1 established 56:19 estimate 10:1 101:1 105:1 127:24 128:25 141:1 144:1 166:17 178:15 179:1, 12, 13, 19, 25 188:1 216:1 222:1 224:1 292:24 298:22 310:22 320:23 estimated 67:15 111:17 127:21 245:1 277:16 295:21, 23 296:1 298:11 312:11 313:11 329:24 330:1, 10 344:12 estimates 35:23 40:1, 1, 12 53:1 103:19 108:16 141:1 156:1, 1, 17, 20 159:17 215:13 216:1, 25 303:25 estimating 108:20 156:18 estimation 31:10 102:12 eval...dietary 272:25 evaluate 55:1 92:1 94:1 208:22 evaluated 47:25 54:16 89:1 93:1 204:12 206:17 210:1 evaluating 47:20



54:21 264:22
evaluation 8:10
94:14 99:15 124:19
142:23 208:1
247:24 269:18
273:1
evaluations 209:1
evaporates 291:15
evening 12:1 39:1
106:22 294:1 306:1
335:17
event 131:19
134:19 138:19
139:1 142:14 208:1 310:22
events 310:20
311:1 336:20
eventually 218:15
everybody 45:21 56:1
161:21 162:22
177:1 204:14
349:1, 23
everybodythan
211:20
everyday 347:17
everyone 2:15 47:1
everyone's 262:1
-
everything 33:13 122:19 172:16
everything 33:13 122:19 172:16
everything 33:13
everything 33:13 122:19 172:16 174:24 203:16
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10</pre>
everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14 194:1 209:18</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14 194:1 209:18 247:13 322:21</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14 194:1 209:18 247:13 322:21 examine 167:1 301:1</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14 194:1 209:18 247:13 322:21 examine 167:1 301:1 examined 305:16</pre>
<pre>everything 33:13 122:19 172:16 174:24 203:16 300:18 342:20 344:24 345:17 everything's 56:1 evidence 18:1 27:14 75:11 76:1 82:19 89:1 146:1 268:11, 12, 16 281:1 312:10 evident 53:1 exact 42:11 93:1 95:1 141:17 187:12 195:17 202:14 275:1, 1 exactly 34:18 42:19 44:18 120:1 132:1 168:14 194:1 209:18 247:13 322:21 examine 167:1 301:1</pre>

105:1 107:24 109:1, 1, 13 111:23, 24 112:25 114:1 116:10 117:1, 1 118:1 120:13 123:1 126:1 139:10 140:13 141:11 145:1, 1, 16 146:11 171:24 175:1, 1, 1 192:1, 1 201:17 206:1 208:15, 16 219:25 220:23 223:1, 21, 23 232:1, 12 245:13 260:25 261:1 286:12 288:10 310:1 318:1 320:1 example...and 266:24 **examples** 16:1 206:18 218:1 224:15 **exams** 295:15 299:11 301:17 exceeded 130:1 305:1 311:22 326:14 exceedence 134:16 exceeding 133:1 307:14 exceeds 330:10 **excel** 93:1, 1 **excellent** 200:10 222:21 **except** 137:1 322:17 323:17 326:1 exception 75:15 196:25 227:23 exceptions 275:1 **excerpt** 258:24 **excess** 330:24 **excluded** 268:18 **excludes** 331:13 excluding 155:1 exclusively 231:18 **excrete** 199:13 excretion 211:1 excretions 43:22 excruciating 89:17 **excuse** 17:1 157:1 **exercise** 112:18

118:19 169:10 193:19 **exertion** 220:25 **exhibit** 106:1, 10 **exist** 9:1, 1, 1 10:19 206:16 224:12, 13 238:1 existing 66:22 222:17 223:1, 22 eyesight...but... it's 308:24 **expand** 34:15 160:1 expanded 94:1 **expect** 56:22 82:1 87:1 90:18 98:11 106:19 110:1 114:16, 19 115:24 116:15, 20 122:23 124:1, 1 127:1 136:1 140:1 157:14 194:17 233:1 238:21 305:1 326:19 expectation 291:1 **expected** 122:1, 1 194:1 298:20 302:1 326:14, 16, 21 expecting 131:1 **experience** 7:1 52:11 70:12 74:1 76:11 142:1, 10 158:1 198:17 201:1, 1 284:1 286:22 299:1 304:22 experienced 6:25 301:23 302:1 304:14 experiencing 142:18, 20 experiment 118:24 241:13 259:21 experiment...at 254:13 experimental 5:24 79:20 125:1 254:14, 18, 22, 23 255:1, 1, 17, 22, 23 256:21 286:11, 13 288:12 315:17 329:1



experiments 241:12	170:1, 15, 18,	146:23 270:1 299:1
expert 2:24 153:15	21 171:15 175:14	316:25
156:25 163:1	178:1 183:1, 11	extensively 93:1
expertise 3:1, 20,	190:18, 21, 22	137:23
24 4:1, 25 5:1, 11	191:11, 12, 13	extent 71:15
experts 59:11	204:1, 1, 14,	125:25 148:23
	15, 19 205:14, 15,	164:19
60:14 62:19 63:1	21, 22, 23	
64:1 67:1 68:1	206:1, 1, 13	external 216:1
70:1 73:1 158:1		extra 167:25
explain 25:1 43:11	207:1, 1 208:21	extracted 18:23
77:1 124:16	209:1, 11 210:1,	extrapolate 224:1
152:1 173:19	19 212:17 213:21	311:1
204:25 216:25	214:1, 13, 17, 17,	extrapolating 48:1
235:12 302:12	21, 24, 25	51:1
313:1 323:1	215:1, 13, 15	
explained 25:1	216:1, 1, 24	extrapolation 9:1,
1 =	217:1, 1, 1, 1,	12 39:15 119:18
54:1 120:1 152:21	10, 17, 18	120:11 257:1, 1
explaining 124:1	218:1, 22 220:1,	286:16 310:24
explains 152:23		extrapolations
explanation 32:10	10, 14, 16, 19	286:14
39:12 174:21 177:1	221:1, 16, 20,	extreme 62:1 112:1
explanatory 143:16	21 222:1 223:12	122:1 174:1 175:1,
	225:22 226:1, 20	1 310:20, 22
exploration 7:1	237:19 240:1	
163:11, 22	242:17 244:11	extremely 80:17
203:13 299:25	245:1, 1 272:13,	157:19 306:22
explore 106:13	21, 24 273:1, 15	
exploring 118:20	274:22 282:17	F
exponential 256:12	295:11, 23 301:1	faces 173:24
257:1, 1 283:19,	309:1 310:19 311:1	<pre>facilitate 238:20</pre>
20 284:1 288:18	312:1, 1 330:13	facilities 294:16
exposed 77:1	331:1	facing 274:11
171:10 251:18		-
	exposurethethe	fact 7:1, 1 11:12,
281:1, 1	274:21	17 21:19 24:13, 16
exposure 5:14 9:1	exposures 80:10 82:1	28:1 32:16 41:21
21:1, 10, 12,	116:1 192:1	44:21 49:16, 20
13, 14 25:21,	204:13, 23, 24	77:11 82:13
22, 24 26:1, 1,	216:10 221:10,	83:14 92:11, 16
15, 16 42:21, 23	24 222:1 225:23	104:23 110:21
43:20 46:1 48:1	233:15 329:12	128:1 138:22 161:1
64:1, 11, 11	334:1	207:14 212:1
69:16, 24 70:1	expressed 85:11	222:16 223:1
79:25 82:10	129:13 184:21	243:13 248:14
84:21 87:1 88:25	185:1 217:11, 17	249:24 252:24
89:18 100:1		253:1, 23 258:1
	221:20 248:16	
101:21, 22 102:1	271:1 310:15	261:1 263:1 266:1,
103:1, 1, 19, 21	exquisite 89:11, 16	19 267:25 268:1,
105:1, 1 113:14	extend 100:11	25 269:1 270:1
119:21 121:17, 21,	extended 134:1	275:25 303:22
22, 24 122:1, 1	extensive 6:19	321:18 324:1, 23
123:1 141:10 144:1	64:14, 15, 18 74:1	factand 232:1
156:1 167:13 168:1	94:13 121:20	factor 5:15 16:21
169:1, 1, 16	J4.13 121.20	61:24 80:12
169:1, 1, 16	0	61:24 80:12



85:19 94:1 121:13 123:1, 13, 21 165:18 166:1, 13 205:1, 11 215:1 216:1 246:1, 1, 1 247:1, 10, 16 248:1, 1, 10 249:21, 22, 23 250:1, 1, 16 251:1 262:23 269:1 270:14, 21, 22 271:1, 1, 1, 15, 19 272:1, 10 273:13 274:1, 10 276:24 277:1, 1, 1 334:1, 1, 1 factors 24:1 54:21 69:21 78:13 83:1 191:12 246:1, 19, 21 247:1, 18 248:1, 1 267:10 268:1 271:20 278:15 313:18 314:1, 1 317:24 323:1 factors...is 276:10 **failing** 145:15 296:17 failure 200:18, 19 272:1 **fair** 32:1 212:1 237:15, 22 fairly 79:1 97:19, 24 107:22, 25 118:15 138:18 195:13 301:13 330:23 336:1 337:13 338:1 339:11 340:1 341:1 **fall** 303:1 345:12 falls 303:1 343:19 **false** 137:10 **f.m.s** 333:16 familiar 26:20 86:1 290:25 296:1 317:20 320:25 331:24 family 197:16 348:22 **famous** 154:19 **fan** 336:17 fantastically 344:1 **f.q.p.a** 333:16

fared 149:14 farm 197:19 308:1 318:16 328:1, 1 342:1 343:13 344:19 347:1 farmer 150:23 197:1, 11 328:1 **farmers** 125:11 153:15 341:12 farming 197:16 198:1 farther 324:13 325:1 **f.t.p.a** 333:20, 25 fasciculations 49:1 fashion 301:1, 16 305:12 fast 103:20 209:15 faster 18:12 143:10 **fate** 95:23 **fats** 336:14 **favor** 175:1 335:18 favored 174:1, 1, 25 175:1 fawcett 70:1 294:20, 21 312:13, 16 331:20 332:1 fda...fmc 245:1 **fearful** 250:25 **feasible** 184:15 february 2:1 **fed** 85:10 184:25 federal 2:1 55:1, 10 56:17 149:1 161:21 163:1, 1 201:20 202:1, 1, 11, 15 203:1 federal...by 201:20 federally 65:1 **feed** 75:17 78:23 81:23 82:1 83:11 106:1 119:22 138:1, 1, 1, 17 160:1, 16 171:25 175:24, 25 176:1, 1, 1 178:1 182:1, 11 feedback 8:21 9:1 feeder 81:1, 18, 20 172:25 174:15, 16 **feeders** 80:19 81:1, 13 174:12,

13 175:12 feeding 68:17 72:15 76:17 77:13, 21 79:1 81:1 82:1 100:25 101:1 105:20 106:1, 1, 10, 20, 25 107:1, 24 108:1, 13, 15 120:12 122:16, 17, 20, 21, 21 137:1 138:10 140:17 143:22 144:16, 18 153:1 159:14, 15, 17, 18, 24 161:1 173:1 183:10, 12 187:1 feeding...this 106:1 **feeds** 104:1 **feel** 43:1 66:15 70:11 136:24 181:18 183:1, 1, 10 201:1 258:23 294:1 312:1 334:22, 23 335:1 **feeling** 183:12 feet 148:18 315:1 326:10 327:15, 15, 18, 25 328:1 **felt** 166:12 172:17 174:18 269:1 female 176:18, 22 females 176:19 199:1 209:18 **fence** 160:21 164:21 165:1 fermintinite 15:1, 20, 22 fertilized 199:1 fertilizer 346:21 **fetuses** 280:24 281:25 few...it's 178:15 fewer 84:1 313:16 fidelity 128:1 field 9:19 10:1, 16 65:20 74:1 76:22 77:1 81:1 82:1 92:20 96:1, 23 97:1, 1, 1, 1, 11, 13, 16, 18, 19 98:1, 1, 1



99:10, 18 100:1,	113:11, 13, 24	207:
18 103 : 12, 23	114:20 115:19,	finds
104:1, 1 108:1, 11	24 117:16 122:1	fine
109:1, 1, 1, 1, 1,	125:1, 12, 16,	254:
10, 14, 14, 18,	21 126:1 127:1,	finel
18, 21, 22, 25	10, 25 129:1	finge
110:1, 1, 1, 1, 1,	131:18 135:25	finis
12, 21, 24 111:13,	136:1 137:23	294:
25 112:1, 1, 13,	138:1, 12, 19	finis
15, 16, 17, 21,	139:1, 1, 23 141:1	fir 8
22, 24 113:1, 1,	144:10 145:14,	firm
1, 1, 1, 10, 10,	14 147:1 149:1, 18	first
18, 20, 21, 23	153:1, 1, 1 156:10	18:1
114:1, 1, 15, 16	177:16 185:14	21:1
115:11 116:1, 20	189:15, 15 320:1	32 : 2
117:1, 11, 12, 18, 21, 25 124:12, 20,	347:14	46:1
21, 25 125:14,	fieldsand 122:1	69 : 1
24 127:21 128:1,	fifra 2:1, 17, 19,	77 : 1
13 129:1, 1, 16,	22 56:10, 12 58:15	93 : 1
17 130:18, 21	70:20	114:
131:1, 1, 12,	fifteen 8:1 18:11	128:
22, 24 135:23	25:17, 18 26:1	167:
143:1, 18 144:18	27:1 f: f+ 13.11	183:
145:14 147:1, 24	fifty 13:11	200:
148:19 149:1,	figure 53:1 107:15 119:11 120:19	205:
11, 17 150:24	170:1, 1 177:12,	223:
151:1 153:1, 11,	22 191:1, 20	232:
12, 15 155:1	193:1, 1 199:1	245:
156:1, 12 158:25	200:1, 13 258:22	259:
159:1, 1 164:1,	278:20 285:10	266: 270:
12, 14, 24	figured 133:1	292:
170:22 183:1 184:1	figures 151:21	300:
185:14, 22 186:1	177:14, 16 200:1	312:
187:1, 1, 18	240:23 298:1	316:
188:14 189:1, 1,	317:19	335:
1, 1, 13, 13,	file 208:24 290:1	first
18, 21, 24	files 75:23 290:1	fish
190:1, 1 191:1, 21	filestheir 235:22	329:
192:1, 1 204:13 336:1 337:16, 17	fill 75:1 145:1	fishe
fieldfield 112:10	273:25	fit 73
	filtered 311:1, 1	120:
fieldhorned 122:1	final 68:1 69:25	218:
fieldthat 111:11	92:1 153:1	256:
fieldthis 138:18	155:11 222:1	257:
fields 95:24 96:1	264:19 332:13, 21	283:
97:22, 24 98:13,	finally 95:21	284:
13 103:13 106:1	99:10 220:18 226:1	311:
108:19, 19, 23 109:1, 17 110:1,	299:20 334:24	fits 2
10 111:1, 1, 10,	finallyand 77:25	fitte
12, 15, 19, 21	finding 178:13	25 2
112:19, 20, 21, 23	findings 196:23	five
<u> </u>	0	

:20 270:1 **102:1** 31:1 50:1 :12 **y** 241:1, 1 ertips 14:1 **sh** 89:1 196:15 :1 332:17 **shing** 69:23 0:1 61:14 : 6:11 14:1 17:1 1 20:17, 18 1 22:1 25:19 20 34:16 39:1 10 48:1 63:15 1 73:13, 16 1 78:15 90:16 1 96:13 99:25 :10 117:16 :22 149:12 :1 169:22 :22 198:17 :1 204:1 :1 206:21 :23 228:21 :11 240:21 :14 252:21 :12 263:1 :13, 21 :18 271:12 :1 295:1 :1 306:14 :16, 20 :1, 13 319:25 :18 349:1 **:...i'm** 63:14 4:1, 1 147:13 :20, 20, 25 er 114:24 3:1 111:16 :22 192:25 :1 222:10 :12, 13, 15 :1 277:13 :18, 20, 21, 25 :10 285:12 :1 333:21 334:1 26:1 192:22, 23 **d** 39:14 256:20, 257:1, 1, 1, 1 15:19 16:21



45:1 57:1 61:1	florida 73:1, 1	82:1, 1, 20, 20
63:15 65:1, 19	304:1 319:1, 15	83:1, 14, 17
68:11, 18 90:21	327:10 332:1	84:1 85:1, 1, 15
135:16 144:23	flour 197:23	95:1, 11, 15
149:24 218:1	flowable 60:19 90:14	
254:14 284:1 332:1		19 104:1 118:25,
five-fold 229:25	115:1 153:19, 25	25 119:1, 1, 11,
	241:1 331:14	14 120:1 124:13
fixed 27:16 164:15	flowers 343:1, 13	
166:20 187:20	344:12 345:1	145:1 159:20
188:1 221:23	flowing 299:1, 21	160:17 165:19
287:23, 25	306:1, 12 311:10	167:1, 10 168:1,
fixes 337:23	332:11	20, 23 169:23,
fledge 149:15	flubber 160:22	24 171:1, 13, 25
fletcher 114:14	fluids 85:1	172:14, 25 175:13,
flew 300:16	fly 162:1, 1	13, 14, 17, 18
flexible 28:13	-	183:13 184:13,
flight 162:1, 1, 12	flying 106:1 138:1	20 185:13, 16,
	flyways 138:20 139:1	22 186:1 188:1
flip 189:1	focal 94:1, 18, 22	191:10 196:1
fmc 20:14, 18, 23	100:22 102:1,	245:1, 10, 12,
28:15 31:1, 16	13, 21 103:1	12 247:1 273:1
32:1 35:22 46:10	113:17 129:1, 1	274:1 276:11, 14
56:22 57:1 58:1	130:17 135:23	334:1 336:12 337:1
60:13 61:1 62:19	136:13 141:1	food-use 9:1
63:12, 17 64:14	144:15 166:17	foodthe 82:1, 20
65:1 69:1 70:1	focus 58:23 60:24	foods 245:1 273:25
71:25 73:23, 24	203:13 211:11	foot 99:20 147:1, 25
88:21 91:1, 14, 25	focused 9:19 63:25	
98:21 162:14 197:1	122:1 159:22	148:10 327:23
203:25 205:24	306:10 309:25	forfor 145:13
207:16 211:16	focuses 58:20 86:1	174:22
212:13 227:17	focusing 8:19	forfrom 111:1
240:20 242:16	fold 17:13 114:1	forin 182:1
244:10, 20	248:1 257:19 267:1	forjust 242:1
247:25 250:10		forthese
257:24 258:1 265:1	foliage 117:13	these 219:11
272:14, 20	foliar 10:1, 16 66:1	forwe 274:24
273:22 275:11	71:1 94:20 115:1	forage 96:23
276:1 280:1, 11	129:1 139:11	112:15 117:1, 18
292:1 294:21 295:1	142:15	137:23 141:1
296:23 298:1 304:1	folic 336:21	153:1, 1 186:1
306:1 308:16, 18	folks 236:13 268:1	foragemake 97:1
312:17 332:16,	follow-up 7:15 11:1,	forages 97:1
21 348:1	10 12:18 26:25	-
fmc's 204:22	46:25 52:23 156:16	foraging 97:1, 17,
215:19 273:1, 1	158:15 167:24	22 98:1 100:24
274:15 298:18	286:20, 21 292:17	105:1, 10, 13
317:19	follow-upthis	106:13 107:11,
	293:18	13 108:1, 17,
fmc/cca 46:14	follow-ups 12:10	18, 19 109:1 110:1
float 338:24	food 77:20 79:1, 17,	111:14, 21 112:15,
floating 6:12 161:16	18, 23 80:1, 16	20 113:1, 1, 11,
162:1	81:1, 1, 25	22 116:1, 1, 22
floor 2:12 20:1	01.1, 1, 20	122:1, 15 124:1,
L	0	



1, 12 125:21 138:11 143:18, 21 145:13 150:24 155:1 159:19 160:10, 11 186:20, 23 189:1, 23 190:1, 13, 16 192:1 foray 160:16 186:1 forays 160:1, 13 force 220:15 221:1 222:14 223:1 forces 59:20 297:10 forensic 87:19 **forget** 47:1 **forgot** 346:17 forgotten 236:11 **form** 172:10 292:22 298:1 333:25 formal 27:1 78:19 **format** 58:18 **forms** 199:15 formula 127:23, 25 128:1, 20 **formulas** 128:16 formulated 242:1 formulation 60:19, 24 238:23 240:1, 16 241:1, 1, 1 forth 24:17 92:10 164:21 281:1, 14, 20 fortunately 348:23 forty-eight 43:21 forward 7:13 10:25 11:15, 24 71:20 90:20 222:16 287:1 296:14 333:17 **fowl** 10:1 **fraction** 190:18 fractional 35:1 261:1, 1, 10, 22, 23 frame 100:11 150:19 frankly 212:25 213:1 **free** 344:1 **freedom** 151:25 **frequency** 71:15 160:1, 12 199:1 306:21 307:1 **frequent** 94:11

frequently 135:25 161:1 306:23 fresh 175:13, 16, 18, 21, 25 176:1, 1, 1 **fqpa** 58:15 70:20 246:1, 22 247:1 249:23 250:1 251:1 262:23 270:21 271:1 272:1 273:11 277:13 friday 7:1, 1 171:19 friend 219:1 **frito** 336:24 **from...between** 120:1 **from...in** 194:18 **from...will** 69:25 front 13:1 16:1 68:1 144:21 147:14 337:10 **full** 7:1 91:17 123:15 163:21 178:1 200:14 203:13 225:1 268:11, 16 294:11 296:12 **full-body** 224:23 fully 6:21 99:16 function 35:1 74:25 86:1 101:12 191:1 217:1 264:11 functional 53:1 264:10 functioning 217:22 functions 55:1 fundamental 10:22 155:17 178:10 **funded** 339:20 **fungus** 199:15 furidan 64:1 150:25 199:23 200:16, 19, 21, 25 241:1 furodan 340:1, 1 342:13, 21, 22 344:18, 22 345:1, 15, 24 347:11 348:25 furrow 94:20 115:1 346:22

future 9:1 10:20 11:1 60:14 65:14 118:21 193:1 G gain 82:14 gallinaceous 161:1 gallon 218:10 219:1, 1 g.m.o 337:19, 24 game 147:13 345:1 gaps 75:1, 1 145:1 garner 114:15 gauze 292:1 293:20 **qc** 11:21 **gavage** 77:13 83:1 180:10 245:20 geared 307:1, 1 308:1, 10 geisy 69:1 74:1 general 5:11 84:11 132:15 223:1 228:16 260:17 generally 68:18 72:21, 23 105:18 133:1 137:20 204:15 211:19 244:21 310:1 324:1 332:1 334:12 generate 76:1 95:17 108:1 121:1 generated 40:11 107:19, 22 136:22 generations 199:1, 1, 1 genes 337:22 **genetic** 339:13 genetically 335:12 337:19 **genetics** 339:19 geo-referencing 322:12 geographic 63:21, 24 67:1 325:15 geographical 319:15 325:23 geography 73:1 geological 306:17 309:1 geometric 222:1, 11 227:1, 1

COURT REPORTING

german 5:22 229:16 278:10 gestational 281:1, 15, 18 gets 85:25 156:1 181:15 190:1, 19 199:17 204:19 248:11 249:19 getting 9:1 50:10 90:15 169:1 175:14 231:1 249:1 286:17 288:13 312:1 **ginger** 29:13 34:18 48:1 53:1 213:10 gingerbread 223:1 **given** 38:1 56:18 83:1, 1 97:16 103:20 114:1 162:19 175:1 228:15 329:18 **gives** 149:17 221:1 316:24 323:1 344:23 giving 39:14 197:1 210:19 297:1 310:18 **glad** 52:1 glenn 132:24 133:15 gnarly 132:1 glyphocate 297:19 going...going 169:21 going...i'm 196:25 going...the 168:24 **golden** 160:22 **gone** 158:1 235:21 335:12 347:11 gone...undergone 94:13 **goose** 138:14 **gorge** 68:17 72:15 75:17 82:1 100:25 106:1, 10, 25 107:1 108:1, 13, 14 122:16, 21, 21 137:1 138:1, 1, 10, 17 140:17 143:22 144:16 153:1 gorge...if 122:18 **gorges** 170:22

gory 115:1 128:14 gotten 61:1 199:21 governed 86:1 government 153:16 281:1 328:1 **grad** 180:22 grade 346:24 347:1 grain 130:10 131:1 grams 117:16 gran...minimal 277:13 grand 155:11 granted 200:19 granular 66:22 114:25 150:17 277:13 331:16 granulars 60:20 **granules** 347:11 **grapes** 152:19 graph 33:20 170:1 183:1 219:20 284:21, 25 285:25 graphic 65:17 graphically 97:14 graphs 28:24 30:1 31:13 33:14 34:18 173:25 174:1, 1 288:1, 11 grass 117:13, 24 186:1 grasshoppers 72:1 grassy 319:1 grateful 42:15 gray 40:19 great 17:21 18:21 42:13 48:1 123:24 188:23 222:23 284:10 greater 13:21 15:17 42:1 80:23 103:1 133:1, 11, 14, 15, 22 134:1 139:19, 23 141:23 142:17 205:23 207:1 267:22 308:11 309:1 315:1, 12, 14 323:14, 23 342:17 344:20 greatest 142:1, 1 green 113:16

140:10 197:22 199:15 297:12 300:20 316:1 grew 197:16 grey 39:14 gross 94:24 ground 19:16, 23 54:1 62:20 67:21 70:1 220:1 221:13, 25 241:1, 1 294:24 295:23, 24 298:18 306:19 312:14, 19, 22 315:1 316:1 325:13 326:10, 11, 19, 20 327:1 332:1, 11 334:10 343:1 346:1, 1, 24 347:1 grounded 54:1 groundwater 63:20 67:1, 25 314:1, 1, 11, 13, 15, 24 317:11, 22 324:22 groundwater...well 67**:**1 group 29:16 86:1, 1 176:18 189:22, 25 203:23, 25 211:19, 22 244:1 263:1 269:13 341:18 groups 31:24, 25 34:17 47:16 111:1 173:13 grow 342:22, 25 344:1, 1 345:10, 16, 25 grower 151:13 growers 61:1 62:1, 10, 11 63:1 153:16 197:14 198:1 294:1 332:20 growing 201:1 grows 199:15 grue 4:1, 1 38:15, 15, 19 181:25 182:1, 1, 1, 14, 19 183:21 184:1, 1 185:1 guard 198:13 quelph 73:14, 22 guess 6:15 37:17



40:20 48:1 55:1 81:10 84:19 165:20 169:17 232:23 239:18 268:21 271:14 284:14 286:21 291:17 292:18 293:19 294:1 334:25 342:1 guidance 76:23 78:22 125:23 220:1 guide 91:19 guideline 26:14, 18 28:1, 12 43:19 76:1, 10 78:19, 20 205:1 242:1 279:25 guidelines 26:20, 21 27:1, 1, 1 28:12 206:16 208:12 210:20 242:12 **guilty** 151:13 gustatory 77:1 gut 77:17, 19, 22 82:24 quys 266:23 280:1 Η habitat 109:18, 19 125:15 148:10 164:19, 20 hair 256:13 257:1 half 14:10 15:1 18:1 56:22 60:11 87:20, 24 99:24 104:1 183:1, 1, 14 200:12 243:12, 14 261:23 275:23 302:24, 25 309:13 315:16, 18, 19, 21, 25 321:11 332:24 343:1, 10 346:20 half-an-hour 14:16, 25 15:1 half-fold 170:23 half-life 7:17 13:23 14:1, 10, 19, 24 15:1, 13 19:1 87:18 88:1, 1, 1 104:1, 1 122:24 145:18, 20 178:12, 15, 17 179:1, 1,

1, 1, 11, 25 209:16 half-lives 15:25 87:17 hall 294:17 hand 43:1 133:13 203:14 223:15 259:1 319:21 handle 7:16 10:1 11:1 100:10 handled 217:1, 11, 12, 13, 18 handler's 215:15 **handlers** 217:24 220:14, 16 221:16 handling 83:19 236:15 280:15 hands 196:20 265:23 handwerger 3:1, 1 280:20, 21 282:13 hap...happy 93:13 happen 30:1 119:1 138:25 139:1 153:1 172:15 176:22 237:1 276:20 281:10 **happened** 125:11 150:1 282:22 happens 53:1 71:1 96:23 117:20 183:1, 13 220:1 225:25 228:14 254:17 290:20 339:1 happens...is 119:1 happy 11:1 201:1 340:17 hard 18:20, 22 75:21, 22 151:1 210:23 255:18 257:15 258:22 285:17 308:24 hard...this 188:24 **hardest** 188:24 harmonized 220:21 **harvest** 198:10 342:19 343:19 has...if 71:19 has...there 276:1 **hatch** 149:14 hattis 5:19, 19

12:24 13:22 15:11, 24 16:1, 1, 10, 13 226:23, 25 227:1, 1 241:10, 17, 23 242:11 340:22, 23 have...adjust 169:1 have...aphids 199:20 have...are 282:18 **have...have** 73:1 have...just 237:24 have...only 189:23 have...they're 190:13 have...where 243:1 haven't 44:19 71:14 157:23, 24 159:1 221:14 281:12 having 8:18 9:15 15:12 30:10, 18 39:18 45:25 130:22 258:1 281:19 323:24 333:1 hazard 5:15 184:1 273:1 he'd 71:20 he'll 205:15 299:24 328:17 338:1 he's 108:25 230:13 he's...he 160:1 head 5:23 264:16, 17 339:1 347:15 heads 64:14 337:16 344:1 health 4:1 5:1, 14 8:20, 24 11:1 12:1 36:1 37:14 58:1 59:1 69:19 70:15 243:21 263:18 264:1 281:23 296:19 336:20 349:15 hear 13:1 59:10 61:19 64:1 67:1 68:1, 20 80:13 93:1 176:19, 22 204:14 246:23 283:23, 24 298:1 336:22 heard 57:25 58:1



60:1, 16 70:1	172:20 177:1 178:1	high 15:1 50:1, 11
75:1, 16 76:1,	181:12, 15, 23	
15 78:24 79:1 81:1	182:18 185:1	121:22 122:1
	106.12 201.11 14	
83:12 85:24	196:12 201:11, 14,	123:1, 1, 10, 12
89:22 90:1 91:1		128:1 132:10
92:10 97:25 110:19	22 213:22, 23	133:13, 16 134:12,
118:1 124:20 125:1	214:1 226:10,	18, 19, 21 135:1
126:14, 20 145:1		137:1, 1, 21
146:1 149:19 151:1	$228 \cdot 1 \ 229 \cdot 11 \ 14$	120.1 12 1/
		14 120 1 1
163:12 205:20		
208:1 209:1, 1	24 234:22 235:1	, - , -
213:1 215:1 231:25	236:1 238:1 239:12	142:20 153:1
245:25 248:17	240:14 241:20,	167:14 170:1, 1,
249:1 253:17		
266:18 272:23		
297:1, 1 302:1	251:14 272:15,	212:19 253:17
305:25 314:1	17 278:1 279:21	301:1 310:1, 1, 19
317:20 319:19	280:1, 19 282:1	311:1 312:1
325:16 327:1, 21	283:16 284:16,	313:1 316:25 317:1
330:16 333:12,		319:1 330:23
13 334:1, 16		
335:25 348:1	200.1, 1200.10	336:21 340:1 343:1
	290:1, 11, 14	
heardyou 124:20	291:22, 25	346:23
hearing 6:16 57:24	292:1, 15 293:12	higher 18:12 30:1
heart 316:19 322:1		48:15 68:17 75:1
heavily 31:21 92:15	331:19 332:10,	84:1 85:11
	23 335:1 340:19	
heavy 130:10 339:1	341:1 342:1 345:19	
343:11, 25	347:1 348:1, 19	
hedging 239:1		
heeringa 2:12, 15,	349:1, 1, 22	180:21 229:25
21 6:1 7:12 11:1	held 16:17 236:17	263:1 267:24, 25
12:1, 12, 15, 19	237:19 343:12	275:22 277:19
		296:1, 20 297:1
17:16, 21, 24 18:1		298:1 310:10 316:1
19:17 20:1 26:23	36:1 38:16 39:1	318:1, 1, 14
27:24 28:17, 25		
32:1 34:13 35:19	43:23 53:19 79:1	320:18 321:1
37:16, 23 38:1	93:1 132:1 241:1	322:25 323:1
39:10 40:21 41:1	244:13, 18	324:14, 17, 19
42:1, 16 43:13	302:12 328:1 345:1	332:1 334:14
	helpful 8:21 25:1	higher-tier 296:15
45:16 46:23	236:1, 1	highest 82:10 116:11
51:24 52:1, 21		-
53:16, 21, 25	helps 196:11	137:24 145:18
55:1, 17 56:1	hence 199:19 284:1	210:10 284:23
57:14 58:19 70:23,	herbicide 297:17, 18	
24 71:1, 22 72:1	here's 109:13 139:14	
73:11 88:14	141:11 219:16	320:20 321:17
152:1 155:20		323:1
	220:1 261:1	highlight 63:11
157:11 158:13	hereand 256:1	
160:18 161:1, 24	hereis 100:1	224:11
162:13, 22 163:1	hev 41:1	highlights 67:19
164:1, 1 165:12		
	hi 23·1 299·1	highly 121:1
167:1, 1 171:1	hi 23:1 299:1 hierarchy 310:1	highly 121:1 123:20 137:22



258:1 348:14 hill 4:11, 11, 22 257:1 288:18 his...his 183:1 historic 57:25 historical 223:11 224:19 313:17 **history** 88:25 hits 342:18 **hitting** 336:20 hoary 99:14 hold 30:25 88:13 155:1 161:1 251:12 holds 262:1 hole 339:1 hollow 329:20 home 3:15 318:16 honestly 166:21 honeydew 199:14, 14, 16 hope 37:20 90:21 144:23 155:16 203:1 204:14 210:13 232:22 274:12 334:1 345:10 hopefully 58:12 125:20 203:1 295:1 302:12 333:13 hoping 131:1 **horizon** 61:10 **horned** 97:15 123:1, 19 170:1 hose 219:1 hot 77:1 310:1, 1 hour 14:1, 11, 11, 12, 19 15:1 21:1, 1, 10, 12 25:19 26:15, 16 27:1 41:24, 24, 25 42:20, 23 43:1, 1, 1, 1 44:13, 15, 23 57:1 88:24 96:16 97:16 101:1, 1 103:18 116:1, 13, 13, 14, 22 119:25 143:20 148:21 183:1, 1, 14 189:1, 1, 13 190:1, 14, 19 210:19 233:11

236:17, 20 237:1, 19, 25 269:1, 24 332:24 342:19 **hour-and-a** 14:10 hourly 80:20, 21 100:1 101:1, 1, 16, 17, 19, 23, 25 119:15, 17 184:16, 19, 21 187:12 191:1, 1 hours 6:14 14:1, 1, 17, 19, 22, 25 15:1, 1 18:11 21:12, 13, 21 25:19, 25, 25 26:11 43:16, 20, 21, 21 44:1, 1, 10 45:1, 1 55:22 56:23 70:16 88:1 99:24 103:18 104:10, 15, 16 106:1 119:21, 21, 22 122:24, 25 138:1 143:1 148:10, 17 149:1 162:14 175:15 185:1 187:1 203:1 209:1, 10, 14, 16 212:16, 16, 18 260:1 269:24 290:20 293:22 315:21 housenger 12:1 246:25 how...how 227:11 **hrb** 268:10 hsrb 13:1 268:1, 18 269:11 270:1 huge 211:25 hugged 135:10 hugs 303:1 human 5:14 8:20, 24 11:1 12:1 13:1, 1 36:1 37:14 54:10, 11, 15, 17, 24 55:1, 14 59:1 69:18 70:15 202:15, 20 208:1, 1 210:22, 24 243:21 263:24 265:20 267:1, 19

268:1, 16, 22 269:1, 1 270:1, 12, 23 271:19 humans 12:25 13:23 14:21 79:12 281:25 humid 324:10 hundred 18:17, 18 30:13 32:24 33:1 40:18 45:14 hundreds 282:16 hybrid 340:1 344:1 hybrids 339:22 hydro 299:1 hydrocarbons 198:19 hydrogenation 336:10 hydrology 306:1 hydrolysis 18:1 78:1 86:1 hydroxy 18:24 348:16 hydroxyl 86:1 hypothesis 83:10 183:1 329:14 hypothesizing 175:1 hypothetical 95:18 102:22 104:1 111:24 195:15 260:24 261:1 288:10 Ι i...as 280:1 **i...but** 270:25 **i...i** 73:17 161:10 183:22 196:1 202:1 203:1 230:1 253:1 272:22 281:11 **i...i'm** 194:13 279:1 **i...i...i** 281:10 **i...i'm** 280:22 **i...in** 71:13 **i...just** 237:24 **i...my** 169:22 **i'd** 3:1 7:1 16:15 21:1 37:1 39:12 42:14 57:1, 17, 25 71:19 73:18 82:18 92:13 120:19 157:18 172:16, 21 195:11 197:1 214:1, 16 217:19



800.262.8777 💪 Historic Jordan Springs 🧯 1160 Jordan Springs Read 💪 Stephenson, VA 22656 💪 540.667.6562

220:18 252:20	203:1, 24, 24	316:16 317:1
278:1 282:1 283:15	209:1 210:22	318:21
294:1, 1, 1	213:20 226:13	<pre>identifying 67:1</pre>
i'll 11:1 12:20	227:17 229:13	75:1
39:21 58:19	231:1 233:25 234:1	: c : 172.1
		ifi 173:1
59:11 62:1 65:13	235:24 239:1, 1,	ifi'm 161:1
70:22 94:14	1, 1, 18, 19 241:1	ifif 283:1
98:1, 16 102:16	244:1 247:17	
		igignore 253:20
108:16 110:14	248:14 249:19	ignore 154:1
117:1 127:13	250:25 251:1, 1	-
		159:21 287:1
134:11, 13 150:1	256:18 260:11,	
		ignored 253:12, 13
156:25 160:1	22 263:16 267:1	282:18
163:23 177:20	272:19, 19, 24	
		ignoring 212:1
181:17 182:16,	280:1, 21 281:14	
23 198:11 204:1	284:17 286:10,	illinois 4:25 150:22
		310:1, 13 322:10
214:20 216:14	17 287:18 289:10	
		327:22 331:23
218:14 219:1 229:1	294:1, 1, 14	347:1
232:1 236:10	309:17 327:24	54/:1
		illustrates 105:1
243:19 244:10, 17,	331:23 336:20	
20, 23 262:1 263:1	340:1	173:1
		-11++
272:20 275:1 278:1	i'mi 213:12	illustration 276:1
		imagine 20:1 223:1
299:1, 12 317:12	i'mi'm 173:24	
328:14 334:23	i've 13:1 15:19	224:21
		inare 228:19
342:1 345:15	20:12 30:1 31:1,	
i'llthis 262:25		inin 78:10
1'11this 202:20	12 41:21 55:21	
i'm 2:1, 11 3:1,	149:20 167:1	80:22 92:1 126:1
		127:13 144:18
1, 1, 1, 11, 13,	201:19 221:22	
15, 18, 20, 22	222:1 224:12	154:16 173:10
		174:11 207:11
4:1, 1, 11, 15,	231:25 235:21	
16, 18, 19, 21	236:11 256:18	215:1, 1 216:24
5:1, 1, 18 6:1	259:1 266:18	217:1 232:20
		269:22 292:22
7:13 15:15 17:11	268:20 270:1	
18:1, 1, 1	285:15	ininin 61 : 1
		65:14 278:20
22:15, 17 26:20	ice 233:10 236:17,	
29:22, 25 30:25	20 237:20	ininner 223:17
31:1, 13 32:21	id 259:1	inis 238:16
36:25 37:21 38:15,		insympathetic
	idea 9:23 35:1	
17 43:10 45:20	37:1 99:17 103:1	253:16
49:23 52:1 53:1	141:20 149:1, 17	intheir 191:1
61:25 63:23	253:15 254:1	<pre>inaccurate 168:1</pre>
67:17 71:25	255:21 309:1 322:1	inactive 171:10
73:22 84:18		
	ideas 175:1	<pre>inadequate 154:20</pre>
88:19 89:10 96:1	identical 178:25	223:24
100:1 117:1		
	<pre>identified 68:1</pre>	inappropriate
123:1 130:24		74:20 88:1
	72:24 73:1	
135:13 146:24		
	125:12 135:22	12/:25 146:12
154:19 156:21	125:12 135:22	127:25 146:12
154:19 156:21	125:12 135:22 250:10 304:20	290:1
154:19 156:21 157:1, 20 159:17	250:10 304:20	290:1
157:1, 20 159:17	250:10 304:20 327:21	290:1 inc 306:1
157:1, 20 159:17 163:20, 24 167:1	250:10 304:20	290:1
157:1, 20 159:17	250:10 304:20 327:21 identifies 301:1	290:1 inc 306:1 inches 342:12 343:1
157:1, 20 159:17 163:20, 24 167:1 171:1, 23 182:1	250:10 304:20 327:21 identifies 301:1 identify 25:20	290:1 inc 306:1
157:1, 20 159:17 163:20, 24 167:1 171:1, 23 182:1 194:16 195:10	250:10 304:20 327:21 identifies 301:1 identify 25:20	290:1 inc 306:1 inches 342:12 343:1 incistates 152:25
157:1, 20 159:17 163:20, 24 167:1 171:1, 23 182:1 194:16 195:10	250:10 304:20 327:21 identifies 301:1 identify 25:20 41:1 68:16	290:1 inc 306:1 inches 342:12 343:1 incistates 152:25 incidence 281:1
157:1, 20 159:17 163:20, 24 167:1 171:1, 23 182:1 194:16 195:10 196:12 197:11	250:10 304:20 327:21 identifies 301:1 identify 25:20	290:1 inc 306:1 inches 342:12 343:1 incistates 152:25
157:1, 20 159:17 163:20, 24 167:1 171:1, 23 182:1 194:16 195:10	250:10 304:20 327:21 identifies 301:1 identify 25:20 41:1 68:16	290:1 inc 306:1 inches 342:12 343:1 incistates 152:25 incidence 281:1



incident 60:1, 1, 1 75:12 149:21 150:1, 21, 22, 22 151:1, 1, 17, 21, 23 153:12 331:13 incidental 44:1 incidently 78:19 incidents 10:16 149:19, 20 150:1, 10, 17 152:1, 12, 15, 18, 24 228:1 **include** 8:1 56:16 66:15 67:1, 21 94:1 95:12 131:25 132:1, 18 154:17 166:19 208:1 218:1 220:13 273:17 274:15 327:10 included 22:21 27:19 66:10, 19, 24 67:1 71:1 89:13 128:17 143:11, 13, 13 147:1 149:25 151:1 155:1 156:1, 1 316:10 includes 8:15 17:1 163:19 214:14 228:1 274:25 276:12 306:18 including 17:1 36:20 48:25 49:1, 1 64:15 198:23 223:22 281:1 306:25 317:10 inclusion 68:12 incorporate 76:1 93:19 94:1 118:1 123:11, 13 154:10 incorporated 76:16 98:22 99:1, 1 118:17 145:10 incorporation 123:1, 1 increase 82:1 83:23 183:11 270:1 increased 76:17, 18 79:10 82:1 87:1 281:1, 1, 19 315:19 344:1

increases 46:1 114:1 119:1 254:1 increasing 79:24 83:24 87:1 119:1 **immature** 49:20 immediate 183:1, 18, 18 immediately 236:16 237:18 291:1 independent 153:1 178:16 190:20 197:11, 13 index 295:14 302:14, 22 303:1, 1, 25 332:1 **indiana** 299:11 301:1, 11, 12, 20 302:13, 19, 24 303:1, 12, 24 304:1, 23 305:1 **indicate** 39:1 96:1 254:10 296:23 indicated 18:1 62:1 92:22 113:19 119:13 168:1 220:1 221:1 222:1 249:12 251:19 252:1 257:13, 20 264:20 indicates 45:1 112:13 136:23 216:1 223:21, 24 228:10 329:22 indicating 13:25 15:23 17:1, 11 29:1 31:10 39:15 63:17 indication 40:1 87:22 117:1 indications 61:1 **indicator** 48:1 305:1 individual 35:25 52:12 63:1 97:22 98:1 107:19 110:1, 1, 12 111:1 113:1 144:11 177:24 189:17 197:14 223:11 248:21 253:11, 20 258:1, 25 259:1, 10, 18, 19 262:11 269:16

278:21 311:1 330:19 individually 63:15 individuals 73:18 110:1 111:12 112:1, 13, 24 145:12 194:16 industry 61:16 280:13 348:1 **inert** 82:21 **infants** 281:19 influence 80:23 143:1, 12 150:16 172:1 196:23 inform 214:25 217:19 information 11:1 17:1, 15 20:10 25:11 27:1 38:13 58:10 60:1 62:12 71:19 75:23 89:1 91:1, 10 92:1 94:21 95:1 100:1, 15 101:1 102:10 105:16 111:1 112:1 113:25 121:1 126:17 144:1 145:1 151:25 156:13 158:10 159:1, 10 171:1 172:24 177:18 208:1, 11 212:1 213:1 233:14 258:1 305:12 **informed** 201:19 infrastructure 338:20 infrequent 138:19 139:1 impact 9:15 103:19 122:14 214:1, 10 299:16 340:15 impacted 336:1 impacting 276:1 **impacts** 124:23 338:22 impervious 327:19 implausible 210:1 implemented 63:12 64:1, 20 65:1 imply 132:12 137:14 **import** 333:17 importance 99:1

105:1 123:23 192:1	346:20
important 8:11 9:1	
21:21 25:1 35:1	215:1, 23, 24
36:1 57:16, 24	216:21 217:1
59:25 62:1 68:13	220:1, 19 222:1, 1
86:15, 17 90:13	225:20
98:25 114:13,	<pre>inherently 215:1</pre>
17, 20 115:16,	inhibit 180:17
25 122:13, 18,	233:12
24 123:15, 18	inhibited 180:14
124:1 126:1	
127:1 158:11, 12	266:14
127.1 100.11, 12	inhibition 9:12
161:1 183:22 184:1	13:16, 19, 21
192:1 200:21 201:1	16:1, 1 25:14
204:10 208:18	26:1, 1 27:20,
210:1 220:10 225:1	23 39:23 40:1 47:1
231:17 250:24	49:10, 12 50:13,
253:1, 1 259:24	22 51:10, 19 53:1,
266:1 268:1	
274:1 294:1 295:16	11 85:1 98:20
	103:23 143:1
297:24 301:1, 22	145:17 181:1
309:20 312:1 313:1	206:25 210:12
315:1, 1 316:21	212:24 229:1, 24
318:1 320:1, 1	230:1, 1 231:1, 1,
321:1, 17	18 233:22 234:1
322:10, 24 323:1	235:16 246:16
333:20 334:17	252:18, 19 253:15,
336:1 340:1, 1	25 254:13, 17,
importantis	
210:24	21 255:1 258:1
	259:1, 1 262:1
importantly 92:1	271:1 279:1, 1, 16
224:23 301:14	284:22, 23
344:20	285:1, 1, 1, 1
importing 340:12	286:23, 25 288:20,
imposition 272:1	20
<pre>impossible 55:24</pre>	inhibitionthere
157:22	285:1
impoundments 308:1	inhibitions 251:17
impressed 157:20	253:10 278:23
1 =	inhibitor 27:1
impression 206:22	
236:22	initicomparing
improve 213:1 223:1	267:1
improved 144:24	initial 56:20
improvement 91:1	79:15 81:1 84:25
improving 63:1	100:1, 14, 18
ingestion 95:1	104:1 115:10
101:1, 1	117:21 171:10
ingredient 59:18, 24	180:15 185:12
60:21 61:1 129:1	191:20 282:19
	initially 83:22
139:12 141:12	180:1 244:19
217:12 239:21	254:25 255:11
304:24 343:1, 10	2J7.2J 2JJ.II

299:1 309:10 **initiate** 172:1 initiated 58:24 63:18 **initiation** 84:1 87:1 inner 223:13 224:1 334:1 **input** 144:1 inputs 89:1 92:1, 1 158:1 **insect** 114:22 198:12, 14, 17 201:1 338:1, 1, 1, 1, 15 339:25 340:14 341:1 346:16 insecticides 199:22 341:1, 1 **insects** 104:1 115:22 117:13 186:1 198:23 199:11 201:1 337:14, 17 338:12 **inside** 109:14 **insight** 195:1 insoluble 239:15, 23 240:17, 25 instance 30:1 33:16 49:22 73:1 instances 331:1 instantaneous 170:13 215:10 **instead** 145:23 205:1 246:22 **intake** 79:23 80:1 81:25 82:1, 1 95:1, 11 104:1 106:22 107:1, 1, 1 118:25 119:1, 1, 1, 11 120:1 124:13 171:25 183:13 186:25 187:12, 19 191:1, 10 245:11 **integral** 344:20 **integrate** 309:21 330:1 integrated 344:25 integrates 86:17 181:1 integration 88:1



```
intend 7:1 217:16
intended 40:17 162:1
intense 149:1
intensities 309:13
intensity 304:22, 23
intensive 323:1, 1
intent 2:20 6:20
 11:11 40:1 56:13
 74:12 204:17
 248:24 270:19
 274:23
intentional 54:16
interactions 330:1
intercepts 330:22
interest 9:1 33:1
 109:20 206:12
 217:1 311:15
 312:17 325:19
interested 5:25
 33:1, 10 38:11, 12
 61:1, 22 75:25
 88:17 94:12 135:15
 144:13 219:21
interesting 82:13
 87:17 107:1
 108:1 130:25 141:1
 169:10 313:1
interestingly 301:25
interferes 199:16
interim 62:17 169:17
 204:17
interior 147:1
interiors 148:20
interjecting 38:16
intermediate 78:1
 132:10 133:18
 134:12 135:1, 1
 137:1, 22 138:15
 139:1 153:1
interpret 10:11, 15,
 17 18:20 165:1
 313:24
interpretation
 9:11 181:10 284:1
interpreting 284:24
interspecies
 246:1, 20 247:1
 249:22 268:1 269:1
 270:14, 21 271:1
 272:10
interval 87:1 150:13
```

intervals 86:23 306:23 311:13 intervention 184:16 **into...into** 184:10 into...through 82:24 **intra** 334:1 intra-animal 253:18 intrafield 115:12, 16 117:1 191:22, 23 intraspecies 246:1, 21 247:1 268:1 269:10 271:1 intrinsik 88:19 introduce 3:1 35:14 43:13 68:23 85:22 193:1 226:19 227:14 231:1 244:1 295:1 introduce...and 68:22 introduced 45:1 introducing 44:24 introduction 57:10 58:20 59:1, 21 **intruder** 200:12 **intuitive** 136:24 **invasive** 119:16 investigate 91:24 123:23 investigated 308:16 investigating 95:25 investigation 321:1 **involve** 105:18 involved 74:23 77:1, 15 108:24 121:24 144:1 147:11 149:18 159:16 160:1 182:15 198:1 216:10 222:20 224:25, 25 286:13 328:10 **involves** 266:1 282:16 309:16 **involving** 121:22 124:22 invoy...avoids 258:10 **iowa** 6:1 318:15 320:22, 25 322:10

ired 329:12, 25 331:1 **is...first** 79:1 **is...here** 140:1 **is...is** 57:17 74:20 138:1 165:1 180:1 217:1 253:1 286:1 293:20 is...is ...is 292:20 **is...it** 264:1 is...it's 88:1 is...predicted 123:14 **is...that** 205:16 250:19 **is...the** 252:17 **is...they're** 195:12 **is...this** 276:18 **is...very** 205:19 **is...was** 106:25 is...we're 283:1 **is...what** 282:23 **is...what's** 234:13 irreversible 243:11 island 313:1, 1, 14 314:10, 20, 25 318:12 327:1 it's 6:20 7:1 8:11, 14 10:1 11:22 13:15 14:10, 12 15:1, 1, 14 17:19 18:1, 10, 11, 12, 22 19:1 21:14 23:1 24:1 28:1, 20 31:1, 1, 21 33:1 40:18 41:22 42:1 44:24 45:1, 1, 10, 11, 12 46:17 47:15 48:16 49:20 50:1, 1, 1, 1, 16, 16 52:13, 15 62:1, 1 73:1 77:1, 11, 20 80:17, 25 81:1 82:1 84:16 87:11, 17 88:1, 1 89:13 96:1 97:16 100:1 103:1 106:1 107:1 108:1, 1 110:24 113:13 114:1, 13 115:25



110 1 100 17	
118:1 123:17	337:1 338:1, 1, 1,
126:1, 1 128:1	1, 11 339:14
130:12, 25	342:24 343:11
132:20 139:1	244.1 21 246.25
132:20 139:1	344:1, 21 346:25
140.11 141.00	2 1 7 . 1
140:11 141:22	347:1
1 4 4 . 1 1 4 C . 0 0 1 4 0 . 1	•••
144:1 146:22 148:1	it'sand 237:23
149:16 151:1, 16	it'schance 294:1
157:22 158:11	it'si 183:1
168:1 170:21	209:25
	209.25
171:1, 1 178:20	it if 235.17
	it'sif 235 : 17
180:19 181:16	
	it'sit's 88:1
182:13 183:1,	
	184:22 290:23
17, 22 184:15,	
	it'sso 81:16
24 185:1 186:18	
24 103.1 100.10	it'sthere 269:15
188:1 189:1 190:16	IC 3CHETE 209.10
100.1 109.1 190.10	itle
100.1 05 100.1	it's
192:1, 25 193:1,	A
1 10 100.1 205.17	toxicologically
1, 19 199:1 205:17	
000.01 007.1	265:11
206:24 207:1,	
	itfigure 191:15
18, 23 208:16,	
01 010 00 011 1 1	itif 170:12
24 210:23 211:1, 1	
	itin 249:24
212:1 215:11, 25	
	itit 99:23
219:17 220:10	ILIL 99.23
	170.1 010.10
222:11 227:1, 19	172:1 213:10
	226.22 227.1
229:1, 1, 1	236:23 237:1
230:11, 14	itit's 210:1
	$0.05 \cdot 1.0 \cdot 1.0$
231:1, 22 232:1,	235:16 238:18
	001.10
14 233:1 235:14,	281:16
17, 18 237:12, 14,	itit'sit 91:1
22 238:13, 22	ititin 172:1
	10101m 1/2.11
239:18, 18, 19,	itso 119:1
	IC30 IIJ.I
23, 24, 25	itthat 166:1
240:1, 25 243:1	
•	itthe 236:24
245:1 248:1	: - 1 2 C - 1
	italic 136:1
250:12, 24	
	isn't 8:13 10:1 33:1
252:23 255:1,	
	45:1 105:22 146:18
12, 14 256:1	
	170:13 213:1 252:1
257:24 258:1	
	isolated 172:1
259:24, 25 263:1	
	item 104:1, 1, 1
264:1, 25 265:1,	
	items 65:1 81:1
1, 15 266:1	
	94:25 101:1 117:13
267:1 272:1, 25	
	190:25 196:19
279:18 282:10,	
	iteration 193:1
14 283:1, 1 285:1,	
	issue 6:21 9:23
17 287:25 290:1,	TARME OFST ALS
	00.1 1C 0/.1
22 291:1 292:22	23:1, 16 24:1,
294:1 297:24	18 27:10 28:12
306:16 310:1	39:22 82:18
313:1, 18 317:21	85:22 117:1 118:16
318:1 320:1 321:17	127:1 141:1 172:18
JIU.I JZU.I JZI.I/	
322:24 324:1,	204:10 205:1, 1
11, 12 328:1 332:1	206:21 229:1
$\perp \downarrow$ $\perp \downarrow$ $\perp \downarrow \downarrow \cup \downarrow \cup \downarrow \cup \downarrow \cup \downarrow \downarrow$	
333:1, 23 334:20	231:17 232:1
335:14 336:21	234:16 236:12, 14,
JJJ.IH JJU:ZI	

14, 15 247:1 250:13 251:25 252:1, 1 253:1, 1 257:14 260:1 265:1 281:22 287:24 341:22 344:25 347:23 issue...the 234:1 **issues** 2:1, 18, 25 5:20 6:1 8:19 9:1, 12 10:22 22:25 23:24 24:15 55:16 56:11 73:25 77:1 86:1 127:1 131:1 153:22 163:22 202:25 203:14 204:1 205:1 208:1 231:1, 24 233:23 242:24 244:23 246:17 247:1 249:13, 18 252:20 258:10 263:1 268:19 281:1 282:18 337:23 ivory 291:1 J jack 12:1 246:25 james 203:22 **jan** 3:1 234:23 289:15 jane 280:1 292:1 293:13 january 75:1 151:14 222:18 **jeff** 240:1 **jeffrey** 69:15 204:1 jesse 198:1 jim 5:16 47:1 69:12 203:24 215:20 225:13 244:1 263:1 337:1, 1, 1 345:21 **job** 341:1 john 4:14 23:1 41:1, 1 52:22 57:1 69:1 74:1 94:1 150:14 join 201:25 joined 2:23 joining 6:11 joint 224:24



jones 12:17 18:1, 1 19:18, 23
jordan 53:18, 24, 25
jorgensen 125:1
judge 127:18
judgment 54:19
juicy 337:16
july 91:16
justthethe
177:20
justice 151:14 347:22
justification 236:1
justified 333:15
justify 288:13
juvenile 35:23 41:17
249:16 251:1,
19, 22 252:1, 17
267:20 272:1
K
k/f 19:1
kansas 338:1, 19
339:1, 13 340:1
342:10 344:11
346:14
kansas-oklahoma
125:1
125:1 k3 78:1 86:1
125:1 k3 78:1 86:1 kehrer 5:16, 16
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1. 14 299:13
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1, 14 299:13 300:1 328:12 340:1
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1, 14 299:13 300:1 328:12 340:1 kick 13:20 337:1
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1, 14 299:13 300:1 328:12 340:1 kick 13:20 337:1 kids 337:18
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1, 14 299:13 300:1 328:12 340:1 kick 13:20 337:1 kids 337:18 kill 142:19 151:1
125:1 k3 78:1 86:1 kehrer 5:16, 16 345:20, 21, 21 keith 69:1 73:14, 21 88:20 91:1 98:19 99:1 104:11 118:1 145:1 173:1 174:1 177:19 180:1 183:1 328:16 ken 3:13 kentucky 5:1 238:11 keptthey're 176:14 kg 104:1, 1 331:1 key 24:14 59:12 86:1 122:14 155:25 245:1, 14 299:13 300:1 328:12 340:1 kick 13:20 337:1 kids 337:18

23 140:1, 1 killed 150:1, 1, 1 151:21 209:19 **kills** 181:1 kinds 9:1 10:1 48:25 50:15 107:18 280:13 281:1 335:25 kleingartener 332:14 kleingartner 244:1 294:1 332:18 335:19, 20, 21 340:20 341:1, 14, 20 345:22 346:1 347:20 **knee** 343:1 346:23 **knew** 260:1 **knock** 343:12 **know...were** 159:23 knowledge 154:11 312:21 341:22 348:1 **known** 65:10 156:1 199:1 L **lab** 4:24 171:21 231:1 232:14 233:1, 1 267:1 lab...adjusted 248:1 label 7:22 8:1, 12, 17 9:25 59:1 60:15 64:1, 20 65:1, 1 66:10, 11, 20, 25 67:1, 20 68:1 72:11 73:1 75:18 94:1 135:17, 18, 19, 21 149:25 150:14, 16 151:1, 16 200:14 248:1 274:25, 25 277:11, 12 285:1, 1, 13 297:10, 15 304:1 313:1 314:1, 11 319:14 321:21 325:22 327:1, 16, 23 335:1 342:25 **labeled** 153:18 307:21 342:23 345:1

labels 67:10, 12 327:1 **laboratories** 50:14 280:12, 15 **laboratory** 20:20, 24 77:12 117:25 119:14, 20 120:1 224:18 231:20 330:13 335:25 laborious 113:13 lack 13:20 207:1 210:12 211:12 251:1 340:13 344:13 **lacked** 305:12 lacrimation 49:1 lag 6:25 118:1, 11 170:11 182:19, 24 183:17 **1b** 217:18 **lam** 69:12, 19 203:22, 24 244:1 263:1 lamb 203:21, 24 214:1 226:10, 23 227:13 228:21 229:11, 13, 17, 22 230:1, 1, 11, 13, 17 231:16 233:19 234:15 235:1, 13 236:1, 1, 22 237:22 238:15 239:1, 1, 11, 16, 22, 25 240:10 243:1, 17 244:1, 1 251:18, 24 262:25 272:15, 16, 18 273:12 274:1 276:23 278:1 279:21, 23 282:1, 14 283:16 290:22 291:11, 17, 20, 24 293:1 **land** 71:11 139:1 295:18 300:19 301:13 303:19 341:13 landscape 96:1 **large** 106:25 107:1, 25 126:1 150:1, 10 151:1



190:1 228:11
275:11 280:18
299:1 307:1
308:1 316:18
328:25
largely 216:23
larger 87:12
267:15 300:13
308:1
largerthis 219:1
largest 217:1 248:10
337:1
lark 97:15 123:1
larks 122:1 123:19
170:1
larry 3:22 69:1
74:1, 1 79:1
171:1, 12, 12, 13 173:18
174:20, 22 182:1
184:14 244:1 294:1
335:19 343:17, 25
larry's 174:13
larvae 338:23, 25
341:1
laser 338:1
last 12:1 13:24
21:10, 15, 20 22:1
28:23 33:24
46:1, 1 47:16
53:16 56:22 59:1
63:13 64:1, 13
85:22 193:21 200:1
203:1 226:12
234:23 252:25
260:1 272:13
280:25 315:14
339:13 345:1
lasts 53:11 315:11
late 57:1 59:15,
19 105:21 106:1
312:24
later 32:1 44:1
45:18 75:1 76:20
80:13 85:1
102:16 107:1
108:1, 14, 16
120:1 181:20, 22
184:1 209:10 236:1
266:18 298:10
309:11 318:10
345:1

latest 335:11 **lc** 330:12 **lc5** 196:1 **1c50** 196:1 **lc95** 196:1 **law** 27:16 70:1 **lay** 336:24 **laying** 341:1 **lays** 338:23 **1d50** 84:15, 16, 17 85:17 102:17 120:24, 24, 25 121:1 168:20, 20 **ld50s** 120:22 **ldc** 279:16 leaching 315:10 325:1, 10 **lead** 82:1 179:1 339:25 **leader** 4:1 176:18 203:23 **leading** 2:13 38:21 **leads** 143:23 179:1 207:12 246:18 247:12 **leaf** 116:1 197:22 **leakage** 218:19 **leaking** 218:20 **lean** 176:12 **learning** 81:1 172:25 **least** 7:15 14:20 25:19 32:1 44:1, 25 47:16 48:22 64:13 76:10 82:16 90:1 94:22 103:1 108:1 125:19 139:25 141:25 142:1 144:12 150:21 153:11 154:1 159:16 162:18, 19 235:1, 20 258:15 260:1, 17 292:18 313:23 321:1 323:11 328:1 331:1 344:16 **leave** 328:14 334:1 **leaves** 199:15 **leaving** 247:1 267:1 **led** 64:23 left-hand 66:1

221:21 left-wing 81:11 legalities 203:15 **legend** 39:1 **legends** 266:24 legislatively 246:1 leisure 219:15 224:1 **length** 25:23 87:1 158:23 164:10 lengthen 87:15 lengths 29:23 31:1 **less** 14:1 21:21 30:10 34:11 48:16 60:1 84:21, 22, 23 103:1 129:18 132:16, 25 133:10, 20 139:18 148:21 154:20 162:19 199:1 200:14 204:19 209:23 218:21 236:16 257:11, 12, 18 260:1, 1 265:1 267:11 279:17 286:16 297:22 298:12 302:25 303:15 311:1 313:19 315:1, 1 320:19 322:19 323:16 324:24 325:24, 25, 25 326:1, 15, 16, 21 327:1 329:21 330:17 331:1 **less...a** 224:22 **lessor** 15:25 **let's** 11:16 12:1, 12 38:11 47:17 56:1 73:12 103:25 111:24 116:1 131:1 139:1 141:20 163:25 165:1 185:1 237:17 290:14 319:20 322:11 332:20 **let's...at** 163:25 **let...because** 162:14 **lg** 218:10 **level** 53:15 67:15 96:1 141:1 207:21 210:1, 10



216:14 220:22	18 60:1, 23 66:23,	92:21 93:17, 17
229:25 235:1, 24	10 00:1, 23 00:23, 23 72:12, 22 73:1 111:22	95:22 96:10, 12,
245:22 254:1. 1. 1	73:1 111:22	18 98:1. 15. 22
259:1 266:15 269:1	144.1 145.1	99:1, 1, 19, 20
	195:1 212:11	
	268:12 269:11	
333:1 339:21	limits 14:1, 15,	11/:10, 20
levels 13:18, 24	18 15:1 224:20 320:15, 16, 18, 19	118:1, 1, 18
19:21 24:1 33:1	320:15, 16, 18, 19	121:20 123:23
34:21 31:1, 19	345:12	124.1, 1 129.1
55:1, 1 98:11	line 39:14 40:1	130:15 131:10,
	47:17 49:1 81:17	
235:10 263:1 265:1	112:1, 12 116:19	20, 21 141:19
266:1 269:15		142:1, 22, 24
lilibrary 93:10	135:1, 1, 1 139:16	143:12, 14, 24
liccione 23:1, 1,	140:1, 1, 10, 11	144:1, 20 146:1
11, 24 24:19, 24	145:21 174:25	147:1 149:21
25.1 26.13 27.1	192:15, 16 194:1	
28.1 /1.1 1 1	195:22 204:16	155:10, 14 157:21
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	206.1 213.15 $2/0.1$	24 163:14 167:1
13, 20, 42.10,	250.1 213.13 249.1	168.1 1 178.10
14, 19, 22 45:1,	206:1 213:15 249:1 251:1 262:24 263:17 269:21	182.13 13
	270.10 200.14	199.17 216.12
licenses 280:15	270:19 288:14 302:18 303:1, 1 311:1, 11 342:19	225.11 240.16
life 18:1 87:25	SUZ:10 SUS:1, 1	liquido 221.11
89:15 104:1	311:1, 11 342:19	14 22
198:1 315:17,	lineandand	14, 23
18, 19, 21, 25	288:24	list 22:20, 22
lifeor 89:15	linear 148:1 179:1	36:1 64:19
lifeor 89:15 light 19:1 40:20	256:18 257:1	105:15 146:1
lifeor 89:15 light 19:1 40:20 119:22 202:17	256:18 257:1 260:17 261:1	105:15 146:1 listed 78:14
lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12	256:18 257:1 260:17 261:1 285:20, 21, 25	105:15 146:1 listed 78:14 191:25 211:10
lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 like eps 232:1	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16
lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 like eps 232:1	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1,</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1,
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15,
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15,
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1	105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12 330:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21 link 227:22	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17 34:15 39:12, 16</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12 330:1 limitplease 57:1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21 link 227:22 lint 199:17, 17	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17 34:15 39:12, 16 40:1 48:14</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12 330:1 limitplease 57:1 limitations 66:25</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21 link 227:22 lint 199:17, 17 liquid 60:19, 24	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17 34:15 39:12, 16 40:1 48:14 49:19, 23 53:19</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12 330:1 limitplease 57:1 limitations 66:25 223:22 224:1, 1</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21 link 227:22 lint 199:17, 17 liquid 60:19, 24 69:1 75:10	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17 34:15 39:12, 16 40:1 48:14 49:19, 23 53:19 59:1 60:12 62:1 65:14 72:1 75:1</pre>
<pre>lifeor 89:15 light 19:1 40:20 119:22 202:17 lighter 297:12 likeepa 232:1 likei 179:18 likelike 115:1 likelihood 40:1, 1, 14 55:23 212:19 331:11 likely 87:21 172:13 237:1 238:19 296:18 300:15, 21 316:1 limb 280:1 limed 18:17 limit 60:1 198:11 224:1 246:1 275:17, 18 278:1 289:23 321:12 330:1 limitplease 57:1 limitations 66:25</pre>	256:18 257:1 260:17 261:1 285:20, 21, 25 286:23 287:1 288:10, 11, 13 289:1 linear-linear 288:14 linearand 260:15 linearity 260:19 288:10, 22, 23 289:1 linearityand 289:1 linearly 257:1 lines 32:21 75:11 76:1 89:1 146:1 193:23, 25 195:20 228:1 311:10, 12 330:21 link 227:22 lint 199:17, 17 liquid 60:19, 24	<pre>105:15 146:1 listed 78:14 191:25 211:10 215:17 216:16 222:1 listen 251:10 literature 78:21 79:1 82:12 91:1, 12 105:13 108:25 124:21, 24 132:15, 24 195:1 281:24 283:1 312:21 316:15 literatureand 116:1 little 6:10 14:1 15:12 18:20 25:10 27:13, 17 34:15 39:12, 16 40:1 48:14 49:19, 23 53:19 59:1 60:12 62:1</pre>



93:1 99:19	log 17:10 80:1 179:1	278:19 320:1
103:15 106:1, 22	222:11 285:17	336:12 338:13,
111:1 114:1	288:12	14 343:22
126:1 127:14 134:1	logic 299:1	lots 335:25
137:16 138:16	logical 98:17	lou 69:1, 1 74:1,
144:1, 1 145:22	long 77:14 100:10	1 90:1 108:24
147:1 148:1 149:19	105:15 106:1	111:1 156:22, 24
150:1, 20 152:1	153:17 171:1, 21	157:1 160:1, 24
172:1, 12 173:19	237:19, 24 260:14,	164:1
174:20 177:13	18 287:22 313:1,	louisiana 197:12
194:25 203:1, 1	1, 14 314:10,	198:1 327:22
208:1 209:1 255:14	20, 25 318:12	love 281:1, 1 336:18
256:1 258:22	327:1 333:1 338:24	low 13:18 15:1 51:1,
266:23 267:11	341:1	1, 19 68:19 114:10
295:1 302:10	longer 15:25 26:17	119:1 122:1
312:20 316:24	39:1 45:1 53:11	123:1 127:1
317:12 333:24	56:24 87:1 97:17	129:17, 25
335:24 337:1, 1	143:1 204:1 297:15	
339:1 342:1	307:21 315:11,	133:1, 1, 1, 12,
343:1 347:14	14 331:17 342:21	20 134:12 135:1,
live 128:10 199:1	longest 15:22	1, 1, 1 136:16,
lives 102:1 103:10	longstanding 74:1	20, 25 137:19,
105:1 243:13, 15	202:13	20 139:1 140:1, 1,
245:16 309:13	look-see 337:25	1 167:14 170:17,
346:10	lose 52:1 82:15	17, 18, 20 196:1
living 198:18	186:20 200:1, 1,	217:1 225:1 245:23
loaded 325:12	20, 21 201:1	250:11 251:1
loaders 206:11	340:11 345:1 346:1	260:18, 19 262:1
loading 64:1	loses 262:15	266:1, 10, 13
218:1, 12 219:22	losing 344:18 345:1	286:14 287:1
221:23 224:14	loss 82:14 156:10	289:1, 1, 1 300:18
321:1 327:17	342:16 343:14	302:1 303:1 310:10
loael 245:24	344:1, 1, 16	316:1 319:1, 12 320:15 321:12
loam 315:1	losses 342:17 345:1	322:19 324:1, 1,
loamy 315:1	lost 20:11, 12	11, 11, 12, 22
local 65:10 71:10	31:1 253:20	326:1, 16 330:1
132:22 133:1	lot 19:1, 14, 25	334:12 336:14
localities 313:1, 1,	30:1 33:14 34:21	343:20, 21
12	48:25 49:16	loware 137:19
locate 39:13	50:16 51:1 62:1	lower 18:13, 18
located 219:1	64:1, 17, 21 82:18	30:11 32:1 48:14
223:1 306:1 322:1	85:24 112:16	106:22 115:23
location 81:1, 1	117:17 118:1	116:14 121:24,
111:1 172:25 302:1	122:1, 1 126:17,	25 130:1 142:21
307:17	18 136:1 140:14	165:24 183:19
locations 223:1	146:1, 13 149:20	194:1 196:1 218:24
322:1	152:24 170:23	220:24 223:15
lock 218:18 294:15	190:13 211:1	224:21, 22
locks 219:1	220:25 222:23 232:1 247:21	235:11 246:1
lod 275:21, 23 276:1	265:15 268:25	256:17 265:1
290:1	265:15 268:25 270:1 276:18, 20	267:25 275:16,
lods 289:16	210.1 210.10, 20	



800.262.8777 💪 Historic Jordan Springs 💪 1160 Jordan Springs Read 🂪 Stephenson, VA 22656 🧲 540.667.6562

18 289:1 308:20 311:10 315:13 316:13 321:12 322:23 324:1, 19 330:1, 17, 17 331:12 337:1 345:12 **lowest** 30:17 87:1 166:1 183:1 254:18 255:1, 23, 24 256:1, 1 266:1, 13 284:23 **lowit** 12:1, 10, 13, 17, 20, 23 16:18 17:16, 19, 22, 25 18:1 20:18, 22 21:11, 16, 18 22:1, 12, 14, 19 23:1, 13 25:12, 22, 25 28:11 29:1 36:11, 14, 17, 20, 23 37:1, 16, 19, 25 38:1, 17 39:1 41:1 51:22 52:1, 1, 1 53:16, 17 **lsu** 198:1 **lu** 5:13, 13 40:21, 22 41:11, 14 42:1, 12 178:1, 1, 1, 1 180:1 181:1, 1, 12, 14, 24 229:15 230:20, 22 232:23, 23 233:18 284:18, 19, 19 285:15 286:19, 21 288:1, 1 341:1, 10, 17 346:17, 25 347:1 lunch 152:1 155:24 157:15 159:1 161:1, 10 162:23 165:14 244:13 lunch...i 161:20 **luncheon** 162:25 **lutz** 5:22 229:16 278:10 М macdonald 5:1, 1 28:18 35:20, 21

36:13, 16, 19, 21, 24 37:12 38:1 39:1, 10, 11 157:11, 18 288:1, 1 349:18 machinery 114:18 magnitude 58:1 134:1 169:25 206:1 263:1 268:24 275:22 303:23 magnitudes 260:21 **main** 30:14 mainly 19:24 287:23 maintain 82:16 maintaining 334:1, 1 **major** 9:14 51:15 65:1 96:1, 12 108:19 121:1 134:19 143:1 204:1 205:1 246:17 247:1 273:19 275:24 312:23 319:22 324:1 336:25, 25 345:1 majority 89:1 112:14 113:1 137:12 142:1 152:12 337:1 males 176:19 209:19 mallard 78:25 166:1, 1 176:18 182:1 mallards 84:1 119:22 165:24 166:1, 18 176:13 184:24 195:1 **mammal** 331:1 mammalian 329:1 331:15 mammals 331:1, 1, 1 **man** 223:1 **manage** 163:23 management 4:1 67:1 200:21 201:1 301:13 345:1 managing 200:25 mandated 246:1 manipulation 212:1 266:1 manipulations 126:19 map 221:1 265:22 308:20 318:23 322:23

march 56:1 margin 205:20 313:25 margins 204:13, 15, 24 205:23 206:1 207:1 225:22 334:15 mark 32:20 233:18 **marked** 281:19 market 59:20 61:23 297:1 342:23 marketplace 61:10 64**:**1 **martin** 70:1 295:1 marty 299:1, 21 306:1, 1 maryland 295:25 313:11, 13 314:24 316:12 318:1, 23 324:1 332:1, 1 mass 131:19 142:13 153:18 317:17 massachusetts 321:14 **massive** 142:19 **master's** 198:1 **match** 13:15 131:1 317:14 **matches** 323:1 matching 93:1 material 36:1 37:1 38:1 77:1, 10, 16, 24 78:1, 17 84:22 161:19 212:20 239:1 240:25 241:1, 11, 14, 15 242:1, 12, 13 280:16 293:1, 14, 15, 16 296:22 331:16 339:13, 22 341:1 materials 226:1 227:1 295:1 300:1, 10 324:18 349:19 math 214:21 251:1 269:13 mathematical 35:1 244:23 251:11 mathematician 260:22 mathematics 5:10 **matrix** 10:12 40:13



76:14 77:18, 21	may 8:22, 23 9:1	286:1 287:18 289:1
82:20, 20, 22	10:19, 21 11:1,	296:18 324:1, 1
83:14, 17, 18	1 12:1 32:1	332:1 338:14 341:1
84:1, 1, 17	38:1, 14 42:1	meaning 291:13
	44:14 46:1 52:1	means 29:1, 1, 12,
	60:25 71:14	24 31:11 54:19
121:16 123:1,	72:24 73:1 83:1	84:20 92:16 134:14
12, 13, 21	87:14 92:23 106:1, 10 153:1 160:20,	136:25 141:21
143:12 154:14	10 153:1 160:20,	157:1 165:1 195:25
165:19 169:1, 19	23 162:1, 1 173:21	199:1 222:1
196:1 349:19	180:1 181:23 195:1	
	202:18, 24 204:1	
19 57:1 161:22, 24	209:1 223:24	268:23 273:1
	226:19 234:1 242:1	
202:1, 1, 1	243:18 244:16	132:11 212:17
349:11, 12, 14	250:25 264:1, 10, 10, 15 268:1	295:19
matter 7:1 31:11	IU, IU, IJ 208:I 270.1 202.1 202.14	meantime 251:10
	279:1 282:1 283:14	measure 27:23
170:17, 20	295:1, 1 296:1 297:18 299:18,	86:18 180:11
180:24 213:10 232:25 243:25	•	184:15 212:24
	315:15 317:20	229:1 263:20
248:1 259:23 300:14	323:1 325:1 346:11	264:12 271:16
matters 24:23 34:25		317:21 325:10
mature 49:17	maybe 11:1 31:19	measured 29:17
	32:1 33:25 39:1	33:1 48:1 79:1
mccarty 4:14, 14 52:21, 22, 22	47:1 50:17 90:19	86:22 100:18
71:1, 1, 13 157:12	182:16 183:21	102:20 104:1
158:13, 14, 20	235:24 236:13	184:13 249:16 341:18
159:1, 1, 12	237:14 255:13	measurement 41:24,
160:18, 19 165:1	280:1 285:1	25 48:1 179:15
280:1, 1 292:1,	313:16, 22	236:21
1 293:10, 12,	332:1, 1 349:18	measurements 19:1
13, 13, 24	mclean 291:12	20:13 21:1 23:1
mccayliss-menton	mcmaster 5:10	24:10 25:14, 17
256:14	methe 204:14	26:1 32:11 47:1
max 112:11 308:12	mean 11:14 21:1	80:18 221:1 223:25
maximized 112:1	24:21 25:21 35:1	259:20 315:1, 1
maximizes 330:13	36:12, 14 40:13	measures 49:1
maximum 40:1, 1,	51:17 79:18	58:24 63:10, 13
13 53:1 102:1, 1	83:16 84:18, 20	64:21 65:1 67:1,
103:1 104:23, 25	87:1 115:21	11 68:1 144:1
105:1 112:1 121:22		263:22 294:24
135:19, 20 217:13,	177:23 178:25	306:1, 1 334:13
14 304:13 307:16	179:18 181:16	measuring 180:1
311:25 321:13	182:11 188:21	181:1 293:25
325:16 326:1, 1	190:1 194:1	mechanism 86:16
329:16 330:1	195:1 197:13 218:1	263:21
maximumor 104:16	222:11, 12 233:1	mechanistic 5:21
mcdaniel 47:1 48:1	235:10 253:11	mechanistically
52:1, 1 232:12	254:13 261:21 278:23 282:1 283:1	35:18
264:13 266:12	210.23 202:1 203:1	median 19:1 95:18



102:23 123:1, 19 137:19 138:15 140:1 170:16 194:11 222:13 **medicine** 3:1, 10 **medium** 121:1 **meet** 56:1 70:20 333:20 349:20, 23 meeting 2:1, 1, 1 3:1 55:13 56:10 90:25 115:15 201:21 meetings 90:10 **meets** 58:15 meets...carbofuran 58:15 melissa 46:1 146:1 151:1 **melon** 62:10 melons 65:20 153:1 275:1 member 3:1, 16, 21 73:23 members 6:1 7:24 61:15, 15 68:24 73:17, 21 74:1 157:13 201:24 222:20 294:25 327:25 328:24 335:1, 1, 22 349:22 mention 42:1 65:24, 25 220:18 229:1 292:23 mentioned 58:19 61:25 63:1, 12 65:1 66:22 102:1 105:1 144:1 178:11 212:22 215:18, 20 218:23 224:1, 12 225:1, 13, 18 237:1 245:1 246:25 247:21 249:15 270:1 274:20 277:17 280:1, 23 329:1 mentioning 221:22 mercury 4:13 mere 82:22 90:1 110:20 **merely** 157:1 merged 98:14

message 59:12 139:1 messy 193:1, 1 **met** 305:18 metabolic 82:16 145:1 188:1 metabolism 18:15 78:13 83:1 84:22 86:13 87:12 88:1 101:13, 14 104:1 122:23 143:1, 1 180:20, 25 181:1 211:1 metabolism...and 77:23 metabolite 179:22 **metal** 176:17, 17 meters 164:13, 14 325:11 326:10 method 24:1 100:1 115:1 127:18 152:20 213:1 223:11, 16 234:1, 1 279:1, 13, 19 280:1, 1, 1, 14, 17 287:1 304:15 320:16 method...and 245:1 methodologies 10:1 methodology 10:17 54:1 185:11 205:16 252:1, 21 methods 10:1 94:19 135:19 206:16 279:11 295:10 methomyl 14:10, 13, 23, 24 15:1, 20, 21 **methyl** 298:15 metric 102:1 105:1 217:10 257:10 **mg** 217:18 331:1 mg/kg 80:1, 1 84:14 87:25 104:1, 17, 24 105:1 117:16 120:1, 21 206:24 229:18 232:15 246:13 266:14 269:25 **mg/kg/day** 206:1 210:1 232:13 247:15 254:18 271:1

mexico 125:1 327:22 **mice** 281:10 michigan 2:22 323:17, 19 microcosm 329:1 330:1, 18 microcosms 330:1 micromatic 218:1, 16 microphone 71:23 213:21 229:12 microsoft 93:1 **mid** 66:12 317:17 mid-december 8:1 middle 15:23 31:1 40:1 107:24 164:12 166:12 311:10 **midline** 164:13, 15 midnight 335:13 **might...might** 167:24 **might...we** 162:1 **migrant** 160:20 migrating 138:21 migration 106:1 138:1 160:23 **mike** 152:10 234:1 **mild** 132:10 mile 125:20 319:1 **miles** 147:1, 17 148:1, 21 149:1 328:1 342:10, 19 milk 275:1 **miller** 337:1 million 59:17 61:1 336:1 mimic 80:16 314:25 min 112:11 **mind** 15:1 23:17 279:1 314:1 345:17 mine 39:13 342:1 mines 6:1 mini 218:1 277:12 minimal 64:11 334:12 minimis 68:19 132:10 133:19 134:13 135:1, 11 136:16, 18 137:18, 20 139:1 140:1 **minimized** 125:20 minimizes 218:18 minimum 112:1 116:13



minnesota 322:10 323:25 346:11 **minor** 117:1 135:10 334:13 137:13 153:1 169:14, 16 336:1 minuets 27:1 **minus** 192:17 278:24 285:1 **minute** 26:1 56:1, 1 85:20 252:25 317:13 319:10 328:15 338:10 349:12 **ml** 218:20 **minutes** 13:13 21:21 25:18, 18, mmc 250:1 19 27:1 37:20, 22 88:24 118:14 152:1 177:1 204:1 209:13, 18, 22, 23 213:14 238:1 265:14 287:24 299:1 minutes...and 57:1 mirror 160:10 168:14 mis 347:25 **mis-apply** 347:24 misleading 285:1 misrepresents 96:22 miss 146:13 229:1 320:1 **missed** 46:1 131:21 153:17 307:1 325:1 missing 25:1 147:22 224:1 mississippi 3:1 316:1 318:17 319:24 **mistaken** 235:24 misunderstood 250:25 **misuse** 150:1, 10 151:1, 15, 18 152:16 331:1, 14 misuse...yesterday 151:11 mitigate 58:25 63:18 217:1 mitigated 152:22 327:1 mitigation 58:24 63:1, 13 64:21

65:1 67:1, 11 68:1 294:24 306:1, 1 mitigations 66:25 **mix** 23:14 315:22 mixed 84:17 290:1 **mixers** 206:10 mixing 64:1 182:10 218:1, 12 219:22 221:23 224:13 321:1 327:17 **mixture** 83:1 96:1 **mm-hmm** 168:1 176:15 **mobile** 19:1 model 35:1 39:24 74:16, 19, 24 75:1, 1, 10, 24 76:1, 16, 19 78:12 80:10, 13 85:21 88:1, 25 89:1, 1, 1, 19, 21 90:1, 1, 1, 13, 15, 17 91:1, 1, 1, 13, 15, 19 92:1, 1, 1, 13, 23 93:1, 1, 1, 1, 15, 16, 18, 20 94:1, 10, 13, 15 95:21 96:1, 1, 1 99:11, 11, 15, 16, 23 100:1, 1, 10, 21 101:1, 1, 21, 23, 24, 24 106:12, 24 107:19 108:1 118:17 119:1, 17 120:1, 1 123:25 124:11, 14, 19 130:22 131:1, 25 132:1 139:1 142:23 144:19 145:1, 1, 1, 11, 19, 21, 24 153:22, 24 154:1, 1, 1, 17, 18 155:1, 10, 18 156:1 157:21, 22, 24 158:1 160:1 166:1 167:1 168:1 178:10 179:12, 20 184:11, 19 185:1, 1, 12

189:12 192:18 193:1, 17 210:16 213:1 244:11 245:1 256:12, 13, 13, 14 257:1, 17 265:24 273:1, 1 283:19, 20 284:1, 1 298:1 299:12, 24 301:18 309:1, 14 325:1, 10, 12 **model...and** 99:25 model...is 107:23 **modeled** 80:1 137:1, 12 **modeler** 256:1 modeling 5:21 73:25 74:1 85:13 95:14 163:13 166:1 214:20 254:19 256:1, 1 286:13 295:13, 14, 20 298:1, 1, 10, 18, 22 299:1 300:1 301:17 326:23 328:11 331:1 models 40:1, 1 76:25 90:1, 1, 11, 14, 22 92:15 94:23 95:1 96:1 110:25 124:11, 16, 18 142:11 144:24 159:21 168:16 188:1 245:1 249:17 256:14, 22 257:1, 1 258:19 283:21 286:1 287:18 288:18, 18 modified 20:14, 19 234:1 279:13 335:13 337:19 **modify** 303:1 **moes** 215:16 216:16, 18, 21 225:24 moisture 344:1 mold 199:18 molecular 3:12 5:18 moment 22:25 36:24 81:12 231:1 243:22 momentarily 110:15 **moments** 59:11 68:10 299:13



301:10 **monday** 171:19 moni...modeled 231:21 **monitor** 294:17 monitoring 124:23 146:1, 1, 10, 17, 23 147:1 148:1 153:12 214:13, 24 220:11 221:1, 1, 1, 12 223:12, 23 225:1 226:1, 20 280:10 298:21 299:23 306:16 307:1 310:17 312:1, 21 313:17, 22 315:1 316:14, 18 317:15 319:20 320:1, 1, 1, 1 322:1, 22 323:1, 1, 1, 1, 11 324:20 325:1 326:24 328:11 332:1 **montgomery** 4:18, 18, 19 71:1 72:1, 1, 10 172:20, 21, 21 173:21 174:1 175:16, 23 176:1, 1, 10, 15 177:1 239:12, 13, 14, 17, 23 240:1, 12, 15 241:1 months 8:1 92:24 moore 69:1, 1 73:15 74:1 75:1 76:19 85:20 88:12, 15, 16, 19 89:13 152:1, 1 155:21 156:1, 1, 21, 24 158:1, 1 159:1 160:1, 1 164:1, 1, 1 165:21 166:1, 21 167:12, 21 168:1, 1, 1, 22 170:1 171:1, 1, 1, 11 175:20 180:1 182:23 184:1, 1, 12 185:17, 19, 24 186:1, 1, 11, 15, 18, 22

187:1, 11, 16, 19, 22, 25 188:1, 10, 15, 18, 23 189:1, 12 190:1, 1, 20, 24 191:1, 1, 18 192:20, 23 193:1 194:13 195:1, 24 196:1, 16 278:1 moore's 331:1 moore...and 182:21 mor...mortality 167:20 more...more 172:13 morning 2:1, 15 3:1, 13 4:1, 1 7:1, 1 14:1 28:19 29:13 39:1 48:1 56:1 57:16, 18 65:25 85:25 88:18 89:23 106:16, 21 107:1, 25 176:1, 1, 1 202:10 209:1, 1 213:1 236:1 243:14 306:1 349:1, 15, 17 morris 69:23 244:10, 25 263:1 272:14, 17, 18, 19 278:21 289:15, 21, 21 290:1 295:1 mortalities 147:17, 21 148:1 149:1 153:18 331:16 mortality 74:16 82:1 86:19 120:21 122:15, 22 123:12, 14, 14, 18 124:1, 17, 25 125:1 126:11 127:14, 16, 17, 21, 24 128:12, 20 129:1, 1, 13, 17, 20, 21, 22, 25 130:1, 1, 1, 1, 1, 13, 16, 24 131:17, 19, 21 132:21 134:15, 19 137:1 139:1, 19, 21, 23 140:1, 19, 24 141:1, 13, 24

142:1, 1, 1, 1, 10, 14, 19, 21 143:24 156:14 169:24 170:1, 12, 18, 20 181:1 mortality...and 84:12 **morton** 230:21 moser 29:13, 14, 20, 25 30:1 31:15 33:10 34:1, 1 48:1, 1 51:1 53:1, 1 213:10 254:1 256:11 257:23 258:25 mostly 19:15 48:22 53:10 137:17 307:1 308:10 **moth** 347:15 **mother's** 348:22 motor 29:16 30:1, 1, 15 34:1 47:1, 10, 24 48:11, 17, 20 49:1, 18 50:1 51:1 232:15 266:17, 20 mountain 36:15 37:21 mourning 149:10 mouse 331:1 move 10:24 11:1 49:19 51:24 55:25 59:1 73:12 97:1 126:1 203:18 213:21 242:19 244:17 251:1 263:1 266:20 272:12, 24 294:10 296:20 315:12 333:17 339:21 moved 93:24 151:10 168:25 266:21 movement 50:1 moving 50:1 52:1 62:16 161:11 304:10 **mules** 197:17 multi-day 2:16 multi-variant 40:12 multiple 97:17 116:1, 1 134:25 192:1 245:21



269:20 multiplicative 78:1 multiplicatively 34:25 multiplied 301:1 multiply 120:1 134:1 **muscle** 49:1 muscular 47:11 **my...my** 154:22 my...my...let 232:24 myelinating 50:1 myself 197:19 326:1 Ν **naive** 234:1 **n-methyl** 243:15 251:1, 1 264:1 **national** 3:15, 23 299:16 304:10 306:15 316:22 317:18 325:1, 1 326:23 332:19 335:19 nationally 299:18 301:1 nationwide 325:20 **native** 337:12, 14, 17, 18 338:1 **natural** 32:11 304:15 naturally 336:1 **nature** 58:1 77:15 164:11 307:24 344:25 **n.w.q.a** 306:15, 15, 18 308:10 312:1, 1 317:1 319:12 320:1, 15 321:10, 23, 23 322:1, 1, 11, 16 323:1 324:23 327:1 329:13 330:18 **navy** 197:19 198:1 **nd** 277:25, 25 nearly 210:1 248:1 275:13, 22 326:1 neat 182:12 333:23 nebraska 4:15 125:1 322:1 323:17, 19 324:15 necessarily 64:17 97:10 110:22

171:20 296:18 necessary 205:12 216:1 296:1, 14 necessitates 161:1 necessitating 215:1 **necessity** 263:23, 24 negative 130:1 negligible 334:1 negotiated 60:22 neighbor 345:1 neighborhood 286:18 neighboring 127:1 neighbors 342:17 345:1 **neither** 168:21 193:24 280:23 neonicotinoids 200:1 **nerve** 35:1 265:18 **nervous** 49:20 50:1 51:13, 16 53:13 78:1 232:1 249:17 263:19 264:1 265:1, 17, 21 **nest** 149:10, 14 160:1, 1, 1, 14, 15 **nesting** 97:1, 15 105:18, 19, 23 106:19 190:12 **nestlings** 105:23, 25 159:17, 20, 21 160:1 **net** 35:22 netherlands 329:10 **network** 43:1 **neuro-tox** 51:17 neuro-toxicity 47:20 neuromuscular 47:1 **neurotox** 249:14 neurotoxicity 264:1, 12, 23 265:25 **ng** 219:16 **new-use** 11:13 **new...new** 58:10 newer 279:1 289:17 **newly** 180:17 **news** 347:22 nice 38:20 229:18 337:16 **nicely** 200:20

niche 72:25 312:1 313:19 **nicotine** 197:21 **niehs** 281:1 **night** 28:23 260:1 nine 15:1, 22 32:1 326:25, 25 **ninety** 326:25 nitty-gritty 38:23 **nmc** 303:17 no-liquid 240:1 **no...no** 173:13 180:25 276:1 no...there's 182:15 **noael** 230:19 235:20 245:24 **noe** 229:18 **noel** 216:1 **noes** 228:11, 20 234:24 **noise** 193:13 nomogram 114:14, 23 115:1 nomograms 95:1 117:11 non-agricultural 300:19 317:1 non-detects 309:1 322:14, 21 non-occlusive 292:1 non-physiological 225:1 non-statisticians 326:1 non-threshold 260:16 non-waterfowl 108:1 124:1 137:17 **noon** 57:1 118:1 **nor** 92:1 96:1 132:1 **normal** 40:12 86:1 172:13 222:11, 12 269:24 301:1 302:19 305:1 normalizing 278:17 normally 43:1 87:1 119:1 238:20 **north** 138:24 144:11 305:11 319:16 327:11 337:13 northeast 197:12

northern 102:1 northwest 62:10 65:22 121:23 316:1 323:1, 16 **not...cannot** 231:14 **not...is** 210:24 **not...not** 74:23 **not...sorry** 84:1 not...there... **there** 182:1 **not...you** 268:1 **note** 104:19 107:21 108:1 111:19 126:1 127:1, 1 131:23 144:1 147:10 148:13 151:19 162:16 177:1 195:16 200:15 323:1 **noted** 93:14 97:21 98:17, 24 99:1, 10 109:1 114:21 127:22 150:15 154:14 191:19 **notes** 55:1 **nothing** 149:16 150:11 179:16 270:1 345:1 **notice** 2:19 11:11 56:12 74:12 84:16 165:25 176:13 204:17 248:24 254:15, 16 261:1 270:19 274:16, 22 336:17 347:24 **noticed** 152:11 165:19 300:17 notification 66:13 **notion** 95:16 **novel** 180:1 **npore** 277:12 **nrid** 221:1 **nu-may** 5:1 **nuances** 202:18 **numb...the** 259:24 numerical 252:22 287:12 numerous 59:15 80:19 149:1 263:11 **nursery** 307:19

nutrition 336:1 0 o'clock 162:1 o'neil 331:20 o'ryan 219:1 objectives 76:1 occasionally 18:24 138:24 occasions 304:1 occlusion 290:21 291:10, 12, 13 occlusive 292:11, 13, 13 occupation 343:16 occupational 64:11 204:1, 23 225:11 226:1 occur 8:23 199:1 210:19 234:12 330:14 331:1 occurred 12:1 58:24 79:11, 13 91:1 102:1, 1 118:1 127:24 150:1 152:15 309:1 313:1 321:19 occurrence 311:19 occurrences 199:1 occurring 150:19 234:11 311:23, 25 occurs 21:1 86:1 118:1, 1 138:23 observable 235:1 observation 79:11 258:13 259:1 276:1 283:14 observations 50:15, 17 108:11 111:1 157:1 158:15 160:1 164:22 258:1 observe...can 132:22 **observer** 109:1 156:1 **obtain** 121:1 305:24 **obtained** 89:1, 1 144:10 329:1 **obvious** 81:21 97:24 224:10 226:17 obviously 34:1 35:12 55:22 57:23 83:1

92:15 109:1 115:1 120:12 137:10 142:10 146:12 154:22, 24 166:15 170:20 173:15 196:21 216:19, 22 218:13, 21 219:1 228:1 229:1 239:19 246:16 286:15 330:1, 10 335:25 obviously...and 220:1 **oddly** 269:22 **october** 91:20 **oecd** 78:20 **of...am** 284:24 of...as 222:17 of...cases 136:14 of...of 68:23 99:25 103:1 117:10 133:1 160:1 190:12 195:14 199:21 218:11 222:14 224:1, 1 281:1 282:1 292:19, 20 of...or 214:1 of...responsible 61:15 of...there 72:17 offer 211:1 offering 172:1 office 2:1 3:15 official 2:1 56:18 161:22 163:1, 1 201:20 202:1, 1 **officials** 153:16 **oh** 29:1 41:1 45:24 46:22 146:16 194:13 195:1 196:11 236:12 284:17 oil 85:17 336:1, 1, 12, 13, 15 337:1 340:13 341:19 348:1, 1, 11, 12, 12, 13 **oils** 348:10 okay 12:1, 12 20:1, 21, 25 21:1, 17 22:13, 19 23:1, 12, 20 24:25 29:1,



11 36:23 39:1, 22,	144:12 196:1	213:1 215:1, 11,
23 41:20 42:12	211:21 266:1 284:1	
43:1 46:17 51:21	316:19	228:23 237:1
53:21 55:17 56:1	onset 208:1	244:15 245:19
57:13 61:23		268:18 269:12
	onto 199:14	
66:1, 14 73:1		orange 112:1, 12
120:1 124:19 132:1	onward 321:10	113:1
140:12 146:1 152:1	open 2:1 11:14	orchard 220:1
159:12 167:1, 22	20:1 28:1 57:1	ord 251:21 254:1
168:1, 17 169:20	73:19 199:17, 18	264:14 279:17
170:1 171:16, 23	218:1, 12	287:24
176:1 177:1 181:14		order 13:10 14:1
182:14, 14, 15	, -	
185:1 186:1, 12,	276:21 278:1	26:1 54:11
	345:17	56:19, 20, 25
19, 22 187:20	opened 348:1	68:22 161:15
188:1, 1, 12,	opening 7:11 57:22	162:11 169:25
15, 18 189:11	58 : 1	228:1 263:1 268:24
191:14 196:11,	operate 344:19	275:22 303:23
12 202:1, 1	operating 83:1	306:23 307:19
219:1 226:24	operation 344:1	308:1 310:1
230:1, 1 236:1	-	311:1 328:1
243:16 253:22	operative 19:1	orders 206:1
255:20 256:10	operator 114:18	ordinary 193:18
257:13 284:20	218:22 220:1	oregon 318:18
285:1 288:1 290:13	opinion 10:24 209:24	-
294:1, 12 332:12	210:13 231:12	organ 161:1
335:1, 16 341:17	317:1 321:1	organic 4:12 20:1
347:1 349:1	opportunities 53:22	48:23
okayed 13:1	opportunity 38:1	organism 77:16
oklahoma 147:24	57:1 88:18 91:1	organisms 79:14
	197:10 333:1	88:10 329:1, 23
old 327:1	349:10	organization 339:20
older 48:21 51:20		organizations 63:1
	opportunitywill	organochlorines
278:1 290:1, 1	229:1	199:22
313:17, 21, 24	opposed 263:21	
omaha 4:16	opposite 176:1, 10	organophosphate
omitted 230:25	324:13	147:20
onin 75:23 117:18	option 337:20, 24	organophosphates
onon 68:11 125:24	options 106:12 168:1	199:22 206:19
135:19 163:22	orall 152:1	209:1 243:1, 10
174:24 185:11	orand 82:1	organs 77:25
228:12	oror 92:1	origin 250:1
onwhat 191:15	108:14 153:1	original 16:21 19:19
	242:25 292:22	32:11 35:12 38:1
on/off 96:21	orso 187:1	94:17, 18 108:21
onceonce 93:15		113:23 114:14
oncology 3:25	oral 9:1 20:16, 17	119:20 184:12
one-and-a 14:16	24:1 27:10, 17	278:14
one-hour 161:20	28:15 31:1 45:13	originally 89:24
oneand 284:1	46:10, 11, 13,	290:22
onejust 74:22	18 99:1 121:14, 16	os 223:1
onethat's 178:16	162:10 205:1, 1	otherand 175:1
ones 122:12 136:1	206:24 207:1 212:1	



others 13:19 38:1 73:21 174:10 306:21, 24 313:16 otherwise 57:1 89:16 138:15 152:1 282:1 otherwise...please 181:17 ought 247:19 255:10 over-predict 144:1 over...basically 274:1 overall 9:1 129:16 132:23 259:22 301:1 overestimates 143:1 overfilled 274:17 overfills 274:1 overlaid 319:1 overlain 322:1 **overlap** 136:1 203:1 330:1 overlapping 199:1 overlay 309:1 329:24 overly 64:24 96:16 overnight 106:14 overstates 85:18 overview 57:10 75:21 214:14 215:1 300:1 312:14 329:1 overwhelmed 20:1 203:1 our...for 57:19, 20 our...our 64:1 68:14 166:1 183:1 192:24 our...the 73:1 outcome 140:1 179:15 285:24 outer 223:13 311:12 outflow 337:22 outline 204:1, 1 214:14 244:19 output 95:21 141:11 outputs 92:1, 11, 16 132:1 outside 109:1, 14 223:13, 13 331:1 **outweigh** 334:18 oxamyl 14:12, 13, 23 15:1, 21 267:1, 24 Ρ

p.c.y 312:1 **pace** 149:1 **pacific** 62:10 65:21 316:1 package 8:15 89:13 91:22 267:1 **packed** 155:15 packet 67:18 334:20 pad 327:19 padia 47:1 52:1 page 28:20 35:23 159:13 171:1 343:17 344:11 **paid** 328:1, 1 paired 125:1, 10, 16, 18, 19 pairs 179:21 **p.m** 294:15 349:25 panel 2:1, 13, 17, 23, 24 3:1, 16, 21 6:1 7:13, 24 8:21 9:1 12:21 16:25 17:14 20:1 38:1 53:20 56:11 57:14, 24 59:11 60:25 62:1, 19 64:1 67:1 68:1, 20 69:1 70:1 73:17, 20, 23, 23 74:1 75:1, 20 88:12, 16, 20 89:1, 25 90:10, 24, 25 91:10, 14 93:21 96:1, 14, 21 97:21 99:10 103:17 107:17 153:1, 1 155:1 157:13 163:15 197:10 201:21, 24 202:16, 24 214:1 222:19, 19 226:1, 16 260:24 263:15 277:22, 23 278:1 294:21, 25 295:11 327:25 328:23 329:1 331:20 333:1, 1 335:1, 1, 1, 12 340:21 345:20 349:22 **panel's** 68:14 panel...we're 155:23

panelists 27:25 196:17, 18 panels 68:25 94:1 163:1 **panger** 146:1 paper 36:22 40:24 41:11, 15, 21 43:1 44:1, 12 47:16 48:1, 24 52:1 85:1 179:1 229:1 250:13 252:1 280:25 paper...support 264:21 **papers** 20:10 36:15 47:1 52:1, 15 235:22 242:17 paragraph 347:25 parallel 13:1 193:23 194:1 266:1 param 69:1 75:10 85:13, 21 88:1 92:21 93:17 95:23 96:10, 12, 18 98:1, 15, 23 99:1, 1, 19, 20 107:1 110:14 111:1, 16 115:1 117:10, 20 118:1, 1, 18 121:21 123:23 124:1, 1 129:1 130:15 131:11, 15 136:1 137:1 141:19 142:1, 22, 24 143:12, 14, 24 144:1, 20 146:1 153:10 155:10 157:21, 24 163:14 167:1 168:1, 1 178:10 parameter 40:11 166:20 179:14 189:1 parameters 40:1 122:12 144:1 178:14 185:25 284:1 309:16 pardon 41:1 214:1 **parent** 179:21 paris 197:22 park 131:1, 11 170:1, 1



part...portion 62:16 parthenogenesis 199:1 participants 90:10 participating 312:18 participation 333:1 349:24 **particle** 291:18 particles 77:20 290:19 291:16 315:1 particular 17:17 48:23 72:1 84:1 99:11 118:1 123:1 130:14 151:1 165:10 166:1 180:1 186:25 187:1, 1 189:21 190:19 196:14 206:23 231:19 232:1, 20 250:1 266:24 291:1 300:22 303:11 323:11 324:10 338:15 particularly 93:23 155:25 190:11 224:1 256:16 328:11 parties...who 197:1 partition 98:15 159:18, 23 189:14 partitioned 98:1 110:13 113:10 145:12 partitioning 113:10 partly 152:23 316:18 pass 88:11 213:20 263:1 299:1 306:1 **passed** 342:1 passerine 105:15, 19 106:18 140:14 160:21 passerines 137:17 161:1, 1 190:12 passing 10:1 **passive** 223:20 **past** 58:25 65:1 66:12, 18 70:12 200:1 201:1 222:16 244:22 263:15 303:17 306:10 308:16 310:14

pasted 241:15 patch 223:1, 23 patches 223:1 224:1 **patent** 306:10 pathogens 339:1 **pathway** 339:1 patience 244:1 333:1 335:10 349:1 pattern 9:1, 10 73:1 79:1 84:11 95:24 106:1, 20, 25 107:1, 11 108:1, 13, 15, 17 122:17 124:1 137:15 141:22 142:16 144:18 160:10, 11 172:1, 1, 14 pattern...that's 122:16 patterns 8:22 9:24, 24 10:19, 21, 23 11:1 52:12 57:11 105:13 107:18 108:1 135:14 136:13 143:22 172:12 308:21 patterns...and 107:21 pause 59:1 65:23 **pay** 162:1 **pdf** 75:23 peak 24:10 25:14 26:1, 1, 1 59:16, 23 104:21, 22 106:21, 21 207:25 208:10 210:19, 25 237:10, 11 265:13 269:1 307:1 310:18 peak...when 237:10 peaks 105:21 106:1, 1 107:25 pediatrician 280:22 pediatrics 3:1 **peer** 38:25 157:23 158:1, 10 269:1 pdp 273:21 275:12, 14 pen 175:1, 1, 1

pending 11:13 65:22 66:1, 1, 14, 16, 18 penetration 207:1 211:1 213:1 peninsula 319:16 327:12 pennsylvania 305:11 327:23 **pens** 176:17 people 12:1 34:1 49:25 56:1, 16 171:22 174:13 236:10 238:18 269:13 281:11 306:25 336:23 337:1 **people's** 162:1 per 19:21 29:18 59:18, 24 60:21 61:1 66:23 96:15 101:1 104:1, 1 116:1, 13, 13, 14, 22 119:21 120:1 125:18 128:10 129:1, 13 139:12 141:12 148:21 164:24, 25 178:1 187:12 190:14 217:18 221:21 269:13 287:17 295:22 296:1 298:12, 17, 20 302:1, 1 304:1, 1, 1, 24 305:1 307:17, 20 309:1 310:14 312:12, 13 314:19, 22 319:1 320:21, 24 321:14, 19, 24, 25 322:17, 18 324:25, 25 326:1, 1, 13, 17, 21 327:1 329:16 331:1 342:19 344:16 percent 30:13 32:21, 22, 23, 25 33:1, 1, 13 35:1, 1, 1, 16 40:23, 24 41:1, 1, 17, 18, 19, 23 42:18 44:1, 1, 1, 16 45:1, 12,



14 59:23 60:17 84:12 87:1 112:14 113:1, 1 120:1, 21 126:11 128:11, 20, 25 129:1, 13, 18, 21, 24 130:1, 1, 16, 20 131:16, 18 132:16, 25 133:1, 10, 11, 14, 15, 21, 22 134:1, 1, 1, 1, 15, 22, 23, 24, 24 136:19, 19, 23 137:1, 1, 14 138:11 139:18, 19, 20, 22, 22 141:14, 14, 22, 23, 25 142:1, 1, 1, 1, 1, 10, 18, 19, 21 156:14 170:1, 12, 14 190:1 192:17 193:25 200:11 218:1 220:1 241:1 246:1 254:1, 1, 17, 21 255:1, 13 256:1 259:12, 15, 16 261:14 269:23 273:1 274:1, 18 277:1 278:23 279:1, 1 285:1, 1, 1 297:25 298:1, 1, 14 300:25 304:1 307:15 311:22 313:20 324:23, 24 325:25, 25 326:1, 25 330:25 percent...a 139:15 percentage 34:19 300:20, 24 301:1 302:1, 16 303:1 305:1 percentages 303:1, 22 percentile 102:17, 18, 19 120:18, 24, 24, 25 139:16 311:12, 21 325:17, 17 326:1 percentiles 194:10 perfect 130:22

190:16 performance 89:1 94:15 99:15, 17 124:19 131:1 142:23 231:1 performed 20:20, 23 131:1 273:20 309:1 **perhaps** 74:1 76:22 87:17 173:1, 19 255:1 perimeter 97:15 147:1 148:10 158:25 159:1 **period** 6:18, 19 37:18 44:13 55:19, 19 56:1, 14, 15 63:1 77:14 82:17 102:1 119:21 153:17 157:14, 15 161:14 163:1 178:1 185:1, 1 196:13 225:1 237:1 291:1 302:1 341:1 346:1 **periods** 306:24 317:15 343:1 peripheral 263:19 264:1 265:1, 17, 21 permanent 3:1, 16, 21 87:22 permissible 55:1 181:22 permission 88:12 **permit** 181:17 permitted 71:16 persistence 315:10, 20 persistent 316:1 person 223:17 269:16 personal 321:1 341:11 personnel 349:15 persons 217:24 220:23 perspective 10:10 61:11 62:1 64:25 67:13, 25 282:1 295:25 302:12 313:10 314:23 318:1 333:11, 16

pertinent 27:11 **pest** 4:1 345:1 pesticide 3:1 5:1 11:23 93:18 100:1 101:1, 1, 16 115:1 126:22 182:11 206:10 215:15 217:23 218:1 220:16 221:15 243:1 245:12 283:1 307:1 317:16 340:1 pesticide-induced 183:24, 25 pesticides 5:15 74:22 90:15, 17 127:1, 1, 11 144:1 225:11 243:1 245:1 280:24 281:1, 16 306:11 309:1 313:1 319:1 340:25 341:12 pests 347:14, 16 **peter** 4:1 5:1 **petition** 66:1, 14 petitioned 66:1 **ph** 18:1, 1, 10, 11, 17, 18 315:1, 1, 1, 14, 18, 19, 21, 24, 25 317:1, 1, 1 324:1, 1, 1, 11, 14, 17 ph's 316:1 317:1, 1 324:1, 1, 19, 19 pharmacal-kinetics 27:1, 12 pharmacodynamic 179:20 208:11 pharmacodynamics 178:14 pharmacokinetic 178:14 207:24 208:11 211:12 212:1 213:19 236:14 pharmacokinetics 213:1 **pharmacy** 5:1, 17 phase 66:21 128:1 178:18 198:1 333:18 337:21 phase-out 66:20

phased 333:18 **phed** 222:1, 1, 17 **pick** 181:21 256:21 343:22 **picked** 150:13 175:1 197:18 picking 165:14 219:1 343:22 pictorial 117:1 262:1 picture 39:11 100:19 102:16 150:18 218:12 219:16 220:1 261:1, 11, 15, 20 345:14 **pictures** 219:19 260:25 261:10 262:1 288:25 289:1, 1 343:17 **phoma** 339:10 **phone** 93:12 phosphates 48:23 340:25 phosphorus 4:13 **photo** 339:1 photolysis 19:1 photosynthesis 199:16 **piece-wise** 256:18 pieces 58:21 61:24 93:24 piercing 52:18 phrase 25:15 26:1 260:10 pigeons 152:17 **pile** 36:22 piles 20:10 235:22 **pilot** 198:1 piloting 220:23 physical 82:22 220:25 pipeline 340:1 **pizzas** 335:15 **placed** 144:16 290:23 305:24 **places** 38:14 285:22 330:23 **plane** 328:17 planning 7:1 **plant** 66:1 198:24 199:12, 13 337:12,

12 341:21 planting 343:1 345:1 346:19 **plasma** 49:1 **plat** 29:1 platforms 164:23 165**:**1 **play** 208:1 **players** 336:17 **plea** 151:13 **please** 12:16, 19 43:13 162:12, 17 192:12 289:15 349:11 **plenty** 274:1 **plot** 16:15, 18 17:1, 17 126:1, 10, 12 128:12, 13 156:11 179:1 254:1, 1 255:1 256:18 285:17, 18 288:13 plots 17:1 125:1, 10, 18, 19 126:20, 21, 24, 25 127:1, 15, 16, 17 129:1, 1 130:1, 12 195:1 plotting 86:24 **plowed** 197:17 pmd 29:1 30:15 47:24 48:1, 1 49:16, 17, 22, 24 50:12, 19 51:1, 1, 1, 11, 12 pmd50s 253:1 **plus** 90:1 101:18 192:17 344:1 349:18 **pnd** 14:24 39:24 **pnd11** 247:13, 24 251:20 252:11, 12 254:1 255:24 256:10 258:25 262:18, 18 272:1 **pnd17** 251:20 252:16 255:1 260:1 **pmra** 224:24 **pod** 271:1 point 14:1, 25 15:1, 21 16:15, 23, 24 19:1, 1, 1 20:12

21:1 23:17 34:1 38:1 41:17 45:1, 22 46:10, 12, 22 51:17, 25 52:1 53:1 54:1 55:17 56:14 57:1 64:1, 23 69:20 70:22 73:12 86:18 90:14 140:25 150:18 163:14, 25 178:1 181:1, 15, 19 183:22 192:1 196:1, 24 203:12 204:12, 18 205:21 206:1, 1, 1, 24 207:23 210:17 211:13 213:16 215:25 225:18 228:25 230:25 231:22 238:1 242:16 243:19 244:1, 1, 21 245:15, 17 246:1, 12 249:1 250:1, 1, 1 251:1 254:1, 16, 20 259:1 262:1, 1 263:1, 11 264:13 266:11 267:1 268:1, 25 270:13 271:1 278:1, 20 282:22 283:1 286:1 287:14, 21 293:21 294:1 299:13 306:1, 1 312:13 321:1, 16 326:25 337:20 342:1 **pointed** 196:1 215:1 303:16 points 16:20 20:1 23:13 32:1 48:25 49:1, 1 63:16 76:24 134:25 145:22 173:20 182:16 206:1 210:18 230:22 233:1 244:16, 24 251:11 256:11, 19 284:1 309:1 310:25 311:1, 16 329:20, 22 330:19 **policy** 2:1 202:13



245:25 polk 318:18 poll 339:20 ppb 277:1, 18 307:14 308:12, 12, 14 311:1, 18, 19, 20 **poorly** 18:23 pop...local 132:17 pops 53:10 population 97:23 98:1 109:1, 1, 15, 25 111:18 112:22 132:18, 23 133:1 156:17, 18 189:22 270:20 307:25 338:11 346:16 population**adjusted** 246:25 populations 132:22 276:12 277:1 339:17 **porent** 324:18 portier 3:13, 14 177:1 178:1, 1 181:25 185:1, 10, 18, 21 186:1, 1, 1, 12, 16, 19, 23 187:1, 13, 17, 20, 23 188:1, 1, 11, 16, 21 189:1, 11 190:1, 1, 17, 22 191:1, 1, 14 192:11, 21 193:1, 21 194:21 195:19, 25 196:11 283:17, 18 284:10 285:16 portion 89:19, 20 188:25 200:1 272:21 299:1 pose 70:14 154:11 277:23 posed 85:18 154:1 164:1 poses 74:13 153:1 position 57:20 60:1 61:19 69:14 92:1 205:10, 14 207:13 250:22 264:1 271:13 333:1

334:1 positioned...they 164:24 positions 176:1 possibility 178:21 possible 25:1 34:1 107:13 143:15 145:1 154:1 244:17 282:1 296:25 337:20 339:23 **possibly** 7:10 78:1 post 21:1, 12 25:21, 22 26:1 60:1 125:1 147:1 148:11, 17 149:1, 12 329:15 post-application 65:21 post-dose 13:13 post-dosing 269:21 post-emergent 139:11 297:18 **posted** 6:14 **postnatal** 246:13 **pot** 286:25 potato 62:1 137:23 275:1, 19 278:1 313:1 314:19 319:23 336:23 potatochip 336:11 potatoes 65:21 121:23 123:1, 19 140:15 153:1 273:21 275:11 277:25 316:1 potency 10:12, 18 16:24 17:1 267:1, 10 potential 58:25 63:19 67:1 72:15 78:1 85:18 138:1 184:1 204:13 265:25 266:1 281:13 299:17 300:1, 13 301:1 304:11 305:1 315:11 327:1, 1 337:21 potentially 68:1 234:11 302:14, 24 303:13 304:20, 25 305:1, 13, 21

318:21 **pots** 251:1 pound 129:1 139:12 141:12 221:21 314:19, 21, 22 326:1 343:1, 10, 13, 14 346:20 pounds 59:18, 24 60:11, 18, 20, 21 61:1, 1 66:23 217:12 304:23 307:20 319:1 power 256:12 283:20, 21, 22, 25 284:1, 1, 1 **ppm** 240:24, 24 practice 4:20 133:1 244:22 275:23 practices 67:1 224:18 301:14 prakashchandra 43:15 45:1, 15 pre 125:1 129:19 130:1 269:20 297:16 329:15 pre-1995 60:1 pre-application 129:22, 23 130:1 pre-dosing 269:17 pre-migratory 128:1 preceding 101:11 118:1 119:1, 24, 25 125:24 191:1 193:1 **precious** 342:13 **precise** 289:20 precluded 248:1 predict 51:13 123:18 302:1 325:13 predicted 74:16 122:15 124:1, 17 130:16 140:24 141:22 142:1 153:18, 20 170:1, 12, 20 310:13 326:1, 1 predicting 40:1 310:1 prediction 40:1 309:22 311:24 312:1

predictions 39:23 131:14 141:21 142:22 143:23 275:20 276:1 predicts 131:16 137:1 predominant 73:1 prefer 181:19 prefer...would 178:1 preference 173:1 174:1 preferences 97:1 173:10 preferentially 225:10, 14 preferred 145:1 174:15 213:1 223:16 272:1 336:15 pregnancy 280:23 281:17, 25 pregnant 280:24 preliminary 16:19 preparation 198:10 **prepare** 37:13 **prepared** 107:16 293:15 presence 79:12 82:22 245:1 324:17 presence/absence 148:13 **present** 57:18 70:17 74:1 77:19 131:23 149:22 150:14 173:1 285:23 316:23 324:21 333:1 presentation 2:11 20:16 38:21 47:23, 23 56:23 57:18 63:17 68:23 69:1, 12, 18, 25 74:1 88:13 127:20 128:24 150:15 155:22 162:18 163:12 165:17 173:22 179:23 183:1 196:14 197:1 201:15 202:1 203:20 204:1 213:25 214:10

230:24 231:1 242:16 243:20 277:22 294:10, 11 329:17 330:16 332:11, 13, 14, 15, 18, 21 347:21 349:12 presentation...but 229:1 presentations 6:17 12:1 56:18, 21 57:19 58:12, 18 59:1 73:13, 19 157:20 161:15 162:15 163:1, 20 196:15 197:1 201:24 203:19 244:12, 19 294:1 331:21 333:12 335:1 presented 60:1 91:16 136:1 139:10 140:20 141:17 151:22 168:12 172:24 173:1 268:14 269:10 276:23 296:23 298:10 333:14 presenter 175:1 presenters 68:24 161:13 163:16 presenting 69:1, 1, 12, 16, 20, 22 270:18 271:1 presents 58:1 president 2:22 pressing 52:1 pressure 217:1 339:1, 12 presumably 124:1 presumption 80:1 **pretty** 13:12 14:20, 22 17:11 19:1 30:1 37:21 39:19 95:1 108:1 130:20 131:1 147:20 186:17 197:20, 22 198:19 209:15 210:21 211:1 213:11 230:19 332:25, 25 342:1

prevent 81:1 198:14 217:23 **previous** 178:25, 25 191:12 314:1 previously 13:1 63:1 103:17 162:20 203:1 316:10 329:14 **prey** 94:25 price 199:19 primarily 4:12 58:20 59:20 63:14 128:1 148:19 207:1 306:20 primary 3:11 9:1 61:1 72:1 217:1 223:1 336:13 principal 68:24 principles 61:17 printouts 349:17 prior 57:18 70:1 115:15 176:14 prism 299:11 301:17 325:1, 1 326:24 prism's 295:15 private 19:13, 24 319:25 320:1, 1, 1 probabilistic 10:15 90:16 probabilities 134:1 311:13 probability 110:1 133:1, 1, 11, 14, 14, 20, 21 134:1, 1, 16, 19, 22, 24 135:10 139:18, 22 140:1, 19 311:1, 19, 20, 25 312:1, 1 330:25 **probable** 166:11 probably 6:24 20:11 39:1 45:1, 21 55:24 59:1 60:1 79:10 85:1 88:1 148:1 171:11 172:1 173:15 174:1, 20 203:11 213:11 224:10 231:14 234:17 236:1 251:25 253:23

257:1 260:24 280:1 64:14 72:1, 25 286:1 291:22 134:1, 1, 1, 20, 300:1, 17 310:1 23, 25 135:1, 1 314:20 321:1 137:24 150:17 330:13 151:1, 15 182:13 problem 24:1 28:1 199:24 200:25 177:13 179:1 209:15 238:22 240:1 242:1 193:12 198:14, 283:1 297:21 16 214:1 234:10 300:22, 22 236:24 279:19 303:14 310:16 338:14 344:1 313:19 314:18 345:22 334:19 336:1 problematic 283:1 338:14, 17 problematical 284:1 340:1, 1, 24 problems 198:25 341:1, 24 342:23 233:1 278:11 345:10 348:1 296:19 338:1 production 57:11 344:10 85:1 198:1 procedure 11:15 200:23 313:1 238:12 295:14 336:1, 13 298:16 337:23, 25 procedures 85:1 338:1, 21 340:1, 227:12 296:16 14, 14 proceed 161:18 products 63:1 171:19 64:1, 1, 16 70:10, proceedings 349:1 21 134:13 199:20 process 6:15, 20 200:1, 10, 14, 8:1, 1 11:20, 24 301:1 312:1 22, 23, 24 32:17 336:14, 24 337:1 38:22 44:20 57:1 products...of 62:14 77:1 78:1 86:1 **profess** 309:1 102:15 113:12, profession 198:1 13 128:17 162:10 professional 317:1 163:1 189:14 199:1 professor 3:1, 18 280:17 282:15, 4:15 5:1, 10 6:1 16 295:13 336:10 **profile** 148:22 337:10 339:23 341:21 348:11 **program** 64:14 71:11 72:1 148:1 processes 78:1 96:17 273:22 275:14 103:20 105:1 143:1 306:16 308:10 203:15 328:1, 1 335:16 processing 338:20 programs 64:15, 20 348:12 328:1 produce 336:15 **prohibit** 327:16 338:16 prohibited 67:22 **producer** 338:1 68:1 313:1 347:23 314:1, 10 319:17 **producers** 340:16 321:22 327:12 producing 53:14 prohibitions 65:11 200:1 68:1 319:15 327:1, product 8:1 11:18 10 61:1, 12, 22 62:15

prohibits 327:17 project 60:14 312:18 projected 60:10, 10 71:1 projections 71:1 promised 262:25 **prompts** 226:16 propensity 81:1 176:25 **proper** 157:17 properly 24:1 217:22 properties 52:13, 16 property 305:1 proportion 107:1 108:18, 22 109:1, 25 110:21, 22, 23 112:20 113:22 124:11 143:17 144:10 145:13 155:1 189:1, 1, 17 224:22 proportionate 225:1 proportionately 178:19 proportions 108:23 proposal 8:14 220:12 294:1 propose 214:11 221:1 226:1 306:1 proposed 2:19 8:1 56:12 59:1 60:15 65:1, 1, 18 66:10, 19, 21, 25 67:1 68:1 212:1 269:1 271:22 304:1 306:1 **proposing** 66:1, 17 67:20 68:15 73:1, 1 214:15 222:1 273:12 333:17 prospective 332:1 **prostate** 281:14 protect 51:18 246:11 283:10 294:24 protected 328:1 protecting 283:11 protection 2:1 5:1 217:20 245:1, 11 247:10 protective 26:1



216:1 263:19 264:1	pulled 17:1	26:10 28:1
protocol 22:1	pv 43:11	32:15, 19 33:1
78:22 119:20	puncture 227:24, 25	36:1, 10 37:14
125:22 184:22	pup 49:24 248:15	40:22 41:10 44:1
209:1 231:1	249:1 260:1 262:11	46:25 47:1 48:1, 1
233:1 236:18	266:1 271:11	53:1 54:1, 1 60:25
237:20 258:1	pups 14:23 15:13,	61:1 72:1, 1, 10
protocols 76:11	16, 18, 25 49:22	118:16 154:12
provide 13:1 34:1	255:24 258:25	155:11 157:1
42:1 53:19 59:1, 1	259:1 260:1	159:13 160:25
66:1 105:25 137:11	262:18, 18 272:1	165:15 167:1, 1,
164:1, 1 213:1	pure 180:24 215:10	23 169:21, 22
221:1 227:1, 1	- purely 267:18	171:12 179:10
230:1 236:1, 1	purple 106:20 107:1	181:16 196:13
263:18 293:1	purported 271:15	229:17 231:1
299:12 300:25	purpose 198:10	232:22, 24
312:14	212:1, 10, 23	233:18 234:1
provideand 210:22	214:1, 10 223:1	236:19 237:23
provided 31:16 62:1,	289:1	238:1 240:22
1, 13 75:20 91:1	purposes 35:16	242:11 243:1
92:1 94:1 96:1	174:23 218:11	277:23 278:13
116:1 125:24	247:23 254:12	279:1, 11 282:1
127:19 128:1,	268:1 271:1 318:13	284:15, 20 285:15,
16, 21, 22 152:1	push 152:1 210:23	23 286:1 288:1
156:12, 14 158:1	putting 265:1 343:1	290:1, 15 292:1
212:1 213:1		293:1, 1, 19
	n_{1}	310.13 320.1
221:1 226:1 311:17	puzzling 288:1	319:13 329:1 341.10 11 15 17
329:1 349:20	pyrethroids 126:23	341:10, 11, 15, 17
329:1 349:20 provides 221:18		341:10, 11, 15, 17 342:1 348:1, 20
329:1 349:20 provides 221:18 225:21	pyrethroids 126:23 127:1 199:23	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14
329:1 349:20 provides 221:18 225:21 providing 11:16	pyrethroids 126:23 127:1 199:23	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1 161:1 165:23	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16,
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13,	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22 published 41:12	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20 quarters 45:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12 155:16, 18, 25
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22 published 41:12 48:22 264:14 317:1	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20 quarters 45:1 quethey 270:1	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12 155:16, 18, 25 156:1 158:14 161:1 163:15, 20
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22 published 41:12 48:22 264:14 317:1 puddle 95:1	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20 quarters 45:1 quethey 270:1 question 7:17	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12 155:16, 18, 25 156:1 158:14 161:1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22 published 41:12 48:22 264:14 317:1 puddle 95:1 puddles 95:1	pyrethroids 126:23 127:1 199:23 quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20 quarters 45:1 quethey 270:1 question 7:17 11:11 12:1, 23	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12 155:16, 18, 25 156:1 158:14 161:1 163:15, 20 164:1, 1, 10 167:1
329:1 349:20 provides 221:18 225:21 providing 11:16 58:19 pt 109:1, 1, 1, 1, 15 110:1, 11 113:1 public 5:14 6:18, 19 52:1 55:19, 19 56:1, 15, 15, 25 57:1 58:1 92:1 146:22 161:13, 25 162:1 163:1 197:1 201:24 319:25 335:17 342:1 349:1 publically 17:22 publication 38:25 publicly 196:22 published 41:12 48:22 264:14 317:1 puddle 95:1	pyrethroids 126:23 127:1 199:23 Q quail 83:23 84:1 161:1 165:23 166:18 195:1 196:1 quality 84:25 114:18 199:19 245:1, 10 247:10 265:1 299:1 306:1, 16 316:22, 25 quantify 98:21 99:1 quantifying 124:25 quantitation 224:20 quantitative 40:17 quantitatively 248:13 quarter 14:16 125:20 quarters 45:1 quethey 270:1 question 7:17	341:10, 11, 15, 17 342:1 348:1, 20 questioni 157:14 questioning 157:15 177:1 questions 2:25 6:16, 22 7:16, 19, 25 8:19 10:25 11:1, 1 12:1, 1 20:1 21:1 26:22 29:1 32:1 45:17, 21 46:1 50:23 53:23 54:1 55:22, 23 56:24 59:1 70:25 73:19 74:1 88:13 90:1 92:23 120:16 153:24 154:1, 1, 1, 12 155:16, 18, 25 156:1 158:14 161:1 163:15, 20 164:1, 1, 10 167:1 171:17 178:1, 10



231:24 233:24	ra
242:19 251:12	r
271:25 278:1, 12	
282:20 292:17,	ra
17 295:1 308:17	
328:12, 22	r
331:20 332:10 333:1 334:21	
335.1 10	r
335:1, 10 340:18, 21 345:20	ra
quick 26:24 40:22	ra
52:23 70:25	
72:10 158:14, 15	ra
159:13 228:1	
286:25 287:21	
300:1 328:1 329:18	
336:1 337:23	ra
341:10	_
quicker 53:14 143:20	rl
quickly 14:1 53:1	
78:1 79:1 85:23	
152:11 181:24	
192:12 199:12,	
13 205:19 210:21	
221:1 232:1, 1	
243:1 244:17 298:1	
304:1 315:24	
333:10, 22 334:24	
quite 31:1, 11 72:18	
77:11 88:1 95:1	
97:1 105:24 109:1,	
11 111:13 113:13	
116:25 117:17	
122:11 123:12 135:25 137:25	
138:1 140:24	
143:17, 18, 21 146:22 150:23	
167:16 172:1	
191:16 200:1	
248:12 302:1, 1	
303:1 304:1 305:19	
333:23 339:1	r
quitequite 142:21	ra
quote 37:1 71:1	r
105:25 154:19	
296:16	r
quoted 44:14	
quotient 10:17	
-	
R	ra
rabbit 206:14 207:18	
	ra

adio-labeled 280:16 adiometric 279:19 280:14 adiometric.. radiometric 279:1 **adius** 158:17 164:25 165:1, 1 **ain** 345:12 **ainfall** 342:12 **aise** 18:17 342:11 344:17 **aised** 18:19 98:10 118:15 191:22 230:24 242:24 260:1 283:14 348:1 **aising** 196:19 283:12 344:12 **bc** 14:1, 1 17:1 23:25 24:1, 1, 1, 1 47:1, 20, 25 48:1 210:12 211:10, 13 228:17, 18, 23 229:1 231:18, 18 232:1, 15 248:17 250:15 251:1, 17, 23 252:1, 1, 13, 17, 18 253:1, 12, 19, 21 254:15, 16 255:1, 1, 25 256:16 257:21, 25 258:1, 19 259:1, 10, 15, 17 261:1, 1, 22 262:1, 16, 17 264:1, 1, 10, 22, 25 265:25 267:20 269:1, 21 271:16 272:1, 1 279:1, 1 **bcs** 265:19 **ampant** 338:16 **an** 129:1 131:15 167:13, 15 **andom** 96:25 97:1 112:21, 23 114:1, 1, 11 176:25 andomization 107:23 125:1 **andomly** 103:1

111:25 112:1 117:11, 15 148:16 176:20, 21 189:18 193:1, 1 **range** 9:24 14:19 15:17, 18 19:1 31:12 87:1, 1 103:1 106:13 111:13 115:19 136:19 137:1 166:1 189:16 215:18 243:14 247:20 249:22 250:1 267:11 270:1 271:1, 21 286:16 287:1 302:1 304:1 308:15 310:1, 18 311:1 323:22 329:22 ranged 302:1 332:1 ranges 15:1 302:20 317:1, 17 **ranging** 13:10, 13 216:16 **rank** 30:16 rapid 21:19 27:1, 18 87:1 88:1, 1 96:17 105:1 114:1 143:1 210:1 233:13 243:1, 1 265:12 **rapidly** 199:1 **rare** 312:22 313:1 324:1 rarely 111:10 320:13 rat 13:1 14:1, 1, 1, 15 41:17, 18 42:18 206:14, 25 207:15 209:25 231:10 246:13 260:1 267:1, 1, 19, 20 271:1 **rate** 76:14 77:18 80:1 81:1, 25 82:1, 1, 1 83:1 85:14 95:1, 11 99:1 100:1 101:12, 13 103:22 104:1 117:24 118:25 119:1, 1, 1, 12 121:23, 25 122:23 126:1 135:20 137:24



Page	422	

139:11 143:1 145:1	ray 197:1, 1	131:10 136:10
157:1 180:18, 23	re 58:16	140:1 141:20
183:13 184:18	re-adjusted 311:14	155:1, 1 170:17,
185:22 187:12,	re-cap 334:21	19, 21 177:1
19 188:1 191:1, 10	-	178:24 181:16
200:12 216:13	re-inhibit 87:14	188:22 191:18
217:14 220:24	re-registration	204:1, 1 205:1
221:17 222:1	62:17 282:20	
	<pre>re-scaling 35:13</pre>	206:12 208:1, 19
228:10 314:19	re-used 219:12	210:22 211:21,
320:13 321:1, 11	rerepresents	23 213:1 231:16,
326:1 343:11	110:16	20 233:20, 21
ratethe 191:1	reach 63:20 291:14	235:14 237:1, 25
rates 9:25 10:1 16:1		238:1, 15 247:1
18:1 63:22, 23, 24	315:13 316:1	250:1 252:1, 1
95:1, 15 100:16,	reaches 315:13	253:1, 14 256:19
17 101:1, 1 124:13	reaching 67:1	259:23, 24 262:19,
126:13 156:10	84:22 312:19	21, 23 264:1
159:14, 15	reacting 79:12	266:1, 1, 1 268:15
185:25 200:14	reaction 86:1	269:13 271:14
220:22 225:1, 1	reactivated 87:13	274:12 280:22
251:20 296:1 313:1	231:11	281:11, 12
320:14		282:13 297:23
		310:1, 1 311:21
rather 28:1 98:20	reactivation 231:1	312:10, 22 314:1
103:19 111:22	233:11	
114:10 154:15,	reading 231:1 259:1	316:1 319:13
17 248:21 273:19	ready 12:1 202:1,	320:13 321:15
296:19 310:20	1 203:18	325:1 326:16
317:1	<pre>reagent 234:1</pre>	328:13 330:1 334:1
ratio 115:20	real 26:24 78:10	336:1, 15, 25
252:14 255:24	175:1 177:15	338:1, 1, 12, 17
256:1, 1 261:15,	211:11 235:18	339:24 340:1, 11
15, 24 262:17	323:19 330:14	reason 26:12 31:25
279:1 287:1, 14,	333:1, 10	33:13 43:1, 16
15, 19, 20 289:1	real-world 70:11	49:13 61:13, 14
301:1 302:18	75:11	85:19 87:1 100:1
305:1, 22		110:15 118:1 130:1
rational 25:1	realistic 81:1 131:1	143:1 145:24
rationale 128:1	reality 97:1	150:13 151:10
	realize 8:11 268:1	152:14 154:11
ratios 257:1	really 15:16 16:23	166:1 211:11, 21
278:19 286:17	20:11 23:20, 23	234:19, 20
302:11	27:21 28:1 30:1	279:12 280:12
rats 12:25 13:24	34:19 35:1, 1	313:1 330:12
14:21, 24 35:23	36:1, 1 37:15 50:1	
42:1 47:21, 24	59:12 60:13, 17	reasonable 37:17, 24
52:25 251:18, 22	61:1 63:16	130:12 163:18
252:1, 12, 17	64:10, 23 73:1	166:13, 17 180:1
258:1 266:16 281:1	76:1 78:1, 12	184:25 333:13
rattle 274:1	85:25 86:12	reasonably 256:15
raw 33:12, 19, 23	90:15 92:17, 18,	257:1
34:1 128:16 156:14	19 103:25 105:22	reasons 22:20 61:1
177:20 212:12,	117:1 120:13	72:17, 19 144:1
14 348:12	126:1, 16 128:1	279:1 296:10
	120.1, 10 120.1	324:18
	0	



reaves 2:11 12:1 13:25 15:14 16:1, 1, 1, 11, 14 29:10 31:1 32:1 46:1, 1, 19, 21 recalculation 249:1 recall 44:1 180:22 **receive** 185:15, 20 **received** 17:18, 20 46:13 66:13 101:14 115:15 198:1, 1 229:1 242:18 268:12 295:19 receiving 81:22 83:19 163:1 307:21 **recent** 16:25 17:15 60:1 95:12 142:13, 17 222:16, 18 275:15 289:19 316:24 317:19 321:13 recently 91:23 159:1 160:20 224:15 339:19 **recess** 163:1 202:1 203:18 294:18 **recipes** 28:13 recognize 339:25 recommend 62:23 294:23 recommendation 68:15 196:23 recommendations 55:12, 16 67:1 91:1 93:25 recommended..the 319:14 reconcile 255:18 reconciles 173:1 reconfiguring 123:24 **record** 12:22 16:17 28:1 208:1 **records** 307:1, 12 308:1 **recover** 54:1 recovers 78:1 232:1 recovery 10:13 14:1 21:19 25:15 26:1 35:1 52:25 53:1, 1, 1, 1, 10, 14 76:14 83:1

85:23 86:23 87:1, 15, 16, 18 88:1, 10 98:18, 19 103:22 104:1 118:13 143:1 145:16 178:12 179:12 180:14, 18, 21, 23 181:1 208:10 243:1, 1 287:21 **red** 9:1 20:13 22:1, 1, 22 24:13, 22 33:18 39:25 40:19 48:13, 16 49:1 74:12 104:18 111:1 139:16 148:1 204:17 233:1 234:1, 11, 16, 17 261:1 263:1, 13, 23 265:1, 1, 20 266:17, 19 311:1 319:1 red-winged 102:10 reduce 77:1, 22 83:1 183:10 191:10, 10 217:1 218:21 272:1 reduced 82:1 85:15 123:14 184:20 192:1 235:11 246:10 303:1 313:18 314:1, 19 321:21 334:1 **reduces** 81:25 143:1 reduces...with 143:1 reducing 8:16 63:1, 22 98:25 272:10 315:19 334:1, 1 reducing...or 63:23 reduction 79:18, 23 80:1 118:24 119:1, 11 120:1 183:13 214:21 218:1 220:1 255:25, 25 259:12, 15 260:20 261:1, 10, 22, 23 270:14 reductions 256:1 259:16 261:1, 24 331:10

reed 5:1, 1 292:15, 16 293:18, 19 **refer** 41:11 89:14 174:1 217:10 218:18 295:1 reference 236:1 247:1 259:1 269:1 references 93:11 referred 221:1 282:24 referring 30:25 108:10 173:25 246:24 **refers** 133:16 **refine** 62:25 76:1 145:21, 24 **refined** 70:17 75:1 89:12 91:13 113:15 121:19 215:19 222:1 226:1 273:1 294:22 296:21 297:1 339:18 348:13 refinement 145:19 refinements 62:25 63:1 154:1 **refines** 58:10 **reflect** 32:17 295:25 reflecting 72:11 254:23 reflection 240:1 **reflects** 150:14 271:18 **regard** 7:16 14:1 17:1 19:19 54:24 74:1 98:11 124:11 132:12 153:22 172:16 176:12 182:1 241:1 279:23 331:21 regarding 14:20 54:1, 15 124:1 140:24 153:24 154:1 155:18 156:14 178:10 283:1 regardless 8:22 9:1 11:1 35:11 138:13 254:19 257:17 regards 156:1



164:1 167:1 **region** 260:18, 19 262:1 286:14 319:11 338:1 340:1 346:10 **regions** 134:11, 11 314:15 **register** 57:1 349:12 **registered** 56:17, 25 61:21 65:1, 10 66:1, 1 67:10 70:1 349:1 registrant 7:23 58:1, 23 61:1 70:1 91:1, 11 92:1 118:13 135:16 152:1 155:12 163:10 333:1 334:22 registrant's 154:25 registration 8:1 11:16 58:13, 16, 17 61:13 282:20 335:1 registrations 72:1 **regression** 48:10, 13 50:21 80:12 118:17, 22 145:1 309:1, 10, 19 311:1 330:21 regula... regulatory 133:1 **regulation** 54:15, 24 55:1 regulations 218:1 regulatorily...the 246:1 **regulatory** 4:1 61:16 70:20 220:21 224:24 337:21 regurgitated 85:1 regurgitation 84:25 85:1 98:25 reinforce 270:1 reiterate 203:12 333:22 334:24 **reject** 54:1 rejected 207:13 208:1 211:11 rejecting 54:1 213:18

relate 328:13 **related** 92:15 94:1 152:19 181:1 188:1 202:23, 25 216:23 255:1 285:16 338:1 348:1, 1 related...in 85:1 **relates** 19:15 184:1 287:22 347:25 relating 70:1 relation 85:1 242:10 relationship 13:23 81:21 87:24 88:1 92:19 118:22 145:20, 25 178:22 179:1, 22 180:1 285:19 303:1 relationships 260:15, 16 261:1 relative 21:1 35:1, 1 40:1, 1 79:19 99:17 109:16 117:1 204:1 218:1 252:1 253:1, 15 257:10, 18 259:1, 17, 20 260:11, 12, 19, 21 261:18 267:21 278:23 279:16 285:1, 1 286:1, 12 288:19 317:21 332:1, 1 348:1 relatively 68:16 72:1 105:20 106:1 116:1 139:1 169:14, 16 211:1 240:25 244:12 310:1 313:1 315:1 **relax** 172:12 **relaxed** 306:24 **release** 347:22 **released** 92:1 180:17 releases 86:1 **relevance** 58:22 60:1 91:24 relevancy 251:23 **relevant** 24:1, 1 26:16 54:25 58:1 60:1 82:1 86:18

91:1 183:1 197:1 214:19 220:13, 15 232:18 252:1 263:1, 1 265:11 276:21 reliability 23:1, 15 32:16 37:1 156:1, 19 reliable 23:1 234:20 263:1 265:1 271:12 reliably 27:23 **relied** 207:1 275:21 **relies** 23:23 **rely** 54:18 331:1 **relying** 54:25 205:10, 14 246:15 262:12 **remain** 6:24 247:1 remaining 43:18 68:18 102:13 107:1 150:1, 1, 12 277:14 290:18 305:20 **remains** 303:10 **remark** 202:1 remarkable 211:25 remarks 58:1 198:11 202:10 **remember** 39:22 41:16 44:15 114:13 115:25 117:1 152:1 158:19 159:1 173:23 283:19 322:16 **reminded** 154:19 163:17 reminder 27:24 reminding 218:11 **remnants** 180:15 **removal** 65:1, 1 72:17 removals 72:18 **remove** 68:15 73:1, 1 77:24 232:1 311:1 327:1 **removed** 72:14 75:18 114:25 115:1 135:18 150:17 183:11 273:11 290:21 304:1 308:1 311:1



removing 72:20 274:1 **repeat** 112:18 **repeated** 103:11, 13 113:12 141:1 174:24 repeatedly 149:13 repeating 268:10 repellancy 183:23 repellence 76:13 77:1 78:16 80:1 81:24 repertoire 50:18 replicate 257:15 313:14 replicated 129:1 130:23 **report** 89:12 91:18 92:1 107:16 108:10 127:19 128:15, 18 129:10 140:21 141:1, 18 146:22 148:1 158:1 159:1 166:1 168:15 171:1 192:25 196:22 230:1 235:1, 17, 19, 22 255:1 293:1 322:1 **reported** 152:13, 24 195:1 255:1 **reporting** 60:1 228:1 298:24 **reports** 60:1, 1 75:22 128:1 149:21 153:13 156:12 211:17 242:18 282:1 **represent** 29:1 32:15 34:19 102:23 111:17 112:1, 19 113:23 116:19 152:16 179:1 216:10 223:1 225:1, 1 representation 65:17 98:1 117:10 representational 35:16 representative 224:13 264:1 307:23 308:1 represented 110:18

224:10 310:1 representing 216:1 332:19 335:19 represents 98:1 155:12 189:16 193:13 194:15 223:15 245:23 263:20 265:1, 1 300:1 represents...the 223:1 reproduce 253:1 reproduction 252:10 reproductive 249:13 **request** 11:15 37:24 73:22 151:25 152:1 154:1 **requested** 148:15 149:1 208:13 requests 56:20 148:24 162:11 require 8:1 **required** 25:11 106:1 154:1 280:1, 16 327:15 requirement 213:19 **requires** 8:1 26:14 43:19 227:23 236:1 262:14 **rerun** 46:14 reschedule 162:1 **research** 3:11, 24 4:1 5:23 163:10 299:1 339:15, 21 340:1, 1 researchers 149:1 153:15 reserve 71:11 72:1 328:1, 1 reservoir-based 305:20 **resi...in** 98:12 residual 12:1 residue 18:21 43:17, 24 44:1 98:11 113:20 114:22 115:10 116:18 147:19 192:1 218:20 290:1 341:18, 22 343:1 **residues** 98:13

113:19, 24 124:12 143:17 145:13 188:17 191:24 273:21 275:1, 19, 25 276:1 348:1, 15 resistance 198:14, 17, 21 199:1 200:21 201:1, 1 340:1 resistant 199:21 339:22 340:1 resistence 346:15 resources 18:25 **resovoir** 295:14 299:1, 17 300:1, 1, 10, 11 301:1, 12 302:15, 22 303:1, 10, 25 304:1, 17 305:1, 1 resovoir-based 305:17 resovoirs 299:11, 18 302:1, 13, 19 303:13 **respect** 215:1 263:17 respectfully 154:1 respective 222:1 respects 110:17 respiration 216:13 220:22 221:17 222:1 225:1 respon...does 293:1 **respond** 232:16 279:15 280:1 283:1, 13 responded 96:10 266:15, 17 responding 18:1, 1 234:19 responds 232:1, 11, 13 responds...it 232:1 **response** 9:1, 1 22:1 24:17 28:22 39:24 40:1 83:23 84:1, 1 102:11, 23 103:1 121:1 145:25 168:24 169:1, 18 170:11 201:13 207:17, 25 210:1, 1 229:19

242:20 245:23 249:11 251:1 256:1, 1, 1 258:11, 18 260:15, 16 262:15 264:10 265:13 266:1, 1, 1, 10 269:1 270:1, 10 285:19, 21 286:23 288:16 289:1, 21 339:12 **responses** 49:18 50:1 249:17 265:13, 18 266:1 responsibilities 71:25 responsibility 70:1 responsible 5:24 280:10 283:1 **rest** 39:1 88:20 106:22 209:22 restrictions 63:22, 25 65:12 67:1, 19 325:15, 23 result 67:13, 14 103:20 111:1 114:24, 25 116:1 117:1 139:1, 14 140:1, 1, 1 141:17 144:25 151:1 152:1 192:1 220:1 273:13, 16 348:14 resulted 32:12 resulting 215:16 225:24 231:1 233:15 277:16 results 21:1 43:1 65:1 76:21 78:1 79:1, 21 80:23 85:16 89:1, 1 98:22 99:1, 1 103:13, 14 104:13, 18, 19 108:15 122:20 123:1, 1 126:1 127:15 129:1, 11, 15 130:15 132:1 135:14 136:1, 11 137:16 140:13 147:1 153:10, 12 166:1, 16 168:12 170:1 182:22

184:10 185:1 215:1, 1 237:21 268:1 284:1 295:24 297:1 298:10 305:15 309:23 311:17 319:20 324:21 325:20, 22 336:10 resume 162:23 201:23 202:1 349:1 **retain** 65:1 retained 65:18 95:1 101:17, 18, 19, 23 102:1 103:1 104:17 retained...in 66:19 **retaining** 61:1 62:1 return 7:1 12:1, 21 45:18 53:22 86:1 160:14 163:25 197:1 199:25 201:23 returnable 218:1 returned 160:1 198:1 219:12 returning 160:1 335:16 reverses 41:1 reversible 27:1 **review** 13:1, 1, 1 38:25 55:14 89:25 90:1, 1 116:1 132:24 146:23 157:23, 24 158:1, 10 161:17, 19 202:16, 20 204:1 208:1 263:17 **reviewed** 105:12 124:21 146:21 148:21 218:1 263:14 264:18 269:1 **reviewing** 69:1 90:1, 1 92:1 108:24 124:23 273:1 **reviews** 330:18 revised 17:1 **revisit** 55:10 **richard** 294:20 **rig** 220:1 right-hand 59:13

65:19 81:17 215:19 218:24 285:10 **rightly** 320:1 **rinsing** 219:13 234:17 **risk** 4:20, 22 5:1, 25 6:1 8:1, 20, 20, 24 9:17, 18, 21 10:1, 1, 1, 15, 17, 23 13:1 16:22 17:23 21:1 22:1, 22 23:22 42:1, 1, 24 43:1 44:11, 19, 21 45:1, 11 46:1, 1, 1, 1 58:1, 10, 22 59:1, 1, 10, 10 62:22 63:1, 1 64:10 67:14 68:11, 16, 19 69:11, 16, 19, 24 70:1, 17 73:24 74:14, 21 75:1, 1 76:1, 24 88:21 89:1, 12, 20 90:14, 17 91:13, 15, 17, 25 92:1 93:18 95:18 96:1 98:25 99:13 102:12 103:1, 13 105:1 108:15, 20 121:19 132:1, 1, 1, 1, 10, 13 133:1, 1, 12, 16, 18, 19 134:1, 1, 1, 12, 12, 12, 13, 13, 18, 18, 20, 21, 23, 24 135:1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 11 136:1, 1, 1, 16, 16, 18, 20, 22, 25 137:1, 1, 1, 1, 13, 14, 16, 18, 20, 22 138:13, 14, 15 139:1, 1, 13, 25 140:1, 1, 1, 16, 18, 20 141:1 142:1, 1 143:1 144:1, 1, 1 149:16 153:1, 1, 25 154:1 155:11, 13 156:1

163:12 168:12 181:1 183:19 203:20 204:1, 11, 22 208:14, 22 210:15 213:1 214:1 225:20 243:21 244:15, 20 245:1, 1, 15 246:1, 24 247:14, 25 248:1, 1, 1, 10 249:11 250:1, 17 263:11, 18 264:1 266:1 267:11, 14 268:1, 23 270:16 271:22 272:19, 21, 22 273:1, 1, 1, 18, 20, 25 274:1, 1, 15, 17 275:24 276:1, 21 277:1, 14, 14 280:24 281:1, 19 282:24 283:1 289:1 294:22 296:1, 12, 24 297:1 312:18 324:22 326:22 331:10, 12 333:11, 16, 21 334:1, 11, 12, 14 340:1 **risk...doing** 74:21 risk...other 63:1 **risks** 12:1 61:23 63:19 68:17 70:14 85:18 153:1 226:1 329:1, 1 330:17 334:14, 18 **risky** 35:13 river 308:1, 13, 15 311:16 **river/bay** 310:25 **rivers** 299:22 riverside 3:19 **robert** 69:23 76:15 244:1 263:1 272:14, 19 289:21 295:1 **rocks** 268:1 **rodent** 263:25 rodents 54:1, 13, 22 **role** 51:15 208:1

222:14 224:1 rolling 244:14 rollins 5:13 **rolls** 344:1 **room** 201:22 274:1 276:15, 25 296:13, 23 297:1, 1 326:22 334:1 349:23 **root** 342:14 **rot** 339:10 **rotation** 344:21 345:14 roughly 14:1, 25 26:17 37:1 59:22 120:1 139:22 260:19 289:1 route 9:1, 1 83:25 84:15 178:17 208:21 215:1, 11, 23 216:20 217:1, 1, 1, 1 222:1 225:14 230:1 route-specific 214:12 226:1 **routes** 169:1 214:17 215:1, 1 216:22 222:1 225:22 routinely 83:16 225:19 row 10:1, 1 109:10 111:1, 14 113:17 153:1 160:21 165:1 **rows** 164:21 **rubbed** 290:19 **ruby** 5:1 293:18 **run** 99:24 171:17 300:11 303:11 **run-off** 300:1 running 93:1 264:15, 17 287:18, 18 **runs** 171:21 325:18 rural 19:13, 24 **rush** 7:1 157:16 S **sack** 197:24 sacrifice 180:11

sacrifice 180:11
209:10, 22
210:1, 20 213:13
sacrificed 291:1

safe 11:18 305:19 320:1 **safely** 70:13 75:14 **safety** 262:23 271:1 313:25 334:1, 1, 1, 15 **sales** 59:17, 23 60:10 197:15 298:1 317:19 **salice** 127:22 **salice's** 137:1 **saliva** 85:1 salivation 49:1 **salt** 130:11 131:1 **same...of** 187:1 same...similar 111:1 **sample** 4:21, 21 31:19, 21 32:12 40:11 96:1 110:1 117:11 118:15 161:1 165:15, 15, 16, 22 166:19 222:24 231:10 232:25 233:1, 10 236:15 237:1 254:10, 11 269:12 270:1 307:1 347:1 **sample's** 167:24 **sampled** 306:22 samples 113:20 115:1 209:19 231:1 236:15 237:17 238:1 275:13 276:1 277:21 289:18, 19 307:13 308:11, 14 337:1 sampling 212:15 225:21 306:21 307:17 309:1 sand 315:1, 1, 1, 1 317:1 323:14 **sandy** 19:25 313:1 314:1 315:1 316:12 323:18 324:10 **sap** 2:1 54:23 57:24 58:1 92:1 98:10, 17, 24 99:1 128:22 210:13 250:13 279:10 329:1 334:22 **saps** 76:1



satisfied 45:22 207:19 saturated 336:14 saturates 337:1 scale 9:19 17:11 32:21, 22, 22 33:21 34:1 80:1, 20 285:1, 25 287:1 288:17, 19, 21 289:11 310:1 325:1 scale...3 261:21 **scaled** 301:1 scales 35:12 286:1 288:11 scaling 295:24 **scatter** 80:15 scattered 319:1, 17 327:13 **save** 39:18 181:19 333:1 **saw** 31:16 35:21 47:10 87:1 128:23 172:1, 1 173:13 174:1 214:20 290:25 308:11 331:1 333:22 scenario 46:11 95:1 100:1 121:22, 24 122:1, 1 123:1 131:16 138:1, 25 142:1, 13 151:1 167:15 168:10 170:1, 15, 18, 22 226:1 320:24 scenarios 9:20 76:18 95:1, 1 121:21 122:1 129:1 131:15 136:12, 17, 20 137:1, 1, 1, 13, 18 141:10 167:13 204:18 215:15 221:22 225:23, 25 226:1 320:10 **scene** 198:20 saying...to...to 65:1 schedule 6:24 161:12 201:1 244:18 scheduled 6:12 162:17

schematic 218:24 223:1 scheme 132:1 310:1 schlenk 3:17, 17 45:24 46:23, 24, 24 50:24 51:21 52:17 **school** 5:13 6:1 214:21 science 2:1, 17, 23 28:10 56:10 61:20 62:1 76:1 89:25 90:10, 18 91:1 94:1 96:1, 13, 14 99:12 107:16 155:13 157:23 210:16 211:1 222:19 263:14 335:1, 1, 11 science...science 90:24 sciences 3:19 88:19 sciences...and 264:15 scientific 2:1, 18, 25 6:17 10:22 20:1 56:11 57:19, 20 58:11, 16 59:1 61:17 62:16, 23 73:13 161:17 202:16, 19 203:13 260:1 268:11 333:1, 12 334:21 scientifically 262:10 268:20 333:14 scientists 269:1 328:10 score 318:1, 1, 1, 1, 1, 12, 16, 18, 19, 24 323:24 324:1 331:24 **scored** 319:1 scores 323:21, 22 **scout** 338:1 346:1, 1 scouting 197:25 **screen** 59:14 66:1 296:17 328:14 screening 296:1

screws 219:18 **seaboard** 319:1 323:1 **sealed** 219:11 **search** 126:1, 12 149:13 156:10 **search...all** 148:24 searched 147:1, 18, 25 148:15, 25 149:1 searchers 147:12 149:1, 18 153:15 **searches** 101:25 126:1 147:1, 1, 1, 10 148:1, 20 149:10 searching 149:18 157:1 **season** 338:24 **second** 2:1, 16 7:14 18:16 20:16, 23 23:16 32:19 33:1 37:10 46:14 55:10 56:10 159:13 167:22 174:14 179:10 183:20 184:1 227:10 249:21 255:13 256:1 285:15 303:1 309:1 341:17 347:24, 25 secondary 339:1 **secondly** 34:22 226:20 seconds 170:1 **section** 31:1 36:1 121:19 200:19 244:25 **secure** 218:10 219:16, 19 **security** 305:1 see...especially 286:24 **seed** 198:1 328:1 341:19 346:20 348:11 **seed...grain** 150:24 **seeds** 104:1 117:13 186:1 336:16 337:1 343:1 **seeing** 124:17



142:12, 17 173:23 180:13, 20 242:21 270:1, 11 **seek** 160:17 **seem** 30:25 190:1 265:15 276:19 345:1 seemed 24:16 91:1, 12 **seems** 23:20 44:1 47:14 114:1 153:19 179:13, 18 186:24 **seen** 15:18 30:1 31:13 71:14 85:1, 1 198:21 211:17 250:1 273:24 288:12 296:11, 22 313:10, 18 315:16 331:1 342:16 **sees** 84:11 **segment** 334:1 segregation 339:17 **seldona** 281:1 **select** 100:24, 24 114:10, 12 206:1 270:12 **selected** 148:16 216:1, 10 224:15 246:12 314:25 318:1 selection 198:10 204:18 206:1 222:1 225:14 235:13, 14 244:21 245:15 **sell** 61:1 **sells** 61:12 **semi** 179:1 285:17 287:10 291:11, 12 semi-elastic 292:10 **semi-log** 287:1, 1 semi-occlusive 292:10, 14 **send** 233:1 **sends** 74:10 **sense** 28:16 54:12 86:13 126:21 181:1 183:1 203:1 204:1 206:21 284:21 293:23

sensitive 24:1, 1 95:18 102:18, 23 121:1 137:22 139:15 228:17, 24 229:1 232:19 248:18 252:18 264:1, 1 272:1 276:12 277:1 283:1, 1 309:19 329:21 331:1, 1, 1 sensitivities 120:17 136:15 141:1 224:21 sensitivity 94:14 95:17 102:15 103:1 120:15, 19 121:18, 20 122:10 123:1, 1, 1, 10, 20, 22 137:19, 21 138:13, 15 140:1 167:13 170:1, 16, 16, 17 194:15, 17, 23 195:10 248:20 251:23 252:1, 1 253:1 257:10, 18 259:17, 20 262:1 271:15 286:1, 12 305:1 329:19 sensitivity...we 140:1 sensory 3:25 **sentence** 264:19, 19 347:25 separate 24:18 55:1 139:1 176:14 185:24 231:17 236:1 258:21 259:1 316:1 343:24 separated 125:19 separating 23:18 september 91:18 **sequence** 78:10 197:1 sequential 209:1 314:16 **series** 56:21 96:11 185:15, 16 186:1, 10, 13 272:13 294:1 309:10 **serine** 86:1 **serious** 7:1 337:11

seriously 70:1 184:17 210:14 **serve** 264:1 **served** 198:1 269:16 **service** 294:1 307:25 317:18 339:16 session 2:17 7:1 56:1, 1 162:25 294:18 349:25 setbacks 68:1 **sets** 224:19 258:21, 21 262:1 299:1 setting 199:15 300:1 settlement 60:22 **setzer** 34:13, 14 35:19 39:21 283:24 **setzer's** 39:13 seven 18:19 21:12, 25 45:1 324:1 seventh 22:1 seventy-five 44:1 seventy-two 43:21 **several** 58:25 68:1, 1 70:16 76:1 92:24 114:1 155:25 162:14 167:1 196:19 198:22, 22 200:1 203:1 250:1 269:1 306:23 328:1 336:1 **severe** 140:19 **sexes** 176:14 **shab** 43:15 45:16 **shallow** 19:1, 25 295:24 314:1, 13 315:1 320:1 325:13 326:11 **shape** 258:18 332:25 **sharlene** 2:1 56:18 161:22 163:1 202:1, 1 244:1 **sharper** 192:16 **shaw** 205:1 207:1, 1 **shed** 202:17 **sheet** 295:1 **shift** 65:1, 1 194:24 195:20, 20, 22 321:1 **shifted** 121:12 **shifting** 64:1 194:1

shifts 84:1 **shipman** 302:22 **shiver** 49:25 **sick** 183:10 **shocking** 178:13 **shook** 197:23 **shop** 337:18 **shore** 160:22 **short** 77:14 116:1 157:15 161:13 197:1 201:21 204:1 244:12 278:12 294:10 343:25 shortened 56:1 **shorter** 15:25 243:12 shortest 15:21 **shortly** 7:16 67:1 68:21 139:1 153:1 155:24 243:18 **shot** 325:19 **should...epa** 213:17 should...should 209:10 **showed** 25:15 124:1 171:14 278:14 279:16 298:19 310:25 343:17 **showing** 24:1 36:1 38:20 49:17 83:22 123:1 254:13 267:1 281:1 298:21 311:18 347:16 **shown** 16:15, 18 29:21 52:11, 24, 24 53:1 79:23 97:14 106:20, 20 107:1, 1, 24 111:1 112:1, 12 113:1 116:18 120:20 121:1 128:14 129:10 139:1 222:1 250:1 252:10 259:1 308:1 312:10 326:23 333:24 **shows** 45:11 47:24 52:18 79:1 107:18 174:25 218:16, 25 274:1 276:23 297:11 298:11 308:20 309:23 318:23

319:1, 1 322:1, 16, 20, 20 **shows...of** 174:25 **sides** 176:10, 25 178:1 319:21 **sielken** 244:1, 22 249:19 251:10, 14, 15, 16 274:1 278:1, 13 279:14, 14, 22 283:18, 23 284:12 285:1, 14 286:1 287:16 288:1, 15, 15 **shrinks** 248:1, 12 **sign** 264:1 significance 34:23 76:17 235:15 significant 58:1 62:12 63:1, 12 79:22 83:1 132:17 192:25 210:1 234:16 248:1 262:19 290:18 337:14 339:11 341:1 significantly 85:15 217:1 218:21 223:1 314:18 signs 13:14, 15, 18, 19 49:21 50:1 55:1 171:15 **silent** 270:24 **silken** 69:21 **similar** 17:1 53:1 63:16 92:16 94:18 95:10, 10, 19 98:10 103:1 108:1 117:18 125:14 208:24 250:15 270:1 273:1 276:12 284:14, 19 285:17 301:1 324:1 331:1 similarities 94:16 similarly 243:1 315:20 **simple** 20:11 55:20 97:19 103:1, 25 105:1 109:1 133:25 136:11 171:17 182:24 192:1 254:1

274:1 284:1, 1 **simpler** 245:17 simplicity 104:1 simplistic 96:16 109:1 117:1 123:25 214:17 **simply** 24:1 40:16 160:1 169:18 196:14 204:1 206:20 217:1 221:18 250:12 279:12 296:17 320:1 **simulate** 144:16 325:1 simulation 102:25 103:11 116:23 185:14 simulations 132:1, 1 141:18 325:14 simultaneous 253:12 simultaneously 159:1 single 13:1 77:13 126:1, 10, 15 135:19 136:1 269:12 304:17 323:25 324:1 **sit** 233:10 site 77:1 78:1 86:1, 14, 15 98:18 128:1 209:17 210:1 212:21 237:1 291:1, 1, 1 292:1 307:1 313:13 314:24 316:12 318:1, 1 321:1 324:1 **sites** 84:23 99:1 148:16 325:1 **sitting** 53:18 108:25 338:1 **situation** 13:17 15:1 66:1 75:17 82:1 128:1 133:20, 25 277:25 308:19 situations 15:1 217:1 310:17 331:1 **six** 19:1 21:1, 13 25:25, 25 26:11, 12, 14, 18 40:23 41:1, 1, 19, 23 42:17 43:1, 1,



1, 1, 16, 19 44:1, 328:18, 24 1, 1, 13, 13 45:1, 332:23 349:16, 17 12 55:21 90:21 **sliding** 196:1 94:11 135:15 **slight** 85:1 105:20 skeptical 49:23 106:1, 21, 21 **size** 31:19, 22 107:1 273:16 275:1 78:1 126:1 188:1 slightly 285:1 222:24 227:22 **sm...fmc** 294:12 269:12 291:19 small 55:24, 24 300:13 310:1 60:19 72:25 **sizes** 32:12 106:1 126:1 133:21 211:19, 22 270:1 160:21 189:23 300:14 223:1 243:25 **skill** 38:10 114:18 269:12 275:1 skin 43:17, 18, 280:21 307:22 23, 25, 25 308:1 310:1, 1 212:20 238:19, 311:1 330:25 24 241:16, 16 **smaller** 117:1 290:17, 20 292:20, 218:1 219:14 21, 25 293:22 303:21 **skip** 187:1 262:1 **smallest** 248:10 skipping 224:1 **slope** 80:11 **slide** 13:25 16:15 102:20, 20 28:20, 21 30:24, 114:17 121:1, 1 166:10, 11 25 31:1 46:1 59:12 60:1 64:1 65:15, 179:1, 1 185:18 194:1, 1, 1, 23 19 67:17 68:1 72:11, 13 78:14 195:1, 1, 22 172:22 173:1 **slope...the** 194:1 174:23 177:10 **slopes** 120:16 178:23 179:1 121:1 195:1, 1, 181:10 185:10 14, 22 261:1 187:14, 14 **slow** 18:15 82:23 189:20 191:16, 180:17, 21 25 192:12 194:22 265:15 302:11 204:1 215:17 **slower** 18:13 82:1 221:18 226:12 **slowly** 211:1 251:1 252:10 262:1 smell 126:1 183:1 263:16 267:1, 1 **smith** 146:21 284:20 297:11 **slurry** 83:1 84:1 303:12 304:16 238:17, 22 319:22, 23 321:1 239:1, 1, 1, 16, 323:12 328:25 18, 19 240:1 331:1 333:22 241:14 242:12 **slide...real** 192:12 290:16, 23 293:15, **slide...you** 195:1 16 **slides** 35:25 75:21 **snack** 336:12 337:1 96:1, 11 98:1 **snap** 325:19 127:14 136:11 snap-shot 26:1 173:24 188:13 **smooth** 186:18, 19 191:17 262:1 **so...and** 79:10 298:23 299:1 306:1

so...i 171:1 **so...so** 190:1 267:1 **so...which** 284:1 **soaked** 337:1 **soap** 291:1 **social** 89:15, 15 society 3:15 **snouts** 343:21 **soil** 18:16 19:25 114:17 309:13 314:1, 15, 22 315:1, 1, 11, 12, 18 316:25 317:1, 1, 1 323:18 324:1 325:15, 23 344:23 **soil's** 325:11 **soils** 63:25 301:13 313:1 314:1, 1, 12, 17 316:12 317:1, 1 323:14, 18, 19, 23 324:10, 11, 14 325:1, 1 **sold** 227:21 **sole** 70:1 **solid** 40:1 292:22 329:22 **solomon** 69:1, 1 73:14, 15, 17, 20, 21 88:14 155:21 172:23 173:1, 1 174:1, 1, 1 177:19, 19 180:1, 1 181:21 196:16 328:16, 21, 23 331:19 solubility 240:22, 22 292:23 **solution** 169:17 239:1 240:19 **solve** 247:22 **space** 277:14 **spacial** 9:19 299:1 **span** 10:1 spanning 9:23 **sparling** 4:23, 23 161:1 167:1, 1, 1, 18, 22 168:1, 17 169:20 170:25 171:1 331:21, 22, 22 347:1, 1,



Page 432

1, 12 **spatial** 116:16, 23 192:1 309:16 325:24 spatially 116:1 192:1 309:22 **some...going** 247:1 some...provide 65:24 **some...that** 210:25 **somebody** 47:1, 1 163:1 229:20 291:20 **somehow** 87:10 92:12 98:1 193:16 someone 41:1 171:21 220:24 **somewhat** 49:21 53:12 105:10 124:14 129:23 177:25 180:1 267:1 281:11 287:1 330:16 **somewhere** 13:10 14:1 15:1 39:22 47:1 113:1 247:20 287:14 307:19 somewhere...it 247:19 **son** 197:1 198:1 **sooner** 149:1 **speak** 56:17, 20 88:18 197:10 244:1, 10, 11, 23 349:1, 11, 11 speaker 214:1 234:1 284:14, 17 **speakers** 27:25 162:1 328:13 342:1 349:1 speaking 244:1 295:12 **special** 65:10 special...special 71:10 specialist 234:1 272:20 specialists 317:1 323:18 **specialize** 4:16 5:20 6:1 **species** 74:15, 17 76:19 78:25 94:1, 10, 18,

22, 22 95:17, 19 100:22, 24 102:1, 13, 17, 18, 19, 19, 21, 21, 24 103:1, 1 105:14, 14, 16, 19 106:18 107:1 108:1, 1, 22 109:1, 20 111:14 113:17 120:15, 23 121:1, 1, 1 122:1, 1, 15 123:1, 17, 20 124:1, 23 125:15 129:1, 1, 1 130:17 131:17 132:19 135:23, 23 136:1, 13 137:17, 18, 21, 23, 25 138:10, 17, 23 139:15, 16 140:10, 14 141:1, 1, 15, 23, 25 142:1, 1, 1, 1, 18, 20 144:12, 15 147:1 148:12, 13 166:16, 17 170:1, 22 187:1, 18, 23 194:16, 18 195:15 283:1 329:18 330:1 334:1, 1 337:12, 19, 22 339:18 species-specific 102:14 136:14 140:23 **species...i** 166:23 specific 2:24 13:17 32:1 67:23 115:1 202:22, 25 216:15 220:22 225:1, 15 244:24 259:23 279:1 296:1 309:12 314:1, 14 316:1 specifically 25:12 27:1 202:20 208:1 216:1 218:1 specifications 218:19 specifics 25:10

209:1 283:15 specified 72:13 117:22 209:1 327:15 specifies 26:18 **specify** 27:1, 1 100:1 101:15 115:1 118:1 242:13 **spelled** 115:1 **spend** 48:1 60:12 62:1, 1 89:1, 10 97:11 108:18 109:21 111:10, 21 112:14, 16 113:1 122:1, 1, 1 176:23 189:23, 25 190:15 299:1 spend...will 112:23 spending 112:24 160:14 **spends** 113:1 189:17 **sperm** 282:1, 1 sophisticated 107:22 108:1 **sorry** 31:1 214:1 218:14 219:1 226:13 229:13 230:1 239:1 247:18 279:21 284:17 294:1 sorry... application 63:23 sorry...closed 219:23 **sorry...for** 110:1 **sort** 6:23 8:14 9:13 13:1, 20 25:10 28:16 31:11 34:24, 25 35:12 38:13, 20 40:1 47:11 49:18 57:1 87:18 140:1 155:11 170:23 179:20 202:21 208:10 223:11 228:12 238:1, 1 284:24 285:20 287:1, 1 303:18, 25 332:1 341:10 **sorts** 156:19 311:1 spillage 79:1 **spit** 336:18



sotera 227:22 sound 61:17, 20 335:1 **sounded** 236:25 237:1 **sounds** 345:23 source 36:1, 12, 18 110:17 168:15 169:15 316:21 321:1, 16 **sources** 19:12 36:1 38:1 98:1, 14, 15 110:13 144:21 169:13 245:12 sourcing 349:19 **south** 319:16 327:11 **southern** 4:25 200:24 331:23 347:1 southwest 322:1 **split** 232:25 sporadic 199:1 sporadically 199:1 **soy** 297:19 **spray** 129:1 139:11 142:15 315:23 346:25 **sprayer** 315:23 347:1 **spread** 77:14 241:16 253:21 293:17 **spring** 307:1 sprinklers 347:17 square 223:1 319:1 **ssd** 121:1 **stab** 306:12 stable 316:1 336:1 **staff** 6:17 20:1 73:21 224:25 stage 57:19 343:1, 1 345:1 346:1 348:12 **stages** 316:1 stainless 219:1 stalk 343:18, 25 344:1, 1 stalks 337:16 343:22 **stand** 230:10 343:15 standard 29:20 31:20 32:1 70:21 79:20 115:20 121:15 171:18 211:18, 18 217:21 227:1 246:20 254:11

278:24 333:21 standardized 215:14 standards 58:16 standpoint 225:1 **stands** 93:17 200:16 306:15 309:1 317:23 **stark** 302:1 start 2:1 12:13, 15, 20 30:18 49:17 57:17 163:1 171:18 186:20 210:1 232:15 244:15 257:20 276:17 278:1 295:1 343:21 344:1 345:1 347:16 started 75:1 104:23 133:1, 1 250:19, 20 **starter** 346:21 **starting** 8:25 54:1 185:12 254:1 **starts** 329:18 **starve** 81:1 **starved** 80:25 **state** 3:1 5:17 6:1 27:25 65:10 125:19 142:11 146:1, 17, 23 147:1, 15 148:1, 23 149:1 152:15 317:1, 1, 16 339:14 344:11 state-of-the-art 64:1 **stated** 12:25 103:17 157:1, 1 217:1 statement 132:18 137:1, 11 statement...using 154:23 statements 48:19 161:14 177:14 282:11 **states** 58:14 68:1 70:13 146:1 152:13 200:25 291:1 305:16, 20 306:22 309:25 316:1, 1, 1 317:1 318:24 319:23, 24

320:21 321:1 322:1, 1 323:13, 15, 17, 21, 23 324:1, 1, 1, 15 325:21 327:14 335:1 336:1, 12 338:15 statewide 67:24, 25 322:1 statistical 29:1 33:11, 22 69:22 108:1 173:15 222:25 235:1, 15 244:23 251:16 299:25 310:24 statistically 262:10 263:1 322:1 statistician 36:25 192:14 193:24 258:23 statisticians 117:1 statistics 3:14 5:10, 12 6:1 136:1 192:24 317:18 **stats** 38:12 **statsco** 317:1 **status** 306:18 **stay** 161:15 163:18 240:19 342:1, 1, 1 **stayed** 279:12 **steel** 219:1 **steep** 195:1, 12 stem 338:1, 22, 22, 23, 24, 25, 25 339:1, 1, 1, 10, 10 341:1 342:14, 16, 24 343:18 **step** 49:24 71:22 74:23 85:12 96:19, 22 97:1, 1, 1, 1, 1, 11, 12, 16, 17 100:1, 1 101:16, 24 103:15, 18 104:14, 14, 18, 19, 22, 24 105:1, 1 106:14 107:10, 12 110:10, 12 113:21 114:1, 10, 11 116:1, 1 118:11 119:12, 17, 17, 25 120:1 123:24 124:1

143:1, 1, 1, 20,
20, 25 182:21
143:1, 1, 1, 20, 20, 25 182:21 183:15 184:10, 19,
22 190:1, 15
191:11 193:1, 10
203:11 302:17
303:1 348:14
steptime 124:1
steps 77:1 78:1
96:15, 16 101:1, 1
102:1 114:1
145:1 193:14
245:14, 14
steve 2:21 7:10
163:1
steward 70:10
stewardship 64:14
-
stick 162:19
243:17 270:24
sticks 344:1
stinchcomb 5:1, 1
238:1, 10, 10, 25 239:1, 1 290:1,
25 239:1, 1 290:1,
1, 13, 16
sub-part 19:21
subject 222:17, 18
335:24
subjects 13:10 225:1
submission 66:17
260:1
submit 39:21
submitted 7:23
8:1, 14 58:1 66:11
69 : 1 89:24
91:17, 20, 25
103:17 107:16
$\pm 0.0 \bullet \pm 1 \pm 0.1 \bullet \pm 0$
152:1 154:25
152:1 154:25 167:25 207:16,
152:1 154:25 167:25 207:16, 18 220:14 221:1,
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21 subsequently 91:17
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21 subsequently 91:17 subset 220:17 303:21
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21 subsequently 91:17 subset 220:17 303:21 308:1
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21 subsequently 91:17 subset 220:17 303:21 308:1 subsoil 317:1
152:1 154:25 167:25 207:16, 18 220:14 221:1, 14 226:1 submitting 38:25 subpart 312:11 subsequent 72:14 82:25 90:1 96:11 97:12 114:11 153:21 subsequently 91:17 subset 220:17 303:21 308:1

substance 77:20 substantial 172:1 247:1 252:1 substantially 167:19 268:13 successful 106:1 successfully 338:17 **suck** 84:19 stochastic 214:20 **stock** 339:20 **stocks** 339:19 **stop** 283:15 **stopped** 296:10 storage 161:1 **story** 324:1 sufficient 246:11 284:12 307:25 **suffolk** 318:12 **straight** 192:15 288:14 342:19 streams 308:1, 1 311:1 327:24 328:1 **stress** 172:10 stretch 56:1 stretched 55:21 **strictly** 122:19 132:11 **strip** 165:1, 10 strong 14:14 61:1 340:12 stronger 117:1 strongly 58:13 70:18 201:1 247:11 struck 178:12 180:1 **structural** 123:24 structure 86:1 89:1 90:1 92:1, 1 153:23, 24 154:1, 1, 1 155:18 185:1 suggest 42:1 90:1 213:24 suggested 40:17 128:1 suggesting 183:25 255:1 287:20 suggestion 287:1 suggestions 80:15 91:1 suggests 153:21 stuart 3:1

student 180:23 192:14 **studies** 5:25 10:11, 16 13:1, 1 16:11 20:15 21:1, 24 22:1 24:1 25:16 26:14 27:11 28:14, 15 36:18 54:16 55:14 62:24 69:1, 13, 13 73:25 74:1 75:1, 11 76:1, 1, 1, 10, 13 78:17 91:1, 24 106:11 115:1, 1, 17 117:25 118:12 124:20, 22, 25 125:1, 1, 1, 22, 24 126:10 128:1 129:1, 1 131:1, 1, 12, 20 135:24 145:1, 1 146:1, 1, 10, 14, 18, 19, 21, 24, 25, 25 147:1 153:11, 12 154:25 155:1 156:1 158:22, 22 159:16 160:1 163:13 164:1 167:25, 25 171:1, 17 202:16, 20, 22, 25 206:10, 18 207:10, 15 208:1, 1 215:21 217:24 218:1 221:1, 1 222:15 224:16, 17 225:1, 10 229:1 232:11 238:12 239:1 242:25 243:1 245:19, 21 250:13 257:24, 24 258:1 263:25 264:15 265:1, 1, 20, 24 266:21 268:16 270:1, 12 279:1, 18, 25 280:10, 13, 18 281:1 282:17, 19 291:1 312:1 313:17, 22, 24 316:15, 18, 20, 22 317:1, 15, 16

320:17, 18 322:1 328:11 330:1 studies...and 121:1 **studies...i** 283:1 290:24 **studying** 345:16 stuff 37:21 205:20 293:1 337:11 **sulfate** 197:21 sulpha-carbofuran 15:1 summaries 53:23 summarize 298:1 303:12 333:1, 11 summarized 217:25 316:16 summarizing 295:1 **summary** 19:18 38:13 149:21 312:1 332:17 340:1 summer 307:10 sunflower 62:11 151:1 294:1 332:19, 20 335:20 336:1, 1, 1, 16 337:1, 1, 12, 16 340:13 341:11, 19 344:1 348:1, 1, 1, 10 sunflowers 65:20 336:18 340:1 342:11, 13, 15, 22 344:1, 1, 20 345:16, 23, 25 346:18 347:1 **sunset** 106:16 supplied 177:21 supplies 19:16 307:24 supply 307:23, 24 308:1 **support** 47:19 75:19 108:11 250:16 270:13 272:1, 1, 10 299:1 333:15 335:1 supported 98:1 274:1 supported...this 264:21 supporting 242:17 supportive 93:23

298:22 supports 58:13 70:19 **suppose** 193:15 supposedly 255:1 supposing 11:11 suppression 210:10 sure 7:1 15:15 16:12 17:11, 14 21:1 23:14, 17 24:1 25:1 36:13 37:1, 21 38:1, 1 41:1 42:12 50:25 52:1, 1 83:18 93:10 94:10 117:1 130:24 163:18, 21 184:12 188:22 191:16 194:13, 16 195:10 226:14 227:14 236:1 242:1, 1 248:14 292:1 294:14 296:1 319:13 327:24 332:25 surface 19:1, 16 62:21 63:20 67:1, 1, 21, 24 70:1 80:16 225:1 294:24 298:1, 24 299:1, 10 306:19 312:1, 19, 23 317:1 323:14 325:11 327:20 334:10, 10 surfactants 240:18 surprised 92:14 280:22 281:11 287:13 312:20 surprising 103:20 105:22 surprisingly 204:1 surrogate 9:22 229:1 263:21 271:16 surrogates 10:1 surrounding 109:18 125:14 surrounding...and 125:15 survey 306:17 329:19 **survey's** 317:14 surveyed 148:1 164:25

surveys 157:1 158:25 164:23, 25 227:10, 18, 19 317:1, 17 320:1 322:1 survival 136:19, 24 137:1, 1, 14 **survive** 87:21 susceptibility 329:23 suspect 56:24 286:1 suspended 240:18 241:1 suspending 241:1, 10, 17 suspension 241:1 **sutor** 132:24 133:16 **switch** 49:15 243:23 switched 81:1 173:1 174:12, 13, 14 175:12, 24 337:1 switching 81:13 symptom 85:1 symptomatic 77:1 symptoms 85:1 183:1, 1, 13 269:25 **synapse** 53:14 synch 264:11 synopsis 6:10 161:11 synthetic 126:23 127:1 199:23 **synthra** 200:12 system 50:1, 1 51:14, 16 53:13 78:1 79:13 81:11 217:20 218:1, 10, 12, 17, 18, 20 219:1, 1, 10, 17, 19 221:23 227:25 232:1 249:17 263:20 264:1 265:1, 17, 21 299:20 301:15, 20 311:16 330:20 331:24 systematic 194:18 195:1 systematically 93:25 systems 19:19, 21

49:20 64:1



214:22 217:22	268:20 277:21	technology 289:17,
218:1 219:23, 24	281:1, 12, 12	19 290:1
224:14 227:24	289:17 292:1	ted 6:1
299:1, 23 301:12		telli 235:21
302:1, 24 304:1,	329:17 330:24	temperatures
12, 17, 21 305:10,	331:10 343:18	18:13, 13 199:10
	talking 13:1 22:15	
		temporal 116:16
306:1, 12 308:1,	29:25 48:1 89:1,	192:10
11 310:25 311:1	10 90:22 159:14	temporally 116:1
313:13	165:17 169:25	192:1
	170:1 178:18	
Τ	179:23 184:14	ten 26:11 29:15,
table 15:1, 1	205:15 246:17	18 31:19 32:1, 23,
		25 33:1, 1 35:1
35:22 37:1 38:10	249:1, 10 251:19	41:25 42:23, 23
39:1 41:1 42:1	265:1, 13 268:1	48:22 144:23 152:1
52:18, 20 55:16	269:1, 1 282:1,	313:23
59:13 74:1 158:1	1 287:13 289:10,	
252:1, 10, 11,	16 297:25 299:1	ten-fold 33:18
		313:25
22 253:1 255:15,	323:18 326:17	tend 14:13 19:13
18 302:21 311:18	338:1	28:14 92:12 266:20
349:19	talks 344:11	324:16
tabled 252:11	tall 164:22	
tables 13:1 31:17	tank 315:23	tendency 15:24
38:1, 19, 24 41:22		221:19
	tanks 240:1	tends 30:1 34:25
128:15	tape 292:1, 1	tenth 322:18
takeintake 246:1	tapes 292:1	
taking 9:1 55:1	target 77:1 78:1	teratogen 281:17
talk 37:10 38:20	84:22 86:1, 14, 15	teratogens 281:17
46:1 75:1 85:20		term 13:20 95:12
	245:10 262:18	118:17 124:15
88:23, 25 89:1,	tarnished 198:24	145:1, 10 188:1
1 94:14 98:16	task 220:15 221:1	263:22
100:1 103:15	222:14 223:1 225:1	
108:18 132:1	268:10	terminate 177:1
146:1, 1 147:1		terms 7:1 8:20 9:17,
148:1 162:13 180:1	tasks 216:15 225:1	25 10:14 19:20
	taste 183:1	33:1 34:22 77:1
181:24 184:1	tdi 186:25 187:1	83:16 86:25
188:14 194:1	188:1, 1, 1 190:18	
204:1, 1 205:1, 1,	teaching 74:1 84:19	87:20 125:14
13 209:1 216:14	-	156:1, 17, 17
232:10 237:1	team 171:22 335:1	160:12 178:19
244:20, 24 245:1	tease 48:18	196:22 216:24
	tech 198:1	225:1 235:1 261:1,
246:23 249:19	technical 39:17	10, 25 287:12
250:1 252:21		•
254:12 260:1 271:1	218:19 239:1	292:20, 24
281:22 299:1, 21	241:1, 11, 14,	293:23 328:25
320:14 336:1	15 242:1, 12, 13	331:1 336:1, 1
338:10	technician 50:17	tertiary 86:1
	technique 79:20	test 78:25 79:1,
talked 65:1 74:1, 19	-	
94:1 98:19 183:1	83:15 296:1	14 85:16 120:23
191:15 193:23	techniques 295:20	121:15, 16
232:1 243:13	technologies 217:20,	180:22 228:10
266:22, 23	22	329:14
		tested 55:1 84:1

87:1 102:21	50:12, 14 52:19	277:24 279:1
	53:1 56:23 57:1	280:16 285:16
testimony 201:1		288:25 289:1
testing 83:1, 10, 17		
183:23 206:15,		290:1, 18 291:17
16 330:12 339:12	77:21 90:13	292:1, 1 296:1
346:15	91:14 93:18	303:1 307:15 308:1
texas 148:1, 1, 1	96:17 97:13, 24	311:23, 25
308:13 324:1	99:11 101:12,	318:1, 1, 15 319:1
327:22	18, 21 103:19	321:10 331:17
texas-new 125:1	108:17 109:1	339:1 341:1
texture 315:1 316:25	110:24 112:1 113:1	342:1 343:19
323:14	118:11 120:1, 1	346:14 348:21
		that'sbut 270:1
thanthan 208:18	126:17 127:1	that'sit 240:1
thank 2:14 6:1	129:1, 24 131:1	that'sthat's
7:12 11:1 19:17	132:1, 1 133:1, 1,	
20:1, 25 26:21	19, 24 134:1, 1,	133:23 149:15
29:1, 19 33:1 34:1	18, 19, 23	203:11 287:1
35:19 39:20	136:12 137:1	thatand 108:13
45:16 53:25 55:1		126:1 228:22
57:13, 14 70:24	139:16, 24	254 : 15
73:11 88:14, 16	140:1, 1, 10, 13	thatfrom 189:18
155:19, 20	141:1, 19 142:1	thathow 166:1
162:22 165:12	151:1 152:19	thati 166:24
170:25 171:1	153:20 160:1, 24	188:21
172:19 177:1	162:1 166:15	thatin 115:14
185:1, 10 196:16	170:15 171:1, 11	thatnow 191:22
197:1 201:1, 11,	172:22 177:1	287:13
14, 16 203:16	180:1, 20 181:22	
213:24 214:1, 1, 1	182:1 183:15	thaton 177:10
226:1, 10, 21,	185:17, 19	thatso 190:17
	186:1, 13 187:1,	193:1
22 231:16 234:1, 22 241:23 242:15	1, 16, 20, 22	thatthat 102:12
	188:10, 23	111:1 118:13
243:16 244:1	189:1, 20 190:1, 1	132:18 144:1
251:12 272:15, 16,	191:1 194:11	192:23 207:15
18 278:1, 1 280:19	195:13, 17	260:1 267:1 271:22
283:16 288:1, 1, 1	200:1, 11	293:1
289:12 331:17	203:21, 24 209:1	thatthat's
332:12, 22 333:1	210:1, 16 213:1,	146:1 190:20
335:1, 1, 1, 1, 21	23 214:18 218:21	191:12 193:18
340:19 345:18,	219:24 228:25	219:1
19 348:18, 19	231:12, 14, 21	thatthe 184:1
349:1, 23		280:1
thanks 162:21 333:1	237:1, 1, 13	thatthere's
that's 13:16	238:1, 1, 1	
17:10, 10 18:12	239:16, 22 240:1	228:25
21:11 23:1 24:1	242:24 243:1	thatthese 178:1
25:1 26:15 29:10	249:16 250:1	thea 165:18
30:1, 13, 13,	253:11, 13	theabout 276:10
22, 23 32:1, 17	254:19 256:24	theafter 237:1
35:17 38:1 39:19	257:23 258:1 260:1	theand 60:16
43:1 45:24 47:21	261:19 262:23	69:14 84:18 105:24
48:1, 1 49:13	269:10 271:1	167:23 206:20
10.1, 1 10.10	274:11 275:12	theas 77:19
•	0	



the...at 228:12 **the...dr** 70:22 **the...dwayne** 168:1 **the...either** 256:22 **the...even** 174:14 **the...for** 99:12 178:1 **the...i** 279:25 287:1 288:16 **the...if** 59:1 232:17 261:17 the...immediately 263:1 **the...in** 79:1 81:23 87:19 156:1 168:16 175:1 181:1 215:1 the...included 66:24 **the...it** 247:22 the...it's 231:16 **the...of** 99:1 174:1 **the...oh** 157:1 **the...on** 80:1 104:10 117:22 177:20 **the...our** 311:24 **the...sorry** 156:1 **the...that** 84:20 139:1 193:25 266:12 the...that's 261:1 **the...the** 63:11 68:23 70:19 80:11 89:1, 12 100:11, 21 105:23 108:1 116:19 119:13 136:22 157:21 159:14 164:10, 11 171:1, 25 173:13 174:1 175:1 179:21 182:10 191:14 193:21 201:23 204:16 210:21 214:1 226:1 231:1, 10 232:25 235:13 236:12 241:1 242:1 243:14 247:14 251:1 263:17 274:11 275:20 279:15 294:11

the...the...it's 275:15 the...the...there 209:21 the...there's 133:23 the...these 217:21 **the...they** 207:20 268:21 the...this 275:14 **the...to** 266:25 **the...what** 180:1 the...which... which 228:1 **the...you** 171:24 their...the 273:25 their...their 57:23 161:14 **their...what** 221:1 their..their 279:20 themselves 3:1 22:16 81:1 94:22 106:1 109:17 159:19, 24 **then...and** 194:1 then...it 250:20 then...so 80:1 **theo** 329:10 there's 7:14, 20 9:22 11:24 16:1 21:24, 24 23:1, 24 24:1 31:14 37:21 46:21 52:1 61:1 62:12 75:22, 24 78:10, 19 80:1 81:1, 20 84:20, 21 86:1, 21 87:11, 12 91:1 98:12 102:1 105:15 106:14 107:12, 23 117:25 118:25 119:1, 1 126:1 128:1, 15 129:16 132:15, 21 133:1 138:16 139:17 140:1 145:24 149:16 152:14, 23 154:15 162:12 167:14 169:1, 1, 1 171:21 172:1, 24 175:1 179:1 182:14 183:17 186:16, 24, 24 189:1 194:19 <u>211:1</u>, 1 218:1

219:14, 19 231:1 246:1, 10 247:1 254:21 255:1 266:25 272:1 273:19 275:12 276:15, 24 284:21, 22, 22, 24 285:1, 11 there's...even 194:25 there's...there's 136:1 **there...as** 93:21 **there...there** 120:17 131:1 164:1 202:18 276:1 **there...they** 72:24 there...things 327:1 thereafter 115:11 119:1 therefore 50:19 54:19 85:16 300:1 315:10 **these...of...of** 63:1 these...this 226:15 **they'll** 118:10 185:20 199:1 240:1 344:1 they're 13:1 28:13 31:1 49:19 50:1, 1, 1 92:15 95:1 97:1 105:22 123:20 140:10 144:20 159:21 160:14 176:13, 17, 20, 23 179:20 180:1 186:17 190:1, 1, 12 195:1, 12 211:25 212:1, 1 235:11 245:20 246:15 250:21 252:16 254:12 264:16 265:18 287:18 288:22 they're...they're 97:10 106:1 160:13 **they've** 36:1 101:14 128:22 191:1 200:1 207:13 221:1 237:12 252:24 263:25 337:14



they...and 174:12 **they...can** 292:1 **they...each** 189:17 **they...the** 209:19 246:20 **they...they** 93:23 97:1 126:1 127:23 160:16 172:10 225:16 **they...they've** 138:1 they...this 108:25 **they...what** 158:24 **they...when** 106:1 thick 112:1, 12 113:1 think...i 282:14 think...with 278:11 **third** 69:18 123:15 276:10 thirds 276:16 thirty 13:11 18:1 19:1 25:18 27:1 this...and 75:16 this...because 181:1 this...does 177:12 this...i'll...i'll 60:12 this...in 75:15 77:1 this...of 60:17 174:23 this...the 233:1 this...these 277:1 this...this 60:1 107:15 169:14 177:23 188:24 239:20 this...what 290:25 **this...when** 71:16 those...50-yard 165:1 those...those 151:1 thoughts 89:1 thousand 32:24 33:1 thousands 32:25 310:1 tied 190:18 tier 75:1 214:18 215:14 273:1 295:13 296:1, 10, 17, 20 297:1 298:1, 1, 13,

18, 22 301:18 302:1, 23 314:23 tiered 296:1 318:21 **tiers** 304:18 **ties** 245:1 threatened 132:19 three-and-a-half 6:13 three-fold 17:10 168:25 170:24 267:1 three-quarters 14:11 three...these 177:15 threshold 80:1, 1, 10, 11 87:19 119:1 133:15 331:1 through...or 165:17 throughout 6:20 31:12 61:19 101:1 105:20 106:1, 1 107:19 120:13 122:17, 20 161:1 168:11 175:15 184:23 199:1 211:1 333:1 throughout... across 223:10 throw 31:18 120:19 268:1 337:15 **throwing** 228:25 **thrown** 32:1 tight 14:15, 20 tightens 116:25 tightly 19:1 thus 9:21 109:1 116:22 221:13 **till** 161:1 251:13 **tilted** 194:1 tim 74:16, 19, 24 75:1 78:12 88:1 89:23 91:23 92:1, 11 93:20 94:16, 19 95:14, 20, 22 96:1, 1, 1, 16, 19, 23 98:13 100:10 107:1, 1, 11 109:24 110:1, 25 113:20 114:1, 23 121:10, 11 124:1, 1, 1 131:12, 16 132:1

136:1 141:16, 21 142:24, 25 143:11, 13, 19 144:1, 19 145:11 153:21, 23 154:1 155:1 189:10 195:17 time...my 209:24 timely 301:16 305:11 timer 172:1 **tip** 311:14 339:1 tissue 10:14 49:1 233:1 234:1, 12 tissues 47:1 234:14 **title** 328:24 **titled** 172:22 titles 37:1, 11 to...especially 172:11 to...for 97:1 168:1 282:1 to...if 240:1 to...in 268:23 to...just 243:25 to...minimal 64:11 to...there 207:17 to...they 165:1 to...to 84:1 105:25 106:1 133:1 144:1 145:25 163:16 172:13 175:14 186:20 217:19 220:12, 17 224:1 253:1 278:13 to...vulner...in 65:13 to...well 174:1 tobacco 198:23, 23 336:19 today 2:23 6:11, 19, 24 32:1 56:1 58:18 61:10, 18 64:1, 17 74:1 75:20 90:1, 20 196:16 197:11 198:1, 11 207:1 236:1 245:17 282:1, 1 313:16, 25 333:12 334:25, 25 349:1, 24 today's 349:1



today...again 244:1 told...i 239:1 tolerances 277:12 333:18 **tolerant** 95:19 102:24 121:1, 1 123:17, 20 140:10 **tomorrow** 336:23 349:1, 24 too...ken 157:13 **tool** 132:11 135:12 200:22 201:1 309:1 317:21 318:20 325:1 tools 205:15 325:1 top 219:1, 1, 10, 18 255:1, 1 267:17 269:18 302:18 325:24 329:24 330:15 339:1 343:1 346:23 topic 2:18 3:1 7:20 11:1 48:1 163:16 295:1 topics 177:1 total 107:1 157:1 171:24 175:15 178:1 186:25 216:21 221:1 225:22 271:20 320:12 344:18, 19 totally 176:20 279:1 292:11, 13 touch 7:21 74:1 146:24 229:12 342:1 touched 65:20 touching 204:10 touchy 76:22 tough 344:1 toward 307:11 308:1 312:12 towards 21:1 81:18, 20 111:20 173:14 175:1 176:25 217:15 244:18 257:1 307:1, 1 308:10 town 280:21 tox 69:13 212:1 216:23 238:12

242:25 290:17 toxic 84:23 86:17 127:1 168:1 181:1 267:21 toxicity 48:1, 1, 21 49:21 50:1, 20 51:1, 10 54:1, 10, 11, 12, 17 55:1 78:17 83:1, 17 84:1, 20 85:16 94:1 98:18 99:1 102:1, 14 121:1, 14 127:1 136:15 140:23 144:14, 15 168:1 263:21 267:21, 22, 23 271:17 329:1 330:11 toxicity's 51:1 toxicological 244:24 263:1 264:14 282:17 toxicologically 82:21 263:1 272:1 toxicologist 4:12 206:1 280:1 toxicologists 267:22 toxicology 3:1, 20 4:10, 13 5:1, 18 69:13, 20 204:1, 1 205:1, 1 206:10, 15 207:1 208:1, 12, 21, 23 212:1 213:1 214:11 215:1, 21 216:19 225:13 226:1 228:15 238:21 265:23 272:1 283:1 328:19 **track** 31:1 **tractor** 220:1, 24 221:25 trade 87:19 256:1 341:18 traditional 85:17 trained 147:11, 12, 15 149:1, 1 153:15 **trans** 337:1 trans-fatty 336:10 transcend 9:24 10:23 transcends 10:19

transcribed 37:1 transcript 28:1 **transect** 158:19 164:12, 14, 18 transects 148:17 158:23, 24 164:11, 16 transient 53:13 translated 298:1 translates 80:1 277:1 translocates 341:1 transparency 16:15, 25 transparent 252:23 transport 306:11 trash 343:24 **treat** 38:24 166:24 258:20 345:23 346:1 **treated** 79:1 82:1 96:1 125:1 127:1, 10, 24 129:1 130:1 131:18 136:1 138:11, 18, 21 139:1, 1, 23 141:1 144:10 149:11 153:1, 1 217:14 225:23 269:18 293:1 295:18 297:21, 23 298:1, 1, 1, 1, 14 300:15, 22, 25 301:1, 1 302:16 303:20, 20, 21 304:1 305:1 312:1 326:1 348:13 treating 19:15 treatment 18:1 19:12, 14 71:1 125:10, 21 127:1 138:23 147:25 148:11, 17 149:1, 12 196:1, 1 213:1, 14 348:14, 15 treatments 66:1 81:21 176:21 196:1 314:16 tree-like 81:16 tremendous 150:1 tremors 49:1, 22, 25



50:1 trend 15:16 53:1 tricky 53:1 **tried** 50:20 94:1 165:1 317:13 **tries** 49:24 trinity 308:13, 15 **trips** 97:1, 18 116:1, 1, 13, 13, 14, 22 160:1 190:13 192:1 trouble 230:13 267:23 314:21 true 126:21, 22 146:18 243:1 257:23, 24 277:20 291:10 315:1 345:24 truly 18:22 231:1 trusted 199:25 **try** 10:11 35:1 50:15 74:24 105:11 127:23 152:1 162:17 163:23 167:1 179:15 193:1 244:17 252:1 284:20 285:17 297:1 308:1, 1 310:21 312:18 313:1, 14 314:25 316:14 317:1, 14 318:21 339:21 trying 10:1, 12 16:22 34:16 35:1 87:12 105:24 171:1, 23 192:1 202:13 244:13 245:22 256:19 260:1 **tube** 180:22 turn 2:11 6:18 7:1 43:10 70:22 155:23 156:21 214:1 243:19 246:18 290:12 298:23 328:16 340:20 turned 80:1 136:18 167:15, 16, 19 turning 45:20 57:1 turns 250:21 298:13 **twelve** 8:1 41:16 55:25 56:1 310:1

twelves 310:1 twenty 13:11 44:1 twenty-five 18:12 twenty-four 42:20 44:10, 15, 22, 23 45:1 twenty-nine 18:19 twenty-one 18:11, 18 21:20 **twice** 100:1 269:19 314:18 two-fold 46:1, 16 170:1 267:12 279:17 **two...two** 73:10 **type** 88:1 114:18 125:15 200:1 218:19 223:23 228:1 239:1 289:11 307:1, 20 308:1 314:15 325:23 **types** 48:20, 21 120:1 227:21 **typical** 26:13 59:16 111:1 139:1 144:18 210:20 239:1 295:14 301:13 310:20 317:1 typically 8:1 25:12 42:24 43:19 116:1 165:1 206:1 207:1 211:17 217:1, 11, 17 222:11 240:13 243:11, 12 263:1 279:24 282:23 **typos** 37:1 U **u.s** 2:1 34:15 70:1 306:17 309:1 325:1 337:1 **u.s.d.a.'s** 339:15 **u.s.g.s** 306:14 **ultimate** 264:19 ultimately 204:11 245:22 250:13 300:25 un-extractable 18:21, 22

unable 305:10, 23 unacceptable 204:21 207:12 uncertain 110:20 154:10 155:1, 1 uncertainties 155:1 226:19 uncertainty 5:20 39:15 40:1 63:1 69:21 112:1 120:11 140:24 144:1, 21 145:1 154:15, 16 166:15, 25 192:16, 19 193:1 246:1, 1, 19, 21 247:16, 18 248:1, 1, 10 249:21 250:1 268:1 269:1 270:14 271:1, 1, 15, 19, 20 272:1, 10 273:13 274:1, 10 276:1, 24 277:1, 1, 1, 1 **uncommon** 324:11 uncontam...but 175:20 uncontaminated 78:23 175:19, 21 under-representative 157**:**1 undergoing 138:1 underlying 9:11 10:22 32:17 212:14 underneath 140:11 223:14, 18 255:1 understand 10:13 21:1, 23 23:19 25:1 30:23 42:25 45:10 47:14 50:18 54:1 76:1 99:1 154:1 160:1 162:1 171:24 178:20 184:14 192:11 193:22 194:12 239:17, 19 299:17 302:13 304:11 311:1 313:1 335:12 understanding 10:11 22:1 28:1

105:12 120:10

132:15 168:1

188:19 202:18 207:19, 23 209:1 236:24 237:12 238:18 249:1 279:18 understands 38:1 understood 21:1 understood...can 77:24 undertaking 216:15 undertook 147:1 268:10 **underway** 202:1 **undiluted** 150:25 undoubtedly 318:1 **uneasy** 145:22 unfortunately 64:16, 19 74:25 128:19 unimportant 115:13 uninterpretable 177:25 **unique** 52:13, 13 75:17 152:19 221:1 307:18 308:19 314:25 340:24 341:1 uniqueness 341:1 **unit** 4:1 33:1 217:10, 17 221:1, 19 222:1, 1 225:23 258:1 **united** 58:14 70:13 200:24 318:24 325:21 335:1 336:1, 11 338:15 units 32:24 33:1, 1, 1, 1 34:1 35:1, 1 221:1, 12 289:10 306:20 unity 267:18 **universe** 320:1 universities 339:15 university 2:21 3:1, 10, 19 4:1, 15, 25 5:1, 11, 14, 17, 20 6:1 73:14, 22 182:1 238:11 331:23 347:1 university's 344:11 **unknown** 149:23 150:1, 11

151:10, 11, 17 unless 181:15 327:18 **unlikely** 132:16 133:1 153:14, 19 **unlimited** 158:16 unnecessary 212:1 262:14 266:1 unrealistic 97:13 unreasonable 70:14 74:14 160:12 unreliable 22:1, 23 24:1, 15 unruh 338:1 340:20 341:15 342:1, 1, 1 345:20, 25 346:10, 19 347:1, 10, 13 348:23 349:1 **untested** 103:1 untreated 82:1 **unusual** 15:12 83:15 **up...do** 287:10 **up...the** 82:25 unvalidated 258:17 updated 17:1 95:10 124:13 268:13 **upon** 8:12 45:13 164:19 199:10 207:1 220:20 246:14 315:17 upper 111:1 117:22 217:15 303:1 304:1 311:1, 11 312:12 upper...upper 223:1 uptake 77:1, 1, 22 82:25 168:1 **urban** 266:24 306:21 **urinary** 43:22 **urine** 44:1 usability 23:16 **usable** 257:25 usage 279:11 308:21 usda's 3:23 275:14 **use...all** 327:1 **use...for** 74:21 **use...i** 57:25 use...is 242:1 used...and 232:19 **used...based** 250:17 **useful** 10:25 35:22 36:1, 1 37:15 38:1 63:1 80:21

124:24 181:1 325:1 **usepa** 43:15 242:1 **user** 91:19 **users** 61:1 64:16 340:15 **uses...and** 65:16 usqs's 310:1 utilizes 218:10 **usual** 162:10 251:12 usually 14:1 26:16 42:1, 23 171:22 206:14 261:1 322:19 348:13 V **vague** 28:1 val...these 115:22 **valid** 160:25 207:1, 12 212:1, 1 225:15 232:20 262:10 266:1, 1 276:1 **validate** 99:16 validation 92:13, 19 99:11, 14 validity 62:23 **valley** 318:19 **valuable** 229:1 value 62:1, 14 87:20 88:1 103:1 109:1 112:1, 1, 10 114:10, 12, 25 116:12 130:1, 17 143:1 151:20, 24 165:19, 24, 25 166:1, 1, 1, 20 177:23 210:21 216:1 222:13 224:1 259:1, 14 263:12 287:12 303:10 305:1 326:1 332:1 **values** 30:12 33:12, 15, 19, 23 34:10 84:1 86:24 104:11 112:1 113:1, 1 114:22 117:15 133:17 178:1 184:20 221:19, 20 222:1, 1, 1, 1 224:1 234:25 235:10 246:1



252:1, 11, 22 **varied** 115:21 122:11 253:21, 22 254:1 varies 109:1, 1, 255:19 257:25 18 196:1 240:23 259:11 260:12, 306:22 20 261:1, 1, 19 variety 127:1, 10 262:1 265:1 218:22 222:24 277:1 288:19 303:1 various 2:13 9:12 312:1 329:1 36:1, 1 68:24 330:11, 22 163:10 173:13 331:25 332:1 180:10 223:10 **valve** 218:1, 17 245:1 246:1 267:17 219:1, 1, 10, 17 349:19 **valves** 219:1 **vary** 105:10, 14 **vapor** 217:1 117:17 195:22 **var...a** 127:10 **vast** 137:12 142:1 variability 5:21 152:12 30:1, 11, 16 **vector** 339:1 31:10, 14 32:1, 11 vegetables 275:1 48:15 110:13, 18 vegetation 115:20, 111:18 112:1 21 113:23 114:1, **vehicle** 121:17 15, 16 115:13, 212:18 238:17 16 117:1, 18 118:1 verified 76:25 191:22, 24 192:1 348:17 194:23 211:13 verified...against 258:10 278:16, 76:22 19 310:12 verified...this variable 30:16 50:16 76:21 51:1 110:20 123:16 **versa** 270:1 164:18 165:1 version 89:23 90:1 264:25, 25 91:23 92:1, 11, 12 265:1, 1 93:20 94:16, 19 variable...pick 95:14, 20, 22 284:1 96:1, 1, 1, 16, **variables** 122:14 19, 23 98:14 143:16 154:10, 100:10 107:1, 1, 11 155:1, 1, 1 11 109:24 110:1, 190:10 25 113:20 114:1, variants 194:1, 1, 23 121:11, 11 10, 14 195:1 124:1, 1, 1 variation 98:1, 131:12, 16 132:1 12, 14, 16 107:11, 136:1 141:16, 21 13 109:25 110:1, 142:24, 25 143:11, 1, 10 115:23 13, 19 144:1, 19 116:11, 15, 21 145:11 153:21 145:12 189:15 154:1 155:1 189:10 191:25 193:13 195:17 245:24 194:15, 17 195:1 270:18 211:22, 24 versions 90:22 variation...and 93:1 153:21, 23 211:16 270:17 variations 115:18 **versus** 9:1 15:13

40:24 109:10 110:1 159:19 169:1 175:13 286:13 **vertical** 33:25 **very...taken** 136:1 **vet** 292:1 veterinary 3:1 **via** 78:1, 1 83:24 84:15 214:22 215:10 **viable** 61:1 62:11 **vice** 270:1 **view** 99:20 181:1 232:1 262:1, 1 **virtually** 348:10 **visually** 172:1 vital 200:23, 25 **vitamin** 336:21 **vivo** 180:1 **vocal** 176:18 **volatile** 284:1 volume 71:1 293:1 346:12 **volumes** 72:25 voluntarily 72:20 volunteer 344:1 volunteers 344:1 **vote** 294:1 vulnerability 299:18 302:16 304:11, 11 305:18, 25 314:1, 1 317:10, 22 318:1 319:1 332:1 vulnerable 63:19, 25 65:12, 13 67:1 68:1 73:1 302:14, 25, 25 303:13, 15 304:20, 25 305:1, 13, 21 314:1, 14, 17, 22 316:11 318:1, 11, 22 321:22 322:1 323:1, 1, 13 324:1 325:1, 1 W w.a.r.p 309:1, 1 310:18 311:24 312:1 waiting 163:1 233:17



walk 63:14 148:20	298:1, 11, 18,	104:1, 1, 1 116:12
346:1	24 299:1, 1, 1,	162:14, 23 163:1
walked 347:13, 18	10, 19, 22, 23	187:1 200:1 201:23
wall 82:24		202:1 203:15 295:1
waning 260:1	304:12, 21 305:10,	298:21 301:1 318:1
warp 299:24 309:24	17 306:1, 1, 12,	319:10 328:22
wasand 260:1	16, 19, 19 307:22,	340:17
waseven 237:1	23, 24, 25	we'lldr 162:13
wasit 191:18	308:1, 1, 1, 10	we'llwe 127:19
269:23	312:1, 11, 14, 19,	we're 2:1, 1, 23
	23 313:12 315:1,	26:1 34:16 35:11
wasno 239:1	13, 20, 22	38:22 41:1 44:1,
wasthis 131:1	316:1, 22 317:1, 1	22 51:1, 16 52:1
washed 43:25	320:1 324:1 325:14	53:17 55:12 56:1
washing 43:20	326:10, 12, 19,	57:1 61:18 66:17
washington 4:1, 1	20, 20 327:1, 20	73:1, 1 90:21
5:17 182:1 318:17	328:20 330:15	108:1 115:1
wasn't 24:18 28:1	331:21 332:1,	131:1 144:12, 24
40:17 147:21	11, 11 334:1, 1,	145:22 162:1 163:1
168:19 184:11	10 342:12 344:25	
188:22 191:16	water's 309:1	181:1 194:1
208:13 236:14	wateri 182:11	196:24, 25
wasn'ti 184:11	wateroh 239:18	198:13 202:1
watched 49:24 345:1	waterborne 306:1	203:14, 18
water 7:17 10:1	325:1	205:23 214:15
18:1, 25 19:11,	waterfowl 68:17	215:20 216:1
12, 16, 16, 19,	75:17 82:1	217:14 222:1
21, 23 20:1	106:1, 24 107:1	243:20 244:13
59:10 62:21	131:23 137:1,	246:24 248:15
63:20 65:13 67:15,	10, 25 138:1, 1,	249:1, 21 250:1
21, 24 70:1, 1	10, 17, 23	251:13, 19, 21, 22
77:20 78:18	140:17 151:20	253:24, 25 254:1
83:1, 1, 11, 15,	140:17 151:20 153:1 161:1	269:1, 1 271:1
24 84:15 85:17	waters 19:1 306:18	281:21 282:1, 1,
86:21 95:1, 1,	watershed 295:19	22 283:1 287:13,
15 100:1, 14,	298:1 300:1, 15,	23 289:1 290:12
17, 20 101:1	19, 21 301:1, 1,	292:18 294:1
121:14 168:10,	21 303:18, 19,	297:24 338:13
15 169:1, 1, 13	20 305:1 309:1, 23	342:1 343:11 345:1
185:13, 16, 23	310:1, 1	we'rewe're
186:1, 10 238:23	watersheds 298:1	202:1 282:23
239:1, 1, 15,	299:15 303:1	we've 20:1, 11 50:20
20, 24 240:1, 1,	322:1, 1	59:1 78:14 113:1
17, 22, 22	waywe 250:11	136:1 151:10 155:1
241:1, 1 245:13	ways 10:19 13:16	157:19 173:12
276:15, 16, 18,	239:1 288:16	180:1 198:15
22, 25 277:1, 1,	we'd 94:1 181:19	199:25 200:1 210:1
15, 16, 20, 21	236:1 244:1	242:18 247:22
290:12, 18, 19 291:1, 15 292:1	we'll 6:18 7:17,	248:1 250:1
293:15 294:11, 23,	18 8:21 9:15 10:25	254:1 263:22
25 295:10, 21, 23,	37:10 45:23	281:1, 12 288:12
24 296:1, 13 297:1	55:24 56:1 88:12	298:25 307:1
	0	313:18 319:20



322:1 337:13 338:24 we've...as 59:1 we...i'll 81:11 we...in 168:1 we...that's...that's 189:1 we...we 122:1, 1 133:16 177:1 198:15 217:15 222:21 274:12 281:23 we...we...they've 248:19 we...when 174:13 we...which 174:19 weak 339:1 weakened 339:1 weakness 200:1 weaknesses 212:1 wear 223:17 week 7:1 164:25 171:18, 21, 22 213:1 weeks 127:1 310:15 weevil 198:18 338:1, 22 339:1 342:14, 16 343:18 345:22 weevils 342:24 weighed 293:16 weight 79:16, 16 80:1 82:14, 15, 15 84:14 88:1 94:24 104:1, 1, 1, 17 120:1, 21 172:1 188:1, 1, 10 217:11 268:11, 12, 16 312:10 weighted 60:1 111:19 weights 79:18 87:1 225:1 weinberg 203:23, 25 244:1 263:1 welcome 2:16 7:13 56:1 241:24 well-known 86:1 well...the 232:10 well...we 166:1 wells 19:13, 24 68:1 312:25 315:13 320:1, 1, 1, 1, 1,

1, 11, 22 321:1 322:12, 16 324:1, 1, 1, 23 327:1 were...dr 65:25 were...that 165:22 were...wanted 260:11 were...was 284:1 were...were 182:1 were..that 305:18 west 318:14 323:25 324:1, 13, 13, 15, 19 western 320:11, 21 338:18 339:13 340:1 346:14 wet 104:1, 1 291:1 293:1 wetable 292:22 what...to 95:20 what...what 183:24 228:19 276:20 whatever 8:22 34:17 95:24 102:1 wheat 342:11 when...when 183:1 186:1 whenever 320:13 whereas 44:12 139:20 238:21 303:1 **whereby** 11:23 whereupon 12:22 16:17 28:22 56:1 162:25 202:1 294:18 349:25 whether 18:22 23:21 25:20 43:23 48:15 54:10 77:1 96:1, 1 97:1, 16 100:25 102:1 105:1 110:12 118:16 122:24 123:21 132:1 149:16 166:16 168:1, 10 208:19 210:24 213:13 228:1 237:10, 11 245:19, 23 247:1 248:13 257:25 261:25 270:24 273:10, 11 280:1 286:10, 14

287:11 292:21 321:15 348:10 whether...you 280:1 which...dead 147:18 which...which 179:25 226:17 white 85:1 wicomico 318:1, 23 who's 50:17 53:18 who's...who's 144:1 who've 281:1 whoa 284:16, 16 whole 19:14 38:1 44:20 49:1 51:13 52:10 98:20 103:12 134:16 143:1 199:12 211:1 263:16 276:20 286:16 311:16 whole-body 223:16 whose 3:11 wide 148:18 164:13 widely 59:14, 15 76:10 widgeon 138:13 width 158:21, 23 159:1 164:10, 12, 15, 18 165:1, 1, 10 wild 149:1 337:22 339:18 wildlife 3:23, 25, 25 4:1, 1, 12, 24 5:1 72:15 148:18 149:1 will...we'll 162:13 willamette 318:19 williams 70:1 295:1 299:1, 21 303:16 306:1, 1, 1 332:1 willing 37:1 173:1 244:1 willing...we 61:21 willingness 92:22 wind 342:18 343:19 349:1, 1 window 233:14 winds 342:19 wing 81:11 221:23 wipe 233:14

wish 281:22 349:11 wishes 54:23 with...excuse 292:16 with...where 196:1 with...with 184:14 women 280:24 281:1, 1, 18 wonder 327:25 wondered 28:19 wonderful 227:11 wondering 47:13 72:16, 18 159:17 173:1, 1 229:19 335:11 work 2:1 35:11 39:13 41:25 42:1, 24 74:1 78:21 93:15 128:1 171:18 223:18 228:1 269:14 281:10 299:1 306:10 307:1 335:23 345:11 work...both 182:20 work...from 64:1 workday 213:1 workdays 225:1 worked 200:1 230:19 238:18 worker 59:1 62:20 64:1, 1 69:11 203:20 204:1, 1, 11, 22 208:14 213:21 214:1 217:1, 20 221:1 240:1, 1, 1 242:17 workers 46:1 64:12 69:17 215:1 216:1, 10, 15 220:11 282:1, 1 334:15 working 63:1 201:1 340:1 works 117:10 121:1 157:25 world 62:19 78:10 330:14 worm 342:14 worms 197:22 worries 319:13 327:1 **worry** 90:1 worst 116:10 117:1 166:1 200:1

226:1 320:10 worth 118:20 204:1 338:19 would...if 116:14 would...would 160:10 184:17 would...you 146:13 wrap 152:1 153:1 199:12 292:1, 10, 11 332:16 335:1 wrap-up 7:1 wrapping 152:1 294:13 written 226:1 227:1 230:1 236:23 237:13 wrong 179:14 Х **xs** 223:1 Υ yellow 310:10 **yesterday** 2:11, 24 6:25 7:20 8:25 9:18 12:1, 11, 18 13:14 16:16, 18 18:1 20:1 25:15 26:1 31:1 35:21 47:1, 23 57:22 58:1, 1, 1 60:1, 17 63:11, 17 69:10 70:1 74:1, 20 76:1, 16 78:24 79:1 81:1 83:13 85:24 89:23 90:1 92:10 93:1, 14 96:1 98:1 99:14 101:10 102:1, 16 103:16 110:20 113:19 114:22 118:1, 16 119:13 120:1, 16 124:21 125:1 126:20 127:22 128:23 137:11 140:25 146:1, 16 149:20 151:1, 22 152:11, 21 173:1, 1, 23 174:1 175:1 179:23

230:24 245:1, 25 247:1 249:12, 15 252:24 255:1 266:23 275:1 283:24 285:18 294:1 329:1 yesterday's 20:15 yet 11:13 44:19 50:1 76:1 205:17 288:11 303:21 **yield** 345:1 york 152:1, 13, 15, 24 313:1 314:10 318:12 you'll 59:10 61:19 64:1 67:1 68:1, 20 80:13 84:1, 15 107:21 108:14 111:19 112:19 151:19 172:14 183:1 200:1, 13 246:23 254:15, 16 261:1 273:10 276:1 277:20 287:13 295:1 297:1 298:1, 10 299:15 308:25 320:1 336:17 you'll...you'll 199:1 you're...i 168:23 you've 17:20 24:13 35:14 44:1 49:23 52:23, 24 89:22 162:16, 19 177:21 185:22 186:1, 13 193:22 205:20 208:1 211:17 227:1 229:1 248:17 249:1 257:21 267:1 272:23 273:1, 24 296:11 302:1 333:11, 13 334:1 339:1 343:25 you...and 194:1 you...because 290:11 you...did 278:18 you...i 211:16 you...if 294:15 **you...you** 159:18 178:11 188:18



237:17 290:1 you...you're 283:12 you...your 230:22 young 51:20 90:18 160:11, 17 197:1, 1, 1, 1, 1, 20 201:11, 12, 16 young...and 197:1 younger 34:11 42:1 49:15 your...in 192:18 290:1 your...jane 280:1 your...the 285:1 yourself 41:1 43:14 127:18 Ζ zero 30:10, 20, 21 79:17 104:15 111:11 112:1, 11 119:1 129:14 141:13, 23 147:1 148:1 149:1 183:16 192:15 257:1 285:1, 1 **zeros** 118:1 267:13 270:20 **zonner** 330:23 **zoology** 4:24

